var images_info;if (!images_info) images_info =[]; images_info["103"]={"103003":{"type":"graphic_table","displayName":"Physical examination correlates in neonatal seizures","title":"Key general physical examination findings for newborns with suspected seizures","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Key general physical examination findings for newborns with suspected seizures</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Physical examination</td> <td class=\"subtitle1\">Diagnostic considerations based on findings</td> </tr> <tr class=\"divider_bottom\"> <td>Head circumference</td> <td> <ul> <li>Macrocephaly - Hydrocephalus or hemimegalencephaly </li> <li>Microcephaly - Congenital CNS infections (especially TORCH infections, Zika virus) or congenital CNS lesions </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Skin examination</td> <td> <ul> <li>Vesicular lesions - Consider HSV infection </li> <li>Vesicular lesions in a dermatomal pattern - Incontinentia pigmenti </li> <li>Port wine stain of the forehead/eyelid - Consider Sturge-Weber syndrome and evaluate for glaucoma </li> <li>Nevus or discoloration in a dermatomal or whorled pattern - Developmental cerebral dysgenesis </li> <li>\"Blueberry muffin\" skin appearance - Congenital Rubella infection (or other TORCH infections) </li> <li>Ash leaf macule - Tuberous sclerosis </li> <li>Cutis aplasia (lack of hair and skin in a localized area) - Associated developmental cerebral dysgenesis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Ophthalmological examination</td> <td> <ul> <li>Hypoplastic optic nerves - Cerebral dysgenesis (eg, septo-optic dysplasia) </li> <li>Chorioretinitis - Congenital CNS infections </li> <li>Abnormal retinal pigmentation - Neuronal ceroid lipofuscinosis </li> <li>Coloboma - Agenesis of the corpus callosum </li> <li>Congenital cataract - Congenital CNS infections (especially TORCH infections) or metabolic (storage) diseases </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Facial (or other) dysmorphism</td> <td> <ul> <li>Hypotelorism, cleft lip/palate (mid-face abnormalities) - Cerebral dysgenesis (eg, holoprosencephaly) </li> <li>Multiple congenital anomalies - Chromosomal abnormalities (trisomy syndromes, partial deletions/duplications) </li> </ul> </td> </tr> <tr> <td>Mental status</td> <td> <ul> <li>Irritable, jittery - Neonatal encephalopathy (eg, due to HIE, neonatal abstinence syndrome) </li> <li>Lethargy, decreased responsiveness - Neonatal encephalopathy (eg, due to HIE); severe systemic illness and/or infection (eg, meningoencephalitis) </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CNS: central nervous system; TORCH: toxoplasmosis, rubella, cytomegalovirus, herpes simplex virus; HSV: herpes&nbsp;simplex virus;&nbsp;HIE: hypoxic-ischemic encephalopathy.</div><div id=\"graphicVersion\">Graphic 103003 Version 3.0</div></div></div>"},"103006":{"type":"graphic_table","displayName":"Screening for motor delays","title":"Screening for motor delays in infants and young children*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Screening for motor delays in infants and young children*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"80%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">The following motor skills should be observed in the young child at the specified visit. These skills are typically acquired at earlier ages, and their absence at these ages signifies delay. Loss of previously attained motor skills should also raise concern.</td> </tr> <tr> <td><strong>9-month visit</strong></td> <td> <ul> <li>Rolls to both sides </li> <li>Sits well without support </li> <li>Demonstrates motor symmetry without established handedness </li> <li>Grasps and transfers objects from hand to hand </li> </ul> </td> </tr> <tr> <td><strong>18-month visit</strong></td> <td> <ul> <li>Sits, stands, and walks independently </li> <li>Grasps and manipulates small objects </li> </ul> </td> </tr> <tr> <td><strong>30-month visit</strong></td> <td> <ul> <li>Evaluate for subtle gross motor, fine motor, speech, and oral motor impairments </li> <li>Evaluate for loss of previously attained gross or fine motor skills </li> </ul> </td> </tr> <tr> <td><strong>48-month visit</strong></td> <td> <ul> <li>Evaluate coordination, fine motor, handwriting, gross motor, communication, and feeding abilities </li> <li>Address any preschool or child care staff concerns about motor development </li> <li>Evaluate for loss of previously attained gross or fine motor skills </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* If screening reveals a neuromotor concern, the clinician should obtain an expanded history and perform a detailed neurologic examination. If abnormal tone is detected on physical examination, referral to early intervention and/or consultation with a pediatric neurologist may be warranted. Additional testing (eg, neuroimaging) may also be warranted. For additional information on the evaluation of children with abnormal motor development, refer to the UpToDate topic on evaluation and diagnosis of cerebral palsy.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Noritz GH, Murphy NA, Neuromotor Screening Expert Panel. Motor delays: early identification and evaluation. Pediatrics 2013; 131:e2016.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103006 Version 1.0</div></div></div>"},"103010":{"type":"graphic_figure","displayName":"Toe crest pad for flexor digitorum longus tendinitis","title":"Toe crest pad for flexor digitorum longus tendinitis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Toe crest pad for flexor digitorum longus tendinitis</div><div class=\"cntnt\"><img style=\"width:449px; height:557px;\" src=\"images/EM/103010_Toe_crest_pad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Toe crest pads are placed in the sulcus of the second through fifth toes distal to the metatarsal heads. They decrease use of the flexor digitorum longus tendon by creating an upward force on the toes&nbsp;and&nbsp;reducing the degree of toe flexion.</div><div id=\"graphicVersion\">Graphic 103010 Version 2.0</div></div></div>"},"103011":{"type":"graphic_figure","displayName":"Too many toes sign","title":"Too many toes sign from tibialis posterior tendon dysfunction","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">Too many toes sign from tibialis posterior tendon dysfunction</div><div class=\"cntnt\"><img style=\"width:517px; height:392px;\" src=\"images/SM/103011_Too_many_toes_sign.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A. Normal posterior view of the foot. B. Evidence of arch collapse with \"too many toes sign\". In this instance, even a portion of the great toe is visible from directly behind the patient. </div><div id=\"graphicVersion\">Graphic 103011 Version 2.0</div></div></div>"},"103013":{"type":"graphic_picture","displayName":"Miliaria crystallina on shoulder","title":"Miliaria crystallina","html":"<div class=\"graphic\"><div style=\"width: 930px\" class=\"figure\"><div class=\"ttl\">Miliaria crystallina</div><div class=\"cntnt\"><img style=\"width:910px; height:989px;\" src=\"images/DERM/103013_Miliaria_crystalline_shldr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Clear, superficial vesicles on the shoulder.</div><div class=\"graphic_reference\">Courtesy of Alan S Boyd, MD.</div><div id=\"graphicVersion\">Graphic 103013 Version 1.0</div></div></div>"},"103014":{"type":"graphic_figure","displayName":"Anatomy of the maxilla and supporting bony structures","title":"Anatomy of the maxilla and supporting bony structures","html":"<div class=\"graphic\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Anatomy of the maxilla and supporting bony structures</div><div class=\"cntnt\"><img style=\"width:528px; height:484px;\" src=\"images/ONC/103014_Anatomy_of_the_maxilla.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103014 Version 1.0</div></div></div>"},"103015":{"type":"graphic_table","displayName":"Causes of hypoglycemia in infants and children","title":"Causes of hypoglycemia in infants and children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of hypoglycemia in infants and children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Other names</td> <td class=\"subtitle1\">OMIM #</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disorders of carbohydrate metabolism</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Disorders of glycogenolysis</strong></td> </tr> <tr> <td class=\"indent2\">Glycogen synthetase deficiency</td> <td>GSD type 0a</td> <td>240600</td> </tr> <tr> <td class=\"indent2\">Glucose-6-phosphatase deficiency</td> <td>GSD type Ia (von Gierke disase) or Ib</td> <td>232200 or 232220</td> </tr> <tr> <td class=\"indent2\">Debrancher deficiency</td> <td>GSD type III</td> <td>232400</td> </tr> <tr> <td class=\"indent2\">Hepatic phosphorylase deficiency</td> <td>GSD type VI</td> <td>232700</td> </tr> <tr> <td class=\"indent2\">Hepatic phosphorylase B kinase deficiency</td> <td>GSD IXa1, IXb-d</td> <td>306000</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Disorders of glycosylation</strong></td> </tr> <tr> <td class=\"indent2\">Phosphoglucomutase&nbsp;1 deficiency </td> <td>Congenital disorder of glycosylation type It</td> <td>614921</td> </tr> <tr> <td class=\"indent2\">Phosphomannomutase 2 deficiency&nbsp;</td> <td>Congenital disorder of glycosylation type Ia</td> <td>212065&nbsp;</td> </tr> <tr> <td class=\"indent2\">Mannosephosphate isomerase deficiency&nbsp;</td> <td>Congenital disorder of glycosylation type Ib</td> <td>602579&nbsp;</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Disorders of gluconeogenesis</strong></td> </tr> <tr> <td class=\"indent2\">Fructose 1,6 bisphosphatase deficiency</td> <td>&nbsp;</td> <td>229700</td> </tr> <tr> <td class=\"indent2\">Pyruvate carboxylase deficiency</td> <td>&nbsp;</td> <td>266150</td> </tr> <tr> <td class=\"indent2\">PEPCK deficiency</td> <td>&nbsp;</td> <td>261650</td> </tr> <tr> <td class=\"indent2\">Galactosemia</td> <td>&nbsp;</td> <td>230400; others</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Hereditary fructose intolerance</td> <td>&nbsp;</td> <td>229600</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disorders of amino acid metabolism</td> </tr> <tr> <td class=\"indent1\">Propionic acidemia</td> <td>&nbsp;</td> <td>606054</td> </tr> <tr> <td class=\"indent1\">Methylmalonic aciduria</td> <td>&nbsp;</td> <td>277400; others</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Glutaric aciduria type 1</td> <td>&nbsp;</td> <td>231670 </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Disorders of fatty acid metabolism</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Medium-chain acyl-CoA dehydrogenase (MCAD) and others</td> <td>&nbsp;</td> <td>201450, others&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Increased utilization of glucose</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Hyperinsulinemia</strong></td> </tr> <tr> <td class=\"indent2\">Persistent hyperinsulinemic hypoglycemia of infancy (PHHI)</td> <td>Familial hyperinsulinemic hypoglycemia; congenital hyperinsulinism</td> <td>256450; 601820; others</td> </tr> <tr> <td class=\"indent2\">Insulinoma (including in association with MEN1)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Exogenous administration of insulin (eg, in Munchausen's syndrome by proxy or diabetes mellitus)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Miscellaneous</td> </tr> <tr> <td class=\"sublist1\"><strong>Ketotic hypoglycemia</strong></td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Hormone deficiencies</strong></td> </tr> <tr> <td class=\"indent2\">Growth hormone deficiency</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Cortisol deficiency</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">&#177; Hypothyroidism</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\" colspan=\"3\"><strong>Ingestions</strong></td> </tr> <tr> <td class=\"indent2\">Oral hypoglycemics (eg, sulfonylureas such as glipizide or glyburide) - cause hyperinsulinemia</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Ethanol</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Salicylates</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Beta blockers</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Pentamidine</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Trimethoprim-sulfamethoxazole (rare)&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Refer to UpToDate table on drugs that cause hypoglycemia&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"sublist1\" colspan=\"2\"><strong>Other</strong></td> </tr> <tr> <td class=\"indent2\">Heart disease</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Surgery</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Critical illness (eg, sepsis)</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr> <td class=\"indent2\">Hepatic failure</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OMIM: on-line Mendelian inheritance in man database; GSD: glycogen storage disease; PEPCK: phosphoenolpyruvate carboxykinase; PHHI: persistent hyperinsulinemic hypoglycemia of infancy; MEN1: multiple endocrine neoplasia type 1; MCAD: medium-chain acyl-CoA dehydrogenase.</div><div class=\"graphic_reference\">Courtesy of Drs. Morey Haymond and Agneta Sunehag.</div><div id=\"graphicVersion\">Graphic 103015 Version 3.0</div></div></div>"},"103017":{"type":"graphic_algorithm","displayName":"Management of diabetic foot wounds","title":"Management of diabetic foot wounds","html":"<div class=\"graphic\"><div style=\"width: 836px\" class=\"figure\"><div class=\"ttl\">Management of diabetic foot wounds</div><div class=\"cntnt\"><img style=\"width:816px; height:1080px;\" src=\"images/SURG/103017_Mgmt_diabetic_foot_wounds.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">SVS: Society for Vascular Surgery; WIfI: Wound, Ischemia, and foot Infection; ABI: ankle-brachial index; I&amp;D: incision and drainage; MRI: magnetic resonance imaging; MRSA: methicillin-resistant <EM>Staphylococcus aureus</EM>.<br />* Signs of severe infection include severe cellulitis, fever, hemodynamic instability, and purulent drainage.<br />¶ Plain foot radiographs may demonstrate gas in the tissues, osteomyelitis, or the presence of a foreign body. Other foot imaging (eg, MRI) may be needed to identify fluid collections or osteomyelitis not detected on physical exam.<br />Δ Severe ischemia is manifest on clinical examination as severely diminished or absent pedal pulses, dependent rubor, ABI &lt;0.40, or toe pressure &lt;30 mmHg. Vascular imaging is warranted for those with obvious limb ischemia. Tissue loss can manifest as ischemic ulceration or as wet or dry gangrene. Patients with stable, dry gangrene do not require immediate debridement; vascular imaging and revascularization are preferentially performed before debridement.<br /><FONT class=lozenge>◊</FONT> For severe infections, broad-spectrum antimicrobial therapy should be initiated and adjusted depending upon the results of tissue culture and sensitivity. For mild-to-moderate infection, antimicrobial therapy should target aerobic gram-positive cocci. For patients with a prior history of MRSA infection or when the local prevalence of MRSA colonization or infection is high, empiric therapy should also be directed against MRSA. The duration of antimicrobial therapy depends upon the severity of infection and organism. Residual infected bone following debridement of necrotic bone may require four to six weeks of treatment or longer.<br />§ All ulcers subjected to excessive pressure benefit from pressure reduction, which is accomplished with mechanical offloading. Foot deformities include hammertoe, bunion, rocker bottom deformity, and Charcot arthropathy. Optimizing foot biomechanics may include Achilles tendon or gastrocnemius tendon lengthening or tendon transfer procedures, among others.<br />¥ Some patients with mild ischemia may also require revascularization to achieve wound healing.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Mills JL, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). J Vasc Surg 2014; 59:220.</LI>&#xD;&#xA;<LI>Hingorani A, LaMuraglia GM, Henke P, et al. The management of diabetic foot: A clinical practice guideline by the Society for Vascular Surgery in collaboration with the American Podiatric Medical Association and the Society for Vascular Medicine. J Vasc Surg 2016; 63:3S.</LI>&#xD;&#xA;<LI>Lipsky BA, Berendt AR, Cornia PB, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 2012; 54:e132.</LI></OL></div><div id=\"graphicVersion\">Graphic 103017 Version 1.0</div></div></div>"},"103023":{"type":"graphic_picture","displayName":"Lisfranc injury mechanism","title":"Lisfranc injury mechanism","html":"<div class=\"graphic\"><div style=\"width: 529px\" class=\"figure\"><div class=\"ttl\">Lisfranc injury mechanism</div><div class=\"cntnt\"><img style=\"width:509px; height:712px;\" src=\"images/SM/103023_Lisfranc_injury_mechanism.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A direct vertical force, such as from a knee or shoulder, onto the heel of a fully planted and plantar flexed foot can cause hyperplantarflexion and subsequent disruption of the Lisfranc ligament.</div><div class=\"graphic_reference\">From: Latterman C, Goldstein JL, Wukich DK, et al. Practical management of Lisfranc injuries in athletes. Clin J Sport Med 2007; 17:311. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2007/07000/Practical_Management_of_Lisfranc_Injuries_in.14.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/JSM.0b013e31811ed0ba</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103023 Version 1.0</div></div></div>"},"103024":{"type":"graphic_diagnosticimage","displayName":"Normal anteroposterior and oblique non–weight-bearing radiograph","title":"Normal anteroposterior and oblique non-weight-bearing radiographs of the foot","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Normal anteroposterior and oblique non-weight-bearing radiographs of the foot</div><div class=\"cntnt\"><img style=\"width:715px; height:347px;\" src=\"images/SM/103024_Nml_ant_oblq_no_wgh_br_rdgr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Normal anteroposterior and oblique non-weight-bearing radiographs of the foot. The arrow on the left marks the medial border of the second metatarsal, which should align directly with the medial border of the middle cuneiform. Any comminution or bony fragments within the circled area should raise suspicion for a Lisfranc injury. The arrow on the right indicates the medial border of the fourth metatarsal, which should align directly with the medial border of the cuboid on the oblique radiograph of the foot.</div><div class=\"graphic_reference\">From: Latterman C, Goldstein JL, Wukich DK, et al. Practical management of Lisfranc injuries in athletes. Clin J Sport Med 2007; 17:311. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2007/07000/Practical_Management_of_Lisfranc_Injuries_in.14.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/JSM.0b013e31811ed0ba</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103024 Version 3.0</div></div></div>"},"103025":{"type":"graphic_diagnosticimage","displayName":"Lateral non-weight-bearing radiograph of right foot","title":"Lateral non-weight-bearing radiograph of right foot","html":"<div class=\"graphic\"><div style=\"width: 633px\" class=\"figure\"><div class=\"ttl\">Lateral non-weight-bearing radiograph of right foot</div><div class=\"cntnt\"><img style=\"width:613px; height:319px;\" src=\"images/SM/103025_Lat_non_wght_br_rdg_rght_ft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lateral non-weight-bearing radiograph of a right foot, showing a normal dorsal cortical line (white line) from the first metatarsal to the medial cuneiform. Any step-off along this tangential may signify instability of the first tarsal-metatarsal joint.</div><div class=\"graphic_reference\">From: Latterman C, Goldstein JL, Wukich DK, et al. Practical management of Lisfranc injuries in athletes. Clin J Sport Med 2007; 17:311. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2007/07000/Practical_Management_of_Lisfranc_Injuries_in.14.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/JSM.0b013e31811ed0ba</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103025 Version 1.0</div></div></div>"},"103026":{"type":"graphic_diagnosticimage","displayName":"Subtle findings of a Lisfranc (tarsometatarsal) injury","title":"Subtle findings of a Lisfranc (tarsometatarsal) injury","html":"<div class=\"graphic\"><div style=\"width: 733px\" class=\"figure\"><div class=\"ttl\">Subtle findings of a Lisfranc (tarsometatarsal) injury</div><div class=\"cntnt\"><img style=\"width:713px; height:430px;\" src=\"images/SM/103026_Sbtl_fnd_lsfrnc_injry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Subtle findings of a Lisfranc injury are found in the plain radiographs above. The image on the left&nbsp;(A) is a non-weight-bearing anteroposterior&nbsp;radiograph showing minimal displacement between the first and second metatarsals that can easily be missed. The&nbsp;image on the right (B)&nbsp;is&nbsp;a weight-bearing film, which accentuates the diastasis and demonstrates a wide gap between the metatarsals.</div><div class=\"graphic_reference\">From: Latterman C, Goldstein JL, Wukich DK, et al. Practical management of Lisfranc injuries in athletes. Clin J Sport Med 2007; 17:311. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2007/07000/Practical_Management_of_Lisfranc_Injuries_in.14.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/JSM.0b013e31811ed0ba</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103026 Version 2.0</div></div></div>"},"103030":{"type":"graphic_diagnosticimage","displayName":"Lisfranc injury on lateral plain radiograph","title":"Lisfranc injury on lateral plain radiograph","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Lisfranc injury on lateral plain radiograph</div><div class=\"cntnt\"><img style=\"width:725px; height:328px;\" src=\"images/SM/103030_Lisfranc_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The lateral x-ray shows a significant subluxation of the first tarsal&ndash;metatarsal joint and disruption of the normal dorsal cortical line from the first metatarsal to the medial cuneiform, suggesting a Lisfranc injury.</div><div class=\"graphic_reference\">From: Latterman C, Goldstein JL, Wukich DK, et al. Practical management of Lisfranc injuries in athletes. Clin J Sport Med 2007; 17:311. DOI: <a href=\"http://journals.lww.com/cjsportsmed/Abstract/2007/07000/Practical_Management_of_Lisfranc_Injuries_in.14.aspx\" spellcheck=\"true\" target=\"_blank\">10.1097/JSM.0b013e31811ed0ba</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007 American Medical Society for Sports Medicine, American Osteopathic Academy of Sports Medicine, Australasian College of Sports Physicians, and Canadian Academy of Sport &amp; Exercise Medicine. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103030 Version 1.0</div></div></div>"},"103032":{"type":"graphic_picture","displayName":"Miliaria rubra histopathology","title":"Miliaria rubra","html":"<div class=\"graphic\"><div style=\"width: 930px\" class=\"figure\"><div class=\"ttl\">Miliaria rubra</div><div class=\"cntnt\"><img style=\"width:910px; height:682px;\" src=\"images/DERM/103032_Mlr_rbr_hstpthlgy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spongiotic vesicle within the dermis surrounding an eccrine duct.</div><div class=\"graphic_reference\">Courtesy of Jeffery Zwerner, MD, PhD.</div><div id=\"graphicVersion\">Graphic 103032 Version 1.0</div></div></div>"},"103034":{"type":"graphic_figure","displayName":"Common tarsometatarsal (Lisfranc) injury patterns","title":"Common tarsometatarsal (Lisfranc) injury patterns","html":"<div class=\"graphic\"><div style=\"width: 553px\" class=\"figure\"><div class=\"ttl\">Common tarsometatarsal (Lisfranc) injury patterns</div><div class=\"cntnt\"><img style=\"width:533px; height:375px;\" src=\"images/SM/103034_Common_Lisfranc_injury_patterns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Common injury patterns of the Lisfranc joint are pictured above. The second through fifth metatarsals are connected by transverse ligaments, but the first metatarsal is not attached to the second metatarsal via a transverse ligament, which contributes to the first metatarsal's propensity to displace when the TMT ligaments are injured. </div><div id=\"graphicVersion\">Graphic 103034 Version 2.0</div></div></div>"},"103035":{"type":"graphic_figure","displayName":"Lisfranc ligament superior view","title":"Lisfranc ligament superior view","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Lisfranc ligament superior view</div><div class=\"cntnt\"><img style=\"width:496px; height:470px;\" src=\"images/SM/103035_Lisfrancligament.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dorsal Lisfranc ligament shown above is one of three ligaments connecting the medial border of the second metatarsal with the lateral aspect of the medial cuneiform.</div><div id=\"graphicVersion\">Graphic 103035 Version 2.0</div></div></div>"},"103036":{"type":"graphic_figure","displayName":"Normal tarsometatarsal (Lisfranc) joint complex","title":"Normal tarsometatarsal (Lisfranc) joint complex","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Normal tarsometatarsal (Lisfranc)&nbsp;joint complex</div><div class=\"cntnt\"><img style=\"width:452px; height:550px;\" src=\"images/SM/103036_Normal_Lisfranc_joint_complex.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The osseous components of the tarsometatarsal (TMT) joint complex include the five metatarsals, the three cuneiforms, and the cuboid. This region is highlighted in pink above.</div><div id=\"graphicVersion\">Graphic 103036 Version 1.0</div></div></div>"},"103037":{"type":"graphic_figure","displayName":"Mechanism of Lisfranc (tarsometatarsal) injury","title":"Mechanism of Lisfranc (tarsometatarsal) injury","html":"<div class=\"graphic\"><div style=\"width: 501px\" class=\"figure\"><div class=\"ttl\">Mechanism of Lisfranc (tarsometatarsal)&nbsp;injury</div><div class=\"cntnt\"><img style=\"width:481px; height:664px;\" src=\"images/SM/103037_Mechanism_of_Lisfranc_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Indirect Lisfranc injuries often result from an axial load placed on a plantar-flexed foot that then forcibly rotates, bends, or is compressed.&nbsp;This mechanism&nbsp;can occur in field sports when a player inadvertently steps or falls&nbsp;onto the heel of an opponent&nbsp;whose foot is forcibly plantar-flexed </div><div id=\"graphicVersion\">Graphic 103037 Version 1.0</div></div></div>"},"103038":{"type":"graphic_table","displayName":"GemCap for advanced pancreatobiliary cancer","title":"Gemcitabine and capecitabine (GemCap) for advanced pancreatobiliary cancer<SUP>[1,2]</SUP>","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Gemcitabine and capecitabine (GemCap) for advanced pancreatobiliary cancer<SUP>[1,2]</SUP></div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td colspan=\"4\">Cycle length: 21 days.</td> </tr> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose and route</td> <td class=\"subtitle1\">Administration</td> <td class=\"subtitle1\">Given on days</td> </tr> <tr> <td><strong>Gemcitabine</strong>*</td> <td>1000 mg/m<sup>2</sup> IV</td> <td>Dilute in 250 mL normal saline (concentration no greater than 40 mg/mL) and administer over 30 minutes.</td> <td>Days 1 and 8</td> </tr> <tr> <td><strong>Capecitabine</strong><sup>&#916;</sup><sup>&#9674;</sup></td> <td>650 mg/m<sup>2</sup> per dose by mouth. </td> <td>Twice daily (total dose 1300 mg/m<sup>2</sup> per day). Swallow whole with water within 30 minutes after a meal, with each dose as close to 12 hours apart as possible. Do not cut or crush tablets<sup>&#167;</sup>.</td> <td>Days 1 through 14</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Pretreatment considerations:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Emesis risk:</strong> LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting in adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Infection prophylaxis:</strong> Primary prophylaxis with G-CSF is not indicated (incidence of neutropenic fever = 2 percent) for this regimen<sup>[2]</sup>. Refer to UpToDate topic on \"Prophylaxis of infection during chemotherapy-induced neutropenia in high-risk adults\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Dose adjustment for baseline liver or renal dysfunction:</strong> A lower starting dose of gemcitabine may be needed for patients with liver impairment. A lower starting dose of capecitabine may be needed for patients with moderate renal impairment<sup>[3]</sup>. Refer to UpToDate topics on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\" and \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Monitoring parameters:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; CBC with differential and platelet count weekly during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Assess basic metabolic panel (including serum creatinine) and liver function tests every three weeks prior to each new cycle and otherwise as indicated during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Monitor for diarrhea and palmar-plantar erythrodysesthesias during treatment.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; Cardiotoxicity observed with capecitabine includes myocardial infarction/ischemia, angina, dysrhythmias, cardiac arrest, cardiac failure, sudden death, electrocardiographic changes, and cardiomyopathy. These adverse reactions may be more common in patients with a prior history of coronary artery disease. Refer to UpToDate topic on \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\".</td> </tr> <tr> <td class=\"subtitle1_single\" colspan=\"4\">Suggested dose modifications for toxicity:</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Myelotoxicity:</strong> This regimen should not be initiated unless neutrophils are &#8805;1500/microL and platelets are &#8805;100,000/microL<sup>[1,2]</sup>. Reduce the day 8 gemcitabine dose by 25 percent for an absolute neutrophil count of 500 to 1000/microL or a platelet count of 50,000 to 100,000/microL<sup>[2]</sup>. Decrease gemcitabine by 25 percent for subsequent cycles for febrile neutropenia, grade 4 hematologic toxicity lasting for more than seven days, or bleeding-associated thrombocytopenia<sup>[2]</sup>.</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; <strong>Nonhematologic toxicity (including hepatotoxicity):</strong> In the initial protocol, capecitabine was interrupted for &#8805;grade 2 nonhematologic toxicity (except alopecia) that was likely related to capecitabine until it decreased to &#8804;grade 1<sup>[2]</sup>. Decrease subsequent capecitabine dose by 25 percent for &#8805;grade 3 nonhematologic toxicity or recurrent grade 2 toxicity (except alopecia).</p> <p>The United States Prescribing Information also contains recommendations for capecitabine dose reduction based upon toxicity. <span style=\"color: black;\">For the first, second, and third occurrence of grade 2 toxicity, hold capecitabine. After resolution to grade 1 or less, resume treatment (first occurrence, no dosage adjustment; second occurrence, 75 percent of the starting dose; third occurrence, 50 percent of the starting dose)<sup>[4]</sup>. For the fourth occurrence of a grade 2 toxicity, discontinue capecitabine therapy. Grade 3: For the first and second occurrence, hold capecitabine therapy. After resolution to grade 1 or less, resume treatment at a reduced dose (first occurrence, 75 percent of the starting dose; second occurrence, 50 percent of the starting dose). For the third occurrence of a grade 3 toxicity, discontinue capecitabine therapy. Grade 4: Discontinue capecitabine therapy. Alternatively, hold capecitabine therapy, and begin next treatment at 50 percent of the starting dose when toxicity resolves to grade 1 or less; discontinue treatment for fist recurrence of grade 4 toxicity.</span></p> <p><span style=\"color: black;\"><strong></strong><strong>NOTE:</strong> Severe diarrhea, mucositis, and myelosuppression after capecitabine should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".</span></p> <p>Hold gemcitabine for &#8805;grade 3 nonhematologic toxicity that is likely related to gemcitabine until it decreases to &#8804;grade 1<sup>[2]</sup>. Gemcitabine is commonly associated with a transient rise in serum transaminases, but these are seldom of clinical significance. There is insufficient information from clinical studies to allow clear dose recommendations in these patients.&nbsp; Refer to UpToDate topic on \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".. Restart gemcitabine with a 25 percent dose reduction.</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"> <p>&#8226; Omitted capecitabine doses for toxicity are not replaced or restored. Resume treatment with the planned next cycle.</p> </td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Pulmonary toxicity:</strong> A variety of manifestations of pulmonary toxicity have been reported in patients treated with gemcitabine. Discontinue gemcitabine immediately and permanently. Refer to UpToDate topic on \"Pulmonary toxicity associated with antineoplastic therapy: Cytotoxic agents\".</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\">&#8226; <strong>Thrombotic microangiopathy:</strong> Thrombotic microangiopathy (TMA, also sometimes called thrombotic thrombocytopenic purpura [TTP] or hemolytic uremic syndrome [HUS]) has been associated with gemcitabine, in individuals who have received a large or small cumulative dose<sup>[3]</sup>. Consider the possibility of TMA if the patient develops Coombs-negative hemolysis, thrombocytopenia, renal failure, and/or neurologic findings. Management consists of drug discontinuation and supportive care, without plasma exchange, as long as there is high confidence in a drug-induced etiology rather than TTP. Refer to UpToDate topic on \"Drug-induced thrombotic microangiopathy\".</td> </tr> <tr> <td colspan=\"4\"><strong>If there is a change in body weight of at least 10 percent, doses should be recalculated.</strong></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><strong>This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.</strong></div><div class=\"graphic_footnotes\">IV: intravenous; G-CSF: granulocyte colony stimulating factor; CBC: complete blood count; INR: international normalized ratio; ULN: upper limit of normal.<br />* Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).<br /><FONT class=lozenge><FONT color=black>◊</FONT></FONT><FONT color=black> No capecitabine dose has been shown to be safe in patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency, and data are insufficient to recommend a dose in patients with partial DPD activity.<br />§ Extemporaneous compounding of liquid dosage forms has been recommended, but IV therapies may be more appropriate for patients with significant swallowing difficulty.</FONT></div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Riechelmann RP, et al. Cancer 2007; 110:1307.</LI>&#xD;&#xA;<LI>Knox JJ, et al. J Clin Oncol 2005; 23:2332. </LI>&#xD;&#xA;<LI>Gemcitabine injection. United States Prescribing Information. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on August 29, 2016). </LI>&#xD;&#xA;<LI>Capecitabine. United States Prescribing Information. US National Library of Medicine. (Available online at www.dailymed.nlm.nih.gov, accessed on August 29, 2016).</LI></OL></div><div id=\"graphicVersion\">Graphic 103038 Version 7.0</div></div></div>"},"103039":{"type":"graphic_figure","displayName":"Open heel blister treatment","title":"Open heel blister treatment using a heel cup","html":"<div class=\"graphic\"><div style=\"width: 560px\" class=\"figure\"><div class=\"ttl\">Open heel blister treatment using a heel cup</div><div class=\"cntnt\"><img style=\"width:540px; height:297px;\" src=\"images/SM/103039_Open_heel_blister_treatment.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The management of unroofed (open) blisters of the heel include the following steps:<br />A. Trim off the roof of the blister. B. Cover the base of the blister with a pad designed for that purpose (eg, Spenco 2nd skin or Band-Aid Advanced Healing Blister). C. Make a heel cup out of elastic tape by cutting the corners off a large square piece of tape and cutting through the edges of the tape but leaving an intact central strip. D&nbsp;Apply the tape as shown. </div><div id=\"graphicVersion\">Graphic 103039 Version 1.0</div></div></div>"},"103041":{"type":"graphic_figure","displayName":"Pathophysiologic assessment in chronic foot ulcers","title":"Pathophysiologic assessment in chronic foot ulcers","html":"<div class=\"graphic\"><div style=\"width: 666px\" class=\"figure\"><div class=\"ttl\">Pathophysiologic assessment in chronic foot ulcers</div><div class=\"cntnt\"><img style=\"width:646px; height:626px;\" src=\"images/SURG/103041_Path_assess_dabtc_ft_ulcers.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The conceptual diagram illustrates the interaction between the main&nbsp;factors that contribute to tissue loss. This scheme is appropriate for any patient with a chronic wound/tissue loss. The clinician should ask,\"Which factor or combination of factors&nbsp;contributes the most&nbsp;to the pathophysiology of the wound? Ischemia? Infection? Wound extent?\" Early assessment helps determine initial wound management priorities, but frequent reassessment is important since the wound environment is dynamic, and the balance toward one or another factor can change. </div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Armstrong DG, Mills JL. Juggling risk to reduce amputations: The three-ring circus of infection, ischemia and tissue loss-dominant conditions. Wound Medicine 2013; 1:13.</LI>&#xD;&#xA;<LI>Zhan LX, Branco BC, Armstrong DG, et al. The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing. Journal of Vascular Surgery 2015; 61:939.</LI>&#xD;&#xA;<LI>Mills JL Sr, Conte MS, Armstrong DG, et al. The Society for Vascular Surgery Lower Extremity Threatened Limb Classification System: risk stratification based on wound, ischemia, and foot infection (WIfI). Journal of Vascular Surgery 2014; 59:220.</LI></OL></div><div id=\"graphicVersion\">Graphic 103041 Version 2.0</div></div></div>"},"103052":{"type":"graphic_table","displayName":"Proposed NCVC criteria diagnosis of CE","title":"Proposed National Cerebral and Cardiovascular Center criteria for the clinical diagnosis of coronary artery embolism","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Proposed National Cerebral and Cardiovascular Center criteria for the clinical diagnosis of coronary artery embolism</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major criteria</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Angiographic evidence of coronary artery embolism and thrombosis without atherosclerotic components </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Concomitant coronary artery embolization at multiple sites* </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Concomitant systemic embolization without left ventricular thrombus attributable to acute myocardial infarction </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Minor criteria</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&#60;25% stenosis on coronary angiography, except for the culprit lesion </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Evidence of an embolic source based on transthoracic echocardiography, transesophageal echocardiography, computed tomography, or MRI </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Presence of embolic risk factors: Atrial fibrillation, cardiomyopathy, rheumatic valve disease, prosthetic heart valve, patent foramen ovale, atrial septal defect, history of cardiac surgery, infective endocarditis, or hypercoagulable state </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Definite CE</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Two or more major criteria, <strong>or</strong> </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>One major criterion plus &#8805;2 minor criteria, <strong>or</strong> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Three minor criteria </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Probable CE</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>One major criterion plus one minor criterion, <strong>or</strong> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Two minor criteria </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">A diagnosis of CE should not be made if there is:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Pathological evidence of atherosclerotic thrombus </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>History of coronary revascularization </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Coronary artery ectasia </li> </ul> </td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Plaque disruption or erosion detected by intravascular ultrasound or optic coherence tomography in the proximal part of the culprit lesion </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The present proposed diagnostic criteria for CE include three major and three minor criteria. Weighted scoring of the criteria is used to differentiate between definite and probable CE in patients with acute myocardial infarction.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; CE: coronary artery embolism.<br />* Indicates multiple vessels within one coronary artery territory or multiple vessels in the coronary tree.</div><div class=\"graphic_reference\">From: Shibata T, Kawakami S, Noguchi T, et al. Prevalence, clinical features, and prognosis of acute myocardial infarction attributable to coronary artery embolism. Circulation 2015; 132:241. DOI: <a href=\"http://circ.ahajournals.org/content/132/4/241.abstract\" target=\"_blank\">10.1161/CIRCULATIONAHA.114.015134</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103052 Version 1.0</div></div></div>"},"103058":{"type":"graphic_table","displayName":"Heavy slow resistance training for chronic Achilles tendinopathy","title":"Heavy slow resistance training for chronic Achilles tendinopathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Heavy slow resistance training for chronic Achilles tendinopathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">1. Exercise selection</td> </tr> <tr> <td class=\"indent1\">Perform three training sessions per week of the following, bilateral resistance exercises:</td> </tr> <tr> <td class=\"indent2\">a. Heel raise and lower with bended knee in seated calf-raise machine</td> </tr> <tr> <td class=\"indent2\">b. Heel raise and lower with straight knee in leg press machine</td> </tr> <tr> <td class=\"indent2\">c. Heel raise and lower with straight knee, forefoot standing on disc weight or comparably elevated surface and barbell&nbsp;on upper back across superior trapezius muscles</td> </tr> <tr> <td class=\"indent1\"> <p>All exercises performed using full ankle range of motion</p> Allow 3 seconds for each eccentric and each concentric movement (ie, 6 seconds total for each repetition)</td> </tr> <tr> <td class=\"subtitle1_single\">2. Number of exercises</td> </tr> <tr> <td class=\"indent1\">a. Perform three to four sets of the required number of repetitions for each exercise, with 2 to 3 minutes rest between sets and 5 minutes rest between exercises</td> </tr> <tr> <td class=\"subtitle1_single\">3. Exercise progression</td> </tr> <tr> <td class=\"indent1\">a. Decrease repetitions and increase load as tendon strengthens; the load should be challenging</td> </tr> <tr> <td class=\"indent1\">b. Week 1: Three sets per exercise each session, 15 repetition maximum per set<br /> Week 2 to 3: Three sets per exercise each session, 12 repetition maximum<br /> Week 4 to 5: Four sets per exercise each session, 10 repetition maximum<br /> Week 9 to 12: Four sets per exercise each session, 6 repetition maximum</td> </tr> <tr> <td class=\"indent1\">c.&nbsp;Discomfort during exercises is acceptable; however, increased pain after training is completed warrants reverting to a lighter load or progressing more slowly</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Source: Beyer R, Kongsgaard M, Hougs Kj&aelig;r B, et al. Heavy slow resistance versus eccentric training as treatment for Achilles tendinopathy: a randomized controlled trial. Am J Sports Med 2015; 43:1704.</div><div id=\"graphicVersion\">Graphic 103058 Version 1.0</div></div></div>"},"103062":{"type":"graphic_table","displayName":"Guidelines for skeletal survey in children with bruising","title":"Guidelines for performing a skeletal survey in children with bruising","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Guidelines for performing a skeletal survey in children with bruising</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">I. Skeletal survey is <em>necessary</em> in children &#60;24 months old with bruising if any of the following features are present:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>History of confessed abuse </li> <li>History of bruising occurring during domestic violence </li> <li>Additional injuries on physical exam (eg, burns, whip marks) </li> <li>Patterned bruising </li> <li>&#62;4 bruises NOT limited to bony prominences </li> <li>Ear, neck, torso, buttocks, genital region, hands, feet <strong>if</strong> there is no history of trauma </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">II. Skeletal survey is also <em>necessary</em> in children &#60;12 months old with bruising in the following locations:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Cheeks, eye area, ear, neck </li> <li>Upper arms or legs (not over bony prominences) </li> <li>Hands, feet </li> <li>Torso, buttocks, genital region </li> <li>&#62;1 bruise NOT limited to bony prominences </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">III. Skeletal survey is also <em>necessary</em> in children &#60;9 months old with bruising in the following locations:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>&#62;1 bruise in ANY location </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">IV. Skeletal survey is also <em>necessary</em> in children &#60;6 months old with bruising in the following locations:</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Bony prominences (head T-shaped area, frontal scalp, extremity bony prominences) EXCEPT if a single bruise and patient presents with history of fall </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These guidelines apply to children who do <STRONG>not</STRONG> have a verifiable mechanism of accidental trauma (ie, MVC or fall in public place), do <STRONG>not</STRONG> have underlying bleeding disorder such as hemophilia, and who do <STRONG>not</STRONG> have a clear history of birth trauma that accounts for the injury.</div><div class=\"graphic_footnotes\">MVC: motor vehicle collision.</div><div class=\"graphic_reference\">Reproduced with permission from Pediatrics, Vol. 135, Pages e312-e320, Copyright &copy; 2015 by the AAP.</div><div id=\"graphicVersion\">Graphic 103062 Version 3.0</div></div></div>"},"103066":{"type":"graphic_figure","displayName":"BP cuff size in neonate","title":"Determining appropriate blood pressure cuff size in neonates","html":"<div class=\"graphic\"><div style=\"width: 549px\" class=\"figure\"><div class=\"ttl\">Determining appropriate blood pressure cuff size in neonates</div><div class=\"cntnt\"><img style=\"width:529px; height:428px;\" src=\"images/PEDS/103066_BP_cuff_size_in_neonate.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The cuff bladder width should be at least 40 percent of the arm circumference (AC) at a point midway between the olecranon and the acromion, and the bladder length should cover 80 to 100 percent of the circumference of the arm at that point.</div><div id=\"graphicVersion\">Graphic 103066 Version 2.0</div></div></div>"},"103086":{"type":"graphic_algorithm","displayName":"Pulse oximetry screening algorithm","title":"Protocol for newborn pulse oximetry screening for critical congenital heart disease","html":"<div class=\"graphic\"><div style=\"width: 788px\" class=\"figure\"><div class=\"ttl\">Protocol for newborn pulse oximetry screening for critical congenital heart disease</div><div class=\"cntnt\"><img style=\"width:768px; height:502px;\" src=\"images/PEDS/103086_Pulse_oximetry_screen_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Screening is recommended in the right hand (preductal) and either foot (postductal). Screening at both locations can occur simultaneously or in direct sequence.</div><div class=\"graphic_reference\">Adapted from: Kemper AR, Mahle WT, Martin GR, et al. Strategies for implementing screening for critical congenital heart disease. Pediatrics 2011; 128:e1259.</div><div id=\"graphicVersion\">Graphic 103086 Version 3.0</div></div></div>"},"103087":{"type":"graphic_table","displayName":"Critical CHD lesions","title":"Common critical* congenital heart defects and their association with cyanosis and dependence upon the ductus arteriosus","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Common critical* congenital heart defects and their association with cyanosis and dependence upon the ductus arteriosus</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Cyanosis?</td> <td class=\"subtitle1\">Ductal-dependent?</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Left-sided obstructive lesions</td> </tr> <tr> <td class=\"indent1\">Hypoplastic left heart syndrome</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">Valvar AS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Critical AS </li> </ul> </td> <td>Cyanosis or differential cyanosis<sup>&#182;</sup></td> <td>Yes</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Moderate to severe AS </li> </ul> </td> <td>No</td> <td>No</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">COA</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Critical COA </li> </ul> </td> <td>Differential cyanosis<sup>&#182;</sup></td> <td>Yes</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Moderate to severe COA </li> </ul> </td> <td>No</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Interrupted aortic arch</td> <td>Differential cyanosis<sup>&#182;</sup> (pattern of cyanosis varies based upon type)</td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Right-sided obstructive lesions</td> </tr> <tr> <td class=\"indent1\">Tetralogy of Fallot</td> <td>Variable</td> <td>Possibly<sup>&#916;</sup></td> </tr> <tr> <td class=\"indent1\">Tetralogy of Fallot with pulmonary atresia</td> <td>Yes</td> <td>Yes (unless multiple or large aorto-pulmonary collaterals are present)</td> </tr> <tr> <td class=\"indent1\">Pulmonary atresia with intact interventricular septum</td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent1\" colspan=\"3\">PS</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Critical PS </li> </ul> </td> <td>Yes</td> <td>Yes</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Severe PS </li> </ul> </td> <td>No</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Tricuspid atresia</td> <td>Yes</td> <td>Possibly<sup>&#916;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Severe neonatal Ebstein anomaly</td> <td>Yes</td> <td>Possibly<sup>&#9674;</sup></td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Parallel circulations</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Transposition of the great arteries</td> <td>Yes<sup>&#167;</sup></td> <td>Yes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Other</td> </tr> <tr> <td class=\"indent1\">TAPVC</td> <td>Yes</td> <td>No<sup>&#165;</sup></td> </tr> <tr> <td class=\"indent1\">Large VSD</td> <td>No</td> <td>No</td> </tr> <tr> <td class=\"indent1\">AV canal defect</td> <td>No</td> <td>No</td> </tr> <tr> <td class=\"indent1\">Truncus arteriosus</td> <td>Yes</td> <td>No</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CHD: congenital heart disease; AS: aortic stenosis; COA: coarctation of the aorta; PS: pulmonic stenosis; TAPVC: total anomalous pulmonary venous connection; VSD: ventricular septal defect; AV: atrioventricular; RV: right ventricle; PDA: patent ductus arteriosus.<br />* Critical CHD refers to lesions requiring surgery or catheter-based intervention in the first year of life. The most common lesions are listed in this table; however, there are other less common congenital heart lesions that may require intervention within the first year of life.<br />¶ In these lesions, the upper half of the body (preductal) is pink and the lower half (postductal) is cyanotic.<br />Δ Infants with tetralogy of Fallot or tricuspid atresia may have ductal-dependent circulation if there is severe RV outflow tract obstruction (ie, critical pulmonary stenosis or atresia).<br /><FONT class=lozenge>◊</FONT> In cases of severe Ebstein anomaly with extreme cyanosis, a PDA may be necessary to maintain pulmonary blood flow until pulmonary vascular resistance drops.<br />§ Reversed differential cyanosis (ie, oxygen saturation higher in the lower than upper extremity) may occur if there is&nbsp;coexisting coarctation of the aorta or pulmonary artery hypertension.<br />¥ Some patients with obstructed TAPVC may require a PDA to maintain systemic cardiac output. However, a PDA may also increase the degree of cyanosis.</div><div id=\"graphicVersion\">Graphic 103087 Version 3.0</div></div></div>"},"103088":{"type":"graphic_table","displayName":"Risk factors for CHD","title":"Factors associated with an increased risk of congenital heart disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Factors associated with an increased risk of congenital heart disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Estimated risk*</td> <td class=\"subtitle1\">Associated CHD lesions</td> </tr> <tr> <td class=\"subtitle2_left\">Prematurity (gestational age &#60;37 weeks)<sup>[1]</sup></td> <td class=\"divider_bottom\">OR 2.4 (95% CI 2.2-2.7)</td> <td class=\"divider_bottom\">Various</td> </tr> <tr> <td class=\"subtitle2_left\">Multifetal pregnancy<sup>[2]</sup></td> <td class=\"divider_bottom\">OR 4.53 (95% CI 4.28-4.8)</td> <td class=\"divider_bottom\">RVOTO lesions, VSD, ASD</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">In utero infection</td> </tr> <tr> <td class=\"indent1\">Rubella<sup>[3]</sup></td> <td>Cardiac defects occur in 10 to 20% of infants with congenital rubella</td> <td>PDA and peripheral pulmonary artery stenosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Maternal influenza or flu-like illness<sup>[4]</sup></td> <td>OR 2.04 (95% CI 1.27-3.27)</td> <td>RVOTO lesions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Maternal factors<sup>[2]</sup></td> </tr> <tr> <td class=\"indent1\">Preeclampsia<sup> [5]</sup></td> <td>&nbsp;RR 1.57 (95% CI 1.48-1.67)</td> <td>Septal defects</td> </tr> <tr> <td class=\"indent1\">PKU<sup>[6]</sup></td> <td>Cardiac defects occur in 15% of infants with poorly controlled maternal PKU</td> <td>COA and HLHS</td> </tr> <tr> <td class=\"indent1\">Diabetes mellitus</td> <td>OR 4.65 (95% CI 4.13-5.24)</td> <td>Heterotaxy syndrome, conotruncal defects, AVSD, LVOTO and RVOTO lesions</td> </tr> <tr> <td class=\"indent1\">Hypertension</td> <td>OR 1.81 (95% CI 1.61-2.03)</td> <td>RVOTO, VSD, ASD</td> </tr> <tr> <td class=\"indent1\">Obesity</td> <td>OR 1.48 (95% CI 1.32-1.65)</td> <td>Various</td> </tr> <tr> <td class=\"indent1\">Thyroid disorders</td> <td>OR 1.45 (95% CI 1.26-1.67)</td> <td>Various</td> </tr> <tr> <td class=\"indent1\">Systemic connective tissue disorders</td> <td>OR 3.01 (95% CI 2.23-4.06)</td> <td>Heterotaxy syndrome</td> </tr> <tr> <td class=\"indent1\">Epilepsy and mood disorders<sup>&#182;</sup></td> <td>OR 1.41 (95% CI 1.16-1.72)</td> <td>Various</td> </tr> <tr> <td class=\"indent1\">Age &#8805;40 years</td> <td>OR 1.48 (95% CI 1.39-1.58)</td> <td>AVSD</td> </tr> <tr> <td class=\"indent1\">Alcohol or substance use</td> <td>OR 1.88 (95% CI 1.74-2.04)</td> <td>RVOTO, VSD, ASD</td> </tr> <tr> <td class=\"indent1\">First trimester cigarette smoking<sup>[7]</sup></td> <td> <p>OR 1.9 (95% CI 1.04-3.45)</p> <p>OR 1.32 (95% CI 1.06-1.65)</p> OR 1.36 (95% CI 1.04-1.78)</td> <td> <p>Truncus arteriosus</p> <p>RVOTO</p> Secundum ASD</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Maternal medications during pregnancy<sup>[6,8]</sup>:</p> Increased risk of CHD has been reported with: thalidomide, ACE inhibitor, retinoic acid, NSAIDs, phenytoin, and lithium</td> <td>Estimates vary</td> <td> <p>Various</p> <p>NSAIDs are associated with d-TGA, AVSD, VSD, bicuspid aortic valve</p> Lithium has been reported to be associated with Ebstein's anomaly<sup>&#916;</sup></td> </tr> <tr> <td class=\"subtitle2_left\">Assisted reproductive technology (ART)<sup>[9]</sup></td> <td class=\"divider_bottom\">RR 1.64 (95% CI 1.30-2.07)</td> <td class=\"divider_bottom\">Various</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Family history of CHD<sup>[10]</sup></td> </tr> <tr> <td class=\"indent1\">First degree relative with any CHD</td> <td>RR 3.21 (95% CI 2.96-3.49)</td> <td>Various</td> </tr> <tr> <td class=\"indent1\">Second degree relative with any CHD</td> <td>RR 1.78 (95% CI 1.09-2.91)</td> <td>Various</td> </tr> <tr> <td class=\"indent1\">First degree relative with heterotaxy</td> <td>RR 79.1 (95% CI 32.9-190)</td> <td>Heterotaxy</td> </tr> <tr> <td class=\"indent1\">First degree relative with RVOTO</td> <td>RR 48.6 (95% CI 27.5-85.6)</td> <td>RVOTO</td> </tr> <tr> <td class=\"indent1\">First degree relative with AVSD</td> <td>RR 24.3 (95% CI 12.2-48.7)</td> <td>AVSD</td> </tr> <tr> <td class=\"indent1\">First degree relative with LVOTO</td> <td>RR 12.9 (95% CI 7.48-22.2)</td> <td>LVOTO</td> </tr> <tr> <td class=\"indent1\">First degree relative with conotruncal defect</td> <td>RR 11.7 (95% CI 8.01-17)</td> <td>Conotruncal defect</td> </tr> <tr> <td class=\"indent1\">First degree relative with isolated ASD</td> <td>RR 7.07 (95% CI 4.51-11.1)</td> <td>ASD</td> </tr> <tr> <td class=\"indent1\">First degree relative with isolated VSD</td> <td>RR 3.41 (95% CI 2.2-5.29)</td> <td>VSD</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OR: odds ratio; RR: relative risk; CHD: congenital heart disease; RVOTO: right ventricular outflow tract obstruction; VSD: ventricular septal defect; ASD: atrial septal defect; PDA: patent ductus arteriosus; AVSD: atrioventricular septal defect; LVOTO: left ventricular outflow tract obstruction; NSAID: nonsteroidal antiinflammatory drug; ACE: angiotensin converting enzyme; COA: coarctation of the aorta; HLHS: hypoplastic left heart syndrome; PKU: phenylketonuria; d-TGA: dextro-transposition of the great arteries.<br />* Baseline risk of CHD is approximately 1 percent.<br />¶ The association of CHD with mood disorders is most likely reflective of the medications used in the treatment of these disorders.<br />Δ The association of lithium with Ebstein's anomaly is controversial; however, screening for CHD is generally recommended for infants exposed to lithium during the first or second trimester of pregnancy. Refer to the UpToDate topics on teratogenic and postnatal risks of lithium and prenatal screening for fetal cardiac abnormalities for more details.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Tanner K, Sabrine N, Wren C. Cardiovascular malformations among preterm infants. Pediatrics 2005; 116:e833.</LI>&#xD;&#xA;<LI>Liu S, Joseph KS, Lisonkova S, et al. Association between maternal chronic conditions and congenital heart defects: a population-based cohort study. Circulation 2013; 128:583.</LI>&#xD;&#xA;<LI>Reef SE, Plotkin S, Cordero JF, et al. Preparing for elimination of congenital Rubella syndrome (CRS): summary of a workshop on CRS elimination in the United States. Clin Infect Dis 2000; 31:85.</LI>&#xD;&#xA;<LI>Oster ME, Riehle-Colarusso T, Alverson CJ, Correa A. Associations between maternal fever and influenza and congenital heart defects. J Pediatr 2011; 158:990.</LI>&#xD;&#xA;<LI>Auger N, Fraset WD, Healy-Profitos J, Abour L. Association Between Preeclampsia and Congenital Heart Defects. JAMA 2015; 314:1588.</LI>&#xD;&#xA;<LI>Jenkins KJ, Correa A, Feinstein JA, et al. Noninherited risk factors and congenital cardiovascular defects: current knowledge: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young: endorsed by the American Academy of Pediatrics. Circulation 2007; 115:2995.</LI>&#xD;&#xA;<LI>Alverson CJ, Strickland MJ, Gilboa SM, Correa A. Maternal smoking and congenital heart defects in the Baltimore-Washington Infant Study. Pediatrics 2011; 127:e647.</LI>&#xD;&#xA;<LI>Diav-Citrin O, Shechtman S, Tahover E, et al. Pregnancy outcome following in utero exposure to lithium: a prospective, comparative, observational study. Am J Psychiatry 2014; 171:785.</LI>&#xD;&#xA;<LI>Wen J, Jiang J, Ding C, et al. Birth defects in children conceived by in vitro fertilization and intracytoplasmic sperm injection: a meta-analysis. Fertil Steril 2012; 97:1331.</LI>&#xD;&#xA;<LI>Øyen N, Poulsen G, Boyd HA, et al. Recurrence of congenital heart defects in families. Circulation 2009; 120:295.</LI></OL></div><div id=\"graphicVersion\">Graphic 103088 Version 2.0</div></div></div>"},"103089":{"type":"graphic_figure","displayName":"Physiologic dead space","title":"Physiologic dead space","html":"<div class=\"graphic\"><div style=\"width: 567px\" class=\"figure\"><div class=\"ttl\">Physiologic dead space</div><div class=\"cntnt\"><img style=\"width:547px; height:628px;\" src=\"images/PULM/103089_Physiologic_dead_space.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The figure depicts dead space. The volume of gas in the airways only (ie, gas&nbsp;proximal to the respiratory bronchiole including mouth, nose, and ventilator tubing) represents anatomic dead space (no gas exchange is possible). Alveolus&nbsp;1&nbsp;(eg, alveoli in apices) is not receiving any blood flow because the normal pulmonary artery pressure is not sufficiently high to pump blood to the apices. The two lower alveoli receive blood flow, but&nbsp;blood flow&nbsp;to one of them is blocked (alveolus 3). Thus, only one alveolus is receiving ventilation and perfusion (alveolus 2); alveolus 1 and 2 are being ventilated but not perfused (ie, alveolar dead space). The physiological dead space is the combination of anatomic and alveolar dead space.</div><div id=\"graphicVersion\">Graphic 103089 Version 1.0</div></div></div>"},"103091":{"type":"graphic_table","displayName":"Etiologies and mechanism of hypercapnia","title":"Etiologies and mechanism of hypercapnia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Etiologies and mechanism of hypercapnia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Respiratory pathway affecting carbon dioxide elimination</td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>Central nervous system</p> <p>&#8595;</p> </td> <td style=\"vertical-align: middle;\" colspan=\"2\"><strong>\"Won't breathe\"</strong></td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>Peripheral nervous system</p> <p>&#8595;</p> </td> <td style=\"vertical-align: middle;\" rowspan=\"4\" colspan=\"2\"><strong>\"Can't breathe\"</strong></td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>Respiratory muscles</p> <p>&#8595;</p> </td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>Chest wall and pleura</p> <p>&#8595;</p> </td> </tr> <tr> <td class=\"centered\" colspan=\"2\"> <p>Upper airway</p> <p>&#8595;</p> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"centered\" colspan=\"2\"> <p>Lungs</p> </td> <td colspan=\"2\"><strong>Abnormal gas exchange: \"Can't breathe enough\"</strong></td> </tr> <tr class=\"divider_bottom\"> <td colspan=\"4\">Schematic figure representing the respiratory pathway, along which a variety of diseases can affect carbon dioxide elimination and result in hypercapnia. Note that gas exchange abnormalities alone are relatively uncommon causes of hypercapnia, but gas exchange problems in the setting of reduced mechanical capability of the ventilatory pump are very common explanations for acute and chronic hypercapnia.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"sublist1 highlight_green_text\" colspan=\"4\">&nbsp;</td> </tr> <tr> <td class=\"subtitle1_left\" colspan=\"4\">Mechanism and etiologies of hypercapnia</td> </tr> <tr> <td class=\"subtitle2_left\">Mechanism</td> <td class=\"subtitle2_left\" colspan=\"3\">Etiologies</td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Decreased minute ventilation (global hypoventilation; extra pulmonary causes)</td> </tr> <tr> <td class=\"indent2\">Decreased central respiratory drive</td> <td colspan=\"3\"> <ul> <li>Sedative overdose (eg, narcotic or benzodiazepine, some anesthetics, tricyclic antidepressants) </li> <li>Encephalitis </li> <li>Stroke </li> <li>Central and obstructive sleep apnea </li> <li>Obesity hypoventilation </li> <li>Congenital central alveolar hypoventilation </li> <li>Brainstem disease </li> <li>Metabolic alkalosis </li> <li>Hypothyroidism* </li> <li>Hypothermia </li> <li>Starvation </li> </ul> </td> </tr> <tr> <td class=\"indent2 divider_bottom\" rowspan=\"2\">Decreased respiratory neuromuscular or thoracic cage function</td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Primary spinal cord/lower motor neuron/muscle disorders</strong> <ul class=\"decimal_heading\"> <li>Cervical spine injury or disease (eg, trauma syringomyelia)<sup>&#182;</sup> </li> <li>Amyotrophic lateral sclerosis </li> <li>Poliomyelitis </li> <li>Guillain-Barr&#233; syndrome </li> <li>Phrenic nerve injury </li> <li>Critical illness polymyoneuropathy </li> <li>Myasthenia gravis </li> <li>Muscular dystrophy </li> <li>Polymyositis </li> <li>Tetanus </li> <li>Transverse myelitis (eg, multiple sclerosis) </li> <li>Tick paralysis </li> <li>Acute intermittent porphyria </li> <li>Eaton Lambert syndrome </li> <li>Neuralgic amyotrophy </li> <li>Periodic paralysis </li> <li>Glycogen storage and mitochondrial diseases </li> </ul> </td> <td class=\"divider_bottom\" rowspan=\"2\"><strong>Thoracic cage disorders</strong> <ul class=\"decimal_heading\"> <li>Kyphoscoliosis </li> <li>Thoracoplasty </li> <li>Flail Chest </li> <li>Ankylosing spondylitis </li> <li>Pectus excavatum </li> <li>Fibrothorax </li> </ul> </td> <td><strong>Metabolic disorders<sup>&#916;</sup></strong> <ul class=\"decimal_heading\"> <li>Hypophosphatemia </li> <li>Hypomagnesemia </li> <li>Hypothyroidism </li> <li>Hyperthyroidism </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Toxins, poisoning, drugs</strong> <ul class=\"decimal_heading\"> <li>Tetanus </li> <li>Dinoflagellate poisoning </li> <li>Shellfish poisoning (red tide) </li> <li>Ciguatera poisoning </li> <li>Botulism </li> <li>Organophosphates </li> <li>Succinylcholine and neuromuscular blockade </li> <li>Procainamide </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Increased dead space (gas exchange abnormalities; pulmonary parenchymal causes or airway disorders)</td> </tr> <tr> <td class=\"indent2\">Anatomic</td> <td colspan=\"3\">Short shallow breathing</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Physiologic</td> <td colspan=\"3\"> <ul> <li>Pulmonary embolism (usually severe) </li> <li>Pulmonary vascular disease (usually severe) </li> <li>Dynamic hyperinflation (eg, upper and lower airway disorders including chronic obstructive pulmonary disease, severe asthma) </li> <li>Endstage interstitial lung disease </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Increased carbon dioxide production</td> </tr> <tr class=\"divider_bottom\"> <td>&nbsp;</td> <td colspan=\"3\"> <ul> <li>Fever </li> <li>Thyrotoxicosis </li> <li>Increased catabolism (sepsis, steroids) </li> <li>Overfeeding </li> <li>Metabolic acidosis </li> <li>Exercise </li> </ul> </td> </tr> <tr> <td class=\"subtitle3_left\" colspan=\"4\">Multifactorial</td> </tr> <tr> <td>&nbsp;</td> <td colspan=\"3\"><strong>Upper airway disorders<sup>&#9674;</sup></strong> <ul class=\"decimal_heading\"> <li>Severe laryngeal or tracheal disorders (stenosis/tumors/angioedema/tracheomalacia) </li> <li>Vocal cord paralysis </li> <li>Epiglottitis </li> <li>Foreign body aspiration </li> <li>Retropharyngeal disorders </li> <li>Obstructive goiter </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Decreased mechanical ventilation can also cause hypercapnic respiratory acidosis (eg, permissive hypercapnia). Importantly, any factor that limits the mechanical function of the ventilatory pump (such as airway obstruction or weak muscles), when combined with a gas exchange abnormality (increased physiological dead space), may lead to hypercapnia. For further details regarding the mechanisms that underlie these pathologies, please refer to the UpToDate topic on mechanisms, causes, and effects of hypercapnia.</div><div class=\"graphic_footnotes\">* Hyperthyroidism is also a rare cause of respiratory muscle weakness.<br />&para; Injury or disease process needs to be between cervical spine level 3 and 5 (C3 to 5) for clinically significant diaphragmatic paresis/paralysis to occur.<br />&Delta; Hypermagnesemia, hypokalemia, and hypercalcemia can also cause respiratory muscle weakness and contribute to hypercapnia.<br /><span class=\"lozenge\">&loz;</span> Upper airway disorders are rare causes of hypercapnia. They either diminish total ventilation or lead to dynamic hyperinflation and reduced tidal volume, while simultaneously causing increased work of breathing and carbon dioxide production.</div><div id=\"graphicVersion\">Graphic 103091 Version 2.0</div></div></div>"},"103093":{"type":"graphic_algorithm","displayName":"Respiratory pathway affecting carbon dioxide elimination","title":"Respiratory pathway affecting carbon dioxide elimination","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory pathway affecting carbon dioxide elimination</div><div class=\"cntnt\"><img style=\"width:350px; height:288px;\" src=\"images/PULM/103093_Respr_pth_affc_crbn_dxd_elm.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic figure representing the respiratory pathway, along which a variety of diseases can affect carbon dioxide elimination and result in hypercapnia. Note that gas exchange abnormalities alone are relatively uncommon causes of hypercapnia, but gas exchange problems in the setting of reduced mechanical capability of the ventilatory pump are very common explanations for acute and chronic hypercapnia.</div><div id=\"graphicVersion\">Graphic 103093 Version 1.0</div></div></div>"},"103094":{"type":"graphic_table","displayName":"Classification of abnormal sleep-related movements","title":"Classification of abnormal sleep-related movements","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Classification of abnormal sleep-related movements</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Simple movements</td> </tr> <tr> <td class=\"indent1\">Involving quick jerks of limbs or body</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hypnic jerks </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Propriospinal myoclonus </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Benign myoclonus of infancy </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Epileptic myoclonus </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Isolated or nonperiodic limb movements </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Involving muscles of mastication</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Bruxism </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Facial myoclonus </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Palatal myoclonus </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Prolonged contractions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Leg cramps </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Periodic movements</td> </tr> <tr> <td class=\"indent1\">Of the limbs</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Periodic limb movements </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Rhythmical movements</td> </tr> <tr> <td class=\"indent1\">Of the limbs</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Hypnic foot tremor </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Alternating leg muscle activation </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Of the body or head</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Rhythmical movement disorder of sleep (body rocking, juxta capita) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Vocalizations</td> </tr> <tr> <td class=\"indent1\">Monotonous (groaning)</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Catathrenia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Utterances of talking</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Without other movements </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>Sleeptalking &ndash; normal variant </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>With movements (see \"Complex movements and behaviors\" below) </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Complex movements and behaviors: Nonstereotyped</td> </tr> <tr> <td class=\"indent1\">NREM sleep-related parasomnias</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Disorders of arousal (from NREM sleep) </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>Confusional arousals </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>Sleepwalking </li> </ul> </td> </tr> <tr> <td class=\"indent3\"> <ul style=\"list-style-type: disc;\"> <li>Sleep terrors </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sleep-related eating disorder </li> </ul> </td> </tr> <tr> <td class=\"indent1\">REM-related parasomnias</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>REM sleep behavior disorder </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Recurrent isolated sleep paralysis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Nightmare disorder </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Other parasomnias</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Exploding head syndrome (sensory) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Sleep-related hallucinations (sensory) </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li class=\"indent2\">Sleep enuresis </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Parasomnia due to a medical disorder</li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Parasomnia due to a medication or substance</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Psychogenic events originating in sleep</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Panic attacks </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Dissociative events </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Complex movements: Stereotyped</td> </tr> <tr> <td class=\"indent1\">Epileptic seizures</td> </tr> <tr> <td class=\"indent1\">Psychogenic events (sometimes)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NREM: non-rapid eye movement; REM: rapid eye movement.</div><div id=\"graphicVersion\">Graphic 103094 Version 1.0</div></div></div>"},"103095":{"type":"graphic_figure","displayName":"CD8+ naïve T cell","title":"Simplified immune synapse in a naïve (CD4 or) CD8 T cell and for an activated CD8+ T cell","html":"<div class=\"graphic\"><div style=\"width: 822px\" class=\"figure\"><div class=\"ttl\">Simplified immune synapse in a na&iuml;ve (CD4 or) CD8 T cell and for an activated CD8+ T cell</div><div class=\"cntnt\"><img style=\"width:802px; height:580px;\" src=\"images/ONC/103095_CD8_naive_T_cell.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Initially, CD8a/b chains recognize the MHC class 1 of a peptide presented by an antigen presented cell, and CD28 binds to CD80/86 to lead to downstream activation (bottom), which releases IL-12, IFN-gamma, and meanwhile leads to feedback production of CTLA-4 in cytoplasm, which is rapidly brought to the surface (red). Additional costimulatory receptors (not pictured) on activated T cell/APC synapses include OX40/OX40-ligand, CD40-L/CD40, glucocorticoid-induced tumor necrosis factor (GITR)/GITR-L.</div><div class=\"graphic_footnotes\">IL: interleukin; IFNg: interferon gamma; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; CD: cluster of differentiation; APC: antigen-presenting cells; MHC: major histocompatibility complex.</div><div id=\"graphicVersion\">Graphic 103095 Version 1.0</div></div></div>"},"103096":{"type":"graphic_table","displayName":"Indications for video PSG in patients with nocturnal events","title":"Indications for video polysomnography in patients with nocturnal events","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Indications for video polysomnography in patients with nocturnal events</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td> <ul> <li>Atypical presentation for a parasomnia (time of night, behavioral description) </li> </ul> </td> </tr> <tr> <td> <ul> <li>Events are injurious or have significant potential for injury or significant disturbance to patient's home life </li> </ul> </td> </tr> <tr> <td> <ul> <li>Unusual age of onset </li> </ul> </td> </tr> <tr> <td> <ul> <li>Unusual frequency of the events </li> </ul> </td> </tr> <tr> <td> <ul> <li>Patient has excessive daytime sleepiness or complaints of insomnia </li> </ul> </td> </tr> <tr> <td> <ul> <li>Complaints suggestive of sleep apnea, periodic limb movements, or other sleep disorders </li> </ul> </td> </tr> <tr> <td> <ul> <li>Events are stereotyped or repetitive </li> </ul> </td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 103096 Version 1.0</div></div></div>"},"103097":{"type":"graphic_figure","displayName":"Prevalence of asymptomatic carotid artery stenosis","title":"Prevalence of asymptomatic carotid artery stenosis in the general population","html":"<div class=\"graphic\"><div style=\"width: 611px\" class=\"figure\"><div class=\"ttl\">Prevalence of asymptomatic carotid artery stenosis in the general population</div><div class=\"cntnt\"><img style=\"width:591px; height:648px;\" src=\"images/NEURO/103097_Prvlnc_asmptm_crtd_artr_stns.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age- and sex-specific prevalence estimates of moderate (A) and severe (B)&nbsp;asymptomatic carotid artery stenosis in men and women.</div><div class=\"graphic_reference\">From: de Weerd M, Greving JP, Hedblad B, et al. Prevalence of asymptomatic carotid artery stenosis in the general population: an individual participant data meta-analysis. Stroke 2010; 41:1294. DOI: <a href=\"http://stroke.ahajournals.org/content/41/6/1294.abstract\" spellcheck=\"true\" target=\"_blank\">10.1161/STROKEAHA.110.581058</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2010 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103097 Version 2.0</div></div></div>"},"103125":{"type":"graphic_picture","displayName":"Thermal burns of tongue","title":"Thermal burns of tongue","html":"<div class=\"graphic\"><div style=\"width: 542px\" class=\"figure\"><div class=\"ttl\">Thermal burns of tongue</div><div class=\"cntnt\"><img style=\"width:522px; height:691px;\" src=\"images/EM/103125_Oralburns.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Oral burn due to exploded lithium ion battery from flashlight held in mouth. Laceration of base of tongue (arrow). Pale areas of full thickness mucosal burn on anterior surface of tongue (arrowheads). All areas subsequently healed without surgical intervention.</div><div class=\"graphic_reference\">Courtesy of Arek Wiktor, MD, FACS.</div><div id=\"graphicVersion\">Graphic 103125 Version 3.0</div></div></div>"},"103136":{"type":"graphic_picture","displayName":"Comparison of endotracheal tube tips","title":"Comparison of endotracheal tube tips","html":"<div class=\"graphic\"><div style=\"width: 479px\" class=\"figure\"><div class=\"ttl\">Comparison of endotracheal tube tips</div><div class=\"cntnt\"><img style=\"width:459px; height:320px;\" src=\"images/ANEST/103136_Comparison_of_endotracheal_tube_tips.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The tip of the ETT can affect the ability to pass the ETT through the vocal cords. The tapered tip on the ETT designed for use with the intubating laryngeal mask airway (A) and the bull nose tip on the Parker Flex-Tip ETT (B) are both designed to facilitate passage of the ETT through the vocal cords, compared with the beveled tip&nbsp;of a standard ETT (C).&nbsp;The tip of the standard ETT tends to catch on&nbsp;one of the&nbsp;vocal cords, while the other&nbsp;two do not. </div><div class=\"graphic_footnotes\">ETT: endotracheal tube.</div><div id=\"graphicVersion\">Graphic 103136 Version 4.0</div></div></div>"},"103137":{"type":"graphic_table","displayName":"Management of PHG","title":"Management of portal hypertensive gastropathy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Management of portal hypertensive gastropathy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"15%\"></colgroup><colgroup width=\"32%\"></colgroup><colgroup width=\"15%\"></colgroup><colgroup width=\"32%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical scenario</td> <td class=\"subtitle1\">Medications to decrease portal hypertension</td> <td class=\"subtitle1\">Management of anemia/blood loss</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Primary prophylaxis</td> <td>Nonselective beta blocker* titrated to HR of 50 to 55 BPM or highest tolerated dose, eg: <ul class=\"decimal_heading\"> <li>Propranolol 20 mg orally twice daily (maximum 160 mg twice daily) <strong>or</strong> </li> <li>Nadolol 40 mg orally once&nbsp;daily (maximum 160 mg daily) </li> </ul> <p>Carvedilol starting at 3.25 mg orally twice daily (maximum 25 mg twice daily) is an alternative to nonselective beta blockers</p> </td> <td>N/A</td> <td>Data supporting primary prophylaxis are lacking. We provide prophylaxis for the following patients: <ul class=\"divider_bottom\"> <li>Patients with severe portal hypertensive gastropathy and other risk factors for bleeding (eg, a coagulopathy or thrombocytopenia) </li> <li>Patients with portal hypertensive gastropathy and varices </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Chronic bleeding</td> <td>Nonselective beta blocker* titrated to HR of 50 to 55 BPM or highest tolerated dose, eg: <ul class=\"decimal_heading\"> <li>Propranolol 20 mg orally twice daily (maximum 160 mg twice daily) <strong>or</strong> </li> <li>Nadolol 40 mg orally once daily (maximum 160 mg daily) </li> </ul> <p>Carvedilol starting at 3.25 mg orally twice daily (maximum 25 mg twice daily) is an alternative to nonselective beta blockers</p> </td> <td> <p>Iron repletion<sup>&#182;</sup></p> Blood transfusion if hemoglobin &#60;7 to 8 g/dL<sup>&#916;</sup></td> <td>The nonselective beta blocker should be continued indefinitely</td> </tr> <tr class=\"divider_bottom\"> <td>Acute bleeding</td> <td>Vasoactive medication, eg: <ul class=\"decimal_heading\"> <li>Octreotide 100 mcg IV&nbsp;bolus followed by an infusion of 25 mcg/hour for 48 hours <strong>or</strong> </li> <li>Somatostatin<sup>&#9674;</sup> 250 mcg IV&nbsp;bolus followed by an infusion of 250 mcg/hour for three days <strong>or</strong> </li> <li>Terlipressin<sup>&#9674;</sup> 0.2 mg IV every four hours for two days or 1 mg IV every four hours for five days </li> </ul> </td> <td>Resuscitation with IV fluids and blood transfusion to maintain hemoglobin between 7 and 8 g/dL in patients with cirrhosis, or &#8805;8 g/dL in patients without cirrhosis</td> <td>Patients with cirrhosis should also receive antibiotic prophylaxis for&nbsp;SBP for&nbsp;seven days<sup>&#167;</sup>, eg: <ul class=\"decimal_heading\"> <li>Ceftriaxone 1 gram IV daily </li> <li>Ciprofloxacin 500 mg orally twice daily <strong>or</strong> </li> <li>Ciprofloxacin 400 mg IV twice daily <strong>or</strong> </li> <li>Trimethoprim-sulfamethoxazole 1&nbsp;DS tablet&nbsp;orally twice daily<strong> or</strong>&nbsp; </li> <li>Norfloxacin<sup>&#9674;</sup> 400 mg orally twice daily </li> </ul> Once the acute bleeding episode is resolved, patients should be started on secondary prophylaxis with a nonselective beta blocker</td> </tr> <tr class=\"divider_bottom\"> <td>Refractory bleeding (chronic or acute)</td> <td>Shunt therapy: <ul class=\"decimal_heading\"> <li>TIPS </li> <li>Surgical shunt </li> </ul> <p>Liver transplantation</p> Endoscopic treatment/APC if a focal lesion is present</td> <td>As above</td> <td>Patients with chronic bleeding who respond appropriately to iron repletion or transfusion may be managed expectantly</td> </tr> <tr> <td>Secondary prophylaxis</td> <td>Nonselective beta blocker* titrated to HR of 50 to 55 BPM or highest tolerated dose, eg: <ul class=\"decimal_heading\"> <li>Propranolol 20 mg orally twice daily (maximum 160 mg twice daily) <strong>or</strong> </li> <li>Nadolol 40 mg orally daily (maximum 160 mg daily) </li> </ul> <p>Carvedilol starting at 3.25 mg orally twice daily (maximum 25 mg twice daily) is an alternative to nonselective beta blockers</p> </td> <td>N/A</td> <td>The nonselective beta blocker should be continued indefinitely</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HR: heart rate; BPM: beats per minute; N/A: not applicable;&nbsp;IV: intravenous; SBP: spontaneous bacterial peritonitis; DS: double strength (ie, trimethoprim 160 mg and sulfamethoxazole 800 mg per tablet); TIPS: transjugular intrahepatic portosystemic shunt; APC: argon plasma coagulation.<br />Antibiotic doses shown are for use in patients with normal renal function. Some agents require dose adjustment in patients with renal impairment.<br />* Provided there are no contraindications to beta blocker therapy. Patients who cannot take or do not tolerate nonselective beta blockers or carvedilol are treated like those with refractory bleeding.<br />¶ Refer to UpToDate topics on treatment of iron deficiency for details on methods for iron repletion.<br />Δ The decision to transfuse blood is complicated and depends on multiple different variables, including the presence of underlying unstable cardiac disease, the acuity and volume of bleeding, the presence of cirrhosis, and other variables.&nbsp;In those with cirrhosis, the target hemoglobin is typically 7 to 8 g/dL.&nbsp;Refer to UpToDate topics on the management of upper gastrointestinal bleeding for details.<br />◊ Not available in United States.<br />§ Refer to UpToDate topics on the management of variceal hemorrhage for detailed discussions of antibiotic selection and administration.</div><div class=\"graphic_reference\">References: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Urrunaga NH, Rockey DC. Portal hypertensive gastropathy and colopathy. Clin Liver Dis 2014; 18:389.</LI>&#xD;&#xA;<LI>Runyon B. Management of adult patients with ascites due to cirrhosis: Update 2012. Available at: <A href=\"http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf\">http://aasld.org/sites/default/files/guideline_documents/adultascitesenhanced.pdf</A> </LI></OL></div><div id=\"graphicVersion\">Graphic 103137 Version 2.0</div></div></div>"},"103140":{"type":"graphic_diagnosticimage","displayName":"Neuroimaging of LCH lesions","title":"Neuroimaging of Langerhans cell histiocytosis lesions","html":"<div class=\"graphic\"><div style=\"width: 653px\" class=\"figure\"><div class=\"ttl\">Neuroimaging of&nbsp;Langerhans cell histiocytosis lesions</div><div class=\"cntnt\"><img style=\"width:633px; height:851px;\" src=\"images/HEME/103140_Neuroimag_LCH_lesions.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These examples demonstrate typical manifestations of LCH CNS and spinal cord lesions.<br />(A) Brain MRI demonstrates T2-hyperintensity in cerebellum classic for LCH neurodegenerative syndrome. In this case, the patient had radiologic and clinical response to treatment with cytarabine.<br />(B) Spinal MRI demonstrates significant spinal cord lesions. This is a somewhat atypical case of a 13-year-old girl who had marginal response to cytarabine, then clofarabine. <em>BRAF-V600E</em> was detected in cells from the CSF, and the patient ultimately had radiologic and clinical response to vemurafenib.<br />(C) Brain MRI demonstrates a pituitary mass classic for LCH, though differential diagnosis also includes germinoma, lymphoma, and pituitary hypophysitis. In this case, the lesion was biopsy proven to be LCH, and the patient responded to cytarabine therapy.</div><div class=\"graphic_footnotes\">LCH: Langerhans cell histiocytosis; CNS: central nervous system; MRI: magnetic resonance imaging; CSF: cerebrospinal fluid.</div><div class=\"graphic_reference\">This research was originally published in Blood. Allen CE, Ladisch S, McClain KL. How I treat Langerhans cell histiocytosis. Blood 2015; 126:26. Copyright &copy; 2015 American Society of Hematology.</div><div id=\"graphicVersion\">Graphic 103140 Version 1.0</div></div></div>"},"103142":{"type":"graphic_table","displayName":"US botulism outbreaks","title":"Outbreaks of botulism with more than 10 cases — United States, 1973 to 2015","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Outbreaks of botulism with more than 10 cases &mdash; United States, 1973 to 2015</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"12%\"></colgroup><colgroup width=\"25%\"></colgroup><colgroup span=\"2\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Year</td> <td class=\"subtitle1\">State</td> <td class=\"subtitle1\">Number of cases</td> <td class=\"subtitle1\">Number of deaths</td> <td class=\"subtitle1\">Implicated food</td> <td class=\"subtitle1\">Home-canned ingredient</td> <td class=\"subtitle1\">Setting</td> </tr> <tr> <td>1977</td> <td>Michigan</td> <td>58</td> <td>0</td> <td>Peppers</td> <td>Yes</td> <td>Restaurant</td> </tr> <tr> <td>1978</td> <td>New Mexico</td> <td>34</td> <td>1</td> <td>Bean and potato salad</td> <td>Unknown</td> <td>Country club</td> </tr> <tr> <td>1983</td> <td>Illinois</td> <td>28</td> <td>0</td> <td>Fried onions</td> <td>No</td> <td>Restaurant</td> </tr> <tr> <td>1994</td> <td>Texas</td> <td>23</td> <td>0</td> <td>Baked potatoes used in skordalia eggplant dip</td> <td>No</td> <td>Restaurant</td> </tr> <tr> <td>2001</td> <td>Texas</td> <td>16</td> <td>0</td> <td>Frozen, canned chili</td> <td>No</td> <td>Church</td> </tr> <tr> <td>2015</td> <td>Ohio</td> <td>29</td> <td>1</td> <td>Potato salad prepared with home-canned potatoes</td> <td>Yes</td> <td>Church</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Centers for Disease Control and Prevention. Foodborne Disease Outbreak Surveillance System, unpublished data.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: McCarty CL, Angelo K, Beer KD, et al. Notes from the field: Large outbreak of botulism associated with a church potluck meal - Ohio, 2015. MMWR Morb Mortal Wkly Rep 2015; 64:802.</div><div id=\"graphicVersion\">Graphic 103142 Version 1.0</div></div></div>"},"103146":{"type":"graphic_table","displayName":"Medications for treatment of symptomatic hemorrhoids in adults","title":"Medications for treatment of symptomatic hemorrhoids in adults*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Medications for treatment of symptomatic hemorrhoids in adults*</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Drug</td> <td class=\"subtitle1\">Dose</td> <td class=\"subtitle1\">Role and precautions</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Anesthetics, local</td> </tr> <tr> <td class=\"indent1\">Benzocaine 5 to 20% rectal ointment (eg, Americaine)</td> <td>Sparingly up to&nbsp;six times per day</td> <td class=\"divider_bottom\" rowspan=\"3\"> <ul> <li>Temporary relief of acute pain and pruritus. </li> <li>Intended for short-term, intermittent use. </li> <li>Local burning is common. </li> <li>Systemic absorption is variable. </li> <li>Rare methemoglobinemia described with use of benzocaine, particularly if excessive. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Dibucaine 1% rectal ointment (eg, Nupercainal)</td> <td>As needed (no more than 30 grams of 1% ointment per day)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Pramoxine 1% rectal foam, ointment, wipes (eg, Proctofoam, Pramox)</td> <td>As needed up to&nbsp;five times daily</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Astringent and protectants, topical</td> </tr> <tr> <td class=\"indent1\">Witch hazel (eg, Tucks, Preparation H pads)</td> <td>As needed up to&nbsp;six times per day or after each bowel movement</td> <td class=\"divider_bottom\" rowspan=\"2\"> <ul> <li>May dry secretions and tighten tissues. </li> <li>Well tolerated; rare allergy. </li> <li>Zinc oxide has protectant, astringent, and antiseptic properties. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Zinc oxide topical paste (eg, Boudreaux's Butt Paste, Desitin)</td> <td>As needed</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Bulk-forming laxatives, oral*</td> </tr> <tr> <td class=\"indent1\">Methylcellulose (eg, Citrucel)</td> <td>Initially 1 tablespoon (&#8773;2 grams fiber) or 4 caplets (500 mg fiber per caplet) once per day; may increase to 1 tablespoon or 4 caplets three times per day</td> <td class=\"divider_bottom\" rowspan=\"4\"> <ul> <li>Reduces bleeding and possibly symptoms in nonprolapsing hemorrhoids; gradual onset of effect over&nbsp;six weeks or more. </li> <li>Useful in patients with inadequate dietary fiber intake who may be at risk for constipation or diarrhea. </li> <li>Adequate oral fluid intake required. </li> <li>Gradually increase dose as needed to minimize gas and bloating. </li> <li>Administer with 180 to 360 mL (6 to 12 ounces) water or fruit juice. </li> <li>Do not administer within one hour of other medications. </li> <li>Avoid in patients with or at risk for stricture. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Polycarbophil (eg, FiberCon, Konsyl)</td> <td>Initially 1 to 2 tablets (500 mg fiber per tablet) per day; may increase to 2 to 4 tabs per day</td> </tr> <tr> <td class=\"indent1\">Psyllium (eg, Metamucil)</td> <td>Initially 1 tablespoon (&#8773;3.5 grams fiber) once per day; may increase to 1 tablespoon three times per day</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Wheat dextrin (eg, Benefiber)</td> <td>Initially 1 caplet (1 gram fiber) or 1 teaspoonsful (1.5 gram fiber) per day; may increase to 1 to 3 caplets or 2 teaspoonsful&nbsp;three times per day</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Corticosteroids, topical</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hydrocortisone rectal creams 1 to 2.5% (eg, Anusol-HC, Preparation H, Proctosol); Hydrocortisone rectal suppository 25 to 30 mg (eg, Anusol-HC)</td> <td> <p>Rectal cream: Apply sparingly up to&nbsp;two times daily</p> Suppository: 1 suppository twice daily</td> <td> <ul> <li>Provides local antiinflammatory and analgesic effect. </li> <li>For intermittent short-term use (ie, no more than&nbsp;seven days) due to risk of mucosal thinning; refer to text.</li> <li>Avoid in persons with local infection. </li> <li>Variable systemic absorption; caution in pregnancy. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Stool softeners, oral</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Docusate sodium</td> <td>100 to 200 mg orally&nbsp;two times per day</td> <td> <ul> <li>Decreases straining. </li> <li>Well tolerated. Use lower dose if administered with another laxative. Contact dermatitis reported. </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Vasoactive agents, topical</td> </tr> <tr> <td class=\"indent1\">Nitroglycerin (glyceryl trinitrate) 0.2 to 0.5% ointment<sup>&#182;</sup></td> <td>Pea-sized amount applied twice per day</td> <td> <ul> <li>Potential option for managing pain associated with anal sphincter spasm or thrombosed external hemorrhoids. </li> <li>Systemic adverse effects (eg, headache) are common. </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Phenylephrine 0.25% (Preparation-H, Rectacaine)</td> <td> <p>Ointment: Apply up to&nbsp;four times per day</p> Suppository: 1 suppository per rectum up to&nbsp;four times per day</td> <td> <ul> <li>Frequent choice for temporary relief of acute symptoms (ie, bleeding or pain on defecation). </li> <li>Well tolerated; rare systemic effects. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><UL>&#xD;&#xA;<LI>Medical therapy for internal hemorrhoids may be useful for controlling symptoms in lower-grade disease and acute bleeding in higher-grade hemorrhoids pending definitive therapy (eg, banding, sclerotherapy, cryotherapy, or surgery).</LI>&#xD;&#xA;<LI>Before applying topical preparations, the affected area should be gently cleansed and allowed to dry.</LI>&#xD;&#xA;<LI>A large number of topical preparations are available in addition to those listed in the table; evidence of efficacy for most is lacking.</LI>&#xD;&#xA;<LI>Trade names shown in parentheses are for products available without a prescription in the United States&nbsp;and some other countries. Most preparations are also available as generic products and marketed under multiple other brand names.</LI></UL></div><div class=\"graphic_footnotes\">* A high-fiber diet and increased fluid intake is recommended in most patients with hemorrhoidal disease to soften stools and prevent the need for straining. Patients should also be counseled to avoid prolonged sitting or straining on toilet, on improving anal hygiene, and on avoiding triggers of constipation or diarrhea. Recommendations on dietary fiber intake are provided elsewhere in UpToDate.<br />¶ 0.4% nitroglycerin rectal ointment is available as a prescription product in the United States&nbsp;and other countries and has been studied for anal fissure. Other strengths of nitroglycerin ointment shown in table are <STRONG>not</STRONG> commercially available products in the&nbsp;United States.</div><div class=\"graphic_reference\">Prepared with data from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Hall JF. Modern management of hemorrhoidal disease. Gastroenterol Clin N Am 2013;&nbsp;42:759.</LI>&#xD;&#xA;<LI>Lorsiriwat V. Hemorrhoids: From basic pathophysiology to clinical management. World J Gastroenterol 2012; 18:2009.</LI>&#xD;&#xA;<LI>Madoff RD, Fleshman JW. American Gastroenterological Association technical review on the diagnosis and treatment of hemorrhoids. Gastroenterology 2004; 126:1463.</LI></OL></div><div id=\"graphicVersion\">Graphic 103146 Version 6.0</div></div></div>"},"103148":{"type":"graphic_table","displayName":"Causes of upper GI bleeding","title":"Disorders that cause upper GI bleeding in adults","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Disorders that cause upper GI bleeding in adults</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"10%\"></colgroup><colgroup span=\"2\" width=\"15%\"></colgroup><colgroup span=\"4\" width=\"30%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Cause</td> <td class=\"subtitle1\">Bleeding manifestations</td> <td class=\"subtitle1\">Associated signs and symptoms</td> <td class=\"subtitle1\">Associated conditions or risk factors</td> <td class=\"subtitle1\">Endoscopic findings*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Ulcerative or erosive</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Duodenal and/or gastric ulcer</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding)</p> Occult blood loss</td> <td> <p>Upper abdominal pain</p> <p>Pain associated with eating (worse when eating suggests gastric ulcer, improvement with eating suggests duodenal ulcer)</p> Dyspepsia<sup>&#182;</sup></td> <td>Infections: <ul class=\"decimal_heading\"> <li><em>Helicobacter pylori</em> </li> <li>CMV </li> <li>HSV </li> </ul> <p>NSAIDs</p> <p>Stress ulcer (eg, in patients who are critically ill)</p> <p>Excess gastric acid production (ZES)</p> Idiopathic</td> <td> <p>Ulcer with smooth, regular, rounded edges; ulcer base often filled with exudate</p> Examination of the ulcer may reveal: <ul class=\"decimal_heading\"> <li>Active bleeding or oozing </li> <li>Nonbleeding visible vessel </li> <li>Adherent clot </li> <li>Flat pigmented spot </li> <li>Clean ulcer base </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Esophagitis</td> <td> <p>Hematemesis</p> <p>Melena</p> Occult blood loss</td> <td> <p>Dysphagia/odynophagia</p> <p>Retrosternal pain</p> Food impaction</td> <td> <p>Gastroesophageal reflux disease</p> Medications: <ul class=\"decimal_heading\"> <li>Tetracycline </li> <li>Doxycycline </li> <li>Clindamycin </li> <li>Trimethoprim-sulfamethoxazole </li> <li>NSAIDs </li> <li>Oral bisphosphonates </li> <li>Potassium chloride </li> <li>Quinidine </li> <li>Iron supplements&nbsp; </li> </ul> Infections: <ul class=\"decimal_heading\"> <li>HSV </li> <li>CMV </li> <li><em>Candida albicans</em> </li> <li>HIV </li> </ul> </td> <td> <p>Erythema, mucosal breaks/erosions, exudative lesions, superficial or deep ulcers, stenosis, scarring</p> <p>Peptic esophagitis:</p> <p class=\"indent1\">The ulcerations are usually irregularly shaped or linear, multiple, and distal; may be accompanied by Barrett's esophagus</p> <p>Pill-induced:</p> <p class=\"indent1\">Ulcerations are usually singular and deep, occurring at points of stasis (especially near the carina), with sparing of the distal esophagus</p> Infectious esophagitis: <ul class=\"decimal_heading\"> <li>HSV &ndash; Discrete, superficial ulcers, with well-demarcated borders that tend to involve the upper or mid-esophagus; vesicles may be seen </li> <li>CMV &ndash; Ulcers range from small and shallow to large (&#62;1 cm) and deep; most patients have multiple lesions </li> <li><em>Candida</em> &ndash; Diffuse white plaques </li> <li>HIV &ndash; Tends to involve the mid to distal esophagus, ulcers may be shallow or deep, and may be large </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <p>Gastritis/gastropathy</p> <p>Duodenitis/duodenopathy</p> </td> <td> <p>Occult blood loss</p> <p>Hematemesis</p> Melena</td> <td>Dyspepsia<sup>&#182;</sup></td> <td>Risk factors: <ul class=\"decimal_heading\"> <li><em>H. pylori</em> </li> <li>NSAIDs </li> <li>Excessive alcohol consumption </li> <li>Radiation injury </li> <li>Physiologic stress </li> <li>Weight loss surgery </li> <li>Bile reflux </li> </ul> Risk factors for bleeding: <ul class=\"decimal_heading\"> <li>Anticoagulant use </li> </ul> </td> <td> <p>Erythematous mucosa</p> <p>Superficial erosions</p> <p>Nodularity</p> Diffuse oozing</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Complications of portal hypertension</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Esophagogastric varices</td> <td> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td>Stigmata of chronic liver disease<sup><span style=\"font-size: 13px;\">&#916;</span></sup>, in particular, signs of portal hypertension (splenomegaly, ascites, thrombocytopenia)</td> <td>Portal hypertension from: <ul class=\"decimal_heading\"> <li>Cirrhosis </li> <li>Portal vein thrombosis </li> <li>Noncirrhotic portal hypertension </li> </ul> </td> <td> <p>Vascular structures that protrude into the esophageal and/or gastric lumen</p> Findings associated with an increased risk of hemorrhage: <ul class=\"decimal_heading\"> <li>Longitudinal red streaks on the varices (red wale marks) </li> <li>Cherry-colored spots that are flat and overlie varices </li> <li>Raised, discrete red spots (hematocystic spots) </li> </ul> Esophageal varices: <ul class=\"decimal_heading\"> <li>F1: Small, straight varices </li> <li>F2: Enlarged, tortuous varices that occupy less than one-third of the lumen </li> <li>F3: Large, coil-shaped varices that occupy more than one-third of the lumen </li> </ul> Gastric varices: <ul class=\"decimal_heading\"> <li>GOV1: Gastroesophageal varices along the lesser curvature of the stomach </li> <li>GOV2: Gastroesophageal varices along the greater curvature of the stomach </li> <li>IGV1: Isolated gastric varices in the fundus </li> <li>IGV2: Isolated gastric varices at other loci in the stomach </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ectopic varices</td> <td> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td>Stigmata of chronic liver disease<sup><span style=\"font-size: 13px;\">&#916;</span></sup>, in particular, signs of portal hypertension&nbsp;(splenomegaly, ascites, thrombocytopenia)</td> <td>Portal hypertension from: <ul class=\"decimal_heading\"> <li>Cirrhosis </li> <li>Portal vein thrombosis </li> <li>Noncirrhotic portal hypertension </li> </ul> </td> <td>Vascular structures that protrude into areas of the gastrointestinal tract lumen other than the esophagus or stomach (eg, small bowel, rectum)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Portal hypertensive gastropathy</td> <td> <p>Occult blood loss</p> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td>Stigmata of chronic liver disease<sup><span style=\"font-size: 13px;\">&#916;</span></sup>, in particular, signs of portal hypertension (splenomegaly, ascites, thrombocytopenia)</td> <td>Portal hypertension from: <ul class=\"decimal_heading\"> <li>Cirrhosis </li> <li>Portal vein thrombosis </li> <li>Noncirrhotic portal hypertension </li> </ul> </td> <td> <p>Mosaic-like pattern that gives the gastric mucosa a \"snakeskin\" appearance</p> Mucosal changes are usually most evident in the fundus and body; in more severe cases, oozing, bleeding, subepithelial hemorrhages, and increased vascularity similar to angiomas are evident, often involving the gastric fundus, gastric body, and antrum</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Vascular lesions</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Angiodysplasia</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia</p> <p>Occult blood loss</p> <p>May have brisk bleeding</p> </td> <td>Cutaneous angiodysplasia in patients with hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu syndrome)</td> <td> <p>End-stage renal disease</p> <p>Aortic stenosis</p> <p>Left ventricular assist device</p> <p>Hereditary hemorrhagic telangiectasia</p> <p>von Willebrand disease</p> <p>Radiation therapy</p> Idiopathic</td> <td>Small (5 to 10 mm), flat, cherry-red lesions, often with a fern-like pattern of arborizing, ectatic blood vessels radiating from a central vessel</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Dieulafoy's lesion</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding; bleeding is often particularly brisk)</p> </td> <td>&nbsp;</td> <td> <p>Etiology unknown</p> Bleeding may be associated with NSAIDs, cardiovascular disease, hypertension, chronic kidney disease, diabetes, or alcohol abuse</td> <td> <p>Usually located in the proximal stomach (within 6 cm of the esophagogastric junction) along the lesser curvature (although can be found anywhere in the GI tract)</p> <p>May have active arterial spurting from the mucosa without an associated ulcer or mass</p> <p>If the bleeding has stopped, there may be a raised nipple or visible vessel without an associated ulcer</p> Endoscopic ultrasound may help confirm the diagnosis</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Gastric antral vascular ectasia (GAVE)</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding)</p> Occult blood loss</td> <td>In patients with cirrhosis, there may be stigmata of chronic liver disease<sup><span style=\"font-size: 13px;\">&#916;</span></sup>, in particular, signs of portal hypertension (splenomegaly, ascites, thrombocytopenia)</td> <td> <p>Idiopathic</p> <p>Cirrhosis with portal hypertension</p> <p>Renal disease/transplantation</p> <p>Diabetes mellitus</p> <p>Systemic sclerosis (scleroderma)</p> Bone marrow transplantation</td> <td>Longitudinal rows of flat, reddish stripes radiating from the pylorus into the antrum that resemble the stripes on a watermelon </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Blue rubber bleb nevus syndrome (Bean syndrome)</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding)</p> Occult blood loss</td> <td>Venous malformations and hemangiomas of any organ, including: <ul class=\"decimal_heading\"> <li>Skin </li> <li>Central nervous system </li> <li>Liver </li> <li>Muscles </li> <li>Lymphatics </li> </ul> Intussusception</td> <td>&nbsp;</td> <td>Blue or purple nodules, round or multilobular; may occur anywhere in the gastrointestinal tract</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Traumatic or iatrogenic</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mallory-Weiss syndrome</td> <td> <p>Hematemesis following an increase in intra-abdominal pressure</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td> <p>Epigastric pain</p> Back pain</td> <td> <p>Vomiting/retching (often related to alcohol consumption)</p> <p>Straining at stool or lifting</p> <p>Coughing</p> <p>Seizures</p> <p>Blunt abdominal trauma</p> Hiatal hernia may increase the risk of developing a tear</td> <td> <p>Tear in the esophagogastric junction</p> <p>Usually singular and longitudinal, but may be multiple</p> <p>Visualization may require retroflexion of the gastroscope in the cardia of the stomach</p> The tear may be covered by an adherent clot</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Foreign body ingestion</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding)</p> Occult blood loss</td> <td> <p>Dysphagia</p> <p>Odynophagia</p> <p>Neck or abdominal pain</p> <p>Choking</p> <p>Hypersalivation</p> Retrosternal fullness</td> <td> <p>Psychiatric disorders</p> <p>Dementia</p> <p>Loose dentures</p> </td> <td>Visualization of the foreign body endoscopically (plain radiographs of the neck, chest, and abdomen may reveal a radiopaque foreign body or signs of perforation)</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Post-surgical anastomotic bleeding (\"marginal ulcers\")</td> <td> <p>Occult blood loss</p> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td> <p>Epigastric pain</p> Nausea</td> <td> <p>Billroth II surgery</p> <p>Gastric bypass surgery</p> <p>NSAID use</p> <p><em>H. pylori</em> infection</p> Smoking</td> <td>Ulceration/friable mucosa at an anastomotic site</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Post-polypectomy/endoscopic resection/endoscopic sphincterotomy</td> <td> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td>Past history of instrumentation (may be as long as three weeks prior to presentation)</td> <td>Large lesions</td> <td>Bleeding at resection site; ulceration at the site may be seen</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Cameron lesions</td> <td> <p>Occult blood loss</p> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td>&nbsp;</td> <td> <p>Hiatal hernia</p> Reflux esophagitis</td> <td>Linear ulcers or erosions on the mucosal folds of a hiatal hernia at the diaphragmatic impression</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Aortoenteric fistula</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates brisk bleeding)</p> May have a \"herald\" bleed followed by massive bleeding</td> <td> <p>Back pain</p> <p>Fever</p> <p>Signs of sepsis</p> <p>Pulsatile abdominal mass</p> Abdominal bruit</td> <td> <p>Infectious aortitis (syphilis, tuberculosis)</p> <p>Prosthetic aortic graft</p> <p>Atherosclerotic aortic aneurysm</p> <p>Penetrating ulcers</p> <p>Tumor invasion</p> <p>Trauma</p> <p>Radiation injury</p> Foreign body perforation</td> <td> <p>Endoscopy is important, primarily to exclude other, more common causes of acute upper GI bleeding</p> Endoscopy with an enteroscope or side-viewing duodenoscope may reveal a graft, an ulcer or erosion at the site of an adherent clot, or an extrinsic pulsatile mass in the distal duodenum or esophagus</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Tumors</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Upper GI tumors</td> <td> <p>Hematemesis</p> <p>Melena</p> <p>Hematochezia (indicates&nbsp;brisk bleeding)</p> Occult blood loss</td> <td> <p>Weight loss</p> <p>Anorexia</p> <p>Nausea/vomiting</p> <p>Early satiety</p> <p>Epigastric pain</p> <p>Dysphagia (for tumors in the esophagus or&nbsp;proximal stomach)</p> <p>Gastric outlet obstruction</p> <p>Palpable mass</p> Paraneoplastic manifestations: <ul class=\"decimal_heading\"> <li>Diffuse seborrheic keratoses </li> <li>Acanthosis nigricans </li> <li>Membranous nephropathy </li> <li>Coagulopathy </li> </ul> </td> <td> <p>Virtually any tumor type may bleed</p> Benign tumors: <ul class=\"decimal_heading\"> <li>Leiomyoma </li> <li>Lipoma </li> <li>Polyp (hyperplastic, adenomatous, hamartomatous, inflammatory) </li> </ul> Malignant tumors: <ul class=\"decimal_heading\"> <li>Adenocarcinoma </li> <li>GI stromal tumors </li> <li>Lymphoma </li> <li>Kaposi sarcoma </li> <li>Carcinoid </li> <li>Melanoma </li> <li>Metastatic tumors </li> </ul> </td> <td> <p>Ulcerated mass in the esophagus, stomach, or duodenum</p> <p>In gastric malignancies, the folds surrounding the ulcer crater may be nodular, clubbed, fused, or stop short of the ulcer margin; the margins may be overhanging, irregular, or thickened</p> Bleeding lymphoma may appear as an ulcerated mass or polypoid lesion or as a gastric ulcer</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"5\">Miscellaneous</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hemobilia</td> <td> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td> <p>Biliary colic</p> <p>Jaundice (obstructive)</p> Sepsis (biliary)</td> <td>Past history of liver or biliary tract instrumentation and/or injury, including the following: <ul class=\"decimal_heading\"> <li>Liver biopsy </li> <li>Cholecystectomy </li> <li>Endoscopic biliary biopsies or stenting </li> <li>TIPS placement </li> <li>Angioembolization </li> <li>Blunt or penetrating abdominal trauma </li> <li>Gallstones </li> <li>Cholecystitis </li> <li>Hepatic or bile duct tumors </li> <li>Intrahepatic stents </li> <li>Hepatic artery aneurysms </li> <li>Hepatic abscesses </li> </ul> </td> <td> <p>Blood or clot emanating from the ampulla (a side-viewing duodenoscope may be required to visualize the ampulla)</p> <p>If a clot has formed in the bile duct, bleeding may not be appreciated until the clot is removed</p> ERCP may reveal a filling defect in the bile duct</td> </tr> <tr> <td class=\"indent1\">Hemosuccus pancreaticus</td> <td> <p>Hematemesis</p> <p>Melena</p> Hematochezia (indicates brisk bleeding)</td> <td> <p>Abdominal pain</p> <p>Past evidence of symptoms/signs of pancreatitis</p> <p>Imaging evidence of pancreatitis (current or in the past)</p> Elevated amylase and lipase (current or in the past)</td> <td> <p>Chronic pancreatitis</p> <p>Pancreatic pseudocysts</p> <p>Pancreatic tumors</p> <p>Pancreatic pseudoaneurysm</p> Therapeutic endoscopy of the pancreas or pancreatic duct: <ul class=\"decimal_heading\"> <li>Pancreatic stone removal </li> <li>Pancreatic duct sphincterotomy </li> <li>Pseudocyst drainage </li> <li>Pancreatic duct stenting </li> </ul> </td> <td> <p>Blood or clot emanating from the ampulla (a side-viewing duodenoscope may be required to visualize the ampulla)</p> Cross-sectional imaging or angiography is often required to confirm the diagnosis</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CMV: cytomegalovirus; HSV: herpes simplex virus; ZES: Zollinger-Ellison syndrome; NSAID: nonsteroidal anti-inflammatory drug; HIV: human immunodeficiency virus; GI: gastrointestinal; TIPS: transjugular intrahepatic portosystemic shunt; ERCP: endoscopic retrograde cholangiopancreatography.<br />* If active bleeding or large amounts of residual blood are present, the characteristic endoscopic findings may be obscured.<br />¶ Postprandial fullness, early satiety, epigastric pain, or burning.<br />Δ Evidence of chronic liver disease includes jaundice, splenomegaly, ascites, thrombocytopenia, palmar erythema, spider angiomata, gynecomastia, testicular atrophy, and Dupuytren's contracture.</div><div id=\"graphicVersion\">Graphic 103148 Version 2.0</div></div></div>"},"103149":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp multiple nodules","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103149_Dssct_clllt_sclp_mltpl_ndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple boggy nodules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103149 Version 1.0</div></div></div>"},"103150":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp multiple draining nodules","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/103150_Dssct_clllt_sclp_mlt_drn_ndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple boggy, draining nodules on the scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103150 Version 1.0</div></div></div>"},"103151":{"type":"graphic_picture","displayName":"Dissecting cellulitis of the scalp on posterior scalp","title":"Dissecting cellulitis of the scalp","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dissecting cellulitis of the scalp</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103151_Dssct_clllt_sclp_pst_sclp.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Boggy nodules with crusting on the posterior scalp.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103151 Version 1.0</div></div></div>"},"103152":{"type":"graphic_figure","displayName":"Posterior shoulder capsule stretching program","title":"Posterior shoulder capsule stretching program","html":"<div class=\"graphic\"><div style=\"width: 994px\" class=\"figure\"><div class=\"ttl\">Posterior shoulder capsule stretching program</div><div class=\"cntnt\"><img style=\"width:974px; height:786px;\" src=\"images/SM/103152_Post_shld_capsule_stretch.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103152 Version 1.0</div></div></div>"},"103153":{"type":"graphic_figure","displayName":"Upper extremity warm up for throwers","title":"Upper extremity warm up for throwers","html":"<div class=\"graphic\"><div style=\"width: 908px\" class=\"figure\"><div class=\"ttl\">Upper extremity warm up for throwers</div><div class=\"cntnt\"><img style=\"width:888px; height:1914px;\" src=\"images/SM/103153_Uppr_extrmty_wrm_thrwrs_ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT.</div><div id=\"graphicVersion\">Graphic 103153 Version 3.0</div></div></div>"},"103155":{"type":"graphic_table","displayName":"Progressive throwing program","title":"Progressive throwing program for rehabilitation or preparation of pitchers and other throwers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Progressive throwing program for rehabilitation or preparation of pitchers and other throwers</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Progressive throwing program for pitchers and other throwers</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">General instructions: <ul class=\"decimal_heading\"> <li>Start with a 5 minute easy cardiovascular warm-up (eg, light jogging or exercise bicycle) </li> <li>Perform the upper extremity active warm-up (refer to&nbsp;warm-up program table) </li> <li>Each session begins with 5 minutes of easy, light lob tossing (50% effort with light arc) from 10 to 20 feet (3 to 6 m) then progress to firm toss throwing for the recommended repetitions and distance </li> <li>No full speed throws are permitted until week 9 </li> <li>If no problems arise, 5 to 10 additional throws may be added&nbsp;to the end of a session&nbsp;in any given week </li> <li>If pain or extreme soreness develops, the thrower is not permitted to advance to the next stage of throwing and should consult their trainer or coach. Throwers may advance when able to complete the current stage without pain. </li> <li>Stretch the shoulder muscles after each throwing session (refer to&nbsp;static stretching program table) </li> <li>Apply ice to the shoulder after the stretching exercises are completed following each session (ice pack 20 minutes, ice cup 7 minutes) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Progressive distance throwing: The exercises for each stage are typically&nbsp;performed three days a week, with a rest day between throwing days. The player should be able to complete each stage with firm tosses (ie, minimal arc in the trajectory,&nbsp;using 80 to 85% of maximum effort) before moving on to the next stage. Typically each stage takes&nbsp;one week to complete.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Stage 1 <ul> <li>Warm-up lob and soft toss* throwing for 5 minutes - initially throwing short distance (eg, 10 to 20 feet; 3 to 6 meters) with no windup, followed by playing catch with easy windup. Overall, make&nbsp;enough throws to warm-up and loosen the muscles, typically 15 to 25 throws. </li> <li>15 minutes or 25 firm toss throws at 30 feet (9 m) </li> <li>Use crow hop technique, which consists of a hop, followed by a skip, and then the throw, with a mild to light arc at 80 to 85% of maximal effort. </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 2 <ul> <li>Warm-up lob and soft throwing for 5 minutes </li> <li>15 minutes or 25 firm toss&nbsp;throws at 45 feet (14 m) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 3 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>20 minutes or 30 to 40 firm toss throws at 60 feet (18 m) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 4 <ul> <li>Warm-up lob and soft&nbsp;throwing for 5 minutes </li> <li>25 minutes or 40 to 50 firm toss throws at 90 feet (27 m) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 5 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>15 minutes or 25 firm toss throws at 90 feet (27 m) </li> <li>Rest 5 minutes </li> <li>15 minutes or 25 on line throws at 90 feet </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 6 <ul> <li>Warm-up soft and lob toss throwing for 5 minutes </li> <li>15 minutes or 25 firm toss throws at 120 feet (36 m) </li> <li>Rest 5 minutes </li> <li>15 minutes or 25 on line throws at 120 feet </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Long toss: On line throwing at 120 feet (36 m) or more. Position players start the long toss program&nbsp;after they complete Stage 6 of the progressive distance throwing protocol (ie, 50 long tosses) without pain or other concerning problems. The long toss program is optional for pitchers.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 1 <ul> <li>Warm-up lob and soft throwing for 5 minutes </li> <li>15 minutes or 25 on line throws at 150 feet (46 m) </li> <li>Rest 5 minutes </li> <li>15 minutes or 25 throws at 150 feet (46 m) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 2 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Progressive long toss of 15 minutes or 25 on line throws at 180 feet (55 m) </li> <li>Rest 5 minutes </li> <li>15 minutes or 25 on line throws at 180 feet (55 m) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Mound throwing program - For pitchers only. To be started&nbsp;after the pitcher completes Stage 6 of the progressive distance throwing protocol (ie, 50 firm to on line long tosses) without pain or other concerning problems. Only fastballs are thrown until volume reaches 75% of the total number of pitches expected for a game. All throwing off the mound should be done in the presence of the pitching coach, who should emphasize proper throwing mechanics. If available, use a speed gun to help the pitcher exercise appropriate restraint (ie, not throwing too hard).</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 1 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Progressive long toss: 15 minutes or 25 firm toss throws, gradually&nbsp;increasing the&nbsp;distance&nbsp;to&nbsp;120 feet (36 m) </li> <li>Rest 5 minutes </li> <li>15 minutes or 25 on line throws at 120 feet (36 m) </li> <li>Rest 5 minutes </li> <li>Mound work - 15 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 2 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Progressive long toss (see Stage 1 for details) </li> <li>Mound work - 30 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 3 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Progressive long toss (see Stage 1 for details) </li> <li>Mound work - 45 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 4 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Progressive long toss (see Stage 1 for details) </li> <li>Mound work - 60 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 5 <ul> <li>Warm-up lob and soft toss&nbsp;throwing for 5 minutes </li> <li>Progressive long toss (see Stage 1 for details) </li> <li>Mound work - 30 throws off mound at 75% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 6 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>30 throws off mound at 75% </li> <li>45 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 7 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>45 throws off mound at 75% of maximal effort </li> <li>15 throws off mound at 50% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 8 <ul> <li>Warm-up lob and soft toss&nbsp;throwing for 5 minutes </li> <li>60 throws off mound at 75% of maximal effort </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 9 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>45 throws off mound at 75% of maximal effort </li> <li>15 throws in batting practice (100% - fastballs only) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 10 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>45 throws off mound at 75% of maximal effort </li> <li>30 throws in batting practice (100% - fastballs only) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 11 <ul> <li>Warm-up lob and soft toss&nbsp;throwing for 5 minutes </li> <li>30 fastballs off mound at 75% of maximal effort </li> <li>15 breaking balls off mound at 50% of maximal effort </li> <li>45 to 60 throws in batting practice (100% - mixed pitches) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 12 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>30 fastballs off mound at 75% of maximal effort </li> <li>30 breaking balls off mound at 75% of maximal effort </li> <li>30 throws in batting practice (100% effort&nbsp;- mixed pitches) </li> </ul> </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\"> <ul> <li>Stage 13 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>30 mixed pitches off mound at 75% of maximal effort </li> <li>60 to 90 throws in batting practice (100% effort&nbsp;- mixed pitches) </li> </ul> </li> </ul> </td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Stage 14 <ul> <li>Warm-up lob and soft toss throwing for 5 minutes </li> <li>Simulated game progressing by 15 throws per workout </li> </ul> </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">*Refer to UpToDate topics discussing treatment of throwing injuries for definitions of types of throws, and details about exercise programs for throwers.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103155 Version 2.0</div></div></div>"},"103159":{"type":"graphic_picture","displayName":"Lying and standing W stretches for chest","title":"Lying and standing W stretches for chest","html":"<div class=\"graphic\"><div style=\"width: 674px\" class=\"figure\"><div class=\"ttl\">Lying and standing W stretches for chest</div><div class=\"cntnt\"><img style=\"width:654px; height:330px;\" src=\"images/SM/103159_Lying_stndng_W_strtchs_chst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two basic static stretches for the chest musculature are pictured above. For the standing stretch, stand about 1 meter (3 feet)&nbsp;from a corner with one hand placed on each wall at shoulder height, elbows at 90 degrees. Lean into the corner slowly.</div><div class=\"graphic_reference\">Courtesy of Craig Young, MD and Mark Lydecker, PT.</div><div id=\"graphicVersion\">Graphic 103159 Version 1.0</div></div></div>"},"103160":{"type":"graphic_algorithm","displayName":"Cell free DNA for secondary screening for Down syndrome","title":"Use of cell free DNA for secondary screening for Down syndrome","html":"<div class=\"graphic\"><div style=\"width: 714px\" class=\"figure\"><div class=\"ttl\">Use of cell free DNA for secondary screening for Down syndrome</div><div class=\"cntnt\"><img style=\"width:694px; height:258px;\" src=\"images/OBGYN/103160_Cell_free_DNA_2nd_screen_DS.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pregnant women can choose to have a blood (serum-based) screening test to find out whether they have a high or low risk of having a baby with Down syndrome. The blood test has been offered for many years. Most women find they have a low risk and continue with routine care. In some women, the blood test will find a high risk. These women can find out for sure if the baby has Down syndrome by having an invasive test like amniocentesis. There is now a new option for the women at high risk (shaded box and dashed arrows): a new blood test that looks at the baby's cell free DNA that is in the mother's blood and again determines if she is high- or low-risk. Most women find they have a low risk and continue with routine care. A few women will have a high risk on the DNA test, and the DNA test does not work (test fails) for some others. These women would still need an invasive test to know for certain if the baby has Down syndrome.</div><div id=\"graphicVersion\">Graphic 103160 Version 1.0</div></div></div>"},"103163":{"type":"graphic_picture","displayName":"SGA cuff pressure gauge","title":"Supraglottic airway cuff pressure gauge","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Supraglottic airway cuff pressure gauge</div><div class=\"cntnt\"><img style=\"width:318px; height:291px;\" src=\"images/ANEST/103163_Ambu_cuff_pres_guage.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With this cuff pressure gauge, the supraglottic airway cuff should be inflated so that the pressure remains in the green, safe inflation pressure zone.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Ambu.</div><div id=\"graphicVersion\">Graphic 103163 Version 2.0</div></div></div>"},"103167":{"type":"graphic_figure","displayName":"Vulvar anatomy dissection","title":"Dissection of vulvar anatomy","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Dissection of vulvar anatomy</div><div class=\"cntnt\"><img style=\"width:678px; height:575px;\" src=\"images/OBGYN/103167_Vlvr_antmy_dssctn.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Originally published in: Sobotta Atlas der Anatomie des Menschen, 22. Auflage, Band 1, Band 2; M&uuml;nchen: Elsevier/Urban &amp; Fischer &copy; 2006. The English translation was undertaken by Lippincott Williams &amp; Wilkins and published in: Anatomy: A Regional Atlas of the Human Body, 6th ed, Clemente CD (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103167 Version 1.0</div></div></div>"},"103171":{"type":"graphic_table","displayName":"Female birth weight by gestational age","title":"Smoothed percentiles of birth weight (g) for female infants based on gestational age: United States (2009 to 2010)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Smoothed percentiles of birth weight (g) for female infants based on gestational age: United States (2009 to 2010)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"11\" width=\"9%\"></colgroup> <tbody> <tr class=\"centered\"> <td class=\"subtitle1\" rowspan=\"2\">Gestational age (week)</td> <td class=\"subtitle1\" colspan=\"7\">Percentile</td> <td class=\"subtitle1\" rowspan=\"2\"><em>n</em></td> <td class=\"subtitle1\" rowspan=\"2\">Mean</td> <td class=\"subtitle1\" rowspan=\"2\">SD</td> </tr> <tr> <td class=\"subtitle2\">3<sup>rd</sup></td> <td class=\"subtitle2\">5<sup>th</sup></td> <td class=\"subtitle2\">10<sup>th</sup></td> <td class=\"subtitle2\">50<sup>th</sup></td> <td class=\"subtitle2\">90<sup>th</sup></td> <td class=\"subtitle2\">95<sup>th</sup></td> <td class=\"subtitle2\">97<sup>th</sup></td> </tr> <tr class=\"centered\"> <td>22</td> <td>299</td> <td>311</td> <td>354</td> <td>463</td> <td>583</td> <td>631</td> <td>663</td> <td>1675</td> <td>467</td> <td>92</td> </tr> <tr class=\"centered\"> <td>23</td> <td>339</td> <td>367</td> <td>416</td> <td>547</td> <td>687</td> <td>742</td> <td>772</td> <td>2094</td> <td>553</td> <td>109</td> </tr> <tr class=\"centered\"> <td>24</td> <td>376</td> <td>416</td> <td>473</td> <td>629</td> <td>790</td> <td>851</td> <td>881</td> <td>2807</td> <td>626</td> <td>129</td> </tr> <tr class=\"centered\"> <td>25</td> <td>419</td> <td>466</td> <td>529</td> <td>718</td> <td>903</td> <td>968</td> <td>1005</td> <td>3152</td> <td>714</td> <td>156</td> </tr> <tr class=\"centered\"> <td>26</td> <td>475</td> <td>528</td> <td>597</td> <td>822</td> <td>1035</td> <td>1110</td> <td>1162</td> <td>3523</td> <td>819</td> <td>186</td> </tr> <tr class=\"centered\"> <td>27</td> <td>543</td> <td>601</td> <td>677</td> <td>941</td> <td>1186</td> <td>1276</td> <td>1344</td> <td>3921</td> <td>935</td> <td>215</td> </tr> <tr class=\"centered\"> <td>28</td> <td>621</td> <td>684</td> <td>770</td> <td>1073</td> <td>1356</td> <td>1461</td> <td>1543</td> <td>4569</td> <td>1073</td> <td>242</td> </tr> <tr class=\"centered\"> <td>29</td> <td>719</td> <td>789</td> <td>882</td> <td>1222</td> <td>1548</td> <td>1668</td> <td>1761</td> <td>5059</td> <td>1211</td> <td>269</td> </tr> <tr class=\"centered\"> <td>30</td> <td>838</td> <td>915</td> <td>1018</td> <td>1391</td> <td>1763</td> <td>1901</td> <td>2007</td> <td>6487</td> <td>1396</td> <td>309</td> </tr> <tr class=\"centered\"> <td>31</td> <td>966</td> <td>1050</td> <td>1166</td> <td>1581</td> <td>2004</td> <td>2160</td> <td>2278</td> <td>8321</td> <td>1588</td> <td>336</td> </tr> <tr class=\"centered\"> <td>32</td> <td>1113</td> <td>1205</td> <td>1335</td> <td>1790</td> <td>2267</td> <td>2436</td> <td>2563</td> <td>12,250</td> <td>1800</td> <td>371</td> </tr> <tr class=\"centered\"> <td>33</td> <td>1296</td> <td>1396</td> <td>1538</td> <td>2024</td> <td>2549</td> <td>2726</td> <td>2857</td> <td>18,456</td> <td>2033</td> <td>405</td> </tr> <tr class=\"centered\"> <td>34</td> <td>1514</td> <td>1621</td> <td>1772</td> <td>2280</td> <td>2845</td> <td>3024</td> <td>3157</td> <td>34,555</td> <td>2296</td> <td>428</td> </tr> <tr class=\"centered\"> <td>35</td> <td>1755</td> <td>1866</td> <td>2021</td> <td>2541</td> <td>3133</td> <td>3315</td> <td>3448</td> <td>63,125</td> <td>2560</td> <td>440</td> </tr> <tr class=\"centered\"> <td>36</td> <td>1995</td> <td>2107</td> <td>2261</td> <td>2786</td> <td>3383</td> <td>3567</td> <td>3698</td> <td>138,274</td> <td>2799</td> <td>441</td> </tr> <tr class=\"centered\"> <td>37</td> <td>2219</td> <td>2330</td> <td>2477</td> <td>3004</td> <td>3588</td> <td>3770</td> <td>3899</td> <td>334,681</td> <td>3028</td> <td>456</td> </tr> <tr class=\"centered\"> <td>38</td> <td>2418</td> <td>2526</td> <td>2665</td> <td>3183</td> <td>3752</td> <td>3933</td> <td>4060</td> <td>746,406</td> <td>3209</td> <td>432</td> </tr> <tr class=\"centered\"> <td>39</td> <td>2572</td> <td>2676</td> <td>2810</td> <td>3315</td> <td>3871</td> <td>4051</td> <td>4175</td> <td>1,202,266</td> <td>3333</td> <td>419</td> </tr> <tr class=\"centered\"> <td>40</td> <td>2671</td> <td>2771</td> <td>2904</td> <td>3407</td> <td>3954</td> <td>4130</td> <td>4252</td> <td>828,314</td> <td>3417</td> <td>416</td> </tr> <tr class=\"centered\"> <td>41</td> <td>2725</td> <td>2824</td> <td>2958</td> <td>3465</td> <td>4015</td> <td>4191</td> <td>4311</td> <td>323,237</td> <td>3486</td> <td>422</td> </tr> <tr class=\"centered\"> <td>42</td> <td>2743</td> <td>2847</td> <td>2985</td> <td>3493</td> <td>4059</td> <td>4239</td> <td>4362</td> <td>62,663</td> <td>3512</td> <td>429</td> </tr> <tr class=\"centered\"> <td>43</td> <td>2713</td> <td>2834</td> <td>2981</td> <td>3501</td> <td>4091</td> <td>4275</td> <td>4407</td> <td>9500</td> <td>3550</td> <td>444</td> </tr> <tr class=\"centered\"> <td>44</td> <td>2645</td> <td>2794</td> <td>2952</td> <td>3502</td> <td>4118</td> <td>4307</td> <td>4456</td> <td>813</td> <td>3505</td> <td>503</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Means, SDs, and smoothed percentiles for birth weight (g) for gestational age within the corrected dataset: US female singleton live births (2009 to 2010). The corrected dataset uses both last menstrual period (LMP) and clinical/obstetric-based estimates of gestational age, and reflects the application of the Basso and Wilcox algorithm<sup>[1]</sup> to correct likely errors in gestational age and excludes implausible birth weights for gestational age.</div><div class=\"graphic_footnotes\">SD: standard deviation.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Basso O, Wilcox A. Mortality risk among preterm babies: immaturity versus underlying pathology. Epidemiology 2010; 21:521.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced with permission from Pediatrics, Vol. 133, Pages 844-53, Copyright &copy; 2014 by the AAP.</div><div id=\"graphicVersion\">Graphic 103171 Version 3.0</div></div></div>"},"103173":{"type":"graphic_table","displayName":"Off season throwing program","title":"Off season throwing program","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Off season throwing program</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" colspan=\"4\">Sample throwing program for off season training</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Week 1 - Soft toss to firm toss throws</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>45 to 60 feet (14 to 18 m) x 7 minutes</td> <td colspan=\"2\">&nbsp;</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>45 to 60 feet x 7 minutes</td> <td colspan=\"2\">60 to 75 feet (18 to 23 m)&nbsp;x 3 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Friday</td> <td>60 to 75 feet x 5 minutes</td> <td colspan=\"2\">60 to 75 feet x 5 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Week 2 - Soft toss to firm toss throws</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>45 to 60 feet (14 to 18 m)&nbsp;x 5 minutes</td> <td>60 to 75 feet (18 to 23 m)&nbsp;x 5 minutes</td> <td>75 to 90 feet (23 to 27 m) x 3 minutes</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>45 to 60 feet x 5 minutes</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 90 feet x 5 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Friday</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 90 feet x 5 minutes</td> <td>90 to 105 feet (27 to 32 m) x 3 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Week 3 - Firm toss to on line throws</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>60 to 75 feet (18 to 23 m)&nbsp;x 5 minutes</td> <td>75 to 90 feet (23 to 27 m)&nbsp;x 5 minutes</td> <td>90 to 105 feet (27 to 32 m)&nbsp;x 3 minutes</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 90 feet x 5 minutes</td> <td>90 to 105 feet x 3 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Friday</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 90 feet x 5 minutes</td> <td>90 to 105 feet x 5 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Week 4 - Firm toss to on line throws</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>60 to 75 feet (18 to 23 m)&nbsp;x 5 minutes</td> <td>75 to 90 feet (23 to 27 m)&nbsp;x 5 minutes</td> <td>90 to 105 feet (27 to 32 m)&nbsp;x 5 minutes</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 105 feet (23 to 32 m)&nbsp;x 5 minutes</td> <td>105 to 120 feet (32 to 37 m) x 5 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Friday</td> <td>60 to 75 feet x 5 minutes</td> <td>75 to 105 feet x 5 minutes</td> <td>105 to 120 feet x 5 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Week 5* - Firm toss to on line throws</td> <td class=\"subtitle2_left\">Pitchers only</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>60 to 90 feet (18 to 27 m)&nbsp;x 5 minutes</td> <td>90 to 120 feet (27 to 37 m)&nbsp;x 5 minutes</td> <td class=\"indent1\">Bull Pen - touch/feel x 3 minutes</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>60 to 90 feet x 5 minutes</td> <td>90 to 120 feet x 5 minutes</td> <td class=\"indent1\">Bull Pen - touch/feel x 5 minutes</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Friday</td> <td>60 to 90 feet x 5 minutes</td> <td>90 to 120 feet x 3 minutes</td> <td class=\"indent1\">Bull Pen - touch/feel x 7 minutes</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Week 6* - Firm toss to on line throws</td> <td class=\"subtitle2_left\">Pitchers only</td> </tr> <tr> <td class=\"indent1\">Monday</td> <td>60 to 90 feet (18 to 27 m)&nbsp;x 3 minutes</td> <td>90 to up to 150 feet (27 to 46 m)&nbsp;x 5 minutes</td> <td class=\"indent1\">Bull Pen - FB x 10 minutes</td> </tr> <tr> <td class=\"indent1\">Wednesday</td> <td>60 to 90 feet x 3 minutes</td> <td>90 to up to 150 feet x 5 minutes</td> <td class=\"indent1\">Bull Pen - FB x 10 minutes</td> </tr> <tr> <td class=\"indent1\">Friday</td> <td>60 to 90 feet x 3 minutes</td> <td>90 to up to 150 feet x 3 minutes</td> <td class=\"indent1\">Bull Pen - FB x 10 minutes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* During weeks 5 and 6, the sessions designated for the \"Bull Pen\" can be performed on any mound and are solely to help pitchers improve their feel for the various pitches they plan to throw during the upcoming season.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103173 Version 3.0</div></div></div>"},"103177":{"type":"graphic_figure","displayName":"Focal adhesions and kindlin-1 protein","title":"Schematic representation of focal adhesions and kindlin-1 protein","html":"<div class=\"graphic\"><div style=\"width: 561px\" class=\"figure\"><div class=\"ttl\">Schematic representation of focal adhesions and kindlin-1 protein</div><div class=\"cntnt\"><img style=\"width:541px; height:628px;\" src=\"images/DERM/103177_Focal_adhesions_kindlin-1_protein.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103177 Version 1.0</div></div></div>"},"103181":{"type":"graphic_picture","displayName":"Skin findings in diffuse cutaneous mastocytosis","title":"Skin findings in diffuse cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 660px\" class=\"figure\"><div class=\"ttl\">Skin findings in&nbsp;diffuse cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:640px; height:476px;\" src=\"images/ALLRG/103181_Thck_skn_dfs_ctn_mstcyt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The skin of this infant demonstrates typical findings of diffuse cutaneous mastocytosis. These include&nbsp;leathery,&nbsp;thickening of the skin (peau d'orange) and multiple nodules (A); exaggerated skin folds in the neck (B) and under the arm (C). Spontaneous Darier's sign (urtication of a lesion after friction) can be seen in the neck area (B) and left chest area (C). A mastocytoma (aggregation of a large number of mast cells) in the temporo-occipital area (D).</div><div class=\"graphic_reference\">Reproduced from: Bankova LG, Walter JE, Iyengar SR, et al. Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. J Allergy Clin Immunol Prac 2013; 1:94. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103181 Version 3.0</div></div></div>"},"103182":{"type":"graphic_picture","displayName":"Histology of cutaneous mastocytosis","title":"Histology of cutaneous mastocytosis","html":"<div class=\"graphic\"><div style=\"width: 663px\" class=\"figure\"><div class=\"ttl\">Histology of cutaneous mastocytosis</div><div class=\"cntnt\"><img style=\"width:643px; height:483px;\" src=\"images/ALLRG/103182_Hstl_ctn_mstcyt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin biopsy demonstrating cutaneous mastocytosis. Hematoxylin and eosin stain showing a dense interstitial and perivascular infiltrate of mononuclear cells in the papillary and reticular dermis at low-power (A) and high-power (B) magnification. By immunohistochemistry, the mononuclear cells are positive for c-kit (CD117) (C) and tryptase (D), which is typical of mast cells.</div><div class=\"graphic_reference\">Reproduced from: Bankova LG, Walter JE, Iyengar SR, et al. Generalized bullous eruption after routine vaccination in a child with diffuse cutaneous mastocytosis. J Allergy Clin Immunol Prac 2013; 1:94. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103182 Version 1.0</div></div></div>"},"103187":{"type":"graphic_table","displayName":"Diuretics used to treat hypertension","title":"Pharmacology of diuretics used to treat hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacology of diuretics used to treat hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"46%\"></colgroup><colgroup span=\"3\" width=\"18%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Bioavailability<br /> (%)</td> <td class=\"subtitle1\">Half-life<br /> (hours)</td> <td class=\"subtitle1\">Duration of action<br /> (hours)</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Thiazide diuretics*</td> </tr> <tr> <td class=\"indent1\">Bendroflumethiazide</td> <td>90</td> <td>3-4</td> <td>6-12</td> </tr> <tr> <td class=\"indent1\">Chlorothiazide</td> <td>9-56 (dose dependent)</td> <td>Biphasic: Initially 1-2, then ~12</td> <td>6-12</td> </tr> <tr> <td class=\"indent1\">Hydrochlorothiazide</td> <td>65-75</td> <td>Biphasic: Initially ~5, then 6-15</td> <td>6-12</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Thiazide-like diuretics</strong></td> </tr> <tr> <td class=\"indent2\">Chlorthalidone</td> <td>65</td> <td>40-60<sup>&#182;</sup></td> <td>24-72</td> </tr> <tr> <td class=\"indent2\">Indapamide</td> <td>90</td> <td>Biphasic: Initially ~14, then 25</td> <td>16-36</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent2\">Metolazone</td> <td>65</td> <td>6-20</td> <td>18-25</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Loop diuretics</td> </tr> <tr> <td class=\"indent1\">Bumetanide</td> <td>80-90</td> <td>1-1.5</td> <td>4-6</td> </tr> <tr> <td class=\"indent1\">Furosemide</td> <td>47-64 (oral absorption is reportedly more variable in organ dysfunction and with gut-wall edema)</td> <td>0.5-2</td> <td>6-8</td> </tr> <tr> <td class=\"indent1\">Torsemide</td> <td>80</td> <td>3.5</td> <td>6-8</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Ethacrynic acid</td> <td>~100</td> <td>2-4</td> <td>12</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Potassium-sparing diuretics</td> </tr> <tr> <td class=\"indent1\">Amiloride</td> <td>15-25 (variable)</td> <td>Biphasic: Initially 6-9, then ~20</td> <td>24</td> </tr> <tr> <td class=\"indent1\">Triamterene</td> <td>50</td> <td>2-4</td> <td>7-9</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>Aldosterone antagonists, potassium sparing</strong></td> </tr> <tr> <td class=\"indent2\">Eplerenone</td> <td>69</td> <td>4-6</td> <td>Insufficient data</td> </tr> <tr> <td class=\"indent2\">Spironolactone</td> <td>65</td> <td>1.5 (15)<sup>&#916;</sup></td> <td>48-72</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Data shown are for oral administration in patients with normal renal and cardiac function.</div><div class=\"graphic_footnotes\">* Maximal antihypertensive effect is seen with low doses after several weeks of use.<br />¶ Prolonged serum half-life of chlorthalidone does not fully predict the duration of clinical effect.<br />Δ The half-life of one active metabolite, canrenone, is 15 hours.</div><div class=\"graphic_reference\">Courtesy of authors with additional&nbsp;data from: Lexicomp Online. Copyright © 1978-2018 Lexicomp, Inc. All Rights Reserved.</div><div id=\"graphicVersion\">Graphic 103187 Version 3.0</div></div></div>"},"103188":{"type":"graphic_algorithm","displayName":"Management of the first pregnancy with Rh(D) alloimmunization","title":"Management of the first pregnancy with Rh(D) alloimmunization","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Management of the first pregnancy with Rh(D) alloimmunization</div><div class=\"cntnt\"><img style=\"width:854px; height:958px;\" src=\"images/OBGYN/103188_Mng_frst_prg_RhD_allommnztn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Rh: Rhesus; MCA-PSV: middle cerebral artery peak systolic velocity; MoMs: multiples of the median.</div><div id=\"graphicVersion\">Graphic 103188 Version 2.0</div></div></div>"},"103189":{"type":"graphic_algorithm","displayName":"Early management of the child with stroke","title":"Pediatric stroke code: early management of the child with stroke","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pediatric stroke code: early management of the child with stroke</div><div class=\"cntnt\"><img style=\"width:399px; height:388px;\" src=\"images/NEURO/103189_Early_mngmnt_chld_strk.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ABC: airway, breathing, circulation; IV: intravenous; NPO: nil per os; MRA: MR angiogram.</div><div class=\"graphic_reference\">Original figure modified for this publication. Elbers J, Wainwright MS, Amlie-Lefond C. The Pediatric Stroke Code: Early Management of the Child with Stroke. J Pediatr 2015; 167:19. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103189 Version 1.0</div></div></div>"},"103190":{"type":"graphic_algorithm","displayName":"Management of the second pregnancy with Rh(D) alloimmunization","title":"Management of women after a previous pregnancy complicated by Rh(D) alloimmunization","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Management of women after a previous pregnancy complicated by Rh(D) alloimmunization</div><div class=\"cntnt\"><img style=\"width:854px; height:772px;\" src=\"images/OBGYN/103190_Mng_scnd_prg_RhD_allommnztn.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">Rh: Rhesus; MCA: middle cerebral artery; PSV: peak systolic velocity; MoMs: multiples of the median; IVIG: intravenous immunoglobulin; SD: standard deviation.</div><div id=\"graphicVersion\">Graphic 103190 Version 1.0</div></div></div>"},"103191":{"type":"graphic_picture","displayName":"US transducer position anterior ankle exam start","title":"US transducer position for start of anterior ankle exam","html":"<div class=\"graphic\"><div style=\"width: 879px\" class=\"figure\"><div class=\"ttl\">US transducer position for start of anterior ankle exam</div><div class=\"cntnt\"><img style=\"width:859px; height:355px;\" src=\"images/SM/103191_US_prb_ant_ankl_exm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probe position to image the anterior tibiotalar joint.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103191 Version 2.0</div></div></div>"},"103192":{"type":"graphic_diagnosticimage","displayName":"US anterior tibiotalar joint sagittal","title":"US anterior tibiotalar joint sagittal","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US anterior tibiotalar joint sagittal</div><div class=\"cntnt\"><img style=\"width:855px; height:404px;\" src=\"images/SM/103192_US_antr_tbtlr_sgttl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal plane ultrasound scan of anterior tibiotalar joint.</div><div class=\"graphic_footnotes\">F: anterior fat pad.<br />Left side of image: caudal; Right side of image: cranial.<br />* articular cartilage.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103192 Version 1.0</div></div></div>"},"103193":{"type":"graphic_diagnosticimage","displayName":"US anterior ankle transverse view","title":"US anterior ankle transverse view","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US anterior ankle transverse view</div><div class=\"cntnt\"><img style=\"width:855px; height:301px;\" src=\"images/SM/103193_US_ant_ankl_trnsvr_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse plane (short axis view) ultrasound scan of anterior ankle tendons.</div><div class=\"graphic_footnotes\">Arrowheads: tibialis anterior tendon; open arrowheads: extensor hallucis longus tendon; arrows: extensor digitorum longus tendon; EHL; distal continuation of extensor hallucis longus muscle.<br />Left side of image: lateral; Right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103193 Version 1.0</div></div></div>"},"103194":{"type":"graphic_diagnosticimage","displayName":"US tibialis anterior tendon sagittal (long axis) view","title":"US tibialis anterior tendon sagittal (long axis) view","html":"<div class=\"graphic\"><div style=\"width: 877px\" class=\"figure\"><div class=\"ttl\">US tibialis anterior tendon sagittal (long axis) view</div><div class=\"cntnt\"><img style=\"width:857px; height:319px;\" src=\"images/SM/103194_US_tbl_antr_tnd_sgt_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the tibialis anterior tendon at the anterior ankle in a long axis view.</div><div class=\"graphic_footnotes\">Arrowheads: tibialis anterior tendon.<br />Left side of image: caudal; Right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103194 Version 1.0</div></div></div>"},"103195":{"type":"graphic_diagnosticimage","displayName":"US deep fibular nerve dorsalis pedis at talar dome","title":"US deep fibular nerve dorsalis pedis artery at talar dome transverse view","html":"<div class=\"graphic\"><div style=\"width: 879px\" class=\"figure\"><div class=\"ttl\">US deep fibular nerve dorsalis pedis artery at talar dome transverse view</div><div class=\"cntnt\"><img style=\"width:859px; height:293px;\" src=\"images/SM/103195_US_dp_fib_nrv_drsl_pds_tlr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image is a transverse view at the level of the talar dome showing the deep fibular nerve, dorsalis pedis artery, and extensor hallucis longus muscle.</div><div class=\"graphic_footnotes\">Dotted ellipse: deep fibular nerve; A: dorsalis pedis artery; EHLm: extensor hallucis longus muscle.<br />Left side of image: lateral; Right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103195 Version 1.0</div></div></div>"},"103223":{"type":"graphic_picture","displayName":"US transducer position for lateral ankle and ATFL","title":"US transducer position for lateral ankle and ATFL","html":"<div class=\"graphic\"><div style=\"width: 968px\" class=\"figure\"><div class=\"ttl\">US transducer position for lateral ankle and ATFL</div><div class=\"cntnt\"><img style=\"width:948px; height:616px;\" src=\"images/SM/103223_US_prb_pstn_lat_ankl_ATFL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Probe position for ultrasound examination of the anterior talofibular ligament is shown above.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103223 Version 3.0</div></div></div>"},"103224":{"type":"graphic_diagnosticimage","displayName":"US anterior talofibular ligament coronal oblique view","title":"US anterior talofibular ligament coronal oblique view","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">US anterior talofibular ligament coronal oblique view</div><div class=\"cntnt\"><img style=\"width:854px; height:386px;\" src=\"images/SM/103224_US_antr_tlfblr_lgm_crnl_obl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the anterior talofibular ligament seen in the long axis along a coronal oblique plane.</div><div class=\"graphic_footnotes\">Arrowheads: talo-fibular ligament; LM: lateral malleolus; TA: talus.<br />Left side of image: cranial; Right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103224 Version 1.0</div></div></div>"},"103225":{"type":"graphic_diagnosticimage","displayName":"US anterior tibiofibular ligament long axis view","title":"US anterior tibiofibular ligament long axis view","html":"<div class=\"graphic\"><div style=\"width: 876px\" class=\"figure\"><div class=\"ttl\">US anterior tibiofibular ligament long axis view</div><div class=\"cntnt\"><img style=\"width:856px; height:219px;\" src=\"images/SM/103225_US_antr_tbfblr_lgm_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse oblique plane ultrasound image of the anterior inferior tibiofibular ligament (long-axis view).</div><div class=\"graphic_footnotes\">Arrowheads: anterior inferior tibiofibular ligament.<br />Left side of image: lateral; Right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103225 Version 1.0</div></div></div>"},"103226":{"type":"graphic_diagnosticimage","displayName":"US transverse view of distal interosseous membrane","title":"US transverse view of distal interosseous membrane","html":"<div class=\"graphic\"><div style=\"width: 871px\" class=\"figure\"><div class=\"ttl\">US transverse view of distal interosseous membrane</div><div class=\"cntnt\"><img style=\"width:851px; height:406px;\" src=\"images/SM/103226_US_trnsvrs_dstl_intrs_mmbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the interosseous membrane in a transverse plane.</div><div class=\"graphic_footnotes\">Arrowheads: interosseous membrane.<br />Left side of image: lateral; Right side of image: medial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103226 Version 1.0</div></div></div>"},"103227":{"type":"graphic_diagnosticimage","displayName":"US calcaneofibular ligament sagittal view","title":"US calcaneofibular ligament sagittal view","html":"<div class=\"graphic\"><div style=\"width: 873px\" class=\"figure\"><div class=\"ttl\">US calcaneofibular ligament sagittal view</div><div class=\"cntnt\"><img style=\"width:853px; height:352px;\" src=\"images/SM/103227_US_clcnfblr_lgm_sgt_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the calcaneofibular ligament in a sagittal oblique plane (long-axis view).</div><div class=\"graphic_footnotes\">Arrowheads: calcaneofibular ligament; Fl: fibularis longus tendon; Fb: fibularis brevis tendon; LM: lateral malleolus.<br />Left side of image: cranial; Right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103227 Version 1.0</div></div></div>"},"103228":{"type":"graphic_diagnosticimage","displayName":"US fibularis tendons transverse view above malleolus","title":"US fibularis tendons transverse view above malleolus","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US fibularis tendons transverse view above malleolus</div><div class=\"cntnt\"><img style=\"width:855px; height:595px;\" src=\"images/SM/103228_US_fblr_tndn_trnsv_abv_mlls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the fibular (or peroneal) tendons in a transverse view (short-axis) above the lateral malleolus.</div><div class=\"graphic_footnotes\">Fl: fibularis longus tendon; Fbt: fibularis brevis tendon; Fbm: fibularis brevis muscle. Left side of image: posterior; Right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103228 Version 1.0</div></div></div>"},"103229":{"type":"graphic_diagnosticimage","displayName":"US fibularis tendons transverse view behind malleolus","title":"US fibularis tendons transverse view behind malleolus","html":"<div class=\"graphic\"><div style=\"width: 873px\" class=\"figure\"><div class=\"ttl\">US fibularis tendons transverse view behind malleolus</div><div class=\"cntnt\"><img style=\"width:853px; height:436px;\" src=\"images/SM/103229_US_fblrs_tndn_trnsv_bhnd_ml.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the fibular (or peroneal) tendons in a transverse view (short-axis) behind (or posterior to) the lateral malleolus.</div><div class=\"graphic_footnotes\">Flt: fibularis longus tendon; Fbt: fibularis brevis tendon; LM: lateral malleolus; *: fibrocartilaginous plate; arrowheads: superior fibular retinaculum.<br />Left side of image: posterior; Right side of image: anterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103229 Version 1.0</div></div></div>"},"103230":{"type":"graphic_diagnosticimage","displayName":"US fibularis tendons in short-axis at fibularis trochlea","title":"US fibularis tendons in short-axis at fibularis trochlea","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US fibularis tendons in short-axis at fibularis trochlea</div><div class=\"cntnt\"><img style=\"width:855px; height:408px;\" src=\"images/SM/103230_US_fbl_tnd_shr_axs_fbl_trch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This is an ultrasound image in a transverse oblique plane of the fibular tendons (short-axis view) at the level of the fibularis trochlea.</div><div class=\"graphic_footnotes\">Fl: fibularis longus tendon; Fb: fibularis brevis tendon; FT: fibularis trochlea.<br />Left side of image: posterior; Right side of image: anterior; Left side of image: plantar; Right side of image: dorsal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103230 Version 1.0</div></div></div>"},"103231":{"type":"graphic_diagnosticimage","displayName":"US fibularis brevis insertion long-axis view","title":"US fibularis brevis insertion long-axis view","html":"<div class=\"graphic\"><div style=\"width: 868px\" class=\"figure\"><div class=\"ttl\">US fibularis brevis insertion long-axis view</div><div class=\"cntnt\"><img style=\"width:848px; height:271px;\" src=\"images/SM/103231_US_fblr_brv_insrt_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image in the sagittal plane shows the fibularis brevis tendon insertion (long-axis view).</div><div class=\"graphic_footnotes\">Arrowheads: fibularis brevis tendon; MT: base of fifth metatarsal.<br />Left side of image: caudal; Right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103231 Version 1.0</div></div></div>"},"103232":{"type":"graphic_diagnosticimage","displayName":"US lateral band plantar fascia","title":"US lateral band plantar fascia","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">US lateral band plantar fascia</div><div class=\"cntnt\"><img style=\"width:754px; height:461px;\" src=\"images/SM/103232_US_ltrl_bnd_plntr_fsc_ed1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sagittal oblique plane ultrasound of the lateral band of the plantar fascia (arrowheads). The left side of image corresponds to the cranial end and the right side represents the caudal end.</div><div class=\"graphic_footnotes\">5th: base of fifth metatarsal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103232 Version 2.0</div></div></div>"},"103233":{"type":"graphic_diagnosticimage","displayName":"US sural nerve short-axis view","title":"US sural nerve short-axis view","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US sural nerve short-axis view</div><div class=\"cntnt\"><img style=\"width:855px; height:448px;\" src=\"images/SM/103233_US_srl_nrv_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Transverse plane ultrasound scan of the sural nerve (short-axis view).</div><div class=\"graphic_footnotes\">Dotted ellipse: sural nerve; V: saphenous vein; Ac: Achilles tendon; FM: fibular muscles.<br />Left side of image: anterior; Right side of image: posterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103233 Version 1.0</div></div></div>"},"103235":{"type":"graphic_table","displayName":"Risk stratification model for solitary fibrous tumors","title":"Risk stratification model for solitary fibrous tumors at all sites","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Risk stratification model for solitary fibrous tumors at all sites</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Risk factor</td> <td class=\"subtitle1\">Score</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Age</td> </tr> <tr> <td class=\"indent1\">&#60;55</td> <td>0</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;55</td> <td>1</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Tumor size (cm)</td> </tr> <tr> <td class=\"indent1\">&#60;5</td> <td>0</td> </tr> <tr> <td class=\"indent1\">5 to &#60;10</td> <td>1</td> </tr> <tr> <td class=\"indent1\">10 to &#60;15</td> <td>2</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;15</td> <td>3</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Mitotic figures (/10 high-power fields)</td> </tr> <tr> <td class=\"indent1\">0</td> <td>0</td> </tr> <tr> <td class=\"indent1\">1 to 3</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&#8805;4</td> <td>2</td> </tr> <tr> <td class=\"subtitle1\">Risk</td> <td class=\"subtitle1\">Total score</td> </tr> <tr> <td>Low</td> <td>0 to 2</td> </tr> <tr> <td>Moderate</td> <td>3 to 4</td> </tr> <tr> <td>High</td> <td>5 to 6</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Reprinted by permission from Macmillan Publishers Ltd: Modern Pathology. Demicco EG, Park MS, Araujo DM, et al. Solitary fibrous tumor: a clinicopathological study of 110 cases and proposed risk assessment model. Mod Pathol 2012; 25:1298. Copyright &copy; 2012. <a href=\"http://www.nature.com/modpathol\" spellcheck=\"true\" target=\"_blank\">www.nature.com/modpathol</a>.</div><div id=\"graphicVersion\">Graphic 103235 Version 1.0</div></div></div>"},"103236":{"type":"graphic_table","displayName":"Antiplatelet agents in patients undergoing cardiac surgery","title":"Antiplatelet agents (P2Y<SUB innerHtml>12 </SUB>receptor blockers) in patients undergoing cardiac surgery","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Antiplatelet agents (P2Y<SUB innerHtml>12 </SUB>receptor blockers) in patients undergoing cardiac surgery</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Clopidogrel</td> <td class=\"subtitle1\">Prasugrel</td> <td class=\"subtitle1\">Ticagrelor</td> <td class=\"subtitle1\">Cangrelor</td> </tr> <tr> <td><strong>Mechanism of action</strong></td> <td>Pro-drug, irreversible</td> <td>Pro-drug, irreversible</td> <td>Direct-acting, reversible</td> <td>Direct-acting, reversible</td> </tr> <tr> <td><strong>Formulation</strong></td> <td>Oral</td> <td>Oral</td> <td>Oral</td> <td>IV</td> </tr> <tr> <td><strong>Onset</strong></td> <td>&#8776;6 hours with 600 mg LD</td> <td>&#8776;60 minutes with 60 mg LD</td> <td>&#8776;30 minutes with 180 mg LD</td> <td>&#8776;2&nbsp;minutes</td> </tr> <tr> <td><strong>Extent of platelet inhibition</strong>*</td> <td>&#8776;56%</td> <td>&#62;75%</td> <td>&#8776;93%</td> <td>&#62;90%</td> </tr> <tr> <td><strong>Metabolic activation enzymes</strong></td> <td> <p>1A2, 2C19 (primarily),</p> <p>2B6, 2C9, 3A4, 3A5</p> </td> <td> <p>Intestinal hydrolysis</p> <p>2C19, 2B6, 2C9, 3A4</p> </td> <td>None<sup>&#182;</sup></td> <td>None</td> </tr> <tr> <td><strong>Pharmacokinetic drug interactions<sup>&#916;</sup></strong></td> <td>Many, including PPIs</td> <td>No major</td> <td>Several including CYP3A4 inhibitors and inducers</td> <td>None</td> </tr> <tr> <td><strong>Time to normalization&nbsp;of platelet function</strong></td> <td>&#8776;7&nbsp;days</td> <td>&#8776;7&nbsp;days</td> <td>&#60;5 days</td> <td>&#8776;60 minutes</td> </tr> <tr> <td><strong>Stop time before cardiac surgery</strong></td> <td>5 to 7 days</td> <td>5 to 7 days</td> <td>1&nbsp;to 5 days</td> <td>1 to 6 hours</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IV: intravenous; LD: loading dose; PPI: proton pump inhibitor.<br />* At steady state on maintenance dose.<br />¶ Ticagrelor is metabolized to an active metabolite via CYP3A4; exposure to the active metabolite is about 30 to 40% of the exposure to ticagrelor.<br />Δ Specific interactions may be determined by use of the Lexi-Interact program included within UpToDate.</div><div id=\"graphicVersion\">Graphic 103236 Version 3.0</div></div></div>"},"103237":{"type":"graphic_table","displayName":"Menstrual terminology historical","title":"Terminology for menstrual abnormalities prior to the FIGO Menstrual Disorders Working Group","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Terminology for menstrual abnormalities prior to the FIGO Menstrual Disorders Working Group</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Major terms</td> </tr> <tr> <td class=\"indent1\">Menorrhagia (all usages, including \"essential menorrhagia,\" \"idiopathic menorrhagia,\" \"primary menorrhagia,\" \"functional menorrhagia,\" and \"ovulatory or anovulatory menorrhagia\")</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Metrorrhagia</td> </tr> <tr> <td class=\"subtitle1_single\">Other terms</td> </tr> <tr> <td class=\"indent1\">Dysfunctional uterine bleeding</td> </tr> <tr> <td class=\"indent1\">Epimenorrhagia</td> </tr> <tr> <td class=\"indent1\">Epimenorrhea</td> </tr> <tr> <td class=\"indent1\">Functional uterine bleeding</td> </tr> <tr> <td class=\"indent1\">Hypermenorrhea</td> </tr> <tr> <td class=\"indent1\">Hypomenorrhea</td> </tr> <tr> <td class=\"indent1\">Menometrorrhagia</td> </tr> <tr> <td class=\"indent1\">Metropathica hemorrhagica</td> </tr> <tr> <td class=\"indent1\">Polymenorrhagia</td> </tr> <tr> <td class=\"indent1\">Polymenorrhea</td> </tr> <tr> <td class=\"indent1\">Uterine hemorrhage</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">FIGO: International Federation of Gynecology and Obstetrics.</div><div id=\"graphicVersion\">Graphic 103237 Version 2.0</div></div></div>"},"103238":{"type":"graphic_table","displayName":"Normal menstruation parameters","title":"Normal menstruation parameters","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal menstruation parameters</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical dimensions of menstruation and menstrual cycle</td> <td class=\"subtitle1\">Descriptive terms</td> <td class=\"subtitle1\">Normal limits (5<sup>th</sup> to 95<sup>th</sup> centiles)</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Frequency of menses (days)</td> <td>Absent</td> <td>&nbsp;</td> </tr> <tr> <td>Infrequent</td> <td>&#62;38</td> </tr> <tr> <td>Normal</td> <td>24 to 38</td> </tr> <tr class=\"divider_bottom\"> <td>Frequent</td> <td>&#60;24</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Regularity of menses (variation defined as shortest to longest cycle length, in days)</td> <td>Regular</td> <td>Variation &#8804;7 to&nbsp;9 days*</td> </tr> <tr class=\"divider_bottom\"> <td>Irregular</td> <td>Variation &#62;7 to 9 days*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Duration of flow (days)</td> <td>Normal</td> <td>&#8804;8 days</td> </tr> <tr class=\"divider_bottom\"> <td>Prolonged</td> <td>&#62;8 days</td> </tr> <tr> <td rowspan=\"3\">Volume of monthly blood loss (objective)&nbsp;</td> <td>Heavy</td> <td>&#62;80</td> </tr> <tr> <td>Normal</td> <td>5 to 80</td> </tr> <tr> <td>Light</td> <td>&#60;5</td> </tr> <tr> <td rowspan=\"3\">Volume of monthly blood loss (subjective)</td> <td>Heavy</td> <td rowspan=\"3\"><span style=\"font-size: 10pt; font-family: 'Verdana',sans-serif;\">Clinical definition is subjective and defined as a volume that does not interfere with a woman's physical, social, emotional, and/or quality of life </span><br /> </td> </tr> <tr> <td>Normal</td> </tr> <tr> <td>Light</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Normal variation depends on age; these data are calculated excluding short and long outliers.</div><div class=\"graphic_reference\">Data from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Fraser IS, Critchley HO, Munro MG, Broder M. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.</li>&#xD;&#xA;    <li>Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod 2007; 22:635.</li>&#xD;&#xA;    <li>Fraser IS, Munro MG, Broder M, Critchley HO. International recommendations on terminologies and definitions for normal and abnormal uterine bleeding. Semin Reprod Med 2011.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103238 Version 2.0</div></div></div>"},"103240":{"type":"graphic_table","displayName":"Uterine bleeding patterns","title":"Uterine bleeding patterns","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Uterine bleeding patterns</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Bleeding pattern</td> <td class=\"subtitle1\">Definition</td> </tr> <tr class=\"divider_bottom\"> <td>Bleeding</td> <td> <ul> <li>Any bloody vaginal discharge that requires the use of such protection as pads or tampons</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Spotting</td> <td> <ul> <li>Any bloody vaginal discharge that is not large enough to require sanitary protection</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Bleeding/spotting episode</td> <td> <ul> <li>One or more consecutive days on which bleeding or spotting has been entered on the diary card</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Bleeding/spotting-free interval</td> <td> <ul> <li>One or more consecutive days on which no bleeding or spotting has been entered on the diary card</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Bleeding/spotting segment</td> <td> <ul> <li>One bleeding/spotting episode and the immediately following bleeding/spotting-free interval</li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Reference period</td> <td> <ul> <li>The number of consecutive days upon which the analysis is based (usually taken as 90 days for women using long-acting hormonal systems, and 28 or 30 days for women using once-a-month systems, including combined oral contraception)</li> </ul> </td> </tr> <tr> <td>Different types of analysis, which can be undertaken on bleeding patterns within a reference period</td> <td> <ul> <li>Number of bleeding/spotting days</li> <li>Number of bleeding/spotting episodes</li> <li>Mean, range of lengths of bleeding/spotting episodes (or medians and centiles for box-whisker plot analysis)</li> <li>Mean, range (medians and centiles) of lengths of bleeding/spotting-free intervals</li> <li>Number of spotting days and spotting-only episodes</li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_reference\">Data from: Fraser IS. Bleeding arising from the use of exogenous steroids. Baillieres Best Pract Res Clin Obstet Gynaecol 1999; 13:203.</div><div id=\"graphicVersion\">Graphic 103240 Version 1.0</div></div></div>"},"103241":{"type":"graphic_figure","displayName":"PALM-COEIN AUB terminology documentation","title":"PALM-COEIN AUB terminology documentation form","html":"<div class=\"graphic\"><div style=\"width: 532px\" class=\"figure\"><div class=\"ttl\">PALM-COEIN AUB terminology documentation form</div><div class=\"cntnt\"><img style=\"width:512px; height:766px;\" src=\"images/OBGYN/103241_PALM-COEIN_AUB_term_doc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Single entity.<br />(B) Multiple entity.</div><div class=\"graphic_footnotes\">AUB: abnormal uterine bleeding; P: polyps; A: adenomyosis; L: leiomyoma; SM: submucosal; M: malignancy and hyperplasia; C: coagulopathy; O: ovulatory disorders; E: endometrial disorders; I: iatrogenic; N: not otherwise classified.</div><div class=\"graphic_reference\">Reproduced with permission from Malcom G Munro, MD, FRCS(c), FACOG.</div><div id=\"graphicVersion\">Graphic 103241 Version 1.0</div></div></div>"},"103249":{"type":"graphic_picture","displayName":"US transducer position for tarsal tunnel","title":"US transducer position for tarsal tunnel","html":"<div class=\"graphic\"><div style=\"width: 869px\" class=\"figure\"><div class=\"ttl\">US transducer position for tarsal tunnel</div><div class=\"cntnt\"><img style=\"width:849px; height:377px;\" src=\"images/SM/103249_US_prb_pstn_trsl_tnnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows the proper ultrasound probe position for obtaining an image of the tarsal tunnel.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103249 Version 2.0</div></div></div>"},"103250":{"type":"graphic_diagnosticimage","displayName":"US tarsal tunnel short axis view","title":"US tarsal tunnel short axis view","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US tarsal tunnel short axis view</div><div class=\"cntnt\"><img style=\"width:855px; height:322px;\" src=\"images/SM/103250_US_trsl_tnnl_shrt_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the structures within the tarsal tunnel in the transverse plane (short-axis view).</div><div class=\"graphic_footnotes\">TP: tibialis posterior tendon; FDL: flexor digitorum longus tendon; FHLt: flexor hallucis longus tendon; FHLm: flexor hallucis longus muscle; V: tibial vein; A: tibial artery; dotted ellipse: tibial nerve; arrowheads: flexor retinaculum.<br />Left side of image: anterior; Right side of image: posterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103250 Version 1.0</div></div></div>"},"103251":{"type":"graphic_diagnosticimage","displayName":"US tarsal tunnel tendons at sustentaculum tali short axis","title":"US tarsal tunnel tendons at sustentaculum tali short axis","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US tarsal tunnel tendons at sustentaculum tali short axis</div><div class=\"cntnt\"><img style=\"width:855px; height:369px;\" src=\"images/SM/103251_US_trsl_tnl_tnd_sstntc_shrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the tendons that traverse the tarsal tunnel (short-axis) at the level of the susentaculum tali in the transverse plane (short axis view). Note the anisotropy of the tibialis posterior.</div><div class=\"graphic_footnotes\">FHL: flexor hallucis longus tendon; FDL: flexor digitorum longus tendon; TP: tibialis posterior tendon; ST: susentaculum tali.<br />Left side of image: cranial; Right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103251 Version 1.0</div></div></div>"},"103252":{"type":"graphic_diagnosticimage","displayName":"US tibialis posterior tendon long axis view","title":"US tibialis posterior tendon long axis view","html":"<div class=\"graphic\"><div style=\"width: 872px\" class=\"figure\"><div class=\"ttl\">US tibialis posterior tendon long axis view</div><div class=\"cntnt\"><img style=\"width:852px; height:259px;\" src=\"images/SM/103252_US_tbls_pst_tndn_lng_axs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal oblique plane ultrasound scan of tibialis posterior tendon (long-axis).</div><div class=\"graphic_footnotes\">Arrowheads: tibialis posterior tendon.<br />Left side of image: caudal; Right side of image: cranial.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103252 Version 1.0</div></div></div>"},"103253":{"type":"graphic_diagnosticimage","displayName":"US FHL at talus transverse view","title":"US FHL at talus transverse view","html":"<div class=\"graphic\"><div style=\"width: 875px\" class=\"figure\"><div class=\"ttl\">US FHL at talus transverse view</div><div class=\"cntnt\"><img style=\"width:855px; height:358px;\" src=\"images/SM/103253_US_FHL_tls_trnsvrs_vw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the flexor hallucis longus tendon in the transverse plane at the level of the concave groove of the talus.</div><div class=\"graphic_footnotes\">FHL: flexor hallucis longus tendon; MT: medial tubercle of talus; LT: lateral tubercle of talus.<br />Left side of image: anterior; Right side of image: posterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103253 Version 1.0</div></div></div>"},"103254":{"type":"graphic_diagnosticimage","displayName":"US tibial nerve at tarsal tunnel","title":"US tibial nerve at tarsal tunnel","html":"<div class=\"graphic\"><div style=\"width: 697px\" class=\"figure\"><div class=\"ttl\">US tibial nerve at tarsal tunnel</div><div class=\"cntnt\"><img style=\"width:677px; height:440px;\" src=\"images/SM/103254_US_tbl_nrv_trsl_tnnl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the tibial nerve in the transverse plane (short-axis) at the level of the tarsal tunnel.</div><div class=\"graphic_footnotes\">Dotted ellipse: tibial nerve; V: tibial vein; A: tibial artery; FHL: flexor hallucis longus tendon.<br />Left side of image: anterior; Right side of image: posterior.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103254 Version 1.0</div></div></div>"},"103255":{"type":"graphic_picture","displayName":"US transducer position Achilles tendon insertion","title":"US transducer position Achilles tendon insertion","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position Achilles tendon insertion</div><div class=\"cntnt\"><img style=\"width:395px; height:841px;\" src=\"images/SM/103255_US_prb_potn_achll_tnd_insrt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photographs shows the proper ultrasound probe position to examine the insertion of the Achilles tendon.</div><div class=\"graphic_footnotes\">Rectangle: ultrasound probe.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103255 Version 2.0</div></div></div>"},"103256":{"type":"graphic_diagnosticimage","displayName":"US distal Achilles tendon long axis view","title":"US distal Achilles tendon long axis view","html":"<div class=\"graphic\"><div style=\"width: 871px\" class=\"figure\"><div class=\"ttl\">US distal Achilles tendon long axis view</div><div class=\"cntnt\"><img style=\"width:851px; height:353px;\" src=\"images/SM/103256_US_dstl_achl_tndn_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound shows the distal portion of the Achilles tendon in the sagittal plane (long-axis view).</div><div class=\"graphic_footnotes\">Arrowheads: Achilles tendon; KFP: Kager's fat pad.<br />Left side of image: cranial; Right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103256 Version 2.0</div></div></div>"},"103257":{"type":"graphic_picture","displayName":"US transducer position planta fascia origin","title":"US transducer position planta fascia origin","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">US transducer position planta fascia origin</div><div class=\"cntnt\"><img style=\"width:391px; height:858px;\" src=\"images/SM/103257_US_prb_pstn_plnt_fsc_orgn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows proper ultrasound probe position to image the planta fascia origin.</div><div class=\"graphic_footnotes\">Rectangle: probe position.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103257 Version 2.0</div></div></div>"},"103258":{"type":"graphic_diagnosticimage","displayName":"US plantar fascia origin long-axis view","title":"US plantar fascia origin long-axis view","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">US plantar fascia origin long-axis view</div><div class=\"cntnt\"><img style=\"width:854px; height:294px;\" src=\"images/SM/103258_US_plntr_fsc_orgn_lng_axs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This ultrasound image shows the plantar fascia origin in the sagittal plane (long-axis view).</div><div class=\"graphic_footnotes\">Arrowheads: plantar fascia; CT: medial tubercle of calcaneus; FDB: flexor digitorum brevis muscle.<br />Left side of image: cranial; Right side of image: caudal.</div><div class=\"graphic_reference\">Courtesy of Mederic Hall, MD and Sathish Rajasekaran, MD.</div><div id=\"graphicVersion\">Graphic 103258 Version 1.0</div></div></div>"},"103263":{"type":"graphic_figure","displayName":"Radiographic measurements of the ankle for syndesmotic injury","title":"Radiographic measurements of the ankle for syndesmotic injury","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Radiographic measurements of the ankle for syndesmotic injury</div><div class=\"cntnt\"><img style=\"width:491px; height:548px;\" src=\"images/SM/103263_Radiographic_measurements_of_the_ankle.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The diagram above shows several important anatomic relationships of the ankle that are used to help diagnose syndesmotic injury. The medial clear space (MCS) is the distance between the medial border of the talus (point E)&nbsp;and the lateral border of the medial malleolus (point F) measured 5 mm below the talar dome. The tibiofibular clear space (TFCS) is the distance between the posterolateral tibia (point D) -&nbsp;sometimes called the incisura fibularis -&nbsp;and the medial fibula (point C) measured 10 mm above the tibial articular surface.</div><div id=\"graphicVersion\">Graphic 103263 Version 2.0</div></div></div>"},"103264":{"type":"graphic_figure","displayName":"Metacarpophalangeal extension block splint ","title":"Metacarpophalangeal extension block splint ","html":"<div class=\"graphic\"><div style=\"width: 525px\" class=\"figure\"><div class=\"ttl\">Metacarpophalangeal extension block splint </div><div class=\"cntnt\"><img style=\"width:505px; height:319px;\" src=\"images/SM/103264_Metacarpophalangeal_extension_block_splint.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Dynamic splints, such as the metacarpophalangeal (MCP) block splint pictured above,&nbsp;are an effective tool for treating stable, extra-articular proximal phalanx fractures, and reduce the number of patients with proximal interphalangeal (PIP) and distal interphalangeal (DIP) joint stiffness&nbsp;following treatment.&nbsp;</div><div id=\"graphicVersion\">Graphic 103264 Version 2.0</div></div></div>"},"103267":{"type":"graphic_table","displayName":"Characteristics of alpha-1 antitrypsin variants","title":"Characteristics of alpha-1 antitrypsin variants","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Characteristics of alpha-1 antitrypsin variants</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">PI allele</td> <td class=\"subtitle1\">Cellular defect</td> <td class=\"subtitle1\">Organs affected</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Normal alleles</td> </tr> <tr> <td class=\"indent1\">M (various subtypes)</td> <td>None</td> <td>None</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">X<sub>christchurch</sub></td> <td>None</td> <td>None</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Deficiency alleles associated with intracellular accumulation</td> </tr> <tr> <td class=\"indent1\">Z</td> <td>Intracellular accumulation; defective inhibition of neutrophil elastase</td> <td>Liver, lung</td> </tr> <tr> <td class=\"indent1\">M<sub>malton</sub></td> <td>Intracellular accumulation</td> <td>Liver, lung</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">S<sub>iiyama</sub></td> <td>Intracellular accumulation</td> <td>Liver, lung</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Deficiency alleles associated with intracellular degradation</td> </tr> <tr> <td class=\"indent1\">M<sub>heerlen</sub></td> <td>Intracellular degradation</td> <td>Lung</td> </tr> <tr> <td class=\"indent1\">M<sub>procida</sub></td> <td>Intracellular degradation</td> <td>Lung</td> </tr> <tr> <td class=\"indent1\">M<sub>mineral springs</sub></td> <td>Intracellular degradation; defective inhibition of neutrophil elastase</td> <td>Lung</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">S</td> <td>Intracellular degradation</td> <td>Lung</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Null alleles*</td> </tr> <tr> <td class=\"indent1\">QO<sub>granite falls</sub></td> <td>Stop codon; no mRNA or protein</td> <td>Emphysema</td> </tr> <tr> <td class=\"indent1\">QO<sub>ludwigshafen</sub></td> <td>mRNA present but abnormal; protein destabilized</td> <td>Liver, lung</td> </tr> <tr> <td class=\"indent1\">QO<sub>hongkong</sub><sup>1</sup></td> <td>Frameshift with stop codon; short protein; intracellular accumulation</td> <td>Early onset emphysema</td> </tr> <tr> <td class=\"indent1\">QO<sub>isola di procida</sub></td> <td>Deletion; no mRNA; no protein</td> <td>High risk of emphysema</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">QO<sub>bolton</sub></td> <td>Stop codon; no mRNA or protein</td> <td>High risk emphysema</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"3\">Dysfunctional alleles</td> </tr> <tr> <td class=\"indent1\">Pittsburg</td> <td>Substitution</td> <td>Bleeding diathesis due change in protein to have antithrombin properties</td> </tr> <tr> <td class=\"indent1\">F</td> <td>Impaired binding to neutrophil elastase</td> <td>Normal serum alpha-1 antitrypsin level but impaired anti-elastase functional activity</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Null alleles have less than 1% of the normal concentration of alpha-1 antitrypsin.</div><div class=\"graphic_reference\">Data adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>DeMeo DL, Silverman EK. Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk. Thorax 2004; 59:259.</li>&#xD;&#xA;    <li>Frazier GC1, Siewertsen MA, Hofker MH, et al. A null deficiency allele of alpha 1-antitrypsin, QOludwigshafen, with altered tertiary structure. J Clin Invest 1990; 86:1878.</li>&#xD;&#xA;    <li>OMIM. <a href=\"http://www.omim.org/allelicVariant/107400\" spellcheck=\"true\" target=\"_blank\">http://www.omim.org/allelicVariant/107400</a> (Accessed on September 14, 2015).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103267 Version 1.0</div></div></div>"},"103268":{"type":"graphic_figure","displayName":"Hands-free pacemaker/defibrillator pad positioning","title":"Options for hands-free pacemaker/defibrillator pad positioning","html":"<div class=\"graphic\"><div style=\"width: 547px\" class=\"figure\"><div class=\"ttl\">Options for hands-free pacemaker/defibrillator pad positioning</div><div class=\"cntnt\"><img style=\"width:527px; height:407px;\" src=\"images/CARD/103268_Defibrillator_pad_placements.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Positioning options for hands-free pacemaker/defibrillator pads showing anterior/lateral positioning (left) and anterior/posterior positioning (right).</div><div id=\"graphicVersion\">Graphic 103268 Version 2.0</div></div></div>"},"103269":{"type":"graphic_figure","displayName":"Extraoral TMJ dislocation reduction","title":"Extraoral temporomandibular joint dislocation reduction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Extraoral temporomandibular joint dislocation reduction</div><div class=\"cntnt\"><img style=\"width:398px; height:724px;\" src=\"images/EM/103269_Extrrlrdcttmpmndbljntdslct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Extraoral manual method for TMJ reduction. On one side, the fingers hold the mandible angle and pull the mandible more anteriorly (arrow). The thumb is placed over the malar eminence and serves as a fulcrum (arrowhead). This maneuver further dislocates the ipsilateral TMJ (dashed arrow), rotates the dislocated jaw, and facilitates the contralateral TMJ reduction.<br />(B) On the other side, the thumb is placed just above the anterior displaced coronoid process and applies persistent pressure to push the dislocated mandible back (arrow). The fingers are placed behind the mastoid process to provide a counteractive force (arrowhead). The dislocated condyle head is pushed back to the mandibular fossa (dashed arrow).</div><div class=\"graphic_footnotes\">TMJ: temporomandibular joint.</div><div class=\"graphic_reference\">From: Chen YC, Chen CT, Lin CH, Chen YR. A safe and effective way for reduction of temporomandibular joint dislocation. Ann Plast Surg 2007; 58:105. DOI: <a href=\"http://journals.lww.com/annalsplasticsurgery/pages/articleviewer.aspx?year=2007&amp;issue=01000&amp;article=00020&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/01.sap.0000232981.40497.32</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103269 Version 5.0</div></div></div>"},"103270":{"type":"graphic_figure","displayName":"Wrist pivot technique for TMJ dislocation reduction","title":"Wrist pivot technique for temporomandibular dislocation reduction","html":"<div class=\"graphic\"><div style=\"width: 507px\" class=\"figure\"><div class=\"ttl\">Wrist pivot technique for&nbsp;temporomandibular dislocation reduction</div><div class=\"cntnt\"><img style=\"width:487px; height:564px;\" src=\"images/EM/103270_WristpivottechniqueforTMJdislocation.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After protecting the fingers with gauze (not shown in the illustration), the clinician applies upward pressure at the point of the chin with the thumbs and downward pressure on the occlusal surfaces of the lower molars with the fingers. By pivoting the wrists forward, the dislocation is reduced.</div><div id=\"graphicVersion\">Graphic 103270 Version 4.0</div></div></div>"},"103271":{"type":"graphic_diagnosticimage","displayName":"Mandibular coronoid process dislocation anatomy","title":"Location of the mandibular coronoid process during temporomandibular dislocation","html":"<div class=\"graphic\"><div style=\"width: 678px\" class=\"figure\"><div class=\"ttl\">Location of the mandibular coronoid process during temporomandibular dislocation</div><div class=\"cntnt\"><img style=\"width:658px; height:573px;\" src=\"images/EM/103271_Mndbl_crnd_prcs_dslct_ant.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">When the TMJ is anteriorly dislocated, the mandible is displaced forward away from its resting position. The anterior part of the ramus and coronoid process become prominent (arrow) and palpable.</div><div class=\"graphic_footnotes\">TMJ: temporomandibular joint.</div><div class=\"graphic_reference\">From: Chen YC, Chen CT, Lin CH, Chen YR. A safe and effective way for reduction of temporomandibular joint dislocation. Ann Plast Surg 2007; 58:105. DOI: <a href=\"http://journals.lww.com/annalsplasticsurgery/pages/articleviewer.aspx?year=2007&amp;issue=01000&amp;article=00020&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/01.sap.0000232981.40497.32</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2007. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103271 Version 1.0</div></div></div>"},"103272":{"type":"graphic_picture","displayName":"Syringe technique for TMJ dislocation reduction","title":"Syringe technique for reduction of temporomandibular joint dislocation","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Syringe technique for reduction of temporomandibular joint dislocation</div><div class=\"cntnt\"><img style=\"width:539px; height:373px;\" src=\"images/EM/103272_SyringetechniqueforTMJdislocationreduction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Dislocated TMJ where the condyle is displaced anterior to the articular eminence with syringe placement between the posterior molars. The patient pushes the chin forward to roll the syringe as shown. <br />(B) On reversing direction of the syringe rolling, the condyle has moved inferiorly and may reduce.<br />(C) Final reduced position of the mandible with the syringe still in place.</div><div class=\"graphic_footnotes\">TMJ: temporomandibular joint; Z: zygomatic bone; C: condyle.</div><div class=\"graphic_reference\">Original figure modified for this publication. Gorchynski J, Karabidian E, Sanchez M. The \"syringe\" technique: a hands-free approach for the reduction of acute nontraumatic temporomandibular dislocations in the emergency department. J Emerg Med 2014; 47:676. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103272 Version 3.0</div></div></div>"},"103274":{"type":"graphic_picture","displayName":"Cutis verticis gyrata primary non-essential","title":"Cutis verticis gyrata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis verticis gyrata</div><div class=\"cntnt\"><img style=\"width:357px; height:236px;\" src=\"images/DERM/103274_Ct_vrtc_gyrt_prm_no_essntl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary non-essential acquired cutis verticis gyrata. Tightly bound folds in the scalp of an 11-year-old girl with mental retardation.</div><div class=\"graphic_reference\">From: Larsen F, Birchall N. Cutis verticis gyrata: three cases with different aetiologies that demonstrate the classification system. Australas J Dermatol 2007; 48:91. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1440-0960.2007.00343.x/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1440-0960.2007.00343.x/abstract</a>. Copyright &copy; 2007 The Australasian College of Dermatologists. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true target=\"_blank\"\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103274 Version 1.0</div></div></div>"},"103275":{"type":"graphic_picture","displayName":"Cutis verticis gyrata Noonan","title":"Cutis verticis gyrata","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Cutis verticis gyrata</div><div class=\"cntnt\"><img style=\"width:357px; height:358px;\" src=\"images/DERM/103275_Cutis_verticis_gyrata.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary non-essential congenital cutis verticis gyrata. Vertical furrows and folds on the anterior scalp of a 13-day-old neonate in association with Noonan's syndrome.</div><div class=\"graphic_reference\">From: Larsen F, Birchall N. Cutis verticis gyrata: three cases with different aetiologies that demonstrate the classification system. Australas J Dermatol 2007; 48:91. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1440-0960.2007.00343.x/abstract\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1440-0960.2007.00343.x/abstract</a>. Copyright &copy; 2007 The Australasian College of Dermatologists. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103275 Version 1.0</div></div></div>"},"103276":{"type":"graphic_picture","displayName":"Necrobiotic xanthogranuloma cholesterol clefts","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:612px; height:480px;\" src=\"images/DERM/103276_Ncrb_xnthgrn_chlst_clft.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Palisading granuloma with necrobiotic debris containing cholesterol clefts rimmed by mononuclear and multinucleate histiocytes and lymphoplasmacytic inflammation.</div><div class=\"graphic_reference\">Courtesy of Janine C Malone, MD.</div><div id=\"graphicVersion\">Graphic 103276 Version 1.0</div></div></div>"},"103277":{"type":"graphic_figure","displayName":"Plantar tarsometatarsal and plantar metatarsal ligaments","title":"Plantar tarsometatarsal ligaments and plantar metatarsal ligaments","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Plantar tarsometatarsal ligaments and plantar metatarsal ligaments</div><div class=\"cntnt\"><img style=\"width:374px; height:552px;\" src=\"images/SM/103277_Plantrtarsometatrslligmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The plantar tarsometatarsal ligaments and plantar metatarsal ligaments are&nbsp;shown above.&nbsp;Note the absence of a plantar metatarsal ligament between the base of the first and second metatarsals. The Plantar Lisfranc ligament (arrow) runs obliquely from the medial cuneiform to the base of the second metatarsal.</div><div class=\"graphic_reference\">Reproduced with permission from: Demetracopoulos CA, Deland JT. Anatomy and biomechanics of the foot and ankle. In: Orthopaedic Surgery Essentials: Foot and Ankle, Thordarson DB (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103277 Version 2.0</div></div></div>"},"103278":{"type":"graphic_picture","displayName":"Necrobiotic xanthogranuloma necrobiosis and giant cells","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:612px; height:480px;\" src=\"images/DERM/103278_Ncrbtc_xnthgrn_ncrbs_gnt_cl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrobiotic debris containing cholesterol clefts and nuclear debris rimmed by mononuclear histiocytes and bizarre multinucleate giant cells.</div><div class=\"graphic_reference\">Courtesy of Janine C Malone, MD.</div><div id=\"graphicVersion\">Graphic 103278 Version 1.0</div></div></div>"},"103279":{"type":"graphic_picture","displayName":"Necrobiotic xanthogranuloma cholesterol clefts and giant cells","title":"Necrobiotic xanthogranuloma","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Necrobiotic xanthogranuloma</div><div class=\"cntnt\"><img style=\"width:612px; height:480px;\" src=\"images/DERM/103279_Ncrb_xnthgr_chlst_clft_gnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Necrobiotic debris containing cholesterol clefts and nuclear debris rimmed by mononuclear histiocytes and multinucleate giant cells.</div><div class=\"graphic_reference\">Courtesy of Janine C Malone, MD.</div><div id=\"graphicVersion\">Graphic 103279 Version 1.0</div></div></div>"},"103281":{"type":"graphic_table","displayName":"Normal BP for infants","title":"Normal blood pressure for infants at one year of age","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Normal blood pressure for infants at one year of age</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"16\" width=\"6%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"3\">Gender</td> <td class=\"subtitle1\" rowspan=\"3\">BP<br /> (percentile)</td> <td class=\"subtitle1\" colspan=\"7\">Systolic BP (mmHg)</td> <td class=\"subtitle1\" colspan=\"7\">Diastolic BP (mmHg)</td> </tr> <tr> <td class=\"subtitle2\" colspan=\"7\">Percentile of height</td> <td class=\"subtitle2\" colspan=\"7\">Percentile of height</td> </tr> <tr> <td class=\"subtitle3\">5<sup>th</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">25<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">75<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">95<sup>th</sup></td> <td class=\"subtitle3\">5<sup>th</sup></td> <td class=\"subtitle3\">10<sup>th</sup></td> <td class=\"subtitle3\">25<sup>th</sup></td> <td class=\"subtitle3\">50<sup>th</sup></td> <td class=\"subtitle3\">75<sup>th</sup></td> <td class=\"subtitle3\">90<sup>th</sup></td> <td class=\"subtitle3\">95<sup>th</sup></td> </tr> <tr class=\"highlight_blue_text centered\"> <td class=\"divider_bottom\" rowspan=\"4\">Boys</td> <td>50<sup>th</sup></td> <td>80</td> <td>81</td> <td>83</td> <td>85</td> <td>87</td> <td>88</td> <td>89</td> <td>34</td> <td>35</td> <td>36</td> <td>37</td> <td>38</td> <td>39</td> <td>39</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>90<sup>th</sup></td> <td>94</td> <td>95</td> <td>97</td> <td>99</td> <td>100</td> <td>102</td> <td>103</td> <td>49</td> <td>50</td> <td>51</td> <td>52</td> <td>53</td> <td>53</td> <td>54</td> </tr> <tr class=\"highlight_blue_text centered\"> <td>95<sup>th</sup></td> <td>98</td> <td>99</td> <td>101</td> <td>103</td> <td>104</td> <td>106</td> <td>106</td> <td>54</td> <td>54</td> <td>55</td> <td>56</td> <td>57</td> <td>58</td> <td>58</td> </tr> <tr class=\"highlight_blue_text centered divider_bottom\"> <td>99<sup>th</sup></td> <td>105</td> <td>106</td> <td>108</td> <td>110</td> <td>112</td> <td>113</td> <td>114</td> <td>61</td> <td>62</td> <td>63</td> <td>64</td> <td>65</td> <td>66</td> <td>66</td> </tr> <tr class=\"highlight_red_text centered\"> <td rowspan=\"4\">Girls</td> <td>50<sup>th</sup></td> <td>83</td> <td>84</td> <td>85</td> <td>86</td> <td>88</td> <td>89</td> <td>90</td> <td>38</td> <td>39</td> <td>39</td> <td>40</td> <td>41</td> <td>41</td> <td>42</td> </tr> <tr class=\"highlight_red_text centered\"> <td>90<sup>th</sup></td> <td>97</td> <td>97</td> <td>98</td> <td>100</td> <td>101</td> <td>102</td> <td>103</td> <td>52</td> <td>53</td> <td>53</td> <td>54</td> <td>55</td> <td>55</td> <td>56</td> </tr> <tr class=\"highlight_red_text centered\"> <td>95<sup>th</sup></td> <td>100</td> <td>101</td> <td>102</td> <td>104</td> <td>105</td> <td>106</td> <td>107</td> <td>56</td> <td>57</td> <td>57</td> <td>58</td> <td>59</td> <td>59</td> <td>60</td> </tr> <tr class=\"highlight_red_text centered\"> <td>99<sup>th</sup></td> <td>108</td> <td>108</td> <td>109</td> <td>111</td> <td>112</td> <td>113</td> <td>114</td> <td>64</td> <td>64</td> <td>65</td> <td>65</td> <td>66</td> <td>67</td> <td>67</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">The 90<sup>th</sup> percentile is 1.28 standard deviation, 95<sup>th</sup> percentile is 1.645 standard deviation, and the 99<sup>th</sup> percentile is 2.326 over the mean.</div><div class=\"graphic_footnotes\">BP: blood pressure.</div><div class=\"graphic_reference\">Data from: Fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. National Heart, Lung, and Blood Institute. National Institutes of Health, May 2004.</div><div id=\"graphicVersion\">Graphic 103281 Version 1.0</div></div></div>"},"103283":{"type":"graphic_table","displayName":"Diagnostic clues to congenital myasthenic syndromes","title":"Diagnostic clues to the defective protein in congenital myasthenic syndromes","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic clues to the defective protein in congenital myasthenic syndromes</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Slow-channel congenital myasthenic syndrome</td> </tr> <tr> <td class=\"indent1\">Dominantly inherited mutation in an acetylcholine receptor subunit gene</td> </tr> <tr> <td class=\"subtitle1_single\">CMS refractory to or worsened by acetylcholinesterase inhibitors</td> </tr> <tr> <td class=\"indent1\">ColQ subunit of the endplate-specific form of acetylcholinesterase, Dok-7, MuSK, agrin, LRP4, plectin, or laminin &#946;2</td> </tr> <tr> <td class=\"subtitle1_single\">Repetitive compound muscle action potential evoked by single nerve stimuli</td> </tr> <tr> <td class=\"indent1\">Slow-channel CMS and ColQ</td> </tr> <tr> <td class=\"subtitle1_single\">Delayed pupillary light response</td> </tr> <tr> <td class=\"indent1\">Some patients with ColQ mutations</td> </tr> <tr> <td class=\"subtitle1_single\">Congenital contractures</td> </tr> <tr> <td class=\"indent1\">Rapsyn, acetylcholine receptor &#948; or &#947; subunit, or choline acetyltransferase</td> </tr> <tr> <td class=\"subtitle1_single\">Greater than 50% decrease of compound muscle action potential amplitude after subtetanic stimulation at 10 Hz for 5 minutes followed by slow recovery over 5 to 10 minutes</td> </tr> <tr> <td class=\"indent1\">Choline acetyltransferase</td> </tr> <tr> <td class=\"subtitle1_single\">Sudden apnoeic episodes induced by fever or stress</td> </tr> <tr> <td class=\"indent1\">Choline acetyltransferase, rapsyin, or sodium channel myasthenia</td> </tr> <tr> <td class=\"subtitle1_single\">Limb-girdle and axial distribution of weakness</td> </tr> <tr> <td class=\"indent1\">Dok7, GFPT1, DPAGT1, ALG2, ALG14, GMPPB; occasionally rapsyn or ColQ</td> </tr> <tr> <td class=\"subtitle1_single\">Tubular aggregates of the sarcoplasmic reticulum in muscle fibres</td> </tr> <tr> <td class=\"indent1\">GFPT1, DPAGT1, ALG2</td> </tr> <tr> <td class=\"subtitle1_single\">Autophagic myopathy</td> </tr> <tr> <td class=\"indent1\">GFPT1, DPAGT1</td> </tr> <tr> <td class=\"subtitle1_single\">Stridor and vocal cord paralysis in neonates or infants</td> </tr> <tr> <td class=\"indent1\">Dok-7</td> </tr> <tr> <td class=\"subtitle1_single\">Nephrotic syndrome and ocular malformations</td> </tr> <tr> <td class=\"indent1\">Laminin &#946;2</td> </tr> <tr> <td class=\"subtitle1_single\">Association with seizures or intellectual disability</td> </tr> <tr> <td class=\"indent1\">DPAGT1</td> </tr> <tr> <td class=\"subtitle1_single\">Association with epidermolysis bullosa simplex and muscular dystrophy</td> </tr> <tr> <td class=\"indent1\">Plectin</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">Hz: hertz.</div><div class=\"graphic_reference\">Modified from: Engel AG, Shen XM, Selcen D, Sine SM. Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment. Lancet Neurol 2015; 14:420. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103283 Version 2.0</div></div></div>"},"103284":{"type":"graphic_table","displayName":"Criteria for palliative care referral chronic lung disease","title":"Criteria for considering a palliative care referral in patients with chronic lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Criteria for considering a palliative care referral in patients with chronic lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Patient characteristics</td> <td class=\"subtitle1\">Social circumstances or issues related to anticipatory bereavement</td> </tr> <tr> <td>Limited options for treatment</td> <td>Limited access to care</td> </tr> <tr> <td>Physical symptoms, such as pain, dyspnea, or cough, that are refractory to conventional management</td> <td>Familial factors, including: <ul class=\"decimal_heading\"> <li>Limitations of the family/caregiver</li> <li>Inadequate family support</li> <li>Family discord</li> <li>History of intensely dependent relationship(s)</li> <li>Parental concerns regarding care of dependents</li> </ul> </td> </tr> <tr> <td>High symptom burden or distress score</td> <td>Financial limitations</td> </tr> <tr> <td>Inability to engage in advance care planning and care plan</td> <td>Unresolved grief or multiple prior losses</td> </tr> <tr> <td>Uncertainty as to prognosis or disease trajectory</td> <td>Spiritual or existential crisis</td> </tr> <tr> <td>Cognitive impairment</td> <td>Need for coordination of care at multiple sites</td> </tr> <tr> <td>Severe or multiple comorbid conditions</td> <td>&nbsp;</td> </tr> <tr> <td>Communication barriers related to language, literacy, or physical issues</td> <td>&nbsp;</td> </tr> <tr> <td>Request for hastened death</td> <td>&nbsp;</td> </tr> <tr> <td>Homebound </td> <td>&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from: NCCN Guidelines Version 2.2012, Palliative Care <A spellcheck=true href=\"http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive\"target=_blank>http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#supportive</A>.</div><div id=\"graphicVersion\">Graphic 103284 Version 1.0</div></div></div>"},"103286":{"type":"graphic_table","displayName":"Primary palliative care assessment in chronic lung disease","title":"Primary palliative care assessment of patients with chronic lung disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Primary palliative care assessment of patients with chronic lung disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Understanding of illness/prognosis and treatment options</td> </tr> <tr> <td class=\"indent1\">Does the patient/family/surrogate understand the current illness, their prognosis for quantity and quality of life, expected disease trajectory/uncertainty about disease trajectory, and treatment options?</td> </tr> <tr> <td class=\"subtitle1_single\">Symptom management</td> </tr> <tr> <td class=\"indent1\">Does the patient have uncontrolled/distressing symptoms? In particular, does the patient have any of the following?</td> </tr> <tr> <td class=\"indent2\"> <ul> <li>Pulmonary symptoms (cough, dyspnea) with daily activities</li> <li>Pain</li> <li>Fatigue and sleep disturbance</li> <li>Distressing psychological symptoms (depression and anxiety)</li> <li>Constitutional symptoms (anorexia and weight loss)</li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Social/spiritual assessment</td> </tr> <tr> <td class=\"indent1\">Are there significant social or spiritual concerns affecting daily life?</td> </tr> <tr> <td class=\"subtitle1_single\">Decision making</td> </tr> <tr> <td class=\"indent1\">Is the patient comfortable making health care decisions? Or, does the patient rely on family members, friends, or health care professionals to make decisions?</td> </tr> <tr> <td class=\"indent1\">Has the patient identified a surrogate decision-maker and talked with this person about their goals and values?</td> </tr> <tr> <td class=\"indent1\">Would the patient/family/surrogate like help with treatment decision-making?</td> </tr> <tr> <td class=\"subtitle1_single\">Identification of patient-centered goals of care</td> </tr> <tr> <td class=\"indent1\">What are the goals for care, as identified by the patient/family/surrogate?</td> </tr> <tr> <td class=\"indent1\">Are treatment options matched to informed patient-centered goals?</td> </tr> <tr> <td class=\"indent1\">Has the patient participated in an advance care planning process?</td> </tr> <tr> <td class=\"indent1\">Has the patient completed an advance care planning document?</td> </tr> <tr> <td class=\"subtitle1_single\">Coping with life-threatening illness</td> </tr> <tr> <td class=\"indent1\">How is the patient coping with their illness?</td> </tr> <tr> <td class=\"indent1\">How are the family/family caregivers coping with the illness?</td> </tr> <tr> <td class=\"subtitle1_single\">Coordination of care</td> </tr> <tr> <td class=\"indent1\">Are there barriers to safe and sustainable transitions from one setting to another (eg, transportation to appointments)?</td> </tr> <tr> <td class=\"indent1\">Are systems in place to enable good communication between multiple providers?</td> </tr> </tbody></table></div><div class=\"graphic_reference\">Adapted from:&#xD;&#xA;<ol>&#xD;&#xA;    <li>​Jacobsen J, Jackson V, Dahlin C, et al. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer. J Palliat Medicine 2011; 14:459.</li>&#xD;&#xA;    <li>Weissman DE, Meier DE. Identifying patients in need of a palliative care assessment in the hospital setting. J Palliat Med 2011; 14:17.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103286 Version 1.0</div></div></div>"},"103287":{"type":"graphic_figure","displayName":"Stage wake","title":"Stage wake","html":"<div class=\"graphic\"><div style=\"width: 1005px\" class=\"figure\"><div class=\"ttl\">Stage wake</div><div class=\"cntnt\"><img style=\"width:985px; height:278px;\" src=\"images/SLEEP/103287_Stage_wake.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage wake with eyes closed, notable for the alpha activity occurring the occipital leads (labeled O2-M1 and O1-M2). The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103287 Version 1.0</div></div></div>"},"103288":{"type":"graphic_figure","displayName":"Stage N1 sleep","title":"Stage N1 sleep","html":"<div class=\"graphic\"><div style=\"width: 1001px\" class=\"figure\"><div class=\"ttl\">Stage N1 sleep</div><div class=\"cntnt\"><img style=\"width:981px; height:299px;\" src=\"images/SLEEP/103288_Stage_N1_sleep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage N1 sleep, notable for the theta activity throughout the first three quarters of the epoch. An arousal occurs at that time (arrow), with a return of alpha activity. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103288 Version 1.0</div></div></div>"},"103289":{"type":"graphic_figure","displayName":"Stage N2 sleep: Spindle","title":"Stage N2 sleep: Spindle","html":"<div class=\"graphic\"><div style=\"width: 1004px\" class=\"figure\"><div class=\"ttl\">Stage N2 sleep: Spindle</div><div class=\"cntnt\"><img style=\"width:984px; height:285px;\" src=\"images/SLEEP/103289_Stg_N2_slp_spndl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage&nbsp;N2 sleep. Most notable is the beta-frequency spindle activity (dashed box), maximally seen in the central EEG leads. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103289 Version 1.0</div></div></div>"},"103290":{"type":"graphic_figure","displayName":"Stage N2 sleep: K-complex","title":"Stage N2 sleep: K-complex","html":"<div class=\"graphic\"><div style=\"width: 1138px\" class=\"figure\"><div class=\"ttl\">Stage N2 sleep: K-complex</div><div class=\"cntnt\"><img style=\"width:1118px; height:301px;\" src=\"images/SLEEP/103290_Stg_N2_slp_K_cmplx.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage N2 sleep. Most notable are the K-complexes (dashed boxes), maximally seen in the frontal and central EEG leads. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103290 Version 2.0</div></div></div>"},"103291":{"type":"graphic_figure","displayName":"Stage N3 sleep","title":"Stage N3 sleep","html":"<div class=\"graphic\"><div style=\"width: 1003px\" class=\"figure\"><div class=\"ttl\">Stage N3 sleep</div><div class=\"cntnt\"><img style=\"width:983px; height:276px;\" src=\"images/SLEEP/103291_Stage_N3_sleep.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage N3 sleep. Most notable are the delta waves throughout the EEG recording (background shading), maximal in the frontal leads. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103291 Version 1.0</div></div></div>"},"103292":{"type":"graphic_figure","displayName":"Stage R sleep: Phasic","title":"Stage R sleep: Phasic","html":"<div class=\"graphic\"><div style=\"width: 1006px\" class=\"figure\"><div class=\"ttl\">Stage R sleep: Phasic</div><div class=\"cntnt\"><img style=\"width:986px; height:280px;\" src=\"images/SLEEP/103292_Stage_R_slp_phsc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage R sleep. Most notable is the cluster of rapid eye movements noted in the eye leads (background shading). The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103292 Version 1.0</div></div></div>"},"103293":{"type":"graphic_figure","displayName":"Stage R sleep: Tonic","title":"Stage R sleep: Tonic","html":"<div class=\"graphic\"><div style=\"width: 1014px\" class=\"figure\"><div class=\"ttl\">Stage R sleep: Tonic</div><div class=\"cntnt\"><img style=\"width:994px; height:278px;\" src=\"images/SLEEP/103293_Stage_R_slp_tnc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage R sleep. Most notable is the absence of rapid eye movements noted in the eye leads (labeled E2-M2 and E1-M2) or phasic EMG activity. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103293 Version 1.0</div></div></div>"},"103294":{"type":"graphic_figure","displayName":"Arousal from sleep","title":"Arousal from sleep","html":"<div class=\"graphic\"><div style=\"width: 1004px\" class=\"figure\"><div class=\"ttl\">Arousal from sleep</div><div class=\"cntnt\"><img style=\"width:984px; height:280px;\" src=\"images/SLEEP/103294_Arousal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This image demonstrates a 30-second recording (Compumedics) of stage N2 sleep. Most notable is the arousal that occurs at the solid arrow, with a switch from theta EEG activity to alpha EEG activity. The top two leads represent the eyes (right and left), the next lead is the chin, then the following six leads are EEG (right and left frontal, central, and occipital), ECG with heart rate below (R-R), and the leg EMG lead.</div><div class=\"graphic_footnotes\">EEG: electroencephalogram; ECG: electrocardiogram; EMG: electromyography.</div><div id=\"graphicVersion\">Graphic 103294 Version 2.0</div></div></div>"},"103295":{"type":"graphic_algorithm","displayName":"Algorithm for evaluation of suspected SSS","title":"Algorithm for evaluation of the patient with suspected sick sinus syndrome (SSS)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Algorithm for evaluation of the patient with suspected sick sinus syndrome (SSS)</div><div class=\"cntnt\"><img style=\"width:407px; height:462px;\" src=\"images/CARD/103295_suspected_sss.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">H&amp;P: history and physical; ECG: electrocardiogram; ETT: exercise treadmill test; PPM: permanent pacemaker; SSS: sick sinus syndrome.</div><div id=\"graphicVersion\">Graphic 103295 Version 1.0</div></div></div>"},"103299":{"type":"graphic_picture","displayName":"UAC complication infarction of toes","title":"Umbilical catheter complication: Embolic thrombi resulting from infarction of the toes (\"cath toes\")","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Umbilical catheter complication: Embolic thrombi resulting from infarction of the toes (\"cath toes\")</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/PEDS/103299_UAC_complic_infarction_toes.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103299 Version 1.0</div></div></div>"},"103301":{"type":"graphic_diagnosticimage","displayName":"Radioisotope cisternography of CSF leak","title":"Radioisotope cisternography in a patient with slow‐flow CSF leak","html":"<div class=\"graphic\"><div style=\"width: 627px\" class=\"figure\"><div class=\"ttl\">Radioisotope cisternography in a patient with slow‐flow CSF leak</div><div class=\"cntnt\"><img style=\"width:607px; height:641px;\" src=\"images/NEURO/103301_Rdstp_cstrn_CSF_lk.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A-D) Cisternographic images of head and entire spine.<br />(E) Lower left panel shows left lateral cisternographic images of head and cervical spine.<br />(F,G) Shows axial view CT-myelograms. Note cephalad expansion of intrathecally-introduced radioisotope and multiple meningeal diverticula and dilated nerve root sleeves (arrows). Sequential imaging at less than 20 minutes, at 2 hours, at 4 hours, and at 24 hours shows that radioactivity even at 24 hours does not reach the sagittal vertex area or much of the cerebral convexities.</div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; CT: computed tomography.</div><div class=\"graphic_reference\">From: Mokri B. Radioisotope cisternography in spontaneous CSF leaks: interpretations and misinterpretations. Headache 2014; 54:1358. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/head.12421/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/head.12421/abstract</a>. Copyright &copy; 2014 American Headache Society. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com%20target=\" spellcheck=\"true\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103301 Version 2.0</div></div></div>"},"103302":{"type":"graphic_table","displayName":"Metered dose inhaler technique without spacer or chamber","title":"Technique for use of a metered dose inhaler (MDI) without a spacer or chamber","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of a metered dose inhaler (MDI) without a spacer or chamber</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Remove the cover of the mouthpiece.</td> </tr> <tr> <td>Prime your inhaler if this is the first time you are using it, if you have not used it for several days, or if you have dropped it. Priming an MDI usually involves shaking it and spraying it into the air (away from your face) a total of up to four times. See the information that came with your inhaler for exact instructions.</td> </tr> <tr> <td>Shake MDI canister vigorously for five seconds.</td> </tr> <tr> <td>Hold the MDI upright with your index finger on the top of the medication canister and your thumb supporting the bottom of the inhaler.</td> </tr> <tr> <td>Breathe out normally.</td> </tr> <tr> <td>Put the mouthpiece between your teeth and close your lips around mouthpiece or position mouthpiece approximately 4 cm (approximately width of two fingers) from your mouth.</td> </tr> <tr> <td>Keep your tongue away from the opening of the mouthpiece.</td> </tr> <tr> <td>Press down the top of the canister with the index finger to release the medication.</td> </tr> <tr> <td>At the same time as the canister is pressed, breathe in deeply and slowly through your mouth until your lungs are completely filled; this should take four to six seconds.</td> </tr> <tr> <td>Hold the medication in your lungs for as long as comfortable (approximately&nbsp;5 to 10&nbsp;seconds) before breathing out.</td> </tr> <tr> <td>If you need a second puff, wait&nbsp;approximately 15 to 30 seconds between puffs. Shake canister again before the next puff.</td> </tr> <tr> <td>When finished, recap mouthpiece.</td> </tr> <tr> <td>If your inhaler contains a steroid medicine (sometimes called glucocorticoid or corticosteroid), rinse your mouth and gargle with water after you use it. Then spit out the water. Do not swallow it.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These instructions do NOT apply to dry powder or soft mist inhalers. Cleaning instructions are provided separately.<br />More detailed information about individual medication formulations can be found at <a href=\"http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm\" target=\"_blank\">http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm</a>.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.</div><div id=\"graphicVersion\">Graphic 103302 Version 4.0</div></div></div>"},"103303":{"type":"graphic_table","displayName":"Metered dose inhaler technique with spacer or chamber","title":"Technique for use of a metered dose inhaler (MDI) with a spacer or chamber*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Technique for use of a metered dose inhaler (MDI) with a spacer or chamber*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Uncap mouthpiece and check for loose objects in the device.</td> </tr> <tr> <td>Prime your inhaler if this is the first time you are using it, if you have not used it for several days, or if you have dropped it. Priming an MDI usually involves shaking it and spraying it into the air (away from your face) a total of up to four times. See the information that came with your inhaler for exact instructions.</td> </tr> <tr> <td>Insert MDI into spacer.</td> </tr> <tr> <td>Shake canister vigorously for&nbsp;approximately five seconds.</td> </tr> <tr> <td>Hold the MDI upright with your index finger on the top of the medication canister and your thumb supporting the bottom of the inhaler. You may need to use the other hand to hold the spacer.</td> </tr> <tr> <td>Breathe out normally through your mouth.</td> </tr> <tr> <td>Put the mouthpiece between your teeth and close your lips tightly around mouthpiece of spacer. (If using a mask attached to the chamber, place the mask completely over your nose and mouth.)</td> </tr> <tr> <td>Make sure your tongue does not block the&nbsp;opening of the mouthpiece of the spacer.</td> </tr> <tr> <td>Press down the top of the canister with your index finger to release the medicine.</td> </tr> <tr> <td>At the same time, breathe in deeply and slowly through your mouth until your lungs are completely filled; this should take three to five seconds.</td> </tr> <tr> <td>Hold the medicine in your lungs for&nbsp;about 5&nbsp;to 10 seconds. If you did not get a full breath or cannot hold your breath long enough, you can inhale a second time to fully empty the chamber and hold your breath again for approximately five seconds.</td> </tr> <tr> <td>If you need more than one puff, wait&nbsp;approximately 15 to 30 seconds between puffs. Shake canister again before the next puff. Do <strong>not</strong> load both puffs into the chamber and then empty the chamber with a single inhalation.</td> </tr> <tr> <td>When finished, recap mouthpiece.</td> </tr> <tr> <td>If your inhaler contains a steroid medicine (sometimes called glucocorticoid or corticosteroid), rinse your mouth and gargle with water after you use it. Then spit out the water. Do not swallow it.</td> </tr> <tr> <td>You can use your spacer for more than one medication. Just remove the first MDI and insert the other one.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These instructions do NOT apply to dry powder or soft mist inhalers. Cleaning instructions are provided separately.</div><div class=\"graphic_footnotes\">MDI: metered dose inhaler.<br />* We prefer to use a \"valved holding chamber\" for the spacer. The valve holds the medicine in the chamber. When you breathe out into the mouthpiece, your breath goes into the room and not into the chamber. This helps get the medicine into your lungs. If your spacer does not have this valve, you should breathe out through your nose or remove the spacer from your mouth before breathing out.</div><div id=\"graphicVersion\">Graphic 103303 Version 4.0</div></div></div>"},"103311":{"type":"graphic_figure","displayName":"Kidney paired donation","title":"Kidney paired donation activity reported to UNOS","html":"<div class=\"graphic\"><div style=\"width: 570px\" class=\"figure\"><div class=\"ttl\">Kidney paired donation activity reported to UNOS</div><div class=\"cntnt\"><img style=\"width:550px; height:353px;\" src=\"images/NEPH/103311_Kidney_pair_donat.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Kidney paired donation activity reported to the UNOS accounts for approximately 7% of live donors transplanted in the United States.</div><div class=\"graphic_footnotes\">UNOS: United Network for Organ Sharing.</div><div class=\"graphic_reference\">Adapted from: OPTN &amp; SRTR Annual Data Report 2011. US Department of Health and Human Services, Health Resources and Services Administration, 2012.</div><div id=\"graphicVersion\">Graphic 103311 Version 1.0</div></div></div>"},"103314":{"type":"graphic_algorithm","displayName":"Approach to the differential diagnosis of cutaneous blisters","title":"Approach to the differential diagnosis of cutaneous blisters","html":"<div class=\"graphic\"><div style=\"width: 1318px\" class=\"figure\"><div class=\"ttl\">Approach to the differential diagnosis of cutaneous blisters</div><div class=\"cntnt\"><img style=\"width:1298px; height:737px;\" src=\"images/DERM/103314_Apr_dif_dig_cutan_blstrs_E1.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HSV: herpes simplex virus; LCV: leukocytoclastic vasculitis; IgA: immunoglobulin A; VZV: varicella zoster virus.</div><div id=\"graphicVersion\">Graphic 103314 Version 2.0</div></div></div>"},"103315":{"type":"graphic_figure","displayName":"Diabetic retinopathy in transplanted and nontransplanted groups","title":"Diabetic retinopathy in transplanted and nontransplanted groups","html":"<div class=\"graphic\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Diabetic retinopathy in transplanted and nontransplanted groups</div><div class=\"cntnt\"><img style=\"width:496px; height:312px;\" src=\"images/NEPH/103315_Diabet_retin_trans_nontrans.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Percentage of patients with improved, stabilized, or worsened diabetic retinopathy in the transplanted and nontransplanted groups.</div><div class=\"graphic_footnotes\">* p&lt;0.01 versus transplanted.</div><div class=\"graphic_reference\">From: Giannarelli R, Coppelli A, Sartini M, et al. Effects of pancreas-kidney transplantation on diabetic retinopathy. Transplant Int 2005; 18:619. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2005.00108.x/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2005.00108.x/abstract</a>. Copyright &copy; 2005 Steunstichting ESOT. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103315 Version 1.0</div></div></div>"},"103316":{"type":"graphic_picture","displayName":"Tonsillar hypertrophy","title":"Tonsillar hypertrophy and appearance after tonsillectomy","html":"<div class=\"graphic\"><div style=\"width: 974px\" class=\"figure\"><div class=\"ttl\">Tonsillar hypertrophy and appearance after tonsillectomy</div><div class=\"cntnt\"><img style=\"width:954px; height:457px;\" src=\"images/PEDS/103316_Tnsllr_hyprtrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Tonsillar hypertrophy.<br />(B) Appearance of the tonsillar fossae after tonsillectomy.</div><div class=\"graphic_reference\">Courtesy of Susan Garetz, MD.</div><div id=\"graphicVersion\">Graphic 103316 Version 1.0</div></div></div>"},"103326":{"type":"graphic_picture","displayName":"Adenoid hypertrophy","title":"Adenoidal hypertrophy pre- and post-adenoidectomy","html":"<div class=\"graphic\"><div style=\"width: 944px\" class=\"figure\"><div class=\"ttl\">Adenoidal hypertrophy pre- and post-adenoidectomy</div><div class=\"cntnt\"><img style=\"width:924px; height:460px;\" src=\"images/PEDS/103326_Adnd_hyprtrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Adenoid hypertrophy with obliteration of nasal choanae.<br />(B) Appearance of nasopharynx after adenoidectomy.</div><div class=\"graphic_reference\">Courtesy of Susan Garetz, MD.</div><div id=\"graphicVersion\">Graphic 103326 Version 1.0</div></div></div>"},"103327":{"type":"graphic_table","displayName":"Delirium versus dementia","title":"Clinical features of delirium versus dementia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features of delirium&nbsp;versus dementia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Delirium</td> <td class=\"subtitle1\">Dementia</td> </tr> <tr> <td><strong>Onset</strong></td> <td>More abrupt decline in cognitive function over hours to days, with waxing and waning course</td> <td>Typically insidious, progressive decline in cognition over months to years</td> </tr> <tr> <td><strong>Attention and orientation</strong></td> <td>Impaired</td> <td>Generally preserved; can be altered in later stages</td> </tr> <tr> <td><strong>Level of consciousness</strong></td> <td>Fluctuating, sometimes reduced</td> <td>Normal</td> </tr> <tr> <td><strong>Speech and language</strong></td> <td>Incoherent, disorganized speech</td> <td>Variable impairments in word retrieval, naming, fluency, and comprehension</td> </tr> <tr> <td><strong>Memory for recent and past events</strong></td> <td>Variable, fluctuating impairments</td> <td>Often impaired for recent events; memory for remote events becomes impaired in later stages</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 103327 Version 1.0</div></div></div>"},"103338":{"type":"graphic_picture","displayName":"Rapid maxillary expansion","title":"Rapid maxillary expansion","html":"<div class=\"graphic\"><div style=\"width: 861px\" class=\"figure\"><div class=\"ttl\">Rapid maxillary expansion</div><div class=\"cntnt\"><img style=\"width:841px; height:328px;\" src=\"images/PEDS/103338_Rpd_mxllry_expn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Narrow palate in patient with obstructive sleep apnea, prior to maxillary expansion (RME).<br />(B) Appearance of maxilla after expansion, with the RME device in place.</div><div class=\"graphic_reference\">Photo courtesy of R.S. Conley, DDS.</div><div id=\"graphicVersion\">Graphic 103338 Version 2.0</div></div></div>"},"103339":{"type":"graphic_figure","displayName":"Simplified immune synapse for an anergic CD8 T cell","title":"Simplified immune synapse for an anergic CD8 T cell","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">Simplified immune synapse for an anergic CD8 T cell</div><div class=\"cntnt\"><img style=\"width:788px; height:430px;\" src=\"images/ONC/103339_Simp_immun_synp_anergic_CD8.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In the absence of the \"second signal,\" which in the na&iuml;ve T cell is CD28 but in activated T cells can be OX40, CD137, etc, T cells can become anergic and do not mount a response to antigen.</div><div class=\"graphic_footnotes\">CD: cluster of differentiation; APC: antigen-presenting cells; MHC: major histocompatibility complex.</div><div id=\"graphicVersion\">Graphic 103339 Version 1.0</div></div></div>"},"103340":{"type":"graphic_figure","displayName":"CTLA-4 as physiologic \"brake\"on costimulation of CD8+ T cell","title":"CTLA-4 acting as physiologic \"brake\" on costimulation of CD8+ T cell","html":"<div class=\"graphic\"><div style=\"width: 808px\" class=\"figure\"><div class=\"ttl\">CTLA-4 acting as physiologic \"brake\" on costimulation of CD8+ T cell</div><div class=\"cntnt\"><img style=\"width:788px; height:280px;\" src=\"images/ONC/103340_CTLA4_physiologic_brake_CD8.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">CTLA4 outcompetes CD28 for CD80 and CD86, and the costimulatory signal ceases as the target is eliminated, reducing the release of pro-effector cytokines such as IL-12 and cytotoxic enzymes such as perforin and granzyme B. Homeostasis is restored.</div><div class=\"graphic_footnotes\">CD: cluster of differentiation; CTLA-4: cytotoxic T-lymphocyte-associated protein 4; APC: antigen-presenting cells; MHC: major histocompatibility complex; IL: interleukin.</div><div id=\"graphicVersion\">Graphic 103340 Version 1.0</div></div></div>"},"103341":{"type":"graphic_figure","displayName":"PD-1-PD-L1 binding leads to peripheral CD8+ T cell \"exhaustion\"","title":"PD-1-PD-L1 binding leads to peripheral CD8+ T cell \"exhaustion\" phenotype","html":"<div class=\"graphic\"><div style=\"width: 838px\" class=\"figure\"><div class=\"ttl\">PD-1-PD-L1 binding leads to peripheral CD8+ T cell \"exhaustion\" phenotype</div><div class=\"cntnt\"><img style=\"width:818px; height:286px;\" src=\"images/ONC/103341_PD1_PDL1_binding_leads_CD8.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In a state of chronic antigen presentation, such as malignancy, the chronic presence of antigen or pro-inflammatory cytokines (IL-12, IFNgamma, etc) can upregulate PD-1 expression on the T cell; tumor clones can also select for PD-L1 expression. With PD-1-PD-L1 binding, even in the presence of the costimulatory molecule, \"peripheral exhaustion\" can occur.</div><div class=\"graphic_footnotes\">PD-L1: programmed death-ligand 1; CD: cluster of differentiation; PD-1: programmed cell death-1; APC: antigen-presenting cells; MHC: major histocompatibility complex; IL: interleukin; IFNgamma: interferon gamma.</div><div id=\"graphicVersion\">Graphic 103341 Version 2.0</div></div></div>"},"103342":{"type":"graphic_figure","displayName":"Cancer immunoediting","title":"Cancer immunoediting","html":"<div class=\"graphic\"><div style=\"width: 712px\" class=\"figure\"><div class=\"ttl\">Cancer immunoediting</div><div class=\"cntnt\"><img style=\"width:692px; height:784px;\" src=\"images/ONC/103342_Cancer_immunoediting.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cancer immunoediting is an extrinsic tumor suppressor mechanism that engages only after cellular transformation has occurred and intrinsic tumor suppressor mechanisms have failed. In its most complex form, cancer immunoediting consists of three sequential phases: elimination, equilibrium, and escape. In the elimination phase, innate and adaptive immunity work together to destroy developing tumors long before they become clinically apparent. Many of the immune molecules and cells that participate in the elimination phase have been identified, but more work is needed to determine their exact sequence of action. If this phase goes to completion, then the host remains free of cancer, and elimination thus represents the full extent of the process. If, however, a rare cancer cell variant is not destroyed in the elimination phase, it may then enter the equilibrium phase, in which its outgrowth is prevented by immunologic mechanisms. T cells, IL-12, and IFN-γ are required to maintain tumor cells in a state of functional dormancy, whereas NK cells and molecules that participate in the recognition or effector function of cells of innate immunity are not required; this indicates that equilibrium is a function of adaptive immunity only. Editing of tumor immunogenicity occurs in the equilibrium phase. Equilibrium may also represent an end stage of the cancer immunoediting process and may restrain outgrowth of occult cancers for the lifetime of the host. However, as a consequence of constant immune selection pressure placed on genetically unstable tumor cells held in equilibrium, tumor cell variants may emerge that (i) are no longer recognized by adaptive immunity (antigen loss variants or tumors cells that develop defects in antigen processing or presentation), (ii) become insensitive to immune effector mechanisms, or (iii) induce an immunosuppressive state within the tumor microenvironment. These tumor cells may then enter the escape phase, in which their outgrowth is no longer blocked by immunity. These tumor cells emerge to cause clinically apparent disease.</div><div class=\"graphic_reference\">Modified with permission from the Annual Review of Immunology. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural Innate and Adaptive Immunity to Cancer. 2011; 29:235. Copyright © 2011 Annual Reviews, <A spellcheck=true href=\"http://www.annualreviews.org/\" target=_blank>http://www.annualreviews.org</A>.</div><div id=\"graphicVersion\">Graphic 103342 Version 1.0</div></div></div>"},"103343":{"type":"graphic_diagnosticimage","displayName":"Delayed response to ipilimumab","title":"Delayed response to ipilimumab therapy","html":"<div class=\"graphic\"><div style=\"width: 667px\" class=\"figure\"><div class=\"ttl\">Delayed response to ipilimumab therapy</div><div class=\"cntnt\"><img style=\"width:647px; height:465px;\" src=\"images/ONC/103343_Rs_iplmmb_thr_ptnt_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This patient with metastatic melanoma had no discernible disease in the liver at baseline. After four doses of ipilimumab, numerous lesions were apparent, classically considered progression. However, two months later, without drug, these lesions regressed. After four additional doses of ipilimumab, the patient had a complete response.</div><div class=\"graphic_reference\">Reproduced with permission from: Saenger YM, Wolchok JD. The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008; 8:1. Copyright &copy; 2008 Jedd D. Wolchok.</div><div id=\"graphicVersion\">Graphic 103343 Version 2.0</div></div></div>"},"103345":{"type":"graphic_figure","displayName":"Changes of sleep as humans age","title":"Graphic representation of the changes of sleep as humans age","html":"<div class=\"graphic\"><div style=\"width: 616px\" class=\"figure\"><div class=\"ttl\">Graphic representation of the changes of sleep as humans age</div><div class=\"cntnt\"><img style=\"width:596px; height:433px;\" src=\"images/SLEEP/103345_Chng_slp_hmn_age.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Age-related trends for stage 1 sleep, stage 2 sleep, slow wave sleep, rapid eye movement sleep, wake after sleep onset, and sleep latency (in minutes).</div><div class=\"graphic_footnotes\">WASO: wake after sleep onset; REM: rapid eye movement; SWS: slow wave sleep.</div><div class=\"graphic_reference\">Republished with permission of Associated Professional Sleep Societies, LLC, from Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan, Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV, Sleep 2004; 27:1255; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 103345 Version 1.0</div></div></div>"},"103346":{"type":"graphic_table","displayName":"EEG pattern labels and associated frequencies","title":"Electroencephalography pattern labels and associated frequencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Electroencephalography pattern labels and associated frequencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup width=\"60%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">EEG pattern</td> <td class=\"subtitle1\">EEG frequency range (Hz)</td> </tr> <tr> <td>Beta</td> <td>&#62;13</td> </tr> <tr> <td>Alpha</td> <td>8 to 13</td> </tr> <tr> <td>Theta</td> <td>4 to 7.99</td> </tr> <tr> <td>Delta</td> <td>0 to 3.99</td> </tr> <tr> <td>Slow wave activity</td> <td>0.5 to 2 (with &#62;75 uV of amplitude peak-to-peak)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 103346 Version 1.0</div></div></div>"},"103349":{"type":"graphic_algorithm","displayName":"Determining when athletes can return to play after URTI","title":"Determining when athletes can return to play after URTI","html":"<div class=\"graphic\"><div style=\"width: 769px\" class=\"figure\"><div class=\"ttl\">Determining when athletes can return to play after URTI</div><div class=\"cntnt\"><img style=\"width:749px; height:284px;\" src=\"images/SM/103349_Returning_play_after_URTI.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">URTI: upper respiratory tract infection.<br />* There may be specific illnesses and circumstances where criteria for return to play differs from the general criteria. Please refer to the UpToDate topic on upper respiratory tract infections in adolescent and adult athletes for further details.</div><div id=\"graphicVersion\">Graphic 103349 Version 2.0</div></div></div>"},"103351":{"type":"graphic_picture","displayName":"The fire triad","title":"The fire triad","html":"<div class=\"graphic\"><div style=\"width: 480px\" class=\"figure\"><div class=\"ttl\">The fire triad</div><div class=\"cntnt\"><img style=\"width:460px; height:331px;\" src=\"images/ANEST/103351_The_fire_triad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Each element of the fire triad is typically controlled by the surgeons, anesthesia providers, or operating room nurses.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2013 Association of Perioperative Registered Nurses (AORN).</div><div id=\"graphicVersion\">Graphic 103351 Version 1.0</div></div></div>"},"103352":{"type":"graphic_picture","displayName":"Alcohol fire","title":"Intense heat and flame in an alcohol fire","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Intense heat and flame in an alcohol fire</div><div class=\"cntnt\"><img style=\"width:710px; height:470px;\" src=\"images/ANEST/103352_Alcohol_fire.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Demonstration of intense heat and flame in an alcohol fire.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 ECRI Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103352 Version 1.0</div></div></div>"},"103353":{"type":"graphic_picture","displayName":"Burning head and drapes","title":"Burning head and drapes in simulation of fire caused by ESU during surgery","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Burning head and drapes in simulation of fire caused by ESU during surgery</div><div class=\"cntnt\"><img style=\"width:655px; height:449px;\" src=\"images/ANEST/103353_Burning_head_drps.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this simulation of fire caused by the ESU, the entire patient head and drapes were in flames 24 seconds after a spark from the ESU.</div><div class=\"graphic_footnotes\">ESU: electrosurgery unit.</div><div class=\"graphic_reference\">From: Barker SJ, Polson JS. Fire in the operating room: a case report and laboratory study. Anesth Analg 2001; 93:960. DOI: <a href=\"http://journals.lww.com/anesthesia-analgesia/pages/articleviewer.aspx?year=2001&amp;issue=10000&amp;article=00031&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/00000539-200110000-00031</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2001 International Anesthesia Research Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103353 Version 1.0</div></div></div>"},"103354":{"type":"graphic_picture","displayName":"Burning endotracheal tube (ETT)","title":"Burning endotracheal tube (ETT)","html":"<div class=\"graphic\"><div style=\"width: 518px\" class=\"figure\"><div class=\"ttl\">Burning endotracheal tube (ETT)</div><div class=\"cntnt\"><img style=\"width:498px; height:167px;\" src=\"images/ANEST/103354_Brn_endtrchl_tb_ETT.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A burning endotracheal tube (ETT) with a high concentration of O<sub>2</sub> or N<sub>2</sub>O will exhibit a \"blowtorch\" effect, and will also produce a large amount of debris.</div><div class=\"graphic_footnotes\">O<SUB innerHtml>2</SUB>: oxygen; N<SUB innerHtml>2</SUB>O: nitrous oxide.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 ECRI Institute. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103354 Version 1.0</div></div></div>"},"103355":{"type":"graphic_table","displayName":"Fuel sources commonly found in the operating room (OR)","title":"Fuel sources commonly found in the operating room (OR)","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fuel sources commonly found in the operating room (OR)</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">\"Prep\" agents</td> <td class=\"subtitle1\">Ointments</td> </tr> <tr> <td>Alcohol</td> <td>Petrolatum</td> </tr> <tr> <td>Degreasers (acetone, ether)</td> <td>Antibiotics (bacitracin, neomycin, polymyxin B)</td> </tr> <tr> <td>Adhesives (tincture of benzoin, Aeroplast)</td> <td>Nitropaste (Nitro-Bid)</td> </tr> <tr> <td>Chlorhexidine digluconate (Hibitane)</td> <td><span style=\"color: black;\">Local anesthetic cream (EMLA [lidocaine 2.5% and priloccaine 2.5%])</span></td> </tr> <tr class=\"divider_bottom\"> <td>Iodophor (Dura-Prep)</td> <td>Lip balms</td> </tr> <tr> <td class=\"subtitle1\">Drapes and covers</td> <td class=\"subtitle1\">Anesthesia equipment</td> </tr> <tr> <td>Patient drapes (paper, plastic, cloth)</td> <td>Breathing circuit hoses</td> </tr> <tr> <td>Equipment drapes (paper, plastic, cloth)</td> <td>Masks</td> </tr> <tr> <td>Blankets and sheets</td> <td>Endotracheal tubes</td> </tr> <tr> <td>Pillows, mattresses, and padding</td> <td>Oral and nasal airways</td> </tr> <tr> <td>Gowns</td> <td>Laryngeal mask airways</td> </tr> <tr> <td>Masks</td> <td>Nasogastric tubes</td> </tr> <tr> <td>Shoe covers</td> <td>Suction catheters and tubing</td> </tr> <tr> <td>Gloves (latex, nonlatex)</td> <td>Scavenger hoses</td> </tr> <tr> <td>Clothing</td> <td>Volatile anesthetics</td> </tr> <tr> <td class=\"divider_bottom\">Compression (anti-embolism) stockings</td> <td>CO<sub>2</sub> absorbers</td> </tr> <tr> <td class=\"subtitle1\">Patient</td> <td>Intravenous tubing</td> </tr> <tr> <td>Hair</td> <td class=\"divider_bottom\">Pressure monitor tubing and plastic transducers</td> </tr> <tr> <td>Alimentary tract gases (methane, hydrogen)</td> <td class=\"subtitle1\">Other equipment</td> </tr> <tr> <td class=\"divider_bottom\">Desiccated tissue</td> <td>Charts and records</td> </tr> <tr> <td class=\"subtitle1\">Dressings</td> <td>Cardboard, wooden, and particleboard boxes and cabinets</td> </tr> <tr> <td>Gauze and sponges</td> <td>Packing materials (cardboard, expanded polystyrene [Styrofoam])</td> </tr> <tr> <td>Petrolatum-impregnated dressings</td> <td>Fiberoptic cable covers</td> </tr> <tr> <td><span style=\"color: black;\">Mesh gauze (</span><span style=\"color: black;\">Xeroform Petrolatum Wound Dressing)</span></td> <td>Wire covers and insulation</td> </tr> <tr> <td>Adhesive tape (cloth, plastic, paper)</td> <td>Fiberoptic endoscope coverings</td> </tr> <tr> <td>Elastic bandages</td> <td>Sphygmomanometer cuffs and tubing</td> </tr> <tr> <td>Stockinettes</td> <td>Pneumatic tourniquet cuffs and tubing</td> </tr> <tr> <td>Sutures</td> <td>Stethoscope tubing</td> </tr> <tr> <td>Steri-strips</td> <td>Vascular shunts (Gore-tex, Dacron)</td> </tr> <tr> <td>Collodion</td> <td>Dialysis and extracorporeal circulation circuits</td> </tr> <tr> <td>&nbsp;</td> <td>Wound drains and collection systems</td> </tr> <tr> <td>&nbsp;</td> <td>Mops and brooms</td> </tr> <tr> <td>&nbsp;</td> <td>Textbooks and instruction manuals</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide.</div><div class=\"graphic_reference\">Reproduced with permission from: Ehrenwerth J, Seifert HA. Electrical and fire safety. In: Clinical Anesthesia, 7th Edition, Barash PG (Ed), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103355 Version 1.0</div></div></div>"},"103356":{"type":"graphic_algorithm","displayName":"ASA operating room fires algorithm","title":"American Society of Anesthesiologists (ASA) operating room fires algorithm","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">American Society of Anesthesiologists (ASA) operating room fires algorithm</div><div class=\"cntnt\"><img style=\"width:678px; height:786px;\" src=\"images/ANEST/103356_ASA_operating_rm_fires_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Algorithm for prevention and management of an operating room (OR) fire.</div><div class=\"graphic_footnotes\">* Ignition sources include but are not limited to electrosurgery or electrocautery units and lasers.<br />&para; An oxidizer-enriched atmosphere occurs when there is any increase in oxygen concentration above room air level, and/or the presence of any concentration of nitrous oxide.<br />&Delta; After minimizing delivered oxygen, wait a period of time (eg, one to three minutes) before using an ignition source. For oxygen-dependent patients, <em>reduce</em> supplemental oxygen delivery to the minimum required to avoid hypoxia. Monitor oxygenation with pulse oximetry, and, if feasible, inspired, inhaled, and/or delivered oxygen concentration.<br /><span class=\"lozenge\">&loz;</span> After stopping the delivery of nitrous oxide, wait a period of time (eg, one to three minutes) before using an ignition source.<br />&sect; Unexpected flash, flame, smoke or heat, unusual sounds (eg, a \"pop,\" \"snap,\" or \"foomp\") or odors, unexpected movement of drapes, discoloration of drapes or breathing circuit, unexpected patient movement or complaint.<br />&yen; In this algorithm, airway fire refers to a fire in the airway or breathing circuit.<br />&Dagger; A CO<sub>2</sub> fire extinguisher may be used on the patient if necessary.</div><div class=\"graphic_reference\">From: Apfelbaum JL, Caplan RA, Barker SJ, et al. Practice advisory for the prevention and management of operating room fires: an updated report by the American Society of Anesthesiologists Task Force on Operating Room Fires. Anesthesiology 2013; 118:271. DOI: <a href=\"http://anesthesiology.pubs.asahq.org/article.aspx?articleid=1918685\" target=\"_blank\">10.1097/ALN.0b013e31827773d2</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2013 American Society of Anesthesiologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103356 Version 2.0</div></div></div>"},"103357":{"type":"graphic_algorithm","displayName":"APSF fire prevention algorithm","title":"Anesthesia Patient Safety Foundation (APSF) fire prevention algorithm","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Anesthesia Patient Safety Foundation (APSF) fire prevention algorithm</div><div class=\"cntnt\"><img style=\"width:762px; height:390px;\" src=\"images/ANEST/103357_APSF_fire_prevention_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Anesthesia Patient Safety Foundation presents a simplified approach to management of surgical fire risk.</div><div class=\"graphic_footnotes\">* Although securing the airway is preferred, for cases where using an airway device is undesirable or not feasible, oxygen accumulation may be minimized by air insufflation over the face and open draping to provide wide exposure of the surgical site to the atmosphere.</div><div class=\"graphic_reference\">Reproduced with permission from: Stoelting RK, Feldman JM, Cowles CE, Bruley ME. Surgical fire injuries continue to occur: Prevention may require more cautious use of oxygen. APSF Newsletter 2012; 26:41. Copyright © 2012 Anesthesia Patient Safety Foundation. <EM>Updated with information from the 2014 APSF OR Fire Prevention Algorithm.</EM></div><div id=\"graphicVersion\">Graphic 103357 Version 2.0</div></div></div>"},"103365":{"type":"graphic_algorithm","displayName":"Algorithm for treatment of patient with complete heart block","title":"Algorithm showing the treatment approach to the patient with complete heart block","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">Algorithm showing the treatment approach to the patient with complete heart block</div><div class=\"cntnt\"><img style=\"width:614px; height:470px;\" src=\"images/CARD/103365_ECG_with_CHB.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; CHB: complete heart block; BP: blood pressure; HF: heart failure; IV: intravenous; PPM: permanent pacemaker.<br />* The initial dose of atropine is 0.5 mg IV. This dose may be repeated every three to five minutes to a total dose of 3 mg.<br />&para; While transcutaneous pacing may be initially successful in stabilizing the patient, it may not be consistently reliable. Central venous access should be considered in the event that urgent transvenous pacing is required.<br />&Delta; Dopamine IV infusion typically begins at a dose of 3 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.<br /><span class=\"lozenge\">&loz;</span> Dobutamine IV infusion typically begins at a dose of 5 mcg/kg/minute and can be titrated up to 20 mcg/kg/minute if needed for heart rate and blood pressure augmentation.</div><div id=\"graphicVersion\">Graphic 103365 Version 3.0</div></div></div>"},"103366":{"type":"graphic_table","displayName":"Splenic MZL prognostic model","title":"Splenic marginal zone lymphoma prognostic model","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Splenic marginal zone lymphoma prognostic model</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"5\" width=\"20%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Points</td> <td class=\"subtitle1\">Risk group</td> <td class=\"subtitle1\">Proportion of patients<br /> (percent)</td> <td class=\"subtitle1\">Five-year OS<br /> (percent)</td> <td class=\"subtitle1\">Cause-specific deaths<br /> (percent)</td> </tr> <tr class=\"centered\"> <td>0</td> <td>Low risk</td> <td>41</td> <td>83</td> <td>16</td> </tr> <tr class=\"centered\"> <td>1</td> <td>Intermediate risk</td> <td>34</td> <td>72</td> <td>30</td> </tr> <tr class=\"centered\"> <td>2 or 3</td> <td>High risk</td> <td>25</td> <td>56</td> <td>54</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">One point is given for each of the following characteristics present in the patient with splenic MZL, for a total score ranging from zero to three: &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI>Hemoglobin &lt;12 g/dL</LI>&#xD;&#xA;<LI>Serum lactate dehydrogenase level greater than normal</LI>&#xD;&#xA;<LI>Serum albumin level &lt;3.5 g/dL</LI></UL>When applied to a study of long-term survival in 309 patients with splenic MZL diagnosed between 1989 and 2004, three risk groups and their corresponding five-year OS and cause-specific death rates were identified.</div><div class=\"graphic_footnotes\">MZL: marginal zone lymphoma; OS: overall survival.</div><div class=\"graphic_reference\">Reference:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Arcaini L, Lazzarino M, Colombo N, et al. Splenic marginal zone lymphoma: a prognostic model for clinical use. Blood 2006; 107:4643.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103366 Version 1.0</div></div></div>"},"103367":{"type":"graphic_diagnosticimage","displayName":"Suprasternal notch view of brachiocephalic vein","title":"Suprasternal notch view of aortic arch and brachiocephalic vein","html":"<div class=\"graphic\"><div style=\"width: 704px\" class=\"figure\"><div class=\"ttl\">Suprasternal notch view of aortic arch and brachiocephalic vein</div><div class=\"cntnt\"><img style=\"width:684px; height:458px;\" src=\"images/CARD/103367_Suprasternal_brchcphlc_vein.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this view, taken with the neck extended and the probe positioned at the suprasternal notch and angled caudally, the aortic arch is visualized centrally. The aortic vessel wall is a linear structure that separates the aorta from the brachiocephalic vein; this should not be confused with a dissection. The brachiocephalic vein has continuous flow in both systole and diastole when visualized by color Doppler, and this further differentiates the structure from the aorta or branch arteries.</div><div id=\"graphicVersion\">Graphic 103367 Version 1.0</div></div></div>"},"103368":{"type":"graphic_movie","displayName":"3D image of mass in descending aorta","title":"Three-dimensional image of mobile mass in descending aorta","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Three-dimensional image of mobile mass in descending aorta</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/103368_3Dmoblmassdescaortavid.mp4\" style=\"width:528px;height:368px\"></div><img style=\"width:544px; height:400px;\" src=\"images/CARD/103368_3Dmoblmassdescaortaimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This three-dimensional view of the descending aorta&nbsp;obtained by transesophageal echocardiogram with the probe in the mid to distal esophagus demonstrates a mobile echodensity. The differential diagnosis includes vegetation, tumor, or thrombus.</div><div id=\"graphicVersion\">Graphic 103368 Version 1.0</div></div></div>"},"103369":{"type":"graphic_movie","displayName":"Two-dimensional image of mobile mass in descending aorta","title":"Two-dimensional image of mobile mass in descending aorta","html":"<div class=\"graphic normal\"><div style=\"width: 548px\" class=\"figure\"><div class=\"ttl\">Two-dimensional image of mobile mass in descending aorta</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/CARD/103369_2Dmoblmassdescaortavid.mp4\" style=\"width:528px;height:368px\"></div><img style=\"width:544px; height:380px;\" src=\"images/CARD/103369_2Dmoblmassdescaortaimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The two-dimensional image shows the attachment of a mass to the wall of the aorta. Thickening of the posterior wall of the aorta is noted, consistent with an inflammatory process. There is no vessel wall shadowing or calcification, which would have suggested an atherosclerotic process. The evidence of inflammation and a fluid-filled structure posterior to the aortic mass is highly suggestive of vegetation with abscess. The patient was diagnosed with endocarditis after blood cultures grew <EM>Staphylococcus aureus</EM>.</div><div id=\"graphicVersion\">Graphic 103369 Version 1.0</div></div></div>"},"103370":{"type":"graphic_table","displayName":"Comparison of PCH, cold agglutinin disease, cryoglobulinemia","title":"Comparison of paroxysmal cold hemoglobinuria, cold agglutinin disease, and cryoglobulinemia","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Comparison of paroxysmal cold hemoglobinuria, cold agglutinin disease, and cryoglobulinemia</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"16%\"></colgroup><colgroup span=\"3\" width=\"28%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Paroxysmal cold hemoglobinuria</td> <td class=\"subtitle1\">Cold agglutinin disease</td> <td class=\"subtitle1\">Cryoglobulinemia</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Presentation</strong></td> <td> <ul> <li>Typically in childhood, rarely adults </li> <li>Dark (red-brown) urine after cold exposure with fever, chills, back or leg pain </li> </ul> </td> <td> <ul> <li>Typically in older women (over 70 years) </li> <li>Anemia symptoms, acrocyanosis </li> </ul> </td> <td> <ul> <li>Typically in older individuals (over 60 years) </li> <li>Palpable purpura, arthralgias, myalgias, may be chronic for decades </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Associated diseases</strong></td> <td> <ul> <li>Secondary or tertiary syphilis </li> <li>Post-viral infection (eg, varicella, measles, mumps, EBV, CMV) </li> <li>Post-bacterial infection (eg, mycoplasma, <em>Klebsiella</em>, <em>E. coli</em>, <em>H. influenzae</em>) </li> <li>Post-measles vaccine </li> <li>Autoimmune disorders </li> <li>Lymphoma or CLL </li> </ul> </td> <td> <ul> <li>Lymphoma or other lymphoproliferative disorder </li> <li>Infection (eg, mycoplasma, infectious mononucleosis) </li> <li>Monoclonal IgM gammopathy </li> <li>Autoimmune disorders </li> </ul> </td> <td> <ul> <li>Infections (eg, adenovirus, hepatitis viruses, HIV, bacteria, spirochetes, fungi, parasites) </li> <li>Autoimmune disorders </li> <li>Inflammatory bowel disease </li> <li>Neoplasms (various) </li> <li>Lymphoproliferative disorders </li> <li>Cirrhosis </li> <li>Vaccinations </li> <li>Familial syndromes </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Clinical findings</strong></td> <td> <ul> <li>Jaundice </li> <li>Hemoglobinemia, hemoglobinuria, and hemosiderinuria </li> <li>Raynaud phenomenon </li> <li>Urticaria </li> <li>Anemia </li> <li>Neutropenia (rare) </li> </ul> </td> <td> <ul> <li>Anemia </li> <li>Livido reticularis </li> <li>Acrocyanosis or Raynaud phenomenon </li> <li>Fatigue, weakness, dyspnea </li> <li>Hemoglobinuria (less common) </li> <li>Dysphagia for cold foods/liquids </li> </ul> </td> <td> <ul> <li>Small to medium vessel vasculitis </li> <li>Macules, papules </li> <li>Arthralgias/myalgias </li> <li>Peripheral neuropathy </li> <li>Raynaud phenomenon </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Characteristics of hemolysis</strong></td> <td> <ul> <li>Intravascular, biphasic </li> <li>DAT positive using anti-C3 and negative using IgG, may be negative between episodes </li> </ul> </td> <td> <ul> <li>Extravascular </li> <li>DAT positive using anti-C3 and negative using IgG (unless patient has an IgG, which may be warm-reacting) </li> </ul> </td> <td> <ul> <li>Not associated with hemolysis </li> </ul> </td> </tr> <tr> <td><strong>Characteristics of antibody</strong></td> <td> <ul> <li>Antigen = \"P antigen\" </li> <li>Cold-reacting IgG </li> <li>Polyclonal </li> <li>Does not cause RBC agglutination </li> <li>Moderate titer (eg, &#60;1:160) </li> <li>Binds RBCs and fixes complement; causes hemolysis upon rewarming (Donath-Landsteiner antibody) </li> </ul> </td> <td> <ul> <li>Antigen = \"I\" or \"i\" antigen </li> <li>Cold-reacting IgM (rarely IgG or IgA) </li> <li>Monoclonal or polyclonal </li> <li>Agglutinates RBCs </li> <li>High titer (eg, &#62;1:2000) </li> <li>Binds RBCs and fixes complement </li> <li>Some cold agglutinins are also cryoglobulins </li> </ul> </td> <td> <ul> <li>Mixture of antibodies and complement </li> <li>Cold-reacting IgM, IgG, IgA, or combinations; may be isolated light chains, may be rheumatoid factor positive&nbsp; </li> <li>Monoclonal, polyclonal, or both </li> <li>Concentration varies, measured in mg/dL </li> <li>Precipitates upon cooling of plasma or serum </li> <li>Complement may be consumed with immune complexes </li> <li>Does not interact with RBCs </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">These clinical features are meant as a guide to typical findings and cannot be used in isolation to confirm or exclude a diagnosis. Refer to UpToDate content on paroxysmal cold hemoglobinuria, cold agglutinin disease, and cryoglobulinemia for further details.</div><div class=\"graphic_footnotes\">PCH: paroxysmal cold hemoglobinuria; CA: cold agglutinin; RBC: red blood cell; EBV: Epstein-Barr virus; CMV: cytomegalovirus; CLL: chronic lymphocytic leukemia; DAT: direct antiglobulin test (Coombs test).</div><div id=\"graphicVersion\">Graphic 103370 Version 1.0</div></div></div>"},"103375":{"type":"graphic_table","displayName":"Fire extinguishers","title":"Fire extinguishers","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Fire extinguishers</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Plain water (A*)</strong></td> <td> <ul> <li>Delivers a stream of water to cool the fire. </li> <li>Fires extinguished with water are prone to re-ignition if any embers remain. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Water mist (AC*)</strong></td> <td> <ul> <li>Delivers a fine mist to cool the fire. </li> <li>Safe for electrical fires (fine dispersal of mist does not allow an arc to be formed, which could result in electrocution). </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>CO<sub>2</sub> (BC*)</strong></td> <td> <ul> <li>Smothers fires. </li> <li>Fires extinguished with CO<sub>2</sub> are prone to re-ignition if any embers remain. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>Dry chemical</strong> <ul class=\"decimal_heading\"> <li><strong>Sodium or potassium bicarbonate (BC*)</strong> </li> <li><strong>Ammonium phosphate (ABC*)</strong> </li> </ul> </td> <td> <ul> <li>Smothers fires. </li> <li>Dry chemical dust in BC and ABC extinguishers can cause respiratory irritation that may hinder rescue and evacuation attempts. Subsequently, this dust is difficult to remove from moist tissues and membranes. </li> <li>Fires extinguished with dry chemical extinguishers are seldom reignited due to the \"blanket effect\" of the dry chemical residue. </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td><strong>FE-36 (HFC-236fa) (ABC*)</strong></td> <td> <ul> <li>\"Clean agent\" (nontoxic, no residue, and ozone-safe). </li> <li>FE-36 (HFC-236fa) sensitizes the myocardium to catecholamines, but to a lesser extent than Halon<sup>[1]</sup>. </li> <li>More expensive than other agents. </li> </ul> </td> </tr> <tr> <td><strong>Halon and Halotron (ABC*)</strong></td> <td> <ul> <li>Extinguishes fires by displacement of oxygen and by cooling. </li> <li>Very portable. </li> <li>\"Clean agent\" (nontoxic, no residue, and ozone-safe). </li> <li>Safest extinguisher to use with sensitive electronic devices. </li> <li>Halon sensitizes the myocardium to catecholamines and may result in lethal cardiac arrhythmias<sup>[2]</sup>. </li> <li>Fires extinguished with this type of extinguisher are prone to re-ignition. </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_lgnd\"><STRONG>* Fire classifications:</STRONG> &#xD;&#xA;<UL class=decimal_heading>&#xD;&#xA;<LI><STRONG>A</STRONG> - Common combustibles (wood, paper, cloth, rubber, plastics, etc).</LI>&#xD;&#xA;<LI><STRONG>B</STRONG> - Flammable liquids and gases (gasoline, propane, and solvent, paint, oil-based products, etc).</LI>&#xD;&#xA;<LI><STRONG>C</STRONG> - Energized live electrical equipment (computers, fax machines, appliances, medical equipment, etc).</LI></UL><STRONG>Other special use (D and K) extinguishers:</STRONG> Extinguishers that are highly specific for certain locations (eg, kitchen and combustible metal extinguishers).</div><div class=\"graphic_footnotes\">CO<sub>2</sub>: carbon dioxide.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>www2.dupont.com/FE/en_US/products/fe36.html (Accessed on April 15, 2015).</li>&#xD;&#xA;    <li>www.h3rcleanagents.com/downloads.htm (Accessed on April 15, 2015).</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103375 Version 1.0</div></div></div>"},"103381":{"type":"graphic_figure","displayName":"Nasal and inspiratory pressure","title":"Relationship between maximal sniff nasal inspiratory or maximal inspiratory pressure and arterial pressure of carbon dioxide","html":"<div class=\"graphic\"><div style=\"width: 906px\" class=\"figure\"><div class=\"ttl\">Relationship between maximal sniff nasal inspiratory or maximal inspiratory pressure and arterial pressure of carbon dioxide</div><div class=\"cntnt\"><img style=\"width:886px; height:344px;\" src=\"images/PULM/103381_Nasal_insprtry_prss.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Relationship between sniff nasal pressure (SNP) and maximal inspiratory pressure (MIP) (percent predicted) and ear lobe partial pressure of carbon dioxide (PCO<SUB>2</SUB> in kilopascals [kPa]) in amyotrophic lateral sclerosis patients. Open symbols represent patients with bulbar weakness and closed symbols represent patients with limb weakness. The lines represent the lower and upper limits of normal for ear lobe PCO<SUB>2</SUB> (4.8 to 6 kPa).</div><div class=\"graphic_reference\">Reproduced with permission from: Lyall R. Respiratory muscle function and non invasive positive pressure ventilation in motor neurone disease, University of London, 2004.</div><div id=\"graphicVersion\">Graphic 103381 Version 1.0</div></div></div>"},"103382":{"type":"graphic_picture","displayName":"Actinic reticuloid histo","title":"Histologic features of actinic reticuloid (chronic actinic dermatitis)","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Histologic features of actinic reticuloid (chronic actinic dermatitis)</div><div class=\"cntnt\"><img style=\"width:648px; height:517px;\" src=\"images/DERM/103382_Actinic_reticuloid_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A dense band-like infiltrate is present in the upper dermis.</div><div id=\"graphicVersion\">Graphic 103382 Version 1.0</div></div></div>"},"103383":{"type":"graphic_picture","displayName":"Actinic reticuloid histo 2","title":"Immunophenotype of actinic reticuloid (chronic actinic dermatitis)","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Immunophenotype of actinic reticuloid (chronic actinic dermatitis)</div><div class=\"cntnt\"><img style=\"width:648px; height:428px;\" src=\"images/DERM/103383_Actinic_reticuloid_histo_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In most cases, actinic reticuloid shows a predominance of CD8+ T cells both in the dermis and epidermis.</div><div id=\"graphicVersion\">Graphic 103383 Version 2.0</div></div></div>"},"103385":{"type":"graphic_figure","displayName":"Malaria map – Eastern Hemisphere","title":"Malaria-endemic countries in the Eastern Hemisphere","html":"<div class=\"graphic\"><div style=\"width: 953px\" class=\"figure\"><div class=\"ttl\">Malaria-endemic countries in the Eastern Hemisphere</div><div class=\"cntnt\"><img style=\"width:933px; height:695px;\" src=\"images/ID/103385_Malaria_map_East_Hem_Edit1.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">In this map, countries with areas endemic for malaria are shaded completely even if transmission occurs only in a small part of the country. For more specific within-country malaria transmission information, see the Yellow Fever &amp; Malaria Information, by Country section in chapter 3 of <em>CDC Health Information for International Travel 2018</em>.</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention and Brunette GW (Ed). CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 103385 Version 2.0</div></div></div>"},"103386":{"type":"graphic_figure","displayName":"Yellow fever vaccine - Africa","title":"Yellow fever vaccine recommendations in Africa","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Yellow fever vaccine recommendations in Africa</div><div class=\"cntnt\"><img style=\"width:756px; height:515px;\" src=\"images/ID/103386_YF_vaccine_Africa_2017.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Yellow fever (YF) vaccination is generally not recommended in areas where there is low potential for YF virus exposure. However, vaccination might be considered for a small subset of travelers to these areas who are at increased risk for exposure to YF virus because of prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Consideration for vaccination of any traveler must take into account the traveler's risk of being infected with YF virus, country entry requirements, and individual risk factors for serious vaccine-associated adverse events (such as age or immune status).</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention. CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 103386 Version 2.0</div></div></div>"},"103387":{"type":"graphic_figure","displayName":"Yellow fever vaccine - Americas","title":"Yellow fever vaccine recommendations in the Americas","html":"<div class=\"graphic\"><div style=\"width: 535px\" class=\"figure\"><div class=\"ttl\">Yellow fever vaccine recommendations in the Americas</div><div class=\"cntnt\"><img style=\"width:515px; height:756px;\" src=\"images/ID/103387_YF_vaccine_Americas_2017.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">* Yellow fever (YF) vaccination is generally not recommended in areas where there is low potential for YF virus exposure. However, vaccination might be considered for a small subset of travelers to these areas who are at increased risk for exposure to YF virus because of prolonged travel, heavy exposure to mosquitoes, or inability to avoid mosquito bites. Consideration for vaccination of any traveler must take into account the traveler's risk of being infected with YF virus, country entry requirements, and individual risk factors for serious vaccine-associated adverse events (such as age or immune status).</div><div class=\"graphic_reference\">Reproduced from: The Centers for Disease Control and Prevention. CDC Health Information for International Travel 2018. Oxford University Press, New York, 2017.</div><div id=\"graphicVersion\">Graphic 103387 Version 2.0</div></div></div>"},"103388":{"type":"graphic_picture","displayName":"HFM sores mouth PI","title":"Hand, foot, and mouth disease - mouth","html":"<div class=\"graphic\"><div style=\"width: 748px\" class=\"figure\"><div class=\"ttl\">Hand, foot, and mouth disease - mouth</div><div class=\"cntnt\"><img style=\"width:728px; height:277px;\" src=\"images/PI/103388_HFM_sores_mouth_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">These pictures show the type of sores that can be caused by hand, foot, and mouth disease. Picture A shows the tongue, and picture B shows the inside of the cheek.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103388 Version 2.0</div></div></div>"},"103389":{"type":"graphic_picture","displayName":"HFM sores foot PI","title":"Hand, foot, and mouth disease - foot","html":"<div class=\"graphic\"><div style=\"width: 668px\" class=\"figure\"><div class=\"ttl\">Hand, foot, and mouth disease - foot</div><div class=\"cntnt\"><img style=\"width:648px; height:486px;\" src=\"images/PI/103389_HFM_sores_foot_PI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This picture shows the type of sores that can be caused by hand, foot, and mouth disease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103389 Version 2.0</div></div></div>"},"103390":{"type":"graphic_table","displayName":"Features atypical for acute viral gastroenteritis in children","title":"Clinical features atypical for acute viral gastroenteritis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features atypical for acute viral gastroenteritis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Historical features</td> </tr> <tr> <td class=\"indent1\">Fever: <ul class=\"decimal_heading\"> <li>&#8805;38&#176;C (100.4&#176;F) in infants &#60;3 months </li> <li>&#8805;39&#176;C (102.2&#176;F) in infants and children &#8805;3 months </li> </ul> </td> <td> <ul> <li>Extraintestinal infection (eg, UTI, otitis media, pneumonia, etc) or bacterial gastroenteritis (particularly if &#62;40&#176;C [104&#176;F]) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Gross blood or mucus in stool</td> <td> <ul> <li>Bacterial gastroenteritis, IBD</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bilious vomiting</td> <td> <ul> <li>Intestinal obstruction </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Projectile vomiting</td> <td> <ul> <li>Pyloric stenosis, intestinal obstruction </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Persistent diarrhea (&#62;7 days)</td> <td> <ul> <li>Underlying gastrointestinal, metabolic, or CNS disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Persistent, recurrent, or isolated vomiting</td> <td> <ul> <li>CNS disease, metabolic disease </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Increased urine output</td> <td> <ul> <li>Diabetic ketoacidosis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Altered consciousness, seizures, focal neurologic abnormalities</td> <td> <ul> <li>Increased ICP (CNS mass, hydrocephalus, idiopathic intracranial hypertension) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">History of trauma</td> <td> <ul> <li>Intracranial or intra-abdominal injury (eg, duodenal hematoma) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Weight loss and multisystem involvement</td> <td> <ul> <li>Parasitic gastroenteritis; underlying gastrointestinal or metabolic disorder </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Recent antibiotic exposure</td> <td> <ul> <li>Antibiotic-associated diarrhea, including <em>Clostridium difficile</em> colitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">International travel</td> <td> <ul> <li>Bacterial or parasitic gastroenteritis, measles </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Exposures: unsafe foods (eg, raw/undercooked meats, eggs, shellfish, unpasteurized milk or juice), farm animals, petting zoo, reptiles, pets with diarrhea, untreated surface water</td> <td> <ul> <li>Bacterial or parasitic gastroenteritis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Examination</td> </tr> <tr> <td class=\"indent1\">Moderate to severe dehydration in a child &#62;2 years</td> <td> <ul> <li>May indicate underlying condition predisposing to dehydration </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bulging fontanelle</td> <td> <ul> <li>Hydrocephalus, meningitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bulging tympanic membrane</td> <td> <ul> <li>Acute otitis media </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypotension disproportionate to apparent illness and/or hyponatremia with hyperkalemia</td> <td> <ul> <li>Adrenal crisis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Tachypnea, retractions, crackles, decreased breath sounds</td> <td> <ul> <li>Pneumonia or other respiratory tract infection </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Marked abdominal distention, peritoneal signs, absent bowel sounds or increased high-pitched bowel sounds (\"borborygmi\")</td> <td> <ul> <li>Acute abdomen (eg, appendicitis, intestinal obstruction) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Focal abdominal tenderness</td> <td> <ul> <li>RLQ: appendicitis, Crohn disease </li> <li>RUQ: gallbladder disease, pancreatitis </li> <li>Suprapubic or flank: UTI </li> <li>Epigastric: pancreatitis, peptic ulcer disease/gastritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Abdominal mass</td> <td> <ul> <li>\"Olive\" at lateral edge of rectus abdominus in RUQ: pyloric stenosis </li> <li>\"Sausage-shaped\" right-sided mass: intussusception </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Petechiae, purpura, bruising</td> <td> <ul> <li>Hemolytic uremic syndrome, trauma, extraintestinal infection (eg, RMSF, meningococcemia) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Jaundice</td> <td> <ul> <li>Viral hepatitis, HUS </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Signs of trauma</td> <td> <ul> <li>Intracranial or intra-abdominal injury (eg, duodenal hematoma) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Increased muscle tone, hyperreflexia</td> <td> <ul> <li>Hyperkalemia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Laboratory findings (if performed)</td> </tr> <tr> <td class=\"indent1\">Abnormal CBC</td> <td> <ul> <li>Anemia, thrombocytopenia, hemolysis: HUS </li> <li>Elevated band count: bacterial gastroenteritis </li> <li>Elevated eosinophil count: parasitic gastroenteritis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Elevated serum C-reactive protein, procalcitonin</td> <td> <ul> <li>Bacterial gastroenteritis, IBD</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Fecal leukocytes, fecal lactoferrin, fecal calprotectin</td> <td> <ul> <li>Bacterial gastroenteritis, IBD</li> </ul> </td> </tr> <tr> <td class=\"indent1\">Eosinophils on fecal smear</td> <td> <ul> <li>Amoeba or other intestinal parasite </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Persistent watery diarrhea</td> <td> <ul> <li>Microsporidia,<em> Cyclospor</em>a, and other intestinal parasites </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">UTI: urinary tract infection; IBD: inflammatory bowel disease; CNS: central nervous system; ICP: intracranial pressure; RLQ: right lower quadrant; RUQ: right upper quadrant; RMSF: Rocky Mountain spotted fever; HUS: hemolytic uremic syndrome; CBC: complete blood count.</div><div id=\"graphicVersion\">Graphic 103390 Version 2.0</div></div></div>"},"103391":{"type":"graphic_table","displayName":"STI screening recommendations by gender and population","title":"STI screening recommendations by gender and population","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">STI screening recommendations by gender and population</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"15%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Gender</td> <td class=\"subtitle1\">Population</td> <td class=\"subtitle1\">Routine screening recommendation</td> <td class=\"subtitle1\">Screening frequency</td> <td class=\"subtitle1\">Additional screening recommendations and comments</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"15\">Women</td> <td class=\"divider_bottom\" rowspan=\"3\">Age &#60;25 years</td> <td>Genital chlamydia</td> <td>Annually</td> <td class=\"divider_bottom\" rowspan=\"3\">Screen for syphilis, trichomoniasis, HBV, and&nbsp;HCV if at increased risk.*</td> </tr> <tr> <td>Genital gonorrhea</td> <td>Annually</td> </tr> <tr class=\"divider_bottom\"> <td>HIV</td> <td>At least once</td> </tr> <tr class=\"divider_bottom\"> <td>Age &#8805;25 years</td> <td>HIV</td> <td>At least once</td> <td>Screen for gonorrhea, chlamydia, syphilis, trichomoniasis, HBV, and&nbsp;HCV if at increased risk.*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"5\">Pregnant</td> <td>Genital chlamydia</td> <td> <p>First trimester</p> <p>(if &#60;25 years or at increased risk*)</p> </td> <td class=\"divider_bottom\" rowspan=\"5\"> <p>Repeat screening for these infections in third trimester if at increased risk.</p> <p>All pregnant women at risk for HCV infection should be screened at the first prenatal visit.</p> <p>Pregnant HIV-infected women are also screened for trichomoniasis at the first prenatal visit.</p> </td> </tr> <tr> <td>Genital gonorrhea</td> <td> <p>First trimester</p> <p>(if &#60;25 years or at increased risk*)</p> </td> </tr> <tr> <td>Syphilis</td> <td>First trimester</td> </tr> <tr> <td>HIV</td> <td>First trimester</td> </tr> <tr class=\"divider_bottom\"> <td>HBV</td> <td>First trimester</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"6\">HIV-infected</td> <td>Genital chlamydia</td> <td>Annually</td> <td class=\"divider_bottom\" rowspan=\"6\">&nbsp;</td> </tr> <tr> <td>Genital gonorrhea</td> <td>Annually</td> </tr> <tr> <td>Genital trichomoniasis</td> <td>Annually</td> </tr> <tr> <td>Syphilis</td> <td>Annually</td> </tr> <tr> <td>HBV</td> <td>First visit</td> </tr> <tr class=\"divider_bottom\"> <td>HCV</td> <td>First visit</td> </tr> <tr class=\"highlight_gray_text\"> <td rowspan=\"25\">Men</td> <td class=\"divider_bottom\">HIV-uninfected MSW</td> <td class=\"divider_bottom\">HIV</td> <td class=\"divider_bottom\">At least once</td> <td class=\"divider_bottom\"> <p>Screen for gonorrhea, chlamydia, syphilis, HBV, and&nbsp;HCV if at increased risk.<sup>&#182;</sup></p> Targeted screening venues for chlamydia include adolescent clinics, STI clinics, and correctional facilities.</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"divider_bottom\" rowspan=\"10\">HIV-uninfected MSM</td> <td>Genital chlamydia</td> <td>At least annually</td> <td class=\"divider_bottom\" rowspan=\"10\">More frequent screening (every 3 months) for chlamydia, gonorrhea, and syphilis is recommended in those with risk factors. More frequent screening for HIV and HCV may also be warranted.<sup>&#916;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td>Rectal chlamydia (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Genital gonorrhea</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Rectal gonorrhea (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Pharyngeal gonorrhea (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Syphilis</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>HIV</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>HAV</td> <td>First visit</td> </tr> <tr class=\"highlight_gray_text\"> <td>HBV&nbsp;</td> <td>First visit&nbsp;</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td>HCV</td> <td>At least once</td> </tr> <tr class=\"highlight_gray_text\"> <td class=\"divider_bottom\" rowspan=\"5\">HIV-infected MSW</td> <td>Genital chlamydia</td> <td>Annually</td> <td class=\"divider_bottom\" rowspan=\"5\">&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td>Genital gonorrhea</td> <td>Annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Syphilis</td> <td>Annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>HBV</td> <td>First visit</td> </tr> <tr class=\"highlight_gray_text divider_bottom\"> <td>HCV</td> <td>First visit</td> </tr> <tr class=\"highlight_gray_text\"> <td rowspan=\"9\">HIV-infected MSM</td> <td>Genital chlamydia</td> <td>At least annually</td> <td rowspan=\"9\">More frequent screening (every 3 months) for chlamydia, gonorrhea, and syphilis is recommended in those with risk factors. More frequent screening for HCV may also be warranted.<sup>&#916;</sup></td> </tr> <tr class=\"highlight_gray_text\"> <td>Rectal chlamydia (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Genital gonorrhea</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Rectal gonorrhea (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Pharyngeal gonorrhea (if exposed)</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>Syphilis</td> <td>At least annually</td> </tr> <tr class=\"highlight_gray_text\"> <td>HAV</td> <td>First visit</td> </tr> <tr class=\"highlight_gray_text\"> <td>HBV&nbsp;</td> <td>First visit&nbsp;</td> </tr> <tr class=\"highlight_gray_text\"> <td>HCV</td> <td>At least annually</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HAV: hepatitis A virus; HBV: hepatitis B virus; HCV: hepatitis C virus; MSW: men who have sex only with women; MSM: men who have sex with men; STI: sexually transmitted infection.<br />* Increased risk factors for gonorrhea, chlamydia, and trichomoniasis in women include prior infection, particularly in the preceding 24 months; multiple sex partners within the past year; suspicion that a recent partner may have had concurrent partners; new sex partner in the past 3 months; exchanging sex for drugs or money within the past year; residing in an area of high STI prevalence.<br />¶&nbsp;Increased risk factors for gonorrhea and chlamydia in MSW include an infection in the preceding 24 months.<br />Δ&nbsp;Increased risk factors for gonorrhea, chlamydia, syphilis, and HIV among MSM include multiple or anonymous partners; intravenous drug use; sex in conjunction with illicit drug use, including methamphetamines; sex partners who engage in these activities. Increased risk factors for hepatitis C infection among MSM include HIV infection, high community HCV prevalence and incidence, high-risk sexual behaviors, and concomitant ulcerative STIs or STI-related proctitis.</div><div class=\"graphic_reference\">Adapted from: California Department of Public Health, Sexually Transmitted Diseases Branch. California STD screening recommendations, 2015. Available at: <A href=\"https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CA_STD-Screening-Recs.pdf#search=std%20screening%20recommendations\">https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CA_STD-Screening-Recs.pdf#search=std%20screening%20recommendations</A> (Accessed on August 30, 2017).</div><div id=\"graphicVersion\">Graphic 103391 Version 6.0</div></div></div>"},"103392":{"type":"graphic_table","displayName":"Pediatric acute gastroenteritis history","title":"Important aspects of the history for a child with acute gastroenteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the history for a child with acute gastroenteritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Historical feature</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr class=\"divider_bottom\"> <td>Duration of illness</td> <td> <ul> <li>Symptoms &#62;7 days may indicate underlying gastrointestinal or metabolic disease, or systemic disease (eg, IBD, celiac disease, immunodeficiency) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Frequency, volume, and character of stools (eg, blood mucus)</td> <td> <ul> <li>Frequent, watery, large volume without blood or mucus favors viral gastroenteritis </li> <li>Small volume, gross blood, or mucus favors bacterial gastroenteritis </li> <li>Blood or mucus also may occur with intussusception, appendicitis, toxic megacolon </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Frequency, volume, and character of emesis (eg, blood, bile, projectile)</td> <td> <ul> <li>Prolonged vomiting increases risk of dehydration and concern for underlying systemic or metabolic disorder </li> <li>Bilious or projectile vomiting may indicate intestinal obstruction (eg, intussusception, pyloric stenosis) </li> <li>Hematemesis may suggest esophageal injury or varices (with underlying liver disease) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Weight before illness</td> <td> <ul> <li>Used to assess degree of dehydration and response to fluid repletion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Urine output</td> <td> <ul> <li>Decreased: suggests dehydration </li> <li>Increased: may indicate diabetes ketoacidosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Associated symptoms: fever, headache, localized abdominal pain, urinary complaints, and others</td> <td> <ul> <li>May suggest alternate etiology (eg, urinary tract infection, appendicitis, and others) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Recent intake of food and fluids</td> <td> <ul> <li>Used to assess degree of dehydration and other causes of diarrhea (eg, starvation stools, food poisoning, food allergy/intolerance, overfeeding [particularly with hyperosmolar fluids]) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Underlying medical problems</td> <td> <ul> <li>May increase risk of complications </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Recent medications (particularly antibiotics) and medications in the home</td> <td> <ul> <li>May be associated with vomiting or diarrhea </li> <li>Clinical manifestations of certain ingestions may mimic findings of acute gastroenteritis (eg, tachypnea and acidosis in salicylate ingestion) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Immunization history (particularly rotavirus)</td> <td> <ul> <li>Rotavirus immunization decreases likelihood of rotavirus gastroenteritis (even after one dose) </li> <li>Incomplete pneumococcal or <em>Haemophilus influenzae</em> type b immunization may increase likelihood of extraintestinal infection with these organisms (eg, otitis media, pneumonia, meningitis) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td>Contacts with acute diarrhea or vomiting</td> <td> <ul> <li>Supports infectious gastroenteritis, may suggest a common source outbreak </li> <li>Symptoms may suggest etiology (eg, prominence of vomiting suggests norovirus) </li> </ul> </td> </tr> <tr> <td>Exposures: <ul class=\"decimal_heading\"> <li>Known source of enteric infection (eg, contaminated food or water) </li> <li>Unsafe foods (eg, raw/undercooked meats, eggs, shellfish, unpasteurized milk or juice) </li> <li>Swimming in or drinking untreated fresh surface water </li> <li>Farm, petting zoo, reptiles, pets with diarrhea </li> <li>International travel </li> </ul> </td> <td> <ul> <li>Increases risk of bacterial or parasitic gastroenteritis </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">IBD: inflammatory bowel disease.</div><div id=\"graphicVersion\">Graphic 103392 Version 1.0</div></div></div>"},"103393":{"type":"graphic_table","displayName":"Pediatric acute gastroenteritis examination","title":"Important aspects of the examination of a child with acute gastroenteritis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Important aspects of the examination of a child with acute gastroenteritis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"50%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical finding</td> <td class=\"subtitle1\">Potential significance</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Growth parameters</td> </tr> <tr> <td class=\"indent1\">Body weight</td> <td> <ul> <li>Used to determine degree of dehydration and response to fluid repletion </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Growth retardation</td> <td> <ul> <li>Chronic underlying condition (eg, gastrointestinal disease, immune deficiency) </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Vital signs</td> </tr> <tr> <td class=\"indent1\">Fever: <ul class=\"decimal_heading\"> <li>&#8805;38&#176;C (100.4&#176;F) in patient &#60;3 months </li> <li>&#8805;39&#176;C (102.2&#176;F) in patient &#8805;3 months </li> </ul> </td> <td> <ul> <li>Temperature elevation tends to be higher in extraintestinal infection or bacterial gastroenteritis (particularly if &#62;40&#176;C [104&#176;F]) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Rapid, weak, or absent pulse</td> <td> <ul> <li>Dehydration </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Decreased blood pressure</td> <td> <ul> <li>Dehydration, shock, sepsis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Hypotension disproportionate to apparent illness</td> <td> <ul> <li>Adrenal crisis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">HEENT</td> </tr> <tr> <td class=\"indent1\">Sunken anterior fontanelle, sunken eyes</td> <td> <ul> <li>Moderate to severe dehydration </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bulging anterior fontanelle</td> <td> <ul> <li>Increased intracranial pressure </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Scleral icterus</td> <td> <ul> <li>HUS, viral hepatitis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Bulging tympanic membrane</td> <td> <ul> <li>Acute otitis media </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tacky, dry, or parched mucous membranes</td> <td> <ul> <li>Dehydration </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neck</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Neck stiffness, nuchal rigidity, other meningeal signs</td> <td> <ul> <li>Meningitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Chest</td> </tr> <tr> <td class=\"indent1\">Deep respirations</td> <td> <ul> <li>Moderate to severe dehydration, acidosis </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Tachypnea, crackles, decreased breath sounds</td> <td> <ul> <li>Pneumonia </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Abdomen</td> </tr> <tr> <td class=\"indent1\">Severe, localized pain, rebound tenderness, marked abdominal distension</td> <td> <ul> <li>Acute abdomen (eg, appendicitis, bowel obstruction, toxic megacolon) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Hypoactive/absent bowel sounds</td> <td> <ul> <li>Hypokalemia </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Flank pain or suprapubic tenderness</td> <td> <ul> <li>UTI </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Abdominal mass</td> <td> <ul> <li>\"Olive\" at lateral edge of rectus abdominus in RUQ: pyloric stenosis </li> <li>\"Sausage-shaped\" right-sided mass: intussusception </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Skin</td> </tr> <tr> <td class=\"indent1\">Cool, mottled, poor capillary refill, decreased turgor</td> <td> <ul> <li>Moderate to severe dehydration, sepsis </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Nonblanching lesions (petechiae, purpura, bruises)</td> <td> <ul> <li>HUS, trauma (intracranial, intra-abdominal) </li> </ul> </td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Jaundice</td> <td> <ul> <li>HUS, viral hepatitis </li> </ul> </td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"2\">Neurologic</td> </tr> <tr> <td class=\"indent1\">Altered consciousness or focal neurologic abnormalities</td> <td> <ul> <li>Toxic ingestion, diabetic ketoacidosis, CNS mass, or inborn error of metabolism </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HEENT: head, eyes, ears, nose, throat; UTI: urinary tract infections; HUS: hemolytic uremic syndrome; RUQ: right upper quadrant; CNS: central nervous system.</div><div id=\"graphicVersion\">Graphic 103393 Version 2.0</div></div></div>"},"103406":{"type":"graphic_diagnosticimage","displayName":"Radiation damage to colon: CT image","title":"Radiation damage to colon: CT image","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Radiation damage to colon: CT image</div><div class=\"cntnt\"><img style=\"width:370px; height:246px;\" src=\"images/SURG/103406_Rdt_dmg_cln_CT_img.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial CT scan at lower section shows focal wall thickening of hepatic flexure of colon (arrow). Colonoscopy and biopsy proved radiation injury.</div><div class=\"graphic_footnotes\">CT: computed tomography.</div><div class=\"graphic_reference\">Reprinted with permission from the American Journal of Roentgenology. Kwek JW, Iyer RB, Dunnington J. Spectrum of imaging findings in the abdomen after radiotherapy. AJR Am J Roentgenol 2006;187:1204. Copyright &copy; 2006 American Roentgen Ray Society.</div><div id=\"graphicVersion\">Graphic 103406 Version 1.0</div></div></div>"},"103418":{"type":"graphic_picture","displayName":"Visual aid for estimating intrapartum blood loss","title":"Visual aid for estimating intrapartum blood loss","html":"<div class=\"graphic\"><div style=\"width: 831px\" class=\"figure\"><div class=\"ttl\">Visual aid for estimating intrapartum blood loss</div><div class=\"cntnt\"><img style=\"width:811px; height:645px;\" src=\"images/OBGYN/103418_Vsl_aid_estmt_intrpr_bld_lss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Visual aid. Pocket card with images of measured volumes of artificial blood.</div><div class=\"graphic_reference\">From: Zuckerwise LC, Pettker CM, Illuzzi J, et al. Use of a novel visual aid to improve estimation of obstetric blood loss. Obstet Gynecol 2014; 123:982. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=05000&amp;article=00013&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/AOG.0000000000000233</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103418 Version 1.0</div></div></div>"},"103422":{"type":"graphic_diagnosticimage","displayName":"Mammary ductogram with filling defect","title":"Mammary ductogram with filling defect","html":"<div class=\"graphic\"><div style=\"width: 643px\" class=\"figure\"><div class=\"ttl\">Mammary ductogram with filling defect</div><div class=\"cntnt\"><img style=\"width:623px; height:349px;\" src=\"images/SURG/103422_Mammary_ductogram_defect.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mammary ductogram with filling defect (arrow) indicating an intraductal mass.</div><div id=\"graphicVersion\">Graphic 103422 Version 1.0</div></div></div>"},"103423":{"type":"graphic_picture","displayName":"Skin incision for subareolar duct excision","title":"Skin incision for subareolar duct excision","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Skin incision for subareolar duct excision</div><div class=\"cntnt\"><img style=\"width:429px; height:320px;\" src=\"images/SURG/103423_Skn_incsn_sbrlr_dct_excsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For complete subareolar duct incision, a periareolar incision along the lateral portion of the areola that circumnavigates no more than 30 percent of the circumference of the areola is preferred.</div><div id=\"graphicVersion\">Graphic 103423 Version 1.0</div></div></div>"},"103424":{"type":"graphic_diagnosticimage","displayName":"Specimen mammogram","title":"Specimen mammogram","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Specimen mammogram</div><div class=\"cntnt\"><img style=\"width:245px; height:245px;\" src=\"images/SURG/103424_Specimen_mammogram_PR.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A specimen mammogram obtained after breast seed localization with letters denoting anterior, posterior, medial and lateral margins.</div><div id=\"graphicVersion\">Graphic 103424 Version 1.0</div></div></div>"},"103467":{"type":"graphic_figure","displayName":"Afferent and efferent loop obstruction","title":"Afferent and efferent loop obstruction","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Afferent and efferent loop obstruction</div><div class=\"cntnt\"><img style=\"width:539px; height:652px;\" src=\"images/SURG/103467_Afferent_and_efferent_loop_obstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Redrawn from: Warren RP. Acute obstruction of afferent or efferent loop, following, antecolic partial gastrectomy, with report of three cases. Ann Surg 1954; 139:202. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright © 1954 American Surgical Association and European Surgical Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103467 Version 1.0</div></div></div>"},"103468":{"type":"graphic_figure","displayName":"Afferent and efferent loops","title":"Afferent and efferent loops","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Afferent and efferent loops</div><div class=\"cntnt\"><img style=\"width:412px; height:365px;\" src=\"images/SURG/103468_Afferent_and_efferent_loops.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The afferent and efferent limbs are two segments of jejunum&nbsp;formed by&nbsp;Billroth II reconstruction after partial gastrectomy. The afferent limb is the duodenojejunal segment proximal to the gastrojejunal anastomosis. The efferent limb is distal to the anastomosis. </div><div id=\"graphicVersion\">Graphic 103468 Version 1.0</div></div></div>"},"103469":{"type":"graphic_table","displayName":"Rev Banff 2013 classification ABMR in renal allografts","title":"Revised (Banff 2013) classification of antibody-mediated rejection in renal allografts","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Revised (Banff 2013) classification of antibody-mediated rejection in renal allografts</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Acute/active ABMR; all three features must be present for diagnosis*<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">1. Histologic evidence of acute tissue injury, including one or more of the following:</td> </tr> <tr> <td class=\"indent3\">Microvascular inflammation (g &#62;0<sup>&#916;</sup> and/or ptc &#62;0)</td> </tr> <tr> <td class=\"indent3\">Intimal or transmural arteritis (v &#62;0)<sup>&#9674;</sup></td> </tr> <tr> <td class=\"indent3\">Acute TMA, in the absence of any other cause</td> </tr> <tr> <td class=\"indent3\">Acute tubular injury, in the absence of any other apparent cause</td> </tr> <tr> <td class=\"indent1\">2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following:</td> </tr> <tr> <td class=\"indent3\">Linear C4d staining in peritubular capillaries (C4d2 or C4d3 by IF on frozen sections, or C4d &#62;0 by IHC on paraffin sections)</td> </tr> <tr> <td class=\"indent3\">At least moderate microvascular inflammation ([g + ptc] &#8805;2)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent3\">Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thoroughly validated<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. Serologic evidence of DSAs (HLA or other antigens)</td> </tr> <tr> <td class=\"subtitle1_single\">Chronic, active ABMR; all three features must be present for diagnosis*<sup>&#135;</sup></td> </tr> <tr> <td class=\"indent1\">1. Morphologic evidence of chronic tissue injury, including one or more of the following:</td> </tr> <tr> <td class=\"indent3\">TG (cg &#62;0)<sup>&#134;</sup>, if no evidence of chronic thrombotic microangiopathy</td> </tr> <tr> <td class=\"indent3\">Severe&nbsp;ptc basement membrane multilayering (requires EM)**</td> </tr> <tr> <td class=\"indent3\">Arterial intimal fibrosis of new onset, excluding other causes<sup>&#182;&#182;</sup></td> </tr> <tr> <td class=\"indent1\">2. Evidence of current/recent antibody interaction with vascular endothelium, including at least one of the following:</td> </tr> <tr> <td class=\"indent3\">Linear C4d staining in ptc (C4d2 or C4d3 by IF on frozen sections, or C4d &#62;0 by IHC on paraffin sections)</td> </tr> <tr> <td class=\"indent3\">At least moderate microvascular inflammation ([g + ptc] &#8805;2)<sup>&#167;</sup></td> </tr> <tr> <td class=\"indent3\">Increased expression of gene transcripts in the biopsy tissue indicative of endothelial injury, if thoroughly validated<sup>&#165;</sup></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">3. Serologic evidence of DSAs (HLA or other antigens)</td> </tr> <tr> <td class=\"subtitle1_single\">C4d staining without evidence of rejection; all three features must be present for diagnosis<sup>&#916;&#916;</sup></td> </tr> <tr> <td class=\"indent1\">1. Linear C4d staining in&nbsp;ptc (C4d2 or C4d3 by IF on frozen sections, or C4d &#62;0 by IHC on paraffin sections)</td> </tr> <tr> <td class=\"indent1\">2. g = 0, ptc = 0, cg = 0 (by light microscopy and by EM if available), v = 0; no TMA, no ptc basement membrane multilayering, no acute tubular injury (in the absence of another apparent cause for this)</td> </tr> <tr> <td class=\"indent1\">3. No acute cell-mediated rejection (Banff 97 type 1A or greater) or borderline changes</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ABMR: antibody-mediated rejection; g: Banff glomerulitis score; ptc: peritubular capillary; v: Banff arteritis score; TMA: thrombotic microangiopathy; IF: immunofluorescence; IHC: immunohistochemistry; DSA: donor-specific antibody; HLA: human leukocyte antigen; TG: transplant glomerulopathy; cg: Banff chronic glomerulopathy score; EM: electron microscopy; TCMR: T-cell-mediated rejection; ENDAT: endothelial activation and injury transcript; GBM: glomerular basement membrane.<br />​* For all ABMR diagnoses, it should be specified in the report whether the lesion is C4d positive (C4d2 or C4d3 by IF on frozen sections; C4d &gt;0 by IHC on paraffin sections) or without evident C4d deposition (C4d0 or C4d1 by IF on frozen sections; C4d0 by IHC on paraffin sections).<br />¶ These lesions may be clinically acute, smoldering, or subclinical. Biopsies showing two of the three features, except those with DSA and C4d without histologic abnormalities potentially related to ABMR or TCMR (C4d staining without evidence of rejection<SUP>ΔΔ</SUP>), may be designated as \"suspicious\" for acute/active ABMR.<br />Δ Recurrent/de novo glomerulonephritis should be excluded.<br /><FONT class=lozenge>◊</FONT> It should be noted that these arterial lesions may be indicative of ABMR, TCMR, or mixed ABMR/TCMR. \"v\" lesions are only scored in arteries having a continuous media with two or more smooth muscle layers.<br />§ In the presence of acute TCMR, borderline infiltrates or evidence of infection, ptc ≥2 alone is not sufficient to define moderate microvascular inflammation, and g must be ≥1.<br />¥ The only validated molecular marker meeting this criterion is ENDAT expression<SUP>[1]</SUP>, and this has only been validated in a single center (University of Alberta). The use of ENDAT expression at other centers or other test(s) of gene expression within the biopsy as evidence of ABMR must first undergo independent validation as was done for ENDAT expression<SUP>[1]</SUP>​.<br />​‡ Lesions of chronic, active ABMR can range from primarily active lesions with early TG evident only by EM (cg1a) to those with advanced TG and other chronic changes in addition to active microvascular inflammation. In the absence of evidence of current/recent antibody interaction with the endothelium (those features in the Second Section), the term active should be omitted; in such cases, DSA may be present at the time of biopsy or at any previous time posttransplantation.<br />† Includes GBM duplication by EM only (cg1a) or GBM double contours by light microscopy.<br />** Seven or more layers in one cortical ptc and ≥5 in two additional capillaries<SUP>[2]</SUP>, avoiding portions cut tangentially.<br />¶¶ While leukocytes within the fibrotic intima favor chronic rejection, these are seen with chronic TCMR as well as chronic ABMR and are therefore helpful only if there is no history of TCMR. An elastic stain may be helpful as absence of elastic lamellae is more typical of chronic rejection, and multiple elastic lamellae are most typical of arteriosclerosis, although these findings are not definitive.<br />ΔΔ The clinical significance of these findings may be quite different in grafts exposed to anti-blood-group antibodies (ABO-incompatible allografts), where they do not appear to be injurious to the graft<SUP>[3,4]</SUP> and may represent accommodation. However, with anti-HLA antibodies, such lesions may progress to chronic ABMR<SUP>[5]</SUP>, and more outcome data are needed.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Sis B, Jhangri G, Bunnag S, et al. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. Am J Transplant 2009; 9:2312.</li>&#xD;&#xA;    <li>Liapis G, Singh HK, Derebail VK, et al. Diagnostic significance of peritubular capillary basement membrane multilaminations in kidney allografts: Old concepts revisited. Transplantation 2012; 94:620.</li>&#xD;&#xA;    <li>Haas M, Rahman MH, Racusen LC, et al. C4d and C3d staining in biopsies of ABO- and HLA-incompatible renal allografts: Correlation with histologic findings. Am J Transplant 2006; 6:1829.</li>&#xD;&#xA;    <li>Setoguchi K, Ishida H, Shimmura H, et al. Analysis of renal transplant protocol biopsies in ABO-incompatible kidney transplantation. Am J Transplant 2008; 8:86.</li>&#xD;&#xA;    <li>Bravou V, Galliford J, McLean A, et al. A case of chronic antibody-mediated rejection in the making. Clin Nephrol 2013; 80:306.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Haas M. An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts. Am J Transplant 2014; 14:272. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/ajt.12590/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/ajt.12590/abstract</a>. Copyright &copy; The American Society of Transplantation and the American Society of Transplant Surgeons. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103469 Version 2.0</div></div></div>"},"103470":{"type":"graphic_figure","displayName":"Reoperation for afferent loop syndrome","title":"Reoperation for afferent loop syndrome","html":"<div class=\"graphic\"><div style=\"width: 511px\" class=\"figure\"><div class=\"ttl\">Reoperation for afferent loop syndrome</div><div class=\"cntnt\"><img style=\"width:491px; height:700px;\" src=\"images/SURG/103470_Reoperation_for_afferent_loop_syndrome.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Surgical treatment of afferent loop syndrome can be performed as a Roux-en-Y anastomosis (left), or a Braun enteroenterostomy between the afferent and efferent loop (right).</div><div id=\"graphicVersion\">Graphic 103470 Version 1.0</div></div></div>"},"103471":{"type":"graphic_figure","displayName":"Schematic drawing of jejunogastric intussusception","title":"Schematic drawing of jejunogastric intussusception","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Schematic drawing of jejunogastric intussusception</div><div class=\"cntnt\"><img style=\"width:420px; height:416px;\" src=\"images/SURG/103471_Schematic_drawing_of_jejunogastric_intussusception.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Jejunogastric intussusception can cause gastric outlet obstruction in postgastrectomy patients.</div><div class=\"graphic_reference\">Modified from: McQuarrie DG, Humphrey EW, Louie JS. Reoperative General Surgery, 2nd Edition. Philadelphia: Mosby-Year Book, Inc., 1997.</div><div id=\"graphicVersion\">Graphic 103471 Version 1.0</div></div></div>"},"103478":{"type":"graphic_table","displayName":"Typical UF rates required to achieve effective convection rates","title":"Typical ultrafiltration (UF) rates required to achieve effective convection rates of 20, 30, and 37.7% of blood flow","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Typical ultrafiltration (UF) rates required to achieve effective convection rates of 20, 30, and 37.7% of blood flow</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"16%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">&nbsp;</td> <td class=\"subtitle1\" colspan=\"2\">Postdilution</td> <td class=\"subtitle1\" colspan=\"3\">Predilution</td> </tr> <tr> <td class=\"subtitle1\" colspan=\"2\">Effective convection rate<br /> (% of blood flow)</td> <td class=\"subtitle1\" colspan=\"3\">Effective convection rate<br /> (% of blood flow)</td> </tr> <tr> <td class=\"subtitle2\">&nbsp;</td> <td class=\"subtitle2\">20%</td> <td class=\"subtitle2\">30%*</td> <td class=\"subtitle2\">20%</td> <td class=\"subtitle2\">30%</td> <td class=\"subtitle2\">37.7%</td> </tr> <tr> <td class=\"subtitle3\">Blood flow (mL/min)</td> <td class=\"subtitle3\">UF rate (mL/min)</td> <td class=\"subtitle3\">UF rate (mL/min)</td> <td class=\"subtitle3\">UF rate (mL/min)</td> <td class=\"subtitle3\">UF rate (mL/min)</td> <td class=\"subtitle3\">UF rate (mL/min)</td> </tr> <tr> <td>250</td> <td>50</td> <td>75</td> <td>75</td> <td>150</td> <td>250</td> </tr> <tr> <td>300</td> <td>60</td> <td>90</td> <td>90</td> <td>180</td> <td>300</td> </tr> <tr> <td>350</td> <td>70</td> <td>105</td> <td>105</td> <td>210</td> <td>350</td> </tr> <tr> <td>400</td> <td>80</td> <td>120</td> <td>120</td> <td>240</td> <td>400</td> </tr> <tr> <td>450</td> <td>90</td> <td>135</td> <td>135</td> <td>270</td> <td>450</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Rates assume hematocrit of 0.35.</div><div class=\"graphic_footnotes\">UF: ultrafiltration.<br />* A filtration fraction of 30% in postdilution is only possible using methods designed to optimize filtration.</div><div class=\"graphic_reference\">Reproduced from: Tattersall JE, Ward RA, EUDIAL group. Online haemodiafiltration: Definition, dose quantification and safety revisited. Nephrol Dial Transplant 2013; 28(3):542-50, by permission of Oxford University Press on behalf of ERA-EDTA. Copyright © 2013 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 103478 Version 4.0</div></div></div>"},"103491":{"type":"graphic_picture","displayName":"Kindler syndrome newborn","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:564px; height:800px;\" src=\"images/DERM/103491_Kindler_synd_newborn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Newborn with Kindler syndrome demonstrating erosions and crusts on the extremities.</div><div id=\"graphicVersion\">Graphic 103491 Version 1.0</div></div></div>"},"103492":{"type":"graphic_picture","displayName":"Kindler syndrome skin atrophy","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 619px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:599px; height:629px;\" src=\"images/DERM/103492_Kndlr_synd_skn_atrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Skin atrophy on the dorsal aspect of the hand in a two-year-old girl with Kindler syndrome.</div><div id=\"graphicVersion\">Graphic 103492 Version 1.0</div></div></div>"},"103493":{"type":"graphic_movie","displayName":"Microductectomy","title":"Microductecotmy","html":"<div class=\"graphic normal\"><div style=\"width: 516px\" class=\"figure\"><div class=\"ttl\">Microductecotmy</div><div class=\"cntnt\"><div class=\"videoplayer\" h264=\"images/SURG/103493_Microductecotmyvid.mp4\" style=\"width:496px;height:384px\"></div><img style=\"width:576px; height:432px;\" src=\"images/SURG/103493_Microductecotmyimg.jpg\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of Roshni Rao, MD, FACS, UT Southwestern Medical Center.</div><div id=\"graphicVersion\">Graphic 103493 Version 2.0</div></div></div>"},"103494":{"type":"graphic_picture","displayName":"Kindler syndrome poikiloderma","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:854px; height:569px;\" src=\"images/DERM/103494_Kndlr_synd_poikiloderma.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Poikiloderma (a combination of skin atrophy, telangiectasia, and pigmentary changes) on the back of a young man with Kindler syndrome.</div><div id=\"graphicVersion\">Graphic 103494 Version 1.0</div></div></div>"},"103496":{"type":"graphic_picture","displayName":"Kindler syndrome hand sclerosis","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 580px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:560px; height:837px;\" src=\"images/DERM/103496_Kndlr_synd_hnd_sclrss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophy of the skin, contracture of the hand, pseudosyndactilies, and pseudoainhum in a young man with Kindler syndrome.</div><div id=\"graphicVersion\">Graphic 103496 Version 1.0</div></div></div>"},"103497":{"type":"graphic_picture","displayName":"Kindler syndrome loss of dermatoglyphics","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 935px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:915px; height:633px;\" src=\"images/DERM/103497_Kndlr_synd_lss_drmtglyph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Loss of dermatoglyphics in a young woman with Kindler syndrome.</div><div id=\"graphicVersion\">Graphic 103497 Version 1.0</div></div></div>"},"103498":{"type":"graphic_picture","displayName":"Kindler syndrome nail dystrophy","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 589px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:569px; height:852px;\" src=\"images/DERM/103498_Kndlr_synd_nail_dystrphy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Atrophic skin and toenail dystrophy in Kindler syndrome.</div><div id=\"graphicVersion\">Graphic 103498 Version 1.0</div></div></div>"},"103499":{"type":"graphic_picture","displayName":"Staphylococcal folliculitis on chest","title":"Staphylococcal folliculitis","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Staphylococcal folliculitis</div><div class=\"cntnt\"><img style=\"width:854px; height:637px;\" src=\"images/DERM/103499_Staphylococcal_fllclts_chst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small inflammatory pustules and papules on the chest.</div><div id=\"graphicVersion\">Graphic 103499 Version 1.0</div></div></div>"},"103500":{"type":"graphic_picture","displayName":"Staphylococcal folliculitis close view","title":"Staphylococcal folliculitis","html":"<div class=\"graphic\"><div style=\"width: 876px\" class=\"figure\"><div class=\"ttl\">Staphylococcal folliculitis</div><div class=\"cntnt\"><img style=\"width:856px; height:551px;\" src=\"images/DERM/103500_Stphylcccl_fllclts_cls.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Small inflammatory papules and pustules.</div><div id=\"graphicVersion\">Graphic 103500 Version 1.0</div></div></div>"},"103501":{"type":"graphic_picture","displayName":"Bacterial folliculitis","title":"Bacterial folliculitis","html":"<div class=\"graphic\"><div style=\"width: 732px\" class=\"figure\"><div class=\"ttl\">Bacterial folliculitis</div><div class=\"cntnt\"><img style=\"width:712px; height:532px;\" src=\"images/DERM/103501_Bacterial_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Suppurative inflammation surrounding a hair follicle.</div><div id=\"graphicVersion\">Graphic 103501 Version 1.0</div></div></div>"},"103502":{"type":"graphic_picture","displayName":"Dermatophyte folliculitis","title":"Dermatophyte folliculitis","html":"<div class=\"graphic\"><div style=\"width: 880px\" class=\"figure\"><div class=\"ttl\">Dermatophyte folliculitis</div><div class=\"cntnt\"><img style=\"width:860px; height:642px;\" src=\"images/DERM/103502_Dermatophyte_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Spores of the large spore endothrix fungus, <EM>Trichophyton tonsurans</EM>, within the hair shaft.</div><div id=\"graphicVersion\">Graphic 103502 Version 1.0</div></div></div>"},"103503":{"type":"graphic_picture","displayName":"Malassezia folliculitis","title":"<em>Malassezia</em> folliculitis (<em>Pityrosporum</em> folliculitis)","html":"<div class=\"graphic\"><div style=\"width: 736px\" class=\"figure\"><div class=\"ttl\"><em>Malassezia</em> folliculitis (<em>Pityrosporum</em> folliculitis)</div><div class=\"cntnt\"><img style=\"width:716px; height:534px;\" src=\"images/DERM/103503_Malassezia_folliculitis.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><em>Malassezia</em> spores in a hair follicle surrounded by inflammation.</div><div id=\"graphicVersion\">Graphic 103503 Version 1.0</div></div></div>"},"103512":{"type":"graphic_picture","displayName":"Lymphomatoid drug eruption","title":"Lymphomatoid drug eruption (T cell pseudolymphoma)","html":"<div class=\"graphic\"><div style=\"width: 889px\" class=\"figure\"><div class=\"ttl\">Lymphomatoid drug eruption (T cell pseudolymphoma)</div><div class=\"cntnt\"><img style=\"width:869px; height:462px;\" src=\"images/DERM/103512_Lymphomatoid_drug_erupt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Lymphomatoid drug eruption without systemic symptoms due to anti-epileptics presenting with a solitary plaque on the back.</div><div class=\"graphic_reference\"><EM>Courtesy of Rein Willemze, MD.</EM></div><div id=\"graphicVersion\">Graphic 103512 Version 3.0</div></div></div>"},"103521":{"type":"graphic_figure","displayName":"Identification of bile and pancreatic duct ampullary resection","title":"Identification of bile duct and pancreatic duct at transduodenal ampullary resection (open)","html":"<div class=\"graphic\"><div style=\"width: 487px\" class=\"figure\"><div class=\"ttl\">Identification of bile duct and pancreatic duct at transduodenal ampullary resection (open)</div><div class=\"cntnt\"><img style=\"width:467px; height:473px;\" src=\"images/SURG/103521_ID_bile_pancreatic_ducts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Traction sutures are placed circumferentially around the ampulla to facilitate excision of the ampullary tumor, following which&nbsp;the structures of common bile duct and pancreatic duct are identified and divided.</div><div class=\"graphic_reference\">Modified from: Targarona Modena J, Rosamedina JL, Garatea R, et al. [Transduodenal ampullectomy: an useful alternative for the treatment of Vater's ampulla lesions. Case reports of an unfrecuent surgical technique]. Rev Gastroenterol Peru 2005; 25:106.</div><div id=\"graphicVersion\">Graphic 103521 Version 2.0</div></div></div>"},"103522":{"type":"graphic_picture","displayName":"CD4+ PCSM-TCL","title":"Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder","html":"<div class=\"graphic\"><div style=\"width: 715px\" class=\"figure\"><div class=\"ttl\">Primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder</div><div class=\"cntnt\"><img style=\"width:695px; height:368px;\" src=\"images/DERM/103522_Idpthc_T_cll_psdlymphm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous CD4<SUP>+</SUP> small/medium T cell lymphoproliferative disorder presenting as a solitary plaque on the forehead. Similar lesions were previously classified as idiopathic (solitary) T cell pseudolymphoma. </div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103522 Version 5.0</div></div></div>"},"103523":{"type":"graphic_figure","displayName":"Transduodenal bile duct reconstruction - open","title":"Transduodenal bile duct reconstruction - open","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Transduodenal bile duct reconstruction - open</div><div class=\"cntnt\"><img style=\"width:427px; height:464px;\" src=\"images/SURG/103523_Bile_duct_reconstruct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">After ampullary resection, the orifices of the common bile duct and pancreatic duct are reimplanted into the back wall of the duodenum with interrupted absorbable sutures. </div><div class=\"graphic_reference\">Modified from: Targarona Modena J, Rosamedina JL, Garatea R, et al. [Transduodenal ampullectomy: an useful alternative for the treatment of Vater's ampulla lesions. Case reports of an unfrecuent surgical technique]. Rev Gastroenterol Peru 2005; 25:106.</div><div id=\"graphicVersion\">Graphic 103523 Version 1.0</div></div></div>"},"103524":{"type":"graphic_figure","displayName":"Elbow injection","title":"Elbow injection","html":"<div class=\"graphic\"><div style=\"width: 488px\" class=\"figure\"><div class=\"ttl\">Elbow injection</div><div class=\"cntnt\"><img style=\"width:468px; height:302px;\" src=\"images/ALLRG/103524_Elbow_injection.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the elbow flexed and pronated, the needle is inserted at the most tender area on the anterolateral aspect of the external condyle of the humerus. A combination of glucocorticoid and local anesthetic is injected in several areas.</div><div class=\"graphic_reference\">Reproduced from Owen DS. Aspiration and injection of joints in soft tissue. In: Textbook of Rheumatology, 4th edition, Kelley WN, Harris ED Jr, Ruddy S, et al (Eds), WB Saunders, Philadelphia 1993. p.545.</div><div id=\"graphicVersion\">Graphic 103524 Version 1.0</div></div></div>"},"103531":{"type":"graphic_picture","displayName":"Idiopathic T cell pseudolymphoma histo","title":"Histologic features of idiopathic T cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of idiopathic T cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:359px; height:800px;\" src=\"images/DERM/103531_Idpthc_T_cll_psdlymphm_hst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idiopathic (solitary) T cell pseudolymphoma, superficial type. Dense infiltrate in the superficial dermis with sharply defined lower border (A and B). High magnification shows scattered medium-sized to large atypical lymphocytes (C). An identical histologic pattern may be observed in lymphomatoid drug eruptions without systemic symptoms.</div><div class=\"graphic_reference\"><EM>Courtesy of Rein Willemze, MD.</EM></div><div id=\"graphicVersion\">Graphic 103531 Version 2.0</div></div></div>"},"103532":{"type":"graphic_picture","displayName":"Idiopathic T cell pseudolymphoma immunophenotype","title":"Immunophenotype of idiopathic T cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 637px\" class=\"figure\"><div class=\"ttl\">Immunophenotype of idiopathic T cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:617px; height:455px;\" src=\"images/DERM/103532_Idpthc_T_cll_psdlymph_imnph.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idiopathic (solitary) pseudo-T-cell lymphoma, superficial type. Predominance of CD4<SUP>+</SUP> T cells.</div><div class=\"graphic_reference\"><EM>Courtesy of Rein Willemze, MD.</EM></div><div id=\"graphicVersion\">Graphic 103532 Version 2.0</div></div></div>"},"103535":{"type":"graphic_picture","displayName":"Majocchi's granuloma on extremity","title":"Majocchi's granuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Majocchi's granuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:524px;\" src=\"images/DERM/103535_Mjcch_grnlm_extrm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papular and pustular eruption on the extremity secondary to dermatophyte infection.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103535 Version 1.0</div></div></div>"},"103536":{"type":"graphic_picture","displayName":"Majocchi's granuloma on hand","title":"Majocchi's granuloma","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Majocchi's granuloma</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103536_Mjcch_grnlm_hnd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Papules and pustules within an erythematous plaque on the dorsal hand.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103536 Version 1.0</div></div></div>"},"103537":{"type":"graphic_picture","displayName":"CD4+ PCSM-TCL histopathology 2","title":"Histologic features of primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder ","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Histologic features of primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder&nbsp;</div><div class=\"cntnt\"><img style=\"width:431px; height:585px;\" src=\"images/DERM/103537_Idptc_T_cll_psdlymphm_hst_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous CD4<SUP>+</SUP> small/medium T cell lymphoproliferative disorder (formerly called idiopathic T cell pseudolymphoma, nodular/diffuse type) shows a dense nodular infiltrate with a tendency to infiltrate the subcutis and minimal or absent epidermotropism.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103537 Version 4.0</div></div></div>"},"103538":{"type":"graphic_picture","displayName":"CD4+ PCSM-TCL immunophenotype","title":"Immunophenotype of primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Immunophenotype of primary cutaneous CD4+ small/medium T cell lymphoproliferative disorder</div><div class=\"cntnt\"><img style=\"width:791px; height:583px;\" src=\"images/DERM/103538_Idpth_T_cll_psdlym_imnph_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Primary cutaneous CD4<SUP>+</SUP> small/medium T cell lymphoproliferative disorder (formerly called idiopathic solitary T cell pseudolymphoma) showing scattered medium-sized to large T cells staining positive for programmed death-1.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103538 Version 4.0</div></div></div>"},"103542":{"type":"graphic_figure","displayName":"Blood and dialysis fluid pathways in HDF","title":"Blood and dialysis fluid pathways in hemodiafiltration","html":"<div class=\"graphic\"><div style=\"width: 650px\" class=\"figure\"><div class=\"ttl\">Blood and dialysis fluid pathways in hemodiafiltration</div><div class=\"cntnt\"><img style=\"width:630px; height:292px;\" src=\"images/NEPH/103542_Bld_dialysis_fluid_path_HDF.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Courtesy of James Tattersall, MD, MRCP and Peter J Blankestijn, MD.</div><div id=\"graphicVersion\">Graphic 103542 Version 1.0</div></div></div>"},"103552":{"type":"graphic_figure","displayName":"Days heroin free","title":"Days heroin free","html":"<div class=\"graphic\"><div style=\"width: 708px\" class=\"figure\"><div class=\"ttl\">Days heroin free</div><div class=\"cntnt\"><img style=\"width:688px; height:526px;\" src=\"images/PSYCH/103552_Days_heroin_free_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103552 Version 1.0</div></div></div>"},"103553":{"type":"graphic_figure","displayName":"Groups attended","title":"Groups attended","html":"<div class=\"graphic\"><div style=\"width: 534px\" class=\"figure\"><div class=\"ttl\">Groups attended</div><div class=\"cntnt\"><img style=\"width:514px; height:310px;\" src=\"images/PSYCH/103553_Groups_attended_PR.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103553 Version 1.0</div></div></div>"},"103568":{"type":"graphic_picture","displayName":"Kindler syndrome mucosal lesions","title":"Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 581px\" class=\"figure\"><div class=\"ttl\">Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:561px; height:722px;\" src=\"images/DERM/103568_Kndlr_syndr_mcsl_les.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Cheilitis angularis and periodontitis in a young woman with Kindler syndrome. Teeth were lost early and replaced.<br />(B) The same patient developed hypertrophic gingivitis several years later.</div><div id=\"graphicVersion\">Graphic 103568 Version 1.0</div></div></div>"},"103581":{"type":"graphic_table","displayName":"Complications of pheochromocytoma-related hypertension","title":"Organ-specific complications of pheochromocytoma-related hypertension","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Organ-specific complications of pheochromocytoma-related hypertension</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"2\" width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Organ</td> <td class=\"subtitle1\">Syndrome</td> <td class=\"subtitle1\">Mechanism</td> </tr> <tr class=\"divider_bottom\"> <td>Heart</td> <td> <p>Acute failure</p> <p>Angina</p> <p>Arrhythmias</p> <p>Cardiomyopathies*</p> <p>Myocardial infarction</p> Myocarditis</td> <td> <p>Coronary spasm</p> <p>Hypoperfusion</p> <p>Positive chronotropic effect</p> <p>Positive inotropic effect</p> Unmatched O<sub>2</sub> demand</td> </tr> <tr class=\"divider_bottom\"> <td>Brain</td> <td> <p>Encephalopathy</p> Stroke</td> <td> <p>Hypoperfusion</p> <p>Unmatched O<sub>2</sub> demand</p> Vasoconstriction</td> </tr> <tr class=\"divider_bottom\"> <td>Vascular</td> <td> <p>Aortic dissection</p> <p>Limb ischemia</p> <p>Organ ischemia</p> <p>Postural hypotension</p> Shock</td> <td> <p>Hypoperfusion</p> <p>Unmatched O<sub>2</sub> demand</p> Vasoconstriction</td> </tr> <tr class=\"divider_bottom\"> <td>Kidneys</td> <td> <p>Acute renal failure</p> Hematuria</td> <td> <p>Hypoperfusion</p> <p>Unmatched O<sub>2</sub> demand</p> Vasoconstriction</td> </tr> <tr class=\"divider_bottom\"> <td>Lungs</td> <td> <p>Acute respiratory distress syndrome</p> <p>Fibrosis (?)</p> <p>Pulmonary edema</p> Pulmonary hypertension (?)</td> <td> <p>Cardiac decompensation</p> Increased permeability</td> </tr> <tr class=\"divider_bottom\"> <td>Gastrointestinal tract</td> <td>Intestinal ischemia (necrosis, peritonitis)</td> <td> <p>Hypoperfusion</p> <p>Unmatched O<sub>2</sub> demand</p> Vasoconstriction</td> </tr> <tr class=\"divider_bottom\"> <td>Ocular</td> <td> <p>Acute blindness</p> Retinopathy</td> <td>Vasoconstriction</td> </tr> <tr> <td>Acute multiorgan failure</td> <td>All of the above</td> <td>&#8212;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Including acute (dilated, tako-tsubo) and chronic (hypertrophic, ischemic, obstructive); ?: uncertain/unclear.</div><div class=\"graphic_reference\">Data from: Zuber SM, Kantorovich V, Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North Am 2011; 40:295.</div><div id=\"graphicVersion\">Graphic 103581 Version 2.0</div></div></div>"},"103584":{"type":"graphic_picture","displayName":"Metastatic Crohn disease","title":"Metastatic Crohn disease","html":"<div class=\"graphic\"><div style=\"width: 703px\" class=\"figure\"><div class=\"ttl\">Metastatic Crohn disease</div><div class=\"cntnt\"><img style=\"width:683px; height:504px;\" src=\"images/GAST/103584_Mtsttc_crhn_dss.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Metastatic Crohn disease presenting with erythematous nodules and plaques.</div><div class=\"graphic_reference\">From: Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous Manifestations in Patients With Inflammatory Bowel Diseases: Pathophysiology, Clinical Features, and Therapy. Inflamm Bowel Dis 2014; 20:213. DOI: <a href=\"http://journals.lww.com/ibdjournal/pages/articleviewer.aspx?year=2014&amp;issue=01000&amp;article=00021&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/01.MIB.0000436959.62286.f9</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 Crohn's and Colitis Foundation of America, Inc. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103584 Version 1.0</div></div></div>"},"103615":{"type":"graphic_figure","displayName":"Incidence adenocarcinoma stomach, esophagus, and GEJ","title":"Incidence of adenocarcinoma of the stomach, esophagus, and GEJ, 1973-2008, United States","html":"<div class=\"graphic\"><div style=\"width: 557px\" class=\"figure\"><div class=\"ttl\">Incidence of adenocarcinoma of the stomach, esophagus, and GEJ, 1973-2008, United States</div><div class=\"cntnt\"><img style=\"width:537px; height:318px;\" src=\"images/ONC/103615_Incdnc_adncr_esph_GEJ_stm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">GEJ: gastroesophageal junction</div><div class=\"graphic_reference\">Reproduced from: Buas MF, Vaughan TL. Epidemiology and risk factors for gastroesophageal junction tumors: understanding the rising incidence of this disease. Semin Radiat Oncol 2013; 23:3. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103615 Version 1.0</div></div></div>"},"103618":{"type":"graphic_picture","displayName":"Kindler syndrome revertant mosaicism","title":"Revertant mosaicism in Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 874px\" class=\"figure\"><div class=\"ttl\">Revertant mosaicism in Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:854px; height:775px;\" src=\"images/DERM/103618_Kndlr_synd_revrtnt_mscsm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the normal-appearing skin patch (outline) surrounded by atrophic skin.</div><div id=\"graphicVersion\">Graphic 103618 Version 1.0</div></div></div>"},"103619":{"type":"graphic_picture","displayName":"Kindler syndrome histo","title":"Histopathology of Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 960px\" class=\"figure\"><div class=\"ttl\">Histopathology of Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:940px; height:384px;\" src=\"images/DERM/103619_Kindler_synd_histo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) Routine hematoxylin and eosin (H&amp;E) staining shows epidermal atrophy and hyperkeratosis. Microblisters can be seen at the dermoepidermal junction. There are dilated vessels in the dermis.<br />(B) Reduction and abnormal aggregation of elastic fibers in the upper dermis can be observed with van Gieson staining.</div><div id=\"graphicVersion\">Graphic 103619 Version 1.0</div></div></div>"},"103627":{"type":"graphic_picture","displayName":"Kindler syndrome IFM mapping","title":"Immunofluorescence antigen mapping of Kindler syndrome","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Immunofluorescence antigen mapping of Kindler syndrome</div><div class=\"cntnt\"><img style=\"width:798px; height:294px;\" src=\"images/DERM/103627_Kndlr_synd_IFM_map.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Laminin-332 staining of Kindler syndrome (A) and normal skin (B).</div><div id=\"graphicVersion\">Graphic 103627 Version 1.0</div></div></div>"},"103629":{"type":"graphic_picture","displayName":"Rubber bar for epicondylitis rehabilitation","title":"Rubber bar for epicondylitis rehabilitation","html":"<div class=\"graphic\"><div style=\"width: 603px\" class=\"figure\"><div class=\"ttl\">Rubber bar for epicondylitis rehabilitation</div><div class=\"cntnt\"><img style=\"width:583px; height:773px;\" src=\"images/SM/103629_Rbbr_bar_epcndylts_rhbin.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The rubber bar pictured above can be used as part of a rehabilitation program for epicondylitis or for strengthening of the wrist flexor and extensor muscles.</div><div class=\"graphic_reference\">Courtesy of Neeru Jayanthi, MD.</div><div id=\"graphicVersion\">Graphic 103629 Version 1.0</div></div></div>"},"103630":{"type":"graphic_picture","displayName":"Hyperemia associated with dermal burns","title":"Hyperemia associated with dermal burns","html":"<div class=\"graphic\"><div style=\"width: 892px\" class=\"figure\"><div class=\"ttl\">Hyperemia associated with dermal burns</div><div class=\"cntnt\"><img style=\"width:872px; height:506px;\" src=\"images/EM/103630_Hyprmasscdrmbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph to the left shows deep partial- and full-thickness flame burns on the patient's back.&nbsp;Note the rim of erythema that exactly follows the wound border.&nbsp;This rim is hyperemia, not cellulitis. The photograph to the right shows full-thickness scald burns of the lower extremities.&nbsp;Note the rim of erythema that exactly follows the wound border,&nbsp;which again&nbsp;is hyperemia, not cellulitis.</div><div class=\"graphic_reference\">Courtesy of Arek Wiktor, MD, FACS.</div><div id=\"graphicVersion\">Graphic 103630 Version 2.0</div></div></div>"},"103631":{"type":"graphic_table","displayName":"Simple or single movements during sleep","title":"Simple or single movements during sleep: Distinguishing clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Simple or single movements during sleep: Distinguishing clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Hypnic jerk</td> <td class=\"subtitle1\">Bruxism</td> <td class=\"subtitle1\">Benign neonatal sleep myoclonus</td> <td class=\"subtitle1\">Propriospinal myoclonus at sleep onset</td> <td class=\"subtitle1\">Nocturnal leg cramp</td> <td class=\"subtitle1\">Exploding head syndrome</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Behavior</strong></td> <td>Quick single jerk with or without tactile, kinetic, visual, or auditory sensation</td> <td>Sudden closure of jaw or grinding of teeth</td> <td>Brief jerks, usually bilateral and symmetric</td> <td>Sudden jerk, typically in the trunk, neck, and limbs</td> <td>Sustained muscle contraction</td> <td>Painless sensation of explosion in the head, may be associated with a startle movement</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age of onset</strong></td> <td>Any</td> <td>Any</td> <td>Infancy</td> <td>Childhood or adulthood</td> <td>Childhood or adulthood</td> <td>Adulthood</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Family history</strong></td> <td>No</td> <td>Variable</td> <td>Variable</td> <td>No</td> <td>Variable</td> <td>No</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time of occurrence</strong></td> <td>Sleep onset</td> <td>Sleep onset or upon resumption of sleep</td> <td>Any time during sleep</td> <td>Light NREM sleep</td> <td>Any</td> <td>Usually near sleep onset but can be variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Frequency</strong></td> <td>Variable</td> <td>Multiple per night</td> <td>Multiple per night</td> <td>Multiple per night</td> <td>Variable</td> <td>Rare</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration</strong></td> <td>Milliseconds</td> <td>Seconds</td> <td>Milliseconds</td> <td>Milliseconds</td> <td>Up to several minutes</td> <td>Seconds</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Memory of event</strong></td> <td>Yes</td> <td>No</td> <td>No</td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stereotypical movements</strong></td> <td>Yes</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes (similar sensation each time)</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PSG findings</strong></td> <td>Sudden jerk at sleep onset</td> <td>Temporalis and masseter activation, rhythmic periodic chin muscle artifact</td> <td>Brief myoclonus</td> <td>Brief myoclonus in NREM sleep</td> <td>Prolonged muscle contraction</td> <td>Usually occurs in light sleep</td> </tr> <tr> <td><strong>Associated clinical findings</strong></td> <td>None (benign)</td> <td>Clenching sound, tooth wear, scars inside cheeks and tongue</td> <td>None (benign)</td> <td>Can be seen in individuals with spinal cord pathology</td> <td>None</td> <td>None (benign)</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PSG: polysomnogram.</div><div id=\"graphicVersion\">Graphic 103631 Version 2.0</div></div></div>"},"103632":{"type":"graphic_picture","displayName":"Cellulitis associated with dermal burn","title":"Cellulitis associated with dermal burn","html":"<div class=\"graphic\"><div style=\"width: 876px\" class=\"figure\"><div class=\"ttl\">Cellulitis associated with dermal burn</div><div class=\"cntnt\"><img style=\"width:856px; height:496px;\" src=\"images/EM/103632_Cllltsasscdrmbrn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This photograph shows deep partial-thickness flame burn to middle finger. Note the erythema extending proximally up the hand and arm,&nbsp;which is cellulitis.</div><div class=\"graphic_reference\">Courtesy of Arek Wiktor, MD, FACS.</div><div id=\"graphicVersion\">Graphic 103632 Version 2.0</div></div></div>"},"103633":{"type":"graphic_table","displayName":"Periodic or rhythmic movements during sleep","title":"Periodic or rhythmic movements during sleep: Distinguishing clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Periodic or rhythmic movements during sleep: Distinguishing clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Periodic limb movements</td> <td class=\"subtitle1\">Hypnagogic foot tremor and ALMA</td> <td class=\"subtitle1\">Sleep-related rhythmic movement disorder</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Behavior</strong></td> <td>Repetitive movement of limbs, typically legs, most commonly with triple flexion</td> <td>Rapid rhythmical movement of one foot or alternating movement of legs</td> <td>Rhythmical movement (rocking&nbsp;or rolling)&nbsp;of body or head</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age of onset</strong></td> <td>Any</td> <td>Any</td> <td>Early childhood</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Family history</strong></td> <td>Variable</td> <td>Unknown</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time of occurrence</strong></td> <td>First half of the night; most commonly during NREM sleep</td> <td>Near sleep onset</td> <td>Before sleep onset</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Frequency</strong></td> <td>Multiple per night</td> <td>Nightly</td> <td>Nightly</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration</strong></td> <td>0.5 to 5 seconds</td> <td>Usually 4 to 15 seconds, may recur</td> <td>Seconds to hours</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Memory of event</strong></td> <td>Variable</td> <td>Variable</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stereotypical movements</strong></td> <td>Yes</td> <td>Yes</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PSG findings</strong></td> <td>Periodic limb movements of sleep</td> <td>Limb movements</td> <td>Rhythmical movement artifact near sleep onset</td> </tr> <tr> <td><strong>Associated clinical findings</strong></td> <td>Commonly seen in association with restless legs syndrome</td> <td>None (benign)</td> <td>May be seen in normal children</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">ALMA: alternating leg muscle activation; PSG: polysomnogram.</div><div id=\"graphicVersion\">Graphic 103633 Version 2.0</div></div></div>"},"103634":{"type":"graphic_table","displayName":"Complex movements during sleep","title":"Complex movements during sleep: Distinguishing clinical features","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Complex movements during sleep: Distinguishing clinical features</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"8\" width=\"12%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Disorders of arousal</td> <td class=\"subtitle1\">Sleep-related eating disorder</td> <td class=\"subtitle1\">REM sleep behavior disorder</td> <td class=\"subtitle1\">REM nightmares</td> <td class=\"subtitle1\">Recurrent isolated sleep paralysis</td> <td class=\"subtitle1\">Psychiatric events</td> <td class=\"subtitle1\">Nocturnal seizures</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Behavior</strong></td> <td>Confused, semi-purposeful movement with eyes open</td> <td>Eating high caloric or unusual foods with eyes open</td> <td>Sometimes combative, violent dream enactment with eyes closed</td> <td>Vivid, disturbing dreams, may end with a sudden jolt or jerk</td> <td>Inability to move with preservation of eye and diaphragmatic movement</td> <td>Variable, may involve panic or dissociative symptoms</td> <td>Dependent on location of epileptic focus; may be brief jerks, simple or complex stereotypical behavior</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Age of onset</strong></td> <td>Childhood or adolescence</td> <td>Variable</td> <td>Older adults</td> <td>Childhood or adulthood</td> <td>Variable</td> <td>Adolescence to adulthood</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Family history</strong></td> <td>Yes</td> <td>Unknown</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Time of occurrence</strong></td> <td>First third of night</td> <td>First half of night</td> <td>During REM sleep</td> <td>Second half of the night most common (during REM sleep)</td> <td>Upon awakening</td> <td>Any time</td> <td>Any time, but more likely in first half of night</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Frequency</strong></td> <td>Once per night but not every night</td> <td>Variable</td> <td>Variable; a few times per month to nightly</td> <td>May be nightly</td> <td>Variable, less than weekly</td> <td>Variable</td> <td>Frontal lobe seizure can occur multiple times per night; less often for temporal lobe seizures</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Duration</strong></td> <td>Minutes</td> <td>Minutes</td> <td>Seconds to a minute</td> <td>Movement lasts seconds</td> <td>Seconds to a minute</td> <td>Variable (usually minutes or longer)</td> <td>Usually less than three minutes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Memory of event</strong></td> <td>Usually none</td> <td>Usually none, or limited</td> <td>Fragmentary to full dream recall</td> <td>Yes</td> <td>Yes</td> <td>None</td> <td>Variable</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Stereotypical movements</strong></td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>No</td> <td>Yes</td> </tr> <tr class=\"divider_bottom\"> <td><strong>PSG findings</strong></td> <td>Arousals from slow-wave sleep</td> <td>Arousal from NREM sleep</td> <td>Excessive EMG tone during REM sleep</td> <td>Awakening out of REM sleep appearing distressed</td> <td>Arousal from REM sleep</td> <td>Occur from wake state</td> <td>Epileptiform activity</td> </tr> <tr> <td><strong>Associated clinical findings</strong></td> <td>May indicate another problem causing arousals (eg, sleep apnea)</td> <td>Morning anorexia, unexplained weight gain, comorbid RLS/WED</td> <td>May be associated with parkinsonism, narcolepsy, or medications (antidepressants)</td> <td>May be associated with stress, psychological trauma, or medication effect</td> <td>None (benign)</td> <td>Other features of an underlying&nbsp;psychiatric disorder (eg, panic, anxiety, depression)</td> <td>May find focal neurologic deficits</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement; PSG: polysomnogram; NREM: non-REM; EMG: electromyography; RLS/WED: restless legs syndrome/Willis-Ekbom disease.</div><div id=\"graphicVersion\">Graphic 103634 Version 1.0</div></div></div>"},"103635":{"type":"graphic_picture","displayName":"Turner-Warwick retractor with blades","title":"Turner-Warwick retractor with blades","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">Turner-Warwick retractor with blades</div><div class=\"cntnt\"><img style=\"width:780px; height:581px;\" src=\"images/OBGYN/103635_Trnr_wrwck_rtrctr_bld.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103635 Version 1.0</div></div></div>"},"103636":{"type":"graphic_picture","displayName":"Turner-Warwick retractor placement","title":"Turner-Warwick retractor placement","html":"<div class=\"graphic\"><div style=\"width: 802px\" class=\"figure\"><div class=\"ttl\">Turner-Warwick retractor placement</div><div class=\"cntnt\"><img style=\"width:782px; height:583px;\" src=\"images/OBGYN/103636_Trnr_wrwck_rtrctr_plcmnt.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103636 Version 1.0</div></div></div>"},"103638":{"type":"graphic_algorithm","displayName":"Diagnostic evaluation for FSHD","title":"Diagnostic evaluation for facioscapulohumeral muscular dystrophy","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Diagnostic evaluation for facioscapulohumeral muscular dystrophy</div><div class=\"cntnt\"><img style=\"width:715px; height:456px;\" src=\"images/NEURO/103638_Dgnstc_evltn_FSHD.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">FSHD: facioscapulohumeral muscular dystrophy; FSHD1: facioscapulohumeral muscular dystrophy type 1; FSHD2: facioscapulohumeral muscular dystrophy type 2; LGMD2A: limb-girdle muscular dystrophy type 2A.</div><div class=\"graphic_reference\">Modified from: Tawil R, Kissel JT, Heatwole C, et al. Evidence-based guideline summary: Evaluation, diagnosis, and management of facioscapulohumeral muscular dystrophy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the Practice Issues Review Panel of the American Association of Neuromuscular &amp; Electrodiagnostic Medicine. Neurology 2015; 85:357.</div><div id=\"graphicVersion\">Graphic 103638 Version 1.0</div></div></div>"},"103649":{"type":"graphic_algorithm","displayName":"Diagnosis and treatment of SIH","title":"Diagnosis and treatment of spontaneous intracranial hypotension","html":"<div class=\"graphic\"><div style=\"width: 766px\" class=\"figure\"><div class=\"ttl\">Diagnosis and treatment of spontaneous intracranial hypotension</div><div class=\"cntnt\"><img style=\"width:746px; height:1434px;\" src=\"images/NEURO/103649_Diagnos_treat_SIH.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; MRI: magnetic resonance imaging; CT: computed tomography.<br />* Considered in patients who present with positional orthostatic headache, with or without associated symptoms, perhaps in the setting of minor trauma, but without a history of dural puncture or other cause of cerebrospinal fluid fistula.<br />¶ Any of the following: Duration &gt;2 weeks, severe headache, disabling symptoms, aggressive precipitating injury, connective tissue disease, or hypermobility.<br />Δ Approximately one-half of patients require more than one epidural blood patch treatment, and some may require several patches.</div><div class=\"graphic_reference\">Adapted from: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Mokri B. Spontaneous Intracranial Hypotension. Continuum (Minneap Minn) 2015; 21:1086.</LI>&#xD;&#xA;<LI>Starling A, Hernandez F, Hoxworth JM, et al. Sensitivity of MRI of the spine compared with CT myelography in orthostatic headache with CSF leak. Neurology 2013; 81:1789.</LI></OL></div><div id=\"graphicVersion\">Graphic 103649 Version 5.0</div></div></div>"},"103669":{"type":"graphic_figure","displayName":"Rodney Smith reconstruction","title":"Rodney Smith reconstruction","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Rodney Smith reconstruction</div><div class=\"cntnt\"><img style=\"width:676px; height:466px;\" src=\"images/SURG/103669_Rodney_Smith_reconstruction.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) The transhepatic tube with appropriate side holes is passed into the mucosal diverticulum and anchored to the Roux-en-Y loop.<br />(B) The sleeve of jejunal mucosa is carried up into the intrahepatic bile ducts by withdrawing on the transhepatic tube. The jejunal wall is then anchored to the liver capsule.</div><div class=\"graphic_reference\">Original figure modified for this publication. Wexler MJ, Smith R. Jejunal mucosal graft: A sutureless technic repair of high bile duct strictures. Am J Surg 1975; 129:204. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103669 Version 1.0</div></div></div>"},"103672":{"type":"graphic_picture","displayName":"Minimally invasive transduodenal ampullary resection","title":"Minimally invasive transduodenal ampullary resection","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Minimally invasive transduodenal ampullary resection</div><div class=\"cntnt\"><img style=\"width:572px; height:382px;\" src=\"images/SURG/103672_Mnmlly_invs_trnsddnl_ampllry.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103672 Version 1.0</div></div></div>"},"103673":{"type":"graphic_picture","displayName":"Minimally invasive transduodenal bile duct resection","title":"Minimally invasive transduodenal bile duct resection","html":"<div class=\"graphic\"><div style=\"width: 591px\" class=\"figure\"><div class=\"ttl\">Minimally invasive transduodenal bile duct resection</div><div class=\"cntnt\"><img style=\"width:571px; height:346px;\" src=\"images/SURG/103673_Mnml_invs_trnsd_bl_dct_rsct.jpg\" alt=\"Image\"/></div><div id=\"graphicVersion\">Graphic 103673 Version 1.0</div></div></div>"},"103682":{"type":"graphic_figure","displayName":"Portal triad","title":"Portal triad","html":"<div class=\"graphic\"><div style=\"width: 746px\" class=\"figure\"><div class=\"ttl\">Portal triad</div><div class=\"cntnt\"><img style=\"width:726px; height:524px;\" src=\"images/SURG/103682_Portal_triad.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Anatomic illustration of the portal triad: the common hepatic artery is generally located to the patient's left of the bile duct; the portal vein is located posterior to both the common bile duct and the common hepatic artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Schulick RD. Hepatobiliary anatomy. In: Greenfield's Surgery: Scientific Principles and Practice, 5th ed, Mulholland MW, Lillemoe KD, Doherty GM, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103682 Version 1.0</div></div></div>"},"103683":{"type":"graphic_picture","displayName":"Hooking the ball during cocking phase of throwing","title":"Hooking the ball during cocking phase of throwing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Hooking the ball during cocking phase of throwing</div><div class=\"cntnt\"><img style=\"width:281px; height:846px;\" src=\"images/SM/103683_Hook_ball_cck_phs_thrw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top photograph shows a normal position during the early part of the cocking phase. The bottom photograph shows a pitcher hooking the ball during the cocking phase.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103683 Version 1.0</div></div></div>"},"103684":{"type":"graphic_picture","displayName":"Excessive horizontal shoulder abduction at foot contact","title":"Excessive horizontal shoulder abduction at foot contact during throwing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Excessive horizontal shoulder abduction at foot contact during throwing</div><div class=\"cntnt\"><img style=\"width:280px; height:867px;\" src=\"images/SM/103684_Excssv_hrz_shold_abdc_ft_cnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top photograph shows normal horizontal shoulder abduction. The bottom photograph shows excessive horizontal abduction of the shoulder at the time of forward foot contact.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103684 Version 1.0</div></div></div>"},"103685":{"type":"graphic_figure","displayName":"Variations in hepatic artery, portal vein, and bile duct","title":"Variations in hepatic artery, portal vein, and bile duct positions","html":"<div class=\"graphic\"><div style=\"width: 828px\" class=\"figure\"><div class=\"ttl\">Variations in hepatic artery, portal vein, and bile duct positions</div><div class=\"cntnt\"><img style=\"width:808px; height:720px;\" src=\"images/SURG/103685_Var_hep_art_prt_vn_bile_dct.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The right hepatic artery generally passes posteriorly (panel A), but occasionally passes anteriorly to the bile duct just above the cystic duct insertion (panel F), and is susceptible to injury.</div><div class=\"graphic_footnotes\">SMA: superior mesenteric artery.</div><div class=\"graphic_reference\">Reproduced with permission from: Schulick RD. Hepatobiliary anatomy. In: Greenfield's Surgery: Scientific Principles and Practice, 5th ed, Mulholland MW, Lillemoe KD, Doherty GM, et al (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2011. Copyright &copy; 2011 Lippincott Williams &amp; Wilkins (<a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>). Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103685 Version 1.0</div></div></div>"},"103686":{"type":"graphic_picture","displayName":"Low shoulder abduction (dropped elbow) at foot contact","title":"Low shoulder abduction (dropped elbow) at foot contact during throwing","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Low shoulder abduction (dropped elbow) at foot contact during throwing</div><div class=\"cntnt\"><img style=\"width:325px; height:870px;\" src=\"images/SM/103686_Lw_shld_abdc_drp_ft_cnt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The top photograph shows normal elbow height at foot contact. The bottom photograph shows a low elbow position at foot contact.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103686 Version 1.0</div></div></div>"},"103687":{"type":"graphic_picture","displayName":"Premature trunk rotation during throwing","title":"Premature trunk rotation during throwing","html":"<div class=\"graphic\"><div style=\"width: 530px\" class=\"figure\"><div class=\"ttl\">Premature trunk rotation during throwing</div><div class=\"cntnt\"><img style=\"width:510px; height:641px;\" src=\"images/SM/103687_Prmtr_trnk_rttn_thrw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows premature trunk rotation during throwing.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103687 Version 1.0</div></div></div>"},"103688":{"type":"graphic_picture","displayName":"Excessive elbow flexion to excessive extension during throwing","title":"Excessive elbow flexion to excessive elbow extension during throwing","html":"<div class=\"graphic\"><div style=\"width: 943px\" class=\"figure\"><div class=\"ttl\">Excessive elbow flexion to excessive elbow extension during throwing</div><div class=\"cntnt\"><img style=\"width:923px; height:671px;\" src=\"images/SM/103688_Excs_elbw_flx_excs_extn_thrw.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photographs above show excessive elbow flexion at foot contact initially (A), moving into excessive elbow extension as the throwing motion continues to ball release (B).</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103688 Version 1.0</div></div></div>"},"103689":{"type":"graphic_picture","displayName":"Inadequate throwing follow through","title":"Inadequate throwing follow through","html":"<div class=\"graphic\"><div style=\"width: 811px\" class=\"figure\"><div class=\"ttl\">Inadequate throwing follow through</div><div class=\"cntnt\"><img style=\"width:791px; height:756px;\" src=\"images/SM/103689_Indqt_thrw_fllw_thrgh.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The photograph above shows inadequate follow through in which the thrower has stopped his motion prematurely.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103689 Version 1.0</div></div></div>"},"103690":{"type":"graphic_table","displayName":"Behavioral pain scale","title":"Behavioral pain scale","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Behavioral pain scale</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Item</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\">Score*</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Facial expression</td> <td>Relaxed</td> <td>1</td> </tr> <tr> <td>Partially tightened (eg, brow lowering)</td> <td>2</td> </tr> <tr> <td>Fully tightened (eg, eyelid closing)</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>Grimacing</td> <td>4</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"4\">Upper limb movements</td> <td>No movement</td> <td>1</td> </tr> <tr> <td>Partially bent</td> <td>2</td> </tr> <tr> <td>Fully bent with finger flexion</td> <td>3</td> </tr> <tr class=\"divider_bottom\"> <td>Permanently retracted</td> <td>4</td> </tr> <tr> <td rowspan=\"4\">Compliance with mechanical ventilation</td> <td>Tolerating movement</td> <td>1</td> </tr> <tr> <td>Coughing but tolerating ventilation for most of the time</td> <td>2</td> </tr> <tr> <td>Fighting ventilator</td> <td>3</td> </tr> <tr> <td>Unable to control ventilation</td> <td>4</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">* Score ranges from 3 (no pain) to 12 (maximum pain).</div><div class=\"graphic_reference\">Republished with permission of American Association of Critical-Care Nurses, from Stites M, Observational pain scales in critically ill adults, Critical Care Nurse, 2013, Vol 33, Pg 68; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 103690 Version 2.0</div></div></div>"},"103691":{"type":"graphic_table","displayName":"Critical care pain observation tool","title":"Critical care pain observation tool","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Critical care pain observation tool</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup width=\"50%\"></colgroup><colgroup width=\"20%\"></colgroup><colgroup width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Indicator</td> <td class=\"subtitle1\">Description</td> <td class=\"subtitle1\" colspan=\"2\">Score</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Facial expression</td> <td>No muscular tension observed</td> <td>Relaxed, neutral</td> <td>0</td> </tr> <tr> <td>Presence of frowning, brow lowering, orbit tightening, and levator contraction</td> <td>Tense</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>All of the above facial movements plus eyelid tightly closed</td> <td>Grimacing</td> <td>2</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Body movements</td> <td>Does not move at all (does not necessarily mean absence of pain)</td> <td>Absence of movements</td> <td>0</td> </tr> <tr> <td>Slow, cautious movements, touching or rubbing the pain site, seeking attention through movements</td> <td>Protection</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Pulling tube, attempting to sit up, moving limbs/thrashing, not following commands, striking at staff, trying to climb out of bed</td> <td>Restlessness</td> <td>2</td> </tr> <tr> <td>Muscle tension</td> <td>No resistance to passive movements</td> <td>Relaxed</td> <td>0</td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"2\">Evaluation by passive flexion and extension of upper extremities</td> <td>Resistance to passive movements</td> <td>Tense, rigid</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Strong resistance to passive movements, inability to complete them</td> <td>Very tense or rigid</td> <td>2</td> </tr> <tr> <td rowspan=\"3\">Compliance with the ventilator (intubated patients)</td> <td>Alarms not activated, easy ventilation</td> <td>Tolerating ventilator or movement</td> <td>0</td> </tr> <tr> <td>Alarms stop spontaneously</td> <td>Coughing but tolerating</td> <td>1</td> </tr> <tr> <td>Asynchrony: blocking ventilation, alarms frequently activated</td> <td>Fighting ventilator</td> <td>2</td> </tr> <tr> <td class=\"indent1\" colspan=\"4\"><strong>OR</strong></td> </tr> <tr> <td class=\"divider_bottom\" rowspan=\"3\">Vocalization (extubated patients)</td> <td>Talking in normal tone or no sound</td> <td>Talking in normal tone or no sound</td> <td>0</td> </tr> <tr> <td>Sighing, moaning</td> <td>Sighing, moaning</td> <td>1</td> </tr> <tr class=\"divider_bottom\"> <td>Crying out, sobbing</td> <td>Crying out, sobbing</td> <td>2</td> </tr> <tr> <td colspan=\"3\"><strong>Total, range</strong></td> <td><strong>0-8</strong></td> </tr> </tbody></table></div><div class=\"graphic_reference\">Republished with permission of American Association of Critical-Care Nurses, from Stites M, Observational pain scales in critically ill adults, Critical Care Nurse, 2013, Vol 33, Pg 68; permission conveyed through Copyright Clearance Center, Inc.</div><div id=\"graphicVersion\">Graphic 103691 Version 2.0</div></div></div>"},"103692":{"type":"graphic_table","displayName":"Ongoing phase III trials evaluating PD-1 and PD-L1 in NSCLC","title":"Ongoing phase III trials evaluating PD-1 and PD-L1 blocking antibodies in NSCLC","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Ongoing phase III trials evaluating PD-1 and PD-L1 blocking antibodies in NSCLC</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"2\" width=\"25%\"></colgroup><colgroup width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Agent</td> <td class=\"subtitle1\">Trial (NCT)*</td> <td class=\"subtitle1\">Histology</td> <td class=\"subtitle1\">Treatment</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">First line therapy for advanced NSCLC</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Nivolumab (anti-PD-1)</td> <td> <p>CheckMate 026<sup>&#182;</sup></p> NCT02041533</td> <td>All</td> <td>Nivolumab versus Chemo</td> </tr> <tr> <td> <p>CheckMate 227</p> NCT02477826</td> <td>All</td> <td> <p>PD-L1-positive: Chemo versus Nivolumab versus</p> <p>Nivolumab + ipilimumab</p> PD-L1-negative: Chemo versus Nivolumab + ipilimumab</td> </tr> <tr> <td class=\"indent1\" rowspan=\"4\">Pembrolizumab (anti-PD-1)</td> <td> <p>Keynote 042</p> NCT02220894</td> <td>All</td> <td> <p>Pembrolizumab versus</p> Chemo</td> </tr> <tr> <td> <p>Keynote 024</p> NCT02142738</td> <td>All</td> <td> <p>Pembrolizumab versus</p> Chemo</td> </tr> <tr> <td> <p>Keynote 189</p> NCT02578680</td> <td>Nonsquam</td> <td>Chemo versus chemo + pembrolizumab</td> </tr> <tr> <td> <p>Keynote 407</p> NCT02775435</td> <td>Squam</td> <td>Chemo versus chemo + pembrolizumab</td> </tr> <tr> <td class=\"indent1\" rowspan=\"5\">Atezolizumab (anti-PD-L1)</td> <td> <p>IMpower111</p> NCT02409355</td> <td>Squam</td> <td> <p>Atezolizumab versus</p> Chemo</td> </tr> <tr> <td> <p>IMpower110</p> NCT02409342</td> <td>Nonsquam</td> <td> <p>Atezolizumab versus</p> Chemo</td> </tr> <tr> <td> <p>IMpower131</p> NCT02367794</td> <td>Squam</td> <td> <p>Atezolizumab + chemo versus</p> Chemo</td> </tr> <tr> <td> <p>IMpower130</p> NCT02367781</td> <td>Nonsquam</td> <td> <p>Atezolizumab + chemo versus</p> Chemo</td> </tr> <tr> <td> <p><em>IMpower150</em></p> NCT02366143</td> <td>Nonsquam</td> <td> <p>Atezolizumab + chemo +/&ndash; bevacizumab versus</p> Chemo + bevacizumab</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Durvalumab<sup>&#916;</sup> (anti-PD-L1)</td> <td> <p>Mystic</p> NCT02453282</td> <td>All</td> <td> <p>Durvalumab + tremelimumab versus</p> <p>Durvalumab versus</p> Chemo</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Salvage therapy for advanced NSCLC after standard platinum doublet chemotherapy</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">Nivolumab</td> <td> <p>CheckMate 017<sup>&#9674;</sup></p> NCT01673867</td> <td>Squam</td> <td> <p>Nivolumab versus</p> Docetaxel</td> </tr> <tr> <td> <p>CheckMate 057<sup>&#9674;</sup></p> NCT01642004</td> <td>Nonsquam</td> <td> <p>Nivolumab versus</p> Docetaxel</td> </tr> <tr> <td class=\"indent1\">Pembrolizumab</td> <td> <p>Keynote 010</p> NCT01905657</td> <td>All</td> <td> <p>Pembrolizumab versus</p> Docetaxel</td> </tr> <tr> <td class=\"indent1\">Atezolizumab</td> <td> <p>Oak</p> NCT02008227</td> <td>All</td> <td> <p>Atezolizumab versus</p> Docetaxel</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Avelumab (Anti-PD-L1)</td> <td> <p>Javelin Lung 200</p> NCT02395172</td> <td>All</td> <td> <p>Avelumab versus</p> Docetaxel</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Salvage therapy for advanced NSCLC after at least two prior lines of chemotherapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Durvalumab</td> <td> <p>Arctic</p> NCT02352948</td> <td>All</td> <td> <p>PD-L1-positive: Chemo or erlotinib versus</p> <p>Durvalumab</p> <p>PD-L1-negative: Durvalumab + tremelimumab versus</p> Chemo versus Durvalumab versus Tremelimumab</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Salvage therapy for advanced EGFR mutant NSCLC after initial EGFR tyrosine kinase inhibitor therapy</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Durvalumab</td> <td> <p>Caural</p> NCT02454933</td> <td> <p>T790M</p> EGFR<sup>&#167;</sup></td> <td> <p>AZD9291 versus</p> AZD9291 + durvalumab</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Consolidation/adjuvant therapy after curative-intent therapy for NSCLC</td> </tr> <tr> <td class=\"indent1\">Durvalumab</td> <td> <p>Pacific</p> NCT02125461</td> <td>All</td> <td> <p>Durvalumab versus</p> Placebo</td> </tr> <tr> <td class=\"indent1\">Durvalumab</td> <td>NCT02273375</td> <td>All</td> <td> <p>Durvalumab versus</p> Placebo</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PD-1: programmed cell death 1; PD-L1: programmed death ligand 1; NSCLC: non-small cell lung cancer; Squam: squamous; Nonsquam: non-squamous; EGFR: epidermal growth factor receptor.<br />* Clinicaltrials.gov.<br />&para; Fully accrued.<br />&Delta; Formerly MEDI4736.<br /><span class=\"lozenge\">&loz;</span> Fully accrued with results available.<br />&sect; T790M mutation in epidermal growth factor receptor.</div><div id=\"graphicVersion\">Graphic 103692 Version 2.0</div></div></div>"},"103693":{"type":"graphic_picture","displayName":"Wrist flexor stretch","title":"Wrist flexor stretch","html":"<div class=\"graphic\"><div style=\"width: 684px\" class=\"figure\"><div class=\"ttl\">Wrist flexor stretch</div><div class=\"cntnt\"><img style=\"width:664px; height:688px;\" src=\"images/SM/103693_Wrst_flxr_strtch.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">To stretch the wrist flexors (volar forearm muscles), straighten the elbow with the palm facing upwards and then use the other hand to extend the wrist, thereby pushing the hand and fingers towards the ground.</div><div class=\"graphic_reference\">Courtesy of Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103693 Version 1.0</div></div></div>"},"103701":{"type":"graphic_picture","displayName":"Injection of pes anserine bursa and the MCL bursa","title":"Injection of the pes anserine bursa and medial collateral ligament bursa","html":"<div class=\"graphic\"><div style=\"width: 886px\" class=\"figure\"><div class=\"ttl\">Injection of the pes anserine bursa and medial collateral ligament bursa</div><div class=\"cntnt\"><img style=\"width:866px; height:653px;\" src=\"images/RHEUM/103701_Injct_pes_ansrn_brsl_MCL.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A 64-year-old woman presented with bilateral medial knee pain that woke her up at night. She was unable to climb stairs due to pain in the left knee. She had mild genu varum, and passive motion of the left knee revealed coarse crepitus. With the legs extended, there was marked tenderness in the bilateral medial knees. When the leg was flexed at 45 degrees, the findings differed between the knees, as shown in the four panels. She received injections in both knees with subsequent improvement in pain and her ability to climb stairs.<br />(A) Right knee. A circle marks the tibial (medial) collateral ligament, and the shaded area indicates the location of the anserine bursa. The tenderness to palpation was localized to the anserine bursa.<br />(B) Right knee. The anserine bursa was injected with a mixture of lidocaine and glucocorticoid.<br />(C) Left knee. The&nbsp;tenderness was localized to the tibial collateral ligament, marked with a circle. There was no tenderness&nbsp;to palpation over the anserine bursa, marked by the shaded area.<br />(D)&nbsp;Left knee. The region of the tibial collateral ligament-medial meniscus was injected with a mixture of lidocaine and glucocorticoid.</div><div class=\"graphic_reference\">Courtesy of Juan Canoso, MD.</div><div id=\"graphicVersion\">Graphic 103701 Version 1.0</div></div></div>"},"103702":{"type":"graphic_figure","displayName":"Schematic of Ebstein's anomaly","title":"Schematic of Ebstein's anomaly","html":"<div class=\"graphic\"><div style=\"width: 493px\" class=\"figure\"><div class=\"ttl\">Schematic of Ebstein's anomaly</div><div class=\"cntnt\"><img style=\"width:473px; height:658px;\" src=\"images/CARD/103702_Schematic_Ebsteins_anomaly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The schematic demonstrates apical displacement (*) of the septal leaflet of the tricuspid valve&nbsp;and the displaced, long (sail-like) anterior leaflet. Note the large atrialized portion of the RV and dilated TVA. </div><div class=\"graphic_footnotes\">RA: right atrium; LA: left atrium; TVA: tricuspid valve annulus; RV: right ventricle; LV: left ventricle.</div><div class=\"graphic_reference\">Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103702 Version 1.0</div></div></div>"},"103708":{"type":"graphic_picture","displayName":"Mucus plug in bronchocentric granulomatosis","title":"Mucus plug from a patient with bronchocentric granulomatosis","html":"<div class=\"graphic\"><div style=\"width: 472px\" class=\"figure\"><div class=\"ttl\">Mucus plug from a patient with bronchocentric granulomatosis</div><div class=\"cntnt\"><img style=\"width:452px; height:339px;\" src=\"images/PULM/103708_Mcs_plg_brnchcnt_grnlmt.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sputum expectorated by a patient with bronchocentric granulomatosis. The particles present in the sputum were gray-black in color and 0.3 &times; 0.5 cm in size. On microscopy, the particles were composed of eosinophils and Charcot-Leyden crystals. A silver methenamine stain was negative for fungus.</div><div class=\"graphic_reference\">Li H, He J, Gu Y, Zhong N. Corticosteroid monotherapy in a case of bronchocentric granulomatosis with a two-year follow-up. J Thorac Dis 2013; 5:E207, reused with permission from AME Publishing Company.</div><div id=\"graphicVersion\">Graphic 103708 Version 1.0</div></div></div>"},"103709":{"type":"graphic_table","displayName":"Diagnostic criteria for narcolepsy type 1","title":"Diagnostic criteria for narcolepsy type 1","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for narcolepsy type 1</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria A and B must be met:</td> </tr> <tr> <td class=\"indent1\">A. The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.*</td> </tr> <tr> <td class=\"indent1\">B. The presence of one or both of the following:</td> </tr> <tr> <td class=\"indent2\"> <ol> <li>Cataplexy and a mean sleep latency of &#8804;8 minutes and two or more SOREMPs on an MSLT performed according to standard techniques. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal PSG may replace one of the SOREMPs on the MSLT.<sup>&#182;</sup> </li> <li>CSF hypocretin-1 concentration, measured by immunoreactivity, is either &#8804;110 pg/mL or &#60;1/3 of mean values obtained in normal subjects with the same standardized assay. </li> </ol> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; MSLT: multiple sleep latency test; PSG: polysomnography; SOREMPs: sleep-onset rapid eye movement periods.<br />* In young children, narcolepsy may sometimes present as excessively long night sleep or as resumption of previously discontinued daytime napping.<br />&para; If narcolepsy type 1 is strongly suspected clinically but the MSLT criteria of B1 are not met, a possible strategy is to repeat the MSLT.</div><div class=\"graphic_reference\">Reproduced with permission from: International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright &copy; 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 103709 Version 1.0</div></div></div>"},"103711":{"type":"graphic_table","displayName":"Diagnostic criteria for narcolepsy type 2","title":"Diagnostic criteria for narcolepsy type 2","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for narcolepsy type 2</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria A through E must be met:</td> </tr> <tr> <td class=\"indent1\">A. The patient has daily periods of irrepressible need to sleep or daytime lapses into sleep occurring for at least three months.</td> </tr> <tr> <td class=\"indent1\">B. A mean sleep latency of &#8804;8 minutes and two or more SOREMPs are found on an MSLT performed according to standard techniques. A SOREMP (within 15 minutes of sleep onset) on the preceding nocturnal PSG may replace one of the SOREMPs on the MSLT.</td> </tr> <tr> <td class=\"indent1\">C. Cataplexy is absent.*</td> </tr> <tr> <td class=\"indent1\">D. Either CSF hypocretin concentration has not been measured or CSF hypocretin concentration measured by immunoreactivity is either &#62;110 pg/mL or &#62;1/3 of mean values obtained in normal subjects with the same standardized assay.<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\">E. The hypersomnolence and/or MSLT findings are not better explained by other causes such as insufficient sleep, obstructive sleep apnea, delayed sleep phase disorder, or the effect of medication or substances or their withdrawal.</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">CSF: cerebrospinal fluid; MSLT: multiple sleep latency test; PSG: polysomnography; SOREMPs: sleep-onset rapid eye movement periods.<br />* If cataplexy develops later, then the disorder should be reclassified as narcolepsy type 1.<br />¶ If the CSF hypocretin-1 concentration is tested at a later stage and found to be either ≤110 pg/mL or &lt;1/3 of mean values obtained in normal subjects with the same assay, then the disorder should be reclassified as narcolepsy type 1.</div><div class=\"graphic_reference\">Reproduced with permission from: International Classification of Sleep Disorders, 3rd ed, American Academy of Sleep Medicine, Darien, IL 2014. Copyright &copy; 2014 American Academy of Sleep Medicine.</div><div id=\"graphicVersion\">Graphic 103711 Version 1.0</div></div></div>"},"103713":{"type":"graphic_algorithm","displayName":"Imaging evaluation for acute low back pain","title":"Imaging evaluation for acute low back pain","html":"<div class=\"graphic\"><div style=\"width: 1174px\" class=\"figure\"><div class=\"ttl\">Imaging evaluation for acute low back pain</div><div class=\"cntnt\"><img style=\"width:1154px; height:870px;\" src=\"images/PC/103713_Img_evl_acute_low_back_pain.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; MM: multiple myeloma; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; IVDU: intravenous drug use; HD: hemodialysis; CT: computed tomography.<br />* MRI generally preferred; CT is an alternative if patient cannot get an MRI.</div><div id=\"graphicVersion\">Graphic 103713 Version 7.0</div></div></div>"},"103718":{"type":"graphic_algorithm","displayName":"Algorithm sinus bradycardia","title":"Algorithm for the diagnosis and management of sinus bradycardia","html":"<div class=\"graphic\"><div style=\"width: 696px\" class=\"figure\"><div class=\"ttl\">Algorithm for the diagnosis and management of sinus bradycardia</div><div class=\"cntnt\"><img style=\"width:676px; height:635px;\" src=\"images/CARD/103718_Sinus_bradycardia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">ECG: electrocardiogram; ETT: exercise tolerance test; TSH: thyroid stimulating hormone; IV: intravenous; MI: myocardial infarction; HR: heart rate; ILR: implantable loop recorder; SSS: sick sinus syndrome; PPM: permanent pacemaker.<br />* If atropine is ineffective, IV infusion of dopamine (2 to 10 mcg/kg/minute) or epinephrine (2 to 10 mcg/minute) may also be considered prior to temporary pacing.</div><div id=\"graphicVersion\">Graphic 103718 Version 1.0</div></div></div>"},"103719":{"type":"graphic_picture","displayName":"B cell pseudolymphoma tattoo","title":"Cutaneous B cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 583px\" class=\"figure\"><div class=\"ttl\">Cutaneous B cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:563px; height:426px;\" src=\"images/DERM/103719_B_cll_psdlymphm_tattoo.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Cutaneous B cell pseudolymphoma presenting as multiple red nodules arising in the red part of a tattoo.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103719 Version 3.0</div></div></div>"},"103720":{"type":"graphic_picture","displayName":"B cell pseudolymphoma forehead","title":"Cutaneous B cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 592px\" class=\"figure\"><div class=\"ttl\">Cutaneous B cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:572px; height:320px;\" src=\"images/DERM/103720_B_cll_psdlymp_frhd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Idiopathic cutaneous B cell pseudolymphoma presenting with two infiltrated plaques on the forehead.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103720 Version 2.0</div></div></div>"},"103721":{"type":"graphic_picture","displayName":"B cell pseudolymphoma Borrelia (borrelial lymphocytoma)","title":"Cutaneous B cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 607px\" class=\"figure\"><div class=\"ttl\">Cutaneous B cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:587px; height:468px;\" src=\"images/DERM/103721_B_cll_psdlymphm_brrl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\"><EM>Borrelia burgdorferi</EM>-associated pseudolymphoma (borrelial lymphocytoma) presenting as a red-bluish nodule on the left earlobe.</div><div class=\"graphic_reference\">Courtesy of Rein Willemze, MD.</div><div id=\"graphicVersion\">Graphic 103721 Version 2.0</div></div></div>"},"103722":{"type":"graphic_picture","displayName":"B cell pseudolymphoma histo","title":"Histologic features and immunophenotype of cutaneous B cell pseudolymphoma","html":"<div class=\"graphic\"><div style=\"width: 717px\" class=\"figure\"><div class=\"ttl\">Histologic features and immunophenotype of cutaneous B cell pseudolymphoma</div><div class=\"cntnt\"><img style=\"width:697px; height:496px;\" src=\"images/DERM/103722_B_cll_psdlymphm_hst.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Histology of cutaneous pseudo-B-cell lymphoma in the red parts of a tattoo. Hematoxylin and eosin (H&amp;E)-stained section shows nodular to diffuse dermal infiltrates with prominent germinal centers (A), which are clearly visible in the CD35-stained section (D). CD79a (B) and CD3 (C) stainings show distinct B-cell and T-cell compartments, respectively. Note pigment in the interfollicular T-cell areas.</div><div class=\"graphic_reference\"><EM>Courtesy of Rein Willemze, MD.</EM></div><div id=\"graphicVersion\">Graphic 103722 Version 2.0</div></div></div>"},"103725":{"type":"graphic_table","displayName":"Major categories of mimics of vasculitis","title":"Major categories of mimics of vasculitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Major categories of mimics of vasculitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>Infectious causes (eg, endocarditis, HBV, HCV, HIV)</td> </tr> <tr> <td>Atherosclerosis</td> </tr> <tr> <td>Thromboembolic disease</td> </tr> <tr> <td>Congenital causes (eg, aortic coarctation, middle aortic syndrome)</td> </tr> <tr> <td>Hereditary disorders (eg, Marfan syndrome, Ehlers-Danlos syndrome)</td> </tr> <tr> <td>Fibromuscular dysplasia</td> </tr> <tr> <td>Hypercoagulable states (eg, APS, TTP)</td> </tr> <tr> <td>Vasospastic disorders (eg, RCVS, drug exposures)</td> </tr> <tr> <td>Other multisystem inflammatory disorders (eg, sarcoidosis, Susac syndrome)</td> </tr> <tr> <td>Malignancy (eg, lymphoma, leukemia)</td> </tr> <tr> <td>Iatrogenic (eg, postradiation therapy)</td> </tr> <tr> <td>IgG4-related disease</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; APS: antiphospholipid syndrome; TTP: thrombotic thrombocytopenic purpura; RCVS: reversible cerebral vasoconstriction syndrome; IgG4: immunoglobulin G4.</div><div id=\"graphicVersion\">Graphic 103725 Version 7.0</div></div></div>"},"103729":{"type":"graphic_figure","displayName":"Two-process model of sleep","title":"Two-process model of sleep","html":"<div class=\"graphic\"><div style=\"width: 818px\" class=\"figure\"><div class=\"ttl\">Two-process model of sleep</div><div class=\"cntnt\"><img style=\"width:798px; height:358px;\" src=\"images/SLEEP/103729_Two_prcss_mdl_slp.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Sleep drive (process S) increases with wakefulness and dissipates with sleep. The circadian signal (process C) oscillates rhythmically across day and night.</div><div id=\"graphicVersion\">Graphic 103729 Version 1.0</div></div></div>"},"103739":{"type":"graphic_table","displayName":"Clinical presentations ABRS children","title":"Clinical presentations of acute bacterial rhinosinusitis in children","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical presentations of acute bacterial rhinosinusitis in children</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Clinical presentation</td> <td class=\"subtitle1\">Description</td> </tr> <tr class=\"divider_bottom\"> <td>Persistent symptoms</td> <td>Nasal discharge or cough or both for &#62;10 days without improvement</td> </tr> <tr class=\"divider_bottom\"> <td>Severe symptoms</td> <td>Onset with temperature of &#8805;39&#176;C (102.2&#176;F) and purulent nasal discharge for &#8805;3 consecutive days</td> </tr> <tr> <td rowspan=\"2\">Worsening symptoms</td> <td>Respiratory symptoms (nasal discharge or cough, or both) that worsen after initial improvement, or</td> </tr> <tr> <td>Onset of new fever or severe headache</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 103739 Version 1.0</div></div></div>"},"103740":{"type":"graphic_table","displayName":"Causes of respiratory alkalosis","title":"Causes of respiratory alkalosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Causes of respiratory alkalosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"30%\"></colgroup><colgroup width=\"70%\"></colgroup> <tbody> <tr class=\"divider_bottom\"> <td><strong>Central nervous system</strong></td> <td> <p>Pain</p> <p>Hyperventilation syndrome</p> <p>Anxiety and panic disorders</p> <p>Psychosis</p> <p>Fever</p> <p>Intracranial pathology (eg, stroke, meningitis encephalitis, tumors, traumatic injury)</p> Drug withdrawal</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Drugs and toxins</strong></td> <td> <p>Overdoses of salicylate, methylxanthine, catecholamines, nicotine</p> <p>Progesterone and medroxyprogesterone</p> <p>Doxapram</p> Toxic shock</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Pulmonary</strong></td> <td> <p>Hypoxemia</p> <p>Pneumothorax</p> <p>Pneumonia</p> <p>Pulmonary edema</p> <p>Pulmonary embolism</p> <p>Aspiration</p> Interstitial lung disease</td> </tr> <tr> <td><strong>Miscellaneous</strong></td> <td> <p>High altitude</p> <p>Right-to-left shunts</p> <p>Pregnancy</p> <p>Hyperthyroidism</p> <p>Severe anemia</p> <p>Hyperventilation on mechanical ventilation</p> <p>Recovery phase metabolic acidosis</p> <p>Chronic liver disease</p> Prolonged paralysis</td> </tr> </tbody></table></div><div id=\"graphicVersion\">Graphic 103740 Version 1.0</div></div></div>"},"103741":{"type":"graphic_picture","displayName":"Iron overload NAFLD","title":"Iron overload in nonalcoholic fatty liver disease","html":"<div class=\"graphic\"><div style=\"width: 597px\" class=\"figure\"><div class=\"ttl\">Iron overload in nonalcoholic fatty liver disease</div><div class=\"cntnt\"><img style=\"width:577px; height:430px;\" src=\"images/GAST/103741_Iron_overload_NAFLD.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There are fine to coarse blue granules in the cytoplasm of hepatocytes corresponding to deposits of iron. Note that these are associated with vacuoles, representing steatosis. (Perls' Prussian blue stain, original magnification x400.)</div><div id=\"graphicVersion\">Graphic 103741 Version 1.0</div></div></div>"},"103742":{"type":"graphic_picture","displayName":"Iron stain hereditary hemochromatosis","title":"Iron overload in hereditary hemochromatosis","html":"<div class=\"graphic\"><div style=\"width: 564px\" class=\"figure\"><div class=\"ttl\">Iron overload in hereditary hemochromatosis</div><div class=\"cntnt\"><img style=\"width:544px; height:407px;\" src=\"images/GAST/103742_Irn_stn_hrdt_hmchrmts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">There is diffuse deposition of coarse iron granules (++++) involving the hepatic parenchyma, the reticuloendothelial system (Kupffer cells and portal macrophages), and endothelial cells. The typical decreasing gradient from periportal to centrilobular zones initially seen in this disease is not apparent due to the panlobular involvement by iron in this case. (Perls' Prussian blue stain, original magnification x400.)</div><div id=\"graphicVersion\">Graphic 103742 Version 1.0</div></div></div>"},"103743":{"type":"graphic_algorithm","displayName":"Pathway that controls ventilation","title":"Respiratory system anatomy: Ventilation control","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Respiratory system anatomy: Ventilation control</div><div class=\"cntnt\"><img style=\"width:165px; height:238px;\" src=\"images/PULM/103743_Pthwy_cntrl_vent.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Schematic figure representing the respiratory pathway, along which a variety of diseases can affect carbon dioxide elimination and result in hypocapnia.</div><div id=\"graphicVersion\">Graphic 103743 Version 1.0</div></div></div>"},"103744":{"type":"graphic_picture","displayName":"Arterial blood gas kit","title":"Components of a typical arterial blood gas kit","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">Components of a typical arterial blood gas kit</div><div class=\"cntnt\"><img style=\"width:520px; height:390px;\" src=\"images/PULM/103744_Artrl_bld_gas_kit.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Image displays a typical arterial blood gas kit: arterial blood gas syringe, protective needle, syringe cap, iodine and alcohol preparation swabs, gauze, patient label, biohazard ice bag, and adhesive bandage.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2016 A-1 Medical Integration.</div><div id=\"graphicVersion\">Graphic 103744 Version 2.0</div></div></div>"},"103747":{"type":"graphic_figure","displayName":"Critical coarctation of the aorta ","title":"Critical coarctation of the aorta","html":"<div class=\"graphic\"><div style=\"width: 476px\" class=\"figure\"><div class=\"ttl\">Critical coarctation of the aorta</div><div class=\"cntnt\"><img style=\"width:456px; height:461px;\" src=\"images/PEDS/103747_Critical_coarctation_of_the_aorta.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coarctation of the aorta is a narrowing of the descending aorta. The narrowing typically is at the isthmus, the segment just distal to the left subclavian artery.&nbsp;In critical coarctation, the narrowing is severe and blood flow to the descending aorta is dependent on a patent ductus arteriosus (PDA). When the PDA closes, neonates with critical coarctation develop heart failure and/or shock. On physical exam, femoral pulses are weak or absent.</div><div id=\"graphicVersion\">Graphic 103747 Version 3.0</div></div></div>"},"103748":{"type":"graphic_figure","displayName":"Interrupted aortic arch variants ","title":"Interrupted aortic arch variants","html":"<div class=\"graphic\"><div style=\"width: 526px\" class=\"figure\"><div class=\"ttl\">Interrupted aortic arch variants</div><div class=\"cntnt\"><img style=\"width:506px; height:582px;\" src=\"images/PEDS/103748_Interrupted_aortic_arch_variants.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Interrupted aortic arch is classified according to location of the interruption. In type A, the interruption occurs distal to the left subclavian arterial origin; in type B, interruption occurs&nbsp;between the origins of the left common carotid and left subclavian arteries; in type C, interruption occurs proximal to the origin of the left common carotid artery. Blood flowing in the arteries proximal to the interruption is fully oxygenated, while blood flowing distal to the interruption is cyanotic. Type B is the most common form (&gt;50 percent), followed by type A (approximately 40 percent). Type C is rare (&lt;5 percent). </div><div class=\"graphic_footnotes\">RS: right subclavian artery; RCC: right common carotid artery; LCC: left common carotid artery; LS: left subclavian artery; PDA: patent ductus arteriosus. </div><div class=\"graphic_reference\">Modified from: Celoria GC, Patton RB. Congenital absence of the aortic arch. Am Heart J 1959; 58:407.</div><div id=\"graphicVersion\">Graphic 103748 Version 1.0</div></div></div>"},"103749":{"type":"graphic_figure","displayName":"High-risk areas of the face","title":"Anatomical high-risk regions of the face","html":"<div class=\"graphic\"><div style=\"width: 556px\" class=\"figure\"><div class=\"ttl\">Anatomical high-risk regions of the face</div><div class=\"cntnt\"><img style=\"width:536px; height:404px;\" src=\"images/DERM/103749_High-risk_areas_of_the_face.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The&nbsp;dark pink-shaded regions of the face (the so-called H zone) are associated with an increased risk of recurrence of malignant epithelial tumors.</div><div id=\"graphicVersion\">Graphic 103749 Version 3.0</div></div></div>"},"103750":{"type":"graphic_table","displayName":"Criteria for MBL","title":"Diagnostic criteria for monoclonal B cell lymphocytosis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Diagnostic criteria for monoclonal B cell lymphocytosis</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td class=\"subtitle1_single\">Criteria</td> </tr> <tr> <td class=\"indent1\"> <p>1. Monoclonal B cell population in the peripheral blood based on at least one of the following*:</p> <p class=\"indent2\">a. A disease-specific immunophenotype</p> <p class=\"indent2\">b. Over 25% of B cells with low or absent surface immunoglobulin</p> <p class=\"indent2\">c. Kappa:lambda ratio &#62;3:1 or &#60;0.3:1</p> </td> </tr> <tr> <td class=\"indent1\">2. Monoclonal B cell population is stable over a three-month period</td> </tr> <tr> <td class=\"indent1\"> <p>3. None of the following exclusion criteria exist:</p> <p class=\"indent2\">a. Lymphadenopathy or organomegaly</p> <p class=\"indent2\">b. Associated autoimmune or infectious disease</p> <p class=\"indent2\">c. B lymphocyte count &#62;5000 cells/microL</p> <p class=\"indent2\">d. Any feature of a B-lymphoproliferative disorder<sup>&#182;</sup></p> </td> </tr> <tr> <td class=\"subtitle1_single\">Subclassification</td> </tr> <tr> <td class=\"indent1\">CLL immunophenotype: CD5<sup>(+)</sup> CD23<sup>(+)</sup></td> </tr> <tr> <td class=\"indent1\">Atypical CLL phenotype: CD5<sup>(+)</sup> CD23<sup>(&ndash;)</sup>; correlate moderate level of CD20 and CD79b expression</td> </tr> <tr> <td class=\"indent1\">Non-CLL lymphoproliferative disease: CD5<sup>(&ndash;)</sup></td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Refer to UpToDate content on monoclonal B cell lymphocytosis for further details.</div><div class=\"graphic_footnotes\">MBL: monoclonal B cell lymphocytosis; CLL: chronic lymphocytic leukemia.<br />* Absolute lymphocyte count and B lymphocyte count may be normal or increased.<br />¶ Paraprotein may be present in MBL and should be evaluated independently.</div><div class=\"graphic_reference\">Modified from: Marti GE, Rawstron AC, Ghia P, et al. Diagnostic criteria for monoclonal B-cell lymphocytosis. Br J Haematol 2005; 130:325.</div><div id=\"graphicVersion\">Graphic 103750 Version 1.0</div></div></div>"},"103786":{"type":"graphic_picture","displayName":"Lichen nitidus","title":"Lichen nitidus","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Lichen nitidus</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103786_Lichen_nitidus.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small papules on the trunk.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103786 Version 2.0</div></div></div>"},"103792":{"type":"graphic_algorithm","displayName":"Surveillance and management Barrett's esophagus","title":"Surveillance and management of Barrett's esophagus","html":"<div class=\"graphic\"><div style=\"width: 839px\" class=\"figure\"><div class=\"ttl\">Surveillance and management of Barrett's esophagus</div><div class=\"cntnt\"><img style=\"width:819px; height:782px;\" src=\"images/GAST/103792_Srvllnc__mng_brt_esphg.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IC: intramucosal carcinoma; EAC: esophageal adenocarcinoma; PPI: proton pump inhibitor; LGD: low-grade dysplasia; HGD: high-grade dysplasia.<br />* The pathologists should have expertise in esophageal histopathology.<br />¶ The choice of treatment will depend on the patient's overall health and the stage of the cancer, and may include chemoradiotherapy with or without esophagectomy, or even endoscopic resection in highly selected cases.<br />Δ Subsequent management will depend on whether dysplasia is present on surveillance biopsies.<br /><FONT class=lozenge>◊</FONT> If the biopsies again are indefinite for dysplasia, initiate surveillance every 12 months or refer the patient to a center that specializes in the management of patients with Barrett's esophagus.<br />§ Endoscopic eradication therapy includes radiofrequency ablation, photodynamic therapy, and spray cryotherapy. The choice of therapy will depend on local expertise. Esophagectomy is an alternative if endoscopic eradication therapy is not available.<br />¥ Patients who do not undergo endoscopic eradication should undergo endoscopic surveillance every 6 months&nbsp;for one year with biopsies obtained at 1 cm intervals and then annually until there is reversion to non-dysplastic Barrett’s.</div><div id=\"graphicVersion\">Graphic 103792 Version 3.0</div></div></div>"},"103798":{"type":"graphic_diagnosticimage","displayName":"CT image of type I rectus sheath hematoma","title":"CT image of type I rectus sheath hematoma","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">CT image of type I rectus sheath hematoma</div><div class=\"cntnt\"><img style=\"width:710px; height:521px;\" src=\"images/SURG/103798_CT_img_typ_I_rct_shth_hmtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan of the pelvis demonstrating a left-sided type I RSH measuring 4.2 x 4.4 x 11 cm in a 78-year-old man under anticoagulation therapy.</div><div class=\"graphic_footnotes\">CT: computed tomography; RSH: rectus sheath hematoma.</div><div class=\"graphic_reference\">Reproduced from: Salemis NS, Gourgiotis S, Karalis G. Diagnostic evaluation and management of patients with rectus sheath hematoma. Int J Surg 2010; 8:290. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103798 Version 1.0</div></div></div>"},"103799":{"type":"graphic_picture","displayName":"Eczema coxsackium","title":"Eczema coxsackium","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Eczema coxsackium</div><div class=\"cntnt\"><img style=\"width:354px; height:720px;\" src=\"images/PEDS/103799_Eczema_coxsackium.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Eruption of painful vesicular lesions in a background of atopic dermatitis of the hands.</div><div class=\"graphic_reference\">From: Nassef C, Ziemer C, Morrel DS. Hand-foot-and-mouth disease: a new look at a classic viral rash. Curr Opin Pediatr 2015; 27:486. DOI: <a href=\"http://journals.lww.com/co-pediatrics/pages/articleviewer.aspx?year=2015&amp;issue=08000&amp;article=00014&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/MOP.0000000000000246</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2015. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103799 Version 1.0</div></div></div>"},"103800":{"type":"graphic_picture","displayName":"OME with retraction","title":"Otitis media with effusion (OME) and tympanic membrane retraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otitis media with effusion (OME) and tympanic membrane retraction</div><div class=\"cntnt\"><img style=\"width:427px; height:451px;\" src=\"images/PEDS/103800_OMErtrctn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Left ear with OME and retraction of the tympanic membrane. The arrow points to posterosuperior retraction with contact with the incus and stapes.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 103800 Version 2.0</div></div></div>"},"103801":{"type":"graphic_picture","displayName":"OME with retraction 2","title":"Otitis media with effusion (OME) and tympanic membrane retraction","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otitis media with effusion (OME) and tympanic membrane retraction</div><div class=\"cntnt\"><img style=\"width:391px; height:364px;\" src=\"images/PEDS/103801_OMErtrctn2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ear with amber effusion and significant posterosuperior retraction of the tympanic membrane. The arrow points to a shallow retraction of the pars flaccida.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 103801 Version 2.0</div></div></div>"},"103802":{"type":"graphic_picture","displayName":"Otitis media with effusion","title":"Otitis media with effusion (OME)","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Otitis media with effusion (OME)</div><div class=\"cntnt\"><img style=\"width:377px; height:382px;\" src=\"images/PEDS/103802_Ottsmediaeffsn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ear with otitis media with effusion. Note the gray-colored fluid and air-fluid level (arrow) behind the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 103802 Version 3.0</div></div></div>"},"103803":{"type":"graphic_picture","displayName":"Tympanic membrane retraction with cholesteatoma","title":"Tympanic membrane retraction with cholesteatoma","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Tympanic membrane retraction with cholesteatoma</div><div class=\"cntnt\"><img style=\"width:380px; height:398px;\" src=\"images/PEDS/103803_TMrtrctnchlsttm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Right ear with retraction of the pars flaccida (arrow) and cholesteatoma visible behind the tympanic membrane.</div><div class=\"graphic_reference\">Courtesy of Glenn Isaacson, MD, FAAP.</div><div id=\"graphicVersion\">Graphic 103803 Version 2.0</div></div></div>"},"103815":{"type":"graphic_diagnosticimage","displayName":"MRI of severe heroin-induced leukoencephalopathy","title":"MRI of severe heroin-induced leukoencephalopathy","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">MRI of severe heroin-induced leukoencephalopathy</div><div class=\"cntnt\"><img style=\"width:725px; height:275px;\" src=\"images/NEURO/103815_MRI_hrn_indc_lkncphlpthy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Axial T2-weighted magnetic resonance images of a severe case of heroin-induced leukoencephalopathy (A through C): In the medulla, signal abnormality is present in the regions of the pyramidal tracts, medial lemnisci, and the nucleus tractus solitaries posteriorly. The white matter of the cerebellar hemispheres is affected symmetrically with relative preservation of the grey matter of the dentate nuclei. Symmetrical signal abnormality extends throughout the supratentorial deep white matter including the posterior limbs of the internal capsules. Note preservation of the basal ganglia and thalami in this case. White matter change extends into the centrum semiovale and subcortical white matter bilaterally including that in the precentral and postcentral gyri (premotor area, primary motor area, and somatic sensory area).</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">Reproduced from: Offiah C, Hall E. Heroin-induced leukoencephalopathy: characterization using MRI, diffusion-weighted imaging, and MR spectroscopy. Clin Radiol 2008; 63:146. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103815 Version 2.0</div></div></div>"},"103816":{"type":"graphic_table","displayName":"Pneumococcal vaccine intervals","title":"Summary of recommended intervals, by risk and age groups, for persons with indications to receive PCV13 and PPSV23 sequence — Advisory Committee on Immunization Practices, United States","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Summary of recommended intervals, by risk and age groups, for persons with indications to receive PCV13 and PPSV23 sequence — Advisory Committee on Immunization Practices, United States</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"20%\"></colgroup><colgroup span=\"8\" width=\"10%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\" rowspan=\"2\">Risk group/underlying medical condition</td> <td class=\"subtitle1\" colspan=\"4\">Intervals for PCV13-PPSV23 sequence, by age group</td> <td class=\"subtitle1\" colspan=\"4\">Intervals for PPSV23-PCV13 sequence, by age group</td> </tr> <tr> <td class=\"subtitle2\">24 to 71 months</td> <td class=\"subtitle2\">6 to 18 years</td> <td class=\"subtitle2\">19 to 64 years</td> <td class=\"subtitle2\">&#8805;65 years</td> <td class=\"subtitle2\">24 to 71 months</td> <td class=\"subtitle2\">6 to 18 years</td> <td class=\"subtitle2\">19 to 64 years</td> <td class=\"subtitle2\">&#8805;65 years</td> </tr> <tr class=\"divider_bottom\"> <td><strong>No underlying chronic conditions</strong></td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">&#8805;1 year</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">&#8805;1 year</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Immunocompetent persons</strong> <ul class=\"decimal_heading\"> <li>Chronic heart disease </li> <li>Chronic lung disease </li> <li>Diabetes mellitus </li> <li>Alcoholism* </li> <li>Chronic liver disease, cirrhosis* </li> <li>Cigarette smoking* </li> </ul> </td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">&#8805;1 year</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">NA</td> <td class=\"centered\">NA</td> <td class=\"centered\">&#8805;1 year</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Immunocompetent persons</strong> <ul class=\"decimal_heading\"> <li>Cerebrospinal fluid leak </li> <li>Cochlear implant </li> </ul> </td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;1 year</td> <td class=\"centered\">&#8805;1 year</td> </tr> <tr class=\"divider_bottom\"> <td><strong>Persons with functional or anatomic asplenia</strong> <ul class=\"decimal_heading\"> <li>Sickle cell disease/other hemoglobinopathy </li> <li>Congenital or acquired asplenia </li> </ul> </td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;1 year</td> <td class=\"centered\">&#8805;1 year</td> </tr> <tr> <td><strong>Immunocompromised persons</strong> <ul class=\"decimal_heading\"> <li>Congenital or acquired immunodeficiency </li> <li>Human immunodeficiency virus infection </li> <li>Chronic renal failure </li> <li>Nephrotic syndrome </li> <li>Leukemia </li> <li>Lymphoma </li> <li>Hodgkin disease </li> <li>Generalized malignancy </li> <li>Iatrogenic immunosuppression </li> <li>Solid organ transplant </li> <li>Multiple myeloma* </li> </ul> </td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;8 weeks</td> <td class=\"centered\">&#8805;1 year</td> <td class=\"centered\">&#8805;1 year</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">NA: not applicable; sequential use of PCV13 and PPSV23 is not recommended for these age and risk groups.<br />* Underlying medical conditions that are not included in the recommendations for children aged &lt;6 years.</div><div class=\"graphic_reference\">Reproduced from: Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2015; 64:944.</div><div id=\"graphicVersion\">Graphic 103816 Version 3.0</div></div></div>"},"103817":{"type":"graphic_diagnosticimage","displayName":"MRI neurosyphilis mimicking viral encephalitis","title":"Brain MRI of temporal lobe-dominant presentation of neurosyphilis mimicking viral encephalitis","html":"<div class=\"graphic\"><div style=\"width: 625px\" class=\"figure\"><div class=\"ttl\">Brain MRI of temporal lobe-dominant presentation of neurosyphilis mimicking viral encephalitis</div><div class=\"cntnt\"><img style=\"width:605px; height:720px;\" src=\"images/NEURO/103817_MRI_nrsyph_mmck_vrl_encphl.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Coronal T2-weighted (A, B) and axial fluid-attenuated inversion recovery (C, D) images of the patient pretreatment (A, C) and post-treatment (B, D) for neurosyphilis. Pretreatment, swelling, and edematous signal change were seen in the right amygdala and hippocampus (arrows) mimicking a viral encephalitis. The follow-up imaging six months post-treatment shows atrophy of the right medial temporal structures.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging.</div><div class=\"graphic_reference\">From: Karsan N, Barker R, O'Dwyer JP. Clinical reasoning: the \"great imitator\". Neurology 2014; 83:e188. DOI: <a href=\"http://www.neurology.org/content/83/22/e188.extract\" spellcheck=\"true\" target=\"_blank\">10.1212/WNL.0000000000001033</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American Academy of Neurology. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103817 Version 2.0</div></div></div>"},"103822":{"type":"graphic_algorithm","displayName":"Treatment severe AA","title":"Algorithm treatment of severe aplastic anemia","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">Algorithm treatment of severe aplastic anemia</div><div class=\"cntnt\"><img style=\"width:706px; height:526px;\" src=\"images/HEME/103822_Trtmnt_severe_AA_edit1.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Inherited bone marrow failure syndromes include Fanconi anemia, dyskeratosis congenita, Shwachman-Diamond syndrome, and congenital amegakaryocytic thrombocytopenia. HCT may be indicated in such patients, but indications and management (eg, use of reduced intensity conditioning) may apply. Patients with another cause of bone marrow hypoplasia that does not respond to therapy (eg, drug discontinuation, treatment of infection) are treated similarly to other patients with severe AA. Refer to UpToDate content on HCT for AA for details regarding donor selection and conditioning regimen, and graft-versus-host disease prophylaxis. Refer to UpToDate content on treatment of AA for details of immunosuppressive therapy.</div><div class=\"graphic_footnotes\">AA: aplastic anemia; HCT: hematopoietic cell transplantation; ATG: anti-thymocyte globulin.<br />* Immunosuppressive therapy is done using eltrombopag, horse ATG, cyclosporine A, and prednisone, as discussed in more detail in the UpToDate topic on treatment of aplastic anemia.</div><div id=\"graphicVersion\">Graphic 103822 Version 2.0</div></div></div>"},"103823":{"type":"graphic_algorithm","displayName":"cfDNA for secondary screening in high-risk women","title":"Use of cell-free DNA for secondary screening in women at high risk of Down syndrome","html":"<div class=\"graphic\"><div style=\"width: 774px\" class=\"figure\"><div class=\"ttl\">Use of cell-free DNA for secondary screening in women at high risk of Down syndrome</div><div class=\"cntnt\"><img style=\"width:754px; height:276px;\" src=\"images/OBGYN/103823_cfDNA_sec_screen_high_women.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The flow chart begins with 6000 singleton pregnancies at high risk (1 in 50) of Down syndrome. Thus, there are 120 Down syndrome and 5880 unaffected pregnancies. The analyses assume a 98% detection rate, a 0.2% false-positive rate, and a 1% test failure rate. Among the 120 Down syndrome,&nbsp;one will have a test failure (1%),&nbsp;one will be falsely negative, and the remaining 118 (98%) will be screen-positive. Among the 5880 euploid pregnancies, 59 will fail and 12 (0.2%) will be falsely positive. The remaining 5809 will have a negative result. The bottom row summarizes the predictive values. Among the 130 women (2.2%) with positive cell-free DNA results (solid lines), about 10 of every 11 will be a true positive. Among the 5810 women (96.8%) with a negative cell-free DNA result (dotted lines), only about 1 in 6000 would have a fetus with Down syndrome. This risk is sufficiently low that diagnostic testing is not warranted. The final group of 60 women (1.0%, dashed lines) had a test failure but can be directly offered diagnostic testing.</div><div id=\"graphicVersion\">Graphic 103823 Version 2.0</div></div></div>"},"103824":{"type":"graphic_table","displayName":"Immunization in primary and secondary immunodeficiencies","title":"Immunization of children and adolescents with primary and secondary immunodeficiencies","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Immunization of children and adolescents with primary and secondary immunodeficiencies</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"15%\"></colgroup><colgroup width=\"55%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Category</td> <td class=\"subtitle1\">Example of specific immunodeficiency</td> <td class=\"subtitle1\">Vaccine contraindications</td> <td class=\"subtitle1\">Effectiveness and comments, including risk-specific vaccines*</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Primary<sup>&#182;</sup></td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">B cell (humoral)</td> <td>Severe antibody deficiencies (eg, X-linked agammaglobulinemia and common variable immunodeficiency)</td> <td>OPV<sup>&#916;</sup>, BCG, smallpox, LAIV, YF, and live-bacteria vaccines<sup>&#9674;</sup>; no data for rotavirus vaccines</td> <td>Effectiveness of any vaccine is uncertain if dependent only on humoral response (eg, PPSV23 or MPSV4); IVIG therapy interferes with response to all vaccines, therefore, annual IIV is the only vaccine given to patients receiving IVIG therapy; routine inactivated vaccines can be given if not receiving IVIG.</td> </tr> <tr> <td>Less severe antibody deficiencies (eg, selective IgA deficiency and IgG subclass deficiencies)</td> <td>OPV<sup>&#916;</sup>, BCG, YF vaccines; other live vaccines<sup>&#167;</sup> appear to be safe</td> <td>All vaccines probably are effective; immune response may be attenuated; vaccines should be given as on the annual immunization schedule for immunocompetent people.</td> </tr> <tr> <td class=\"indent1\" rowspan=\"2\">T cell (cell mediated and humoral)</td> <td>Complete defects (eg, severe combined immunodeficiency, complete DiGeorge syndrome)</td> <td>All live vaccines<sup>&#9674;</sup><sup>&#167;</sup><sup>&#165;</sup></td> <td>All inactivated vaccines probably are ineffective. The only vaccine that should be given if the patient is receiving IVIG is annual IIV if there is some residual antibody production.</td> </tr> <tr> <td>Partial defects (eg, most patients with DiGeorge syndrome, hyperimmunoglobulin M syndrome, Wiskott-Aldrich syndrome, ataxia-telangiectasia)</td> <td>All live vaccines<sup>&#9674;</sup><sup>&#167;</sup></td> <td>Effectiveness of any inactivated vaccine depends on degree of immunosuppression. Routine inactivated vaccines should be given. Those with &#8805;500 CD3+ T lymphocytes/mm<sup>3</sup>, &#8805;200 CD8+ T lymphocytes/mm<sup>3</sup>, and normal mitogen response should receive MMR and VAR vaccine (but not MMRV). PPSV23 in addition to PCV13 is indicated in ataxia-telangiectasia.</td> </tr> <tr> <td class=\"indent1\">Complement</td> <td>Persistent complement component, properdin, or mannose-binding lectin (MBL) deficiency</td> <td>None</td> <td>All inactivated and live-virus vaccines on the annual immunization schedule are safe and probably are effective; PPSV23 at two years or older and an MCV4 vaccine are recommended in addition to standard vaccines.</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">Phagocytic function</td> <td>Chronic granulomatous disease, leukocyte adhesion defects, myeloperoxidase deficiency</td> <td> <p>Live-bacteria vaccines<sup>&#9674;</sup></p> OPV<sup>&#916;</sup>, smallpox, BCG, combined MMRV, LAIV<sup>&#167;</sup>; withhold MMR and varicella in highly immunocompromised children; YF vaccine may have a contraindication or precaution depending on indicators of immune function<sup>&#135;</sup></td> <td>All inactivated vaccines are safe and probably are effective<sup>&#134;</sup>; live-virus vaccines probably are safe and effective.</td> </tr> <tr> <td class=\"subtitle2_left\" colspan=\"4\">Secondary*</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>HIV/AIDS</td> <td>&nbsp;</td> <td>Rotavirus vaccine is recommended on standard schedule; MMR and VAR are recommended for HIV-infected children who are asymptomatic and are not highly immunocompromised**<sup>,&#182;&#182;</sup>; all inactivated vaccines, including IIV, may be effective; PPSV23 is recommended in addition to the standard PCV13 vaccine; consider Hib vaccine if not administered during infancy and MCV4 at 2 through 10 years of age.</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Malignant neoplasm, transplantation, autoimmune disease, immunosuppressive or radiation therapy</td> <td>Live-virus and live-bacteria vaccines, depending on immune status<sup>&#9674;</sup><sup>&#167;</sup></td> <td>Effectiveness of any vaccine depends on degree of immunosuppression; annual IIV is recommended unless receiving intensive chemotherapy or on anti-B cell antibodies; inactivated standard; PPSV23 is recommended at least eight weeks after last dose of PCV13. Vaccines are indicated if not highly immunosuppressed, but doses should be repeated after chemotherapy ends.</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Asplenia (functional, congenital anatomic, surgical)</td> <td>None</td> <td>All standard vaccines are safe and likely effective; PPSV23 at 24 months or older; MCV4-D (Menactra) should not be used before four weeks after completion of the four-dose series of PCV13 (eg, 22 months of age or older), because of interference with antibody response to PCV13 when vaccines are administered concurrently; other MCV4 vaccines are used in infants and toddlers as licensed by age without concern for interference with PCV13. In addition to standard vaccines, consider Hib vaccine if not administered during infancy.</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>Chronic&nbsp;kidney disease</td> <td>LAIV</td> <td>All standard vaccines are indicated; PPSV23 is recommended at 24 months or older in addition to standard PCV13.</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td>CNS anatomic barrier defect (cochlear implant, congenital dysplasia of the inner ear, persistent CSF communication with naso-/oropharynx)</td> <td>None</td> <td>All standard vaccines are indicated; PCV13 if not received as standard; PPSV23 at two years or older (&#8805;8 weeks after receipt of PCV13).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">OPV: oral poliovirus; BCG: Bacille Calmette-Guérin; LAIV: live-attenuated influenza vaccine; YF: yellow fever; PPSV23: 23-valent pneumococcal polysaccharide vaccine; MPSV4: quadrivalent meningococcal polysaccharide vaccine; IVIG: intravenous immune globulin; IIV: inactivated influenza vaccine; IgA: immunoglobulin A; IgG: immunoglobulin G; IgM: immunoglobulin M; MMR: measles-mumps-rubella; VAR: varicella vaccine; MMRV: measles-mumps-rubella-varicella; PCV13: 13-valent pneumococcal conjugate vaccine; MCV4: quadrivalent meningococcal conjugate vaccine; HIV: human immunodeficiency virus; AIDs: acquired immunodeficiency syndrome;&nbsp; Hib: <EM>Hemophilius influenzae</EM> type b; CNS: central nervous system; CSF: cerebrospinal fluid; cART: combination antiretroviral therapy.<br />* Other vaccines that are recommended universally or routinely should be given if not contraindicated.<br />¶ All children and adolescents should receive an annual age-appropriate inactivated influenza vaccine. LAIV is indicated only for healthy people 2 through 49 years of age.<br />Δ OPV vaccine no longer is available in the United States.<br /><FONT class=lozenge>◊</FONT> Live-bacteria vaccines: BCG and Ty21a <EM>Salmonella typhi</EM> vaccine.<br />§ Live-virus vaccines: LAIV, MMR, VAR, MMRV, herpes zoster (HZV), OPV, YF, vaccinia (smallpox), and rotavirus.<br />¥ Regarding T-lymphocyte immunodeficiency as a contraindication to rotavirus vaccine, data only exist for severe combined immunodeficiency syndrome.<br />‡ YF vaccine is contraindicated in HIV-infected children younger than six years who are highly immunosuppressed. There is precaution for use of YF vaccine in asymptomatic HIV-infected children younger than six years with total lymphocyte percentage of 15 to 24% and older than six years with CD4+ T-lymphocyte counts of 200 to 499 cells/mm<SUP>3</SUP>.<SUP>[1]</SUP><br />† Additional pneumococcal vaccine is not indicated for children with chronic granulomatous disease beyond age-based standard recommendations for PCV13, because these children are not at increased risk for pneumococcal disease.<br />** HIV-infected children should receive immune globulin after exposure to measles and may receive varicella vaccine if CD4+ T-lymphocyte count ≥15% of expected for age for those younger than five years, or CD4+ T-lymphocyte count ≥200 cells/mm<SUP>3</SUP> for those five years or older.<br />¶¶ People with perinatal HIV infection who were vaccinated with a measles, rubella, or mumps-containing vaccine prior to the establishment of cART should be considered unvaccinated and should receive two appropriately spaced doses of MMR vaccine once effective cART has been established (at least six months with CD4+ T-lymphocyte percentage ≥15% for children younger than five years or CD4+ T-lymphocyte count ≥200 cells/mm<SUP>3</SUP> for children five years or older).</div><div class=\"graphic_reference\">Reference: &#xD;&#xA;<OL>&#xD;&#xA;<LI>Centers for Disease Control and Prevention. Yellow fever vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.</LI></OL>From: Kimberlin DW, Brady MT, Jackson MA, Long SS (Eds). Red Book: 2015 Report of the Committee on Infectious Diseases, 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015: 74-89. Copyright © 2015 American Academy of Pediatrics. Reproduced with permission.</div><div id=\"graphicVersion\">Graphic 103824 Version 4.0</div></div></div>"},"103827":{"type":"graphic_table","displayName":"Prenatal screening for microdeletion/microduplication syndromes","title":"Prenatal screening for microdeletion and microduplication syndromes using cell-free DNA","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Prenatal screening for microdeletion and microduplication syndromes using cell-free DNA</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"40%\"></colgroup><colgroup span=\"4\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Disorder/syndrome</td> <td class=\"subtitle1\">Prevalence<br /> (per 100,000)</td> <td class=\"subtitle1\">Size<br /> (Mbases)</td> <td class=\"subtitle1\">Shotgun/counting</td> <td class=\"subtitle1\">SNP-based</td> </tr> <tr> <td>22q11.2 DiGeorge</td> <td class=\"centered\">25 to 50</td> <td class=\"centered\">1.5 to 3</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>5p Cri-du-chat</td> <td class=\"centered\">2 to 5</td> <td class=\"centered\">30</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>15q Prader-Willi</td> <td class=\"centered\">3 to 10</td> <td class=\"centered\">5.9</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>15q Angelman</td> <td class=\"centered\">2 to 8</td> <td class=\"centered\">5.9</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>1p36 deletion</td> <td class=\"centered\">10 to 20</td> <td class=\"centered\">10</td> <td class=\"centered\">X</td> <td class=\"centered\">X</td> </tr> <tr> <td>4p16.3 Wolf-Hirschhorn</td> <td class=\"centered\">2</td> <td class=\"centered\">1 to 10</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>8q Langer-Giedion syndrome</td> <td class=\"centered\">Rare</td> <td class=\"centered\">1 to 25</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>11q Jacobsen syndrome</td> <td class=\"centered\">1</td> <td class=\"centered\">7 to 20</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Trisomy 16 (duplication)</td> <td class=\"centered\">2</td> <td class=\"centered\">90</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> <tr> <td>Trisomy 22 (duplication)</td> <td class=\"centered\">2</td> <td class=\"centered\">51</td> <td class=\"centered\">X</td> <td class=\"centered\">&nbsp;</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">SNP: single nucleotide polymorphism.</div><div id=\"graphicVersion\">Graphic 103827 Version 1.0</div></div></div>"},"103830":{"type":"graphic_picture","displayName":"Clean based gastric ulcer","title":"Gastric ulcer","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Gastric ulcer</div><div class=\"cntnt\"><img style=\"width:582px; height:460px;\" src=\"images/GAST/103830_Clean_based_gastric_ulcer.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Note the clean white base in the ulcer crater with no evidence of active bleeding.</div><div class=\"graphic_reference\">Courtesy of Nimish Vakil, MD.</div><div id=\"graphicVersion\">Graphic 103830 Version 1.0</div></div></div>"},"103833":{"type":"graphic_picture","displayName":"Multiple antral gastric ulcers","title":"Multiple antral gastric ulcers","html":"<div class=\"graphic\"><div style=\"width: 605px\" class=\"figure\"><div class=\"ttl\">Multiple antral gastric ulcers</div><div class=\"cntnt\"><img style=\"width:585px; height:459px;\" src=\"images/GAST/103833_Multiple_antral_gstrc_ulcrs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple antral gastric ulcers due to nonsteroidal anti-inflammatory drug (NSAID) use. The white depressed areas are all individual ulcers.</div><div class=\"graphic_reference\">Courtesy of Nimish Vakil, MD.</div><div id=\"graphicVersion\">Graphic 103833 Version 1.0</div></div></div>"},"103834":{"type":"graphic_figure","displayName":"Grading of tonsil size","title":"Standardized grading of tonsil size","html":"<div class=\"graphic\"><div style=\"width: 559px\" class=\"figure\"><div class=\"ttl\">Standardized grading of tonsil size</div><div class=\"cntnt\"><img style=\"width:539px; height:462px;\" src=\"images/SLEEP/103834_Grading_of_tonsil_size.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Tonsil size is most often described on a scale from 0 to 5:<br /><UL>&#xD;&#xA;<LI>0&nbsp;—&nbsp;Tonsils are entirely within the tonsillar pillar, or previously removed by surgery.</LI>&#xD;&#xA;<LI>1+&nbsp;—&nbsp;Tonsils occupy less than 25 percent of the lateral dimension of the oropharynx, as measured between the anterior tonsillar pillars (solid yellow arrow).&nbsp;</LI>&#xD;&#xA;<LI>2+&nbsp;—&nbsp;Tonsils occupy 26 to 50 percent of the lateral dimension of the oropharynx.&nbsp;</LI>&#xD;&#xA;<LI>3+&nbsp;—&nbsp;Tonsils occupy 51 to 75 percent of the lateral dimension of the oropharynx.&nbsp;</LI>&#xD;&#xA;<LI>4+&nbsp;—&nbsp;Tonsils occupy more than 75 percent of the lateral dimension of the oropharynx.</LI></UL></div><div class=\"graphic_reference\">Drawing based on text&nbsp;description in: Brodsky L. Modern assessment of tonsils and adenoids. Pediatr Clin North Am 1989; 36:1551.</div><div id=\"graphicVersion\">Graphic 103834 Version 2.0</div></div></div>"},"103835":{"type":"graphic_table","displayName":"Conditions with increased risk for OSA","title":"Conditions with increased risk for obstructive sleep apnea or respiratory complications following adenotonsillectomy","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Conditions with increased risk for obstructive sleep apnea or respiratory complications following adenotonsillectomy</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup width=\"75%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Condition/disease</td> <td class=\"subtitle1\">Comments</td> </tr> <tr class=\"divider_bottom\"> <td>Obesity (BMI &#62;95%ile)</td> <td>Risk for obstructive sleep apnea generally increases with the severity of obesity.</td> </tr> <tr class=\"divider_bottom\"> <td>Down syndrome</td> <td> <p>Evaluate for atlantoaxial instability and hypothyroidism prior to surgery.</p> These patients are likely to require adjuvant surgical procedures or therapy to manage residual sleep apnea after adenotonsillectomy, due to multiple sites of obstruction.</td> </tr> <tr class=\"divider_bottom\"> <td>Craniofacial anomalies</td> <td> <p>Severity and sites of airway obstruction vary depending on the anomaly.</p> These patients are likely to require adjuvant procedures or therapy to manage sleep apnea, due to multiple sites of obstruction.</td> </tr> <tr class=\"divider_bottom\"> <td>Neuromuscular disorders</td> <td>These children also may have significant hypoventilation, in addition to obstructive symptoms.</td> </tr> <tr class=\"divider_bottom\"> <td>Mucopolysaccharidosis</td> <td>Pulmonary and cardiac dysfunction may also be present.</td> </tr> <tr> <td>Sickle cell disease</td> <td> <p>Increased adenoid and tonsil size compared with normal volunteers.</p> <p>Increased risk for respiratory complications in the immediate perioperative period.</p> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">BMI: body mass index.</div><div id=\"graphicVersion\">Graphic 103835 Version 3.0</div></div></div>"},"103845":{"type":"graphic_diagnosticimage","displayName":"CT image of type II rectus sheath hematoma","title":"CT image of type II rectus sheath hematoma","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">CT image of type II rectus sheath hematoma</div><div class=\"cntnt\"><img style=\"width:780px; height:624px;\" src=\"images/SURG/103845_CT_img_typ_II_rct_shth_hmtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan of the abdomen demonstrating a left-sided type II RSH in a 38-year-old man after laparoscopic cholecystectomy.</div><div class=\"graphic_footnotes\">CT: computed tomography; RSH: rectus sheath hematoma.</div><div class=\"graphic_reference\">Reproduced from: Salemis NS, Gourgiotis S, Karalis G. Diagnostic evaluation and management of patients with rectus sheath hematoma. Int J Surg 2010; 8:290. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103845 Version 2.0</div></div></div>"},"103846":{"type":"graphic_diagnosticimage","displayName":"CT image of type III rectus sheath hematoma","title":"CT image of type III rectus sheath hematoma","html":"<div class=\"graphic\"><div style=\"width: 800px\" class=\"figure\"><div class=\"ttl\">CT image of type III rectus sheath hematoma</div><div class=\"cntnt\"><img style=\"width:780px; height:638px;\" src=\"images/SURG/103846_CT_img_typ_III_rct_shth_hmtm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Computed tomography scan of the abdomen demonstrating a large left-sided type III RSH measuring 18x17x7 cm in a 46-year-old man with chronic renal failure.</div><div class=\"graphic_footnotes\">CT: computed tomography; RSH: rectus sheath hematoma.</div><div class=\"graphic_reference\">Reproduced from: Salemis NS, Gourgiotis S, Karalis G. Diagnostic evaluation and management of patients with rectus sheath hematoma. Int J Surg 2010; 8:290. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103846 Version 1.0</div></div></div>"},"103856":{"type":"graphic_diagnosticimage","displayName":"Posterior cruciate ligament tear on MRI","title":"Sagittal view of posterior cruciate ligament tear on magnetic resonance imaging","html":"<div class=\"graphic\"><div style=\"width: 523px\" class=\"figure\"><div class=\"ttl\">Sagittal view of posterior cruciate ligament tear on magnetic resonance imaging</div><div class=\"cntnt\"><img style=\"width:503px; height:254px;\" src=\"images/SM/103856_Post_cruciate_liga_tear_MRI.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Above is a side-by-side comparison of two sagittal view MRI images. Image A shows a normal ligament within the red oval that appears curvilinear and dark on T1 or T2 sequences, while image B shows a torn PCL within the red oval associated with a loss of normal contours and density.</div><div class=\"graphic_footnotes\">MRI: magnetic resonance imaging; PCL: posterior cruciate ligament injury.</div><div class=\"graphic_reference\">Courtesy of James MacDonald, MD and Richard Rodenberg, MD.</div><div id=\"graphicVersion\">Graphic 103856 Version 2.0</div></div></div>"},"103858":{"type":"graphic_picture","displayName":"Calcaneal compression test for calcaneal apophysitis","title":"Calcaneal compression test for calcaneal apophysitis (Sever disease)","html":"<div class=\"graphic\"><div style=\"width: 533px\" class=\"figure\"><div class=\"ttl\">Calcaneal compression test for calcaneal apophysitis (Sever disease)</div><div class=\"cntnt\"><img style=\"width:513px; height:684px;\" src=\"images/EM/103858_Calcaneal_comp_tst_apphysts.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">With the patient supine, the examiner compresses the calcaneus from the medial and lateral side as shown. Pain with this maneuver suggests the presence of calcaneal apophysitis (Sever disease).</div><div class=\"graphic_reference\">Courtesy of Joseph Chorley, MD.</div><div id=\"graphicVersion\">Graphic 103858 Version 1.0</div></div></div>"},"103859":{"type":"graphic_diagnosticimage","displayName":"Posterior cruciate ligament avulsion injury","title":"Posterior cruciate ligament avulsion injury","html":"<div class=\"graphic\"><div style=\"width: 782px\" class=\"figure\"><div class=\"ttl\">Posterior cruciate ligament avulsion injury</div><div class=\"cntnt\"><img style=\"width:762px; height:399px;\" src=\"images/SM/103859_Post_crct_ligamnt_avlsn_inj.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The images above show&nbsp;a posterior cruciate ligament (PCL) injury. Image A shows discontinuity of the posterior tibial plateau secondary to a distal&nbsp;PCL avulsion in a football player. Image B is the corresponding sagittal T1 image of the same patient demonstrating a bony avulsion (arrowhead) of the distal PCL footprint.</div><div class=\"graphic_reference\">Reproduced with permission from: Chew NS, Robinson P, Harris Jr. JH. Knee. In: Harris &amp; Harris' The Radiology of Emergency Medicine, 5th Ed, Pope TL, Harris Jr. JH (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103859 Version 1.0</div></div></div>"},"103861":{"type":"graphic_table","displayName":"Basic exercise program for throwers without expert supervision","title":"Basic exercise program for throwers without expert supervision","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic exercise program for throwers without expert supervision</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td><strong>Warm-up</strong></td> </tr> <tr> <td><strong>Strength exercises* for rotator cuff and scapular stabilizers:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Shoulder abduction to 90 degrees </li> <li>Side-lying external rotation </li> <li>Prone horizontal abduction </li> <li>Prone rowing </li> <li>Prone rowing to external rotation </li> </ul> </td> </tr> <tr> <td><strong>General strength exercises*:</strong></td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>Plank </li> <li>Left and right side plank </li> <li>Bridges with leg extensions </li> <li>Press-ups </li> <li>Push-ups </li> </ul> </td> </tr> <tr> <td><strong>Mobility exercises*:</strong></td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Internal rotation (sleeper) stretch </li> <li>Posterior rotator cuff stretch </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">*Please refer to the UpToDate topic that discusses the treatment of Throwing injuries for descriptions of how to perform individual exercises.</div><div class=\"graphic_reference\">Courtesy of Karl B Fields, MD and Mark Lydecker, MPT, OCS, ATC.</div><div id=\"graphicVersion\">Graphic 103861 Version 3.0</div></div></div>"},"103862":{"type":"graphic_table","displayName":"Basic rehabilitation program for isolated, acute PCL tears","title":"Basic rehabilitation program for isolated, acute posterior cruciate ligament (PCL) tears","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Basic rehabilitation program for isolated, acute posterior cruciate ligament (PCL) tears</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr class=\"divider_bottom\"> <td>Important note: Rehabilitation is function-based, not time based. Individual patients will progress through this program at different rates.</td> </tr> <tr> <td class=\"subtitle1_single\">Stage I: Initial 4 to 6 weeks after injury</td> </tr> <tr> <td class=\"indent1\">Basic care and protection:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>PRICE-M (Protection with brace, Rest, Ice, Compression with elastic wrap, Elevation, Medication [analgesics] as needed) </li> <li>PCL brace worn at all times including sleep (minimum 12 weeks) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Goals:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Protect injured knee </li> <li>Minimize strength and mobility loss </li> <li>Decrease effusion and soft tissue swelling </li> <li>Gradually increase knee range of motion </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Guidelines:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Avoid knee hyperextension (12 weeks) </li> <li>Prevent posterior tibial translation (12 weeks) </li> <li>No isolated hamstring exercises </li> <li>Partial weight bearing with crutches as necessary (2 weeks) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Exercises:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Gentle range of motion (ROM) exercises <ul> <li>Includes ankle pumps: Active dorsiflexion and plantar flexion of ankles to alleviate lower extremity edema </li> </ul> </li> <li>Prone passive knee motion; gradually increase to 90 degrees over first 2 to 3 weeks, then gradually progress to full ROM </li> <li>Patellar mobilizations </li> <li>Quadriceps activation <ul> <li>Begins with quad sets: Active, isometric contraction of quadriceps while thigh rests on a surface </li> <li>Advance to straight leg raises (SLR) once quadriceps can maintain knee in terminal extension without posterior lag </li> </ul> </li> <li>Gastrocnemius stretching </li> <li>Hip abduction/adduction exercises </li> <li>Calf raises and single leg balance when weaned from crutches </li> <li>Maintain upper body and core strength using non-weightbearing exercises that do not place stress on injured knee </li> <li>Stationary bike with zero resistance when knee ROM &#62;120 degrees </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Criteria for advancing to Stage II:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Achieve active ROM of knee of 0 to &#8805;120 degrees; no posterior lag during repeated SLR (3 sets x 10 repetitions); no or minimal swelling or effusion </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Stage II: Generally weeks 6 to 12 after injury</td> </tr> <tr> <td class=\"indent1\">Goals:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Achieve full knee ROM </li> <li>Improve endurance of supporting musculature </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Guidelines:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Prevent posterior tibial translation </li> <li>Avoid knee hyperextension </li> <li>Limit leg strength exercises to no more than 70 degrees of knee flexion </li> <li>PCL brace worn at all times </li> <li>Use set and repetition scheme emphasizing endurance for all strength exercises: 3 x 20 </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Exercises:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Gastrocnemius stretching and light hamstring stretching </li> <li>Leg press </li> <li>Squat progression (squat; squat with calf raise; squat with weight shift - slowly transfer weight from side to side while maintaining half-squat position) </li> <li>Static lunge (assume lunge position and hold for time; build to 3 sets of 45 second holds) </li> <li>Hamstring bridges on ball with knees extended </li> <li>Single leg dead lift with knee extended </li> <li>Proprioceptive and balance exercises (use static&nbsp;exercises [eg, \"Stork stance\"] and dynamic&nbsp;exercises [eg, playing catch while on one leg]; gradually advance from stable to unstable surface [eg, foam pad])</li> <li>Stationary bike: Gradually increase resistance </li> <li>Light kicking in pool </li> <li>Incline treadmill walking (gradually increase incline from 7 to 12 degrees) </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Criteria for advancing to Stage III:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Full knee ROM; quadriceps strength 85 percent of uninjured, contralateral leg; no gait abnormalities; proper lower extremity mechanics; minimal to no pain with activities </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Stage III: 13 to 18 weeks after injury</td> </tr> <tr> <td class=\"indent1\">Goals:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Improve strength and mobility </li> <li>Prepare athlete for sport-specific activity </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Guidelines:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Discontinue PCL brace </li> <li>Use set and repetition scheme emphasizing strength development for all strength exercises: 3 x 8 to 10</li> <li>Gradually increase weight used for strength exercises</li> <li>Gradually increase knee flexion during strength exercises to &#62;70 degrees </li> <li>Isolated hamstring exercises may begin after week 12 </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Exercises:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Double leg press; advance to single leg press </li> <li>Single leg knee bends </li> <li>Balance squats </li> <li>Single leg dead lift </li> <li>Single leg bridges </li> <li>Single leg balancing exercises, gradually incorporating unstable surfaces (eg, foam pads, wobble boards, balance balls) </li> <li>Continue stationary bike and treadmill walking </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Running permitted when patient demonstrates sufficient strength and stability with functional exercises, and quadriceps girth &#8805;90 percent of contralateral, uninjured thigh</td> </tr> <tr> <td class=\"indent1\">Running program:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Week 1: 4 minute walk; 1 minute jog for 15 to 20 minutes </li> <li>Week 2: 3 minute walk; 2 minute jog for 20 minutes </li> <li>Week 3: 2 minute walk; 3 minute jog for 20 minutes </li> <li>Week 4: 1 minute walk; 4 minute jog for 20 minutes </li> </ul> Once running progression completed, gradually progress to multi-planar agility exercises</td> </tr> <tr> <td class=\"indent1\">Criteria for advancing to Stage IV:</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Normal clinical examination; proper performance of rehabilitation exercises; clinician judgment about patient preparedness for next stage; patient/family preferences and goals </li> </ul> </td> </tr> <tr> <td class=\"subtitle1_single\">Stage IV: Approximately 19 weeks after injury; varies depending on evidence of healing and performance of functional exercises during Stage III</td> </tr> <tr> <td class=\"indent1\">Goals:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Return to full activity </li> <li>Content and duration of this stage depends heavily on patient/family preferences and goals </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Guidelines:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Use set and repetition scheme emphasizing power development for strength exercises: 3 x 4 to 8 </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Exercises:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Continue strength and balance exercises from Stage III </li> <li>Add sport-specific agility exercises </li> </ul> </td> </tr> <tr> <td class=\"indent1\">Athlete may return to full contact sport when meets following criteria:</td> </tr> <tr> <td class=\"indent1\"> <ul class=\"decimal_heading\"> <li>Full active knee ROM </li> <li>No evidence of knee instability </li> <li>Single leg balance can be maintained, with hip level, for 30 seconds </li> <li>Quadriceps strength &#62;85 to 90 percent of uninjured extremity </li> <li>Function of injured knee approximately 90 percent of uninjured knee with sport-specific testing </li> <li>Athlete mentally prepared for return to sport; no fear of re-injury </li> </ul> </td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PCL: posterior cruciate ligament.</div><div class=\"graphic_reference\">Adapted from: Pierce CM, O'Brien L, Griffin LW, LaPrade RF. Posterior cruciate ligament tears: functional and postoperative rehabilitation. Knee Surg Sports Traumatol Arthrosc. 2013; 21:1071.</div><div id=\"graphicVersion\">Graphic 103862 Version 2.0</div></div></div>"},"103863":{"type":"graphic_picture","displayName":"Partially inflated LMA Classic","title":"A partially inflated LMA Classic","html":"<div class=\"graphic\"><div style=\"width: 651px\" class=\"figure\"><div class=\"ttl\">A partially inflated LMA Classic</div><div class=\"cntnt\"><img style=\"width:631px; height:466px;\" src=\"images/ANEST/103863_Prtlly_inflt_LMA_clssc.jpg\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103863 Version 1.0</div></div></div>"},"103864":{"type":"graphic_picture","displayName":"Family of LMAs","title":"Family of LMAs","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Family of LMAs</div><div class=\"cntnt\"><img style=\"width:612px; height:469px;\" src=\"images/ANEST/103864_Family_LMAs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The LMA family of supraglottic airways includes both single-use and reusable products intended for a variety of clinical situations. For example, the LMA Proseal works well with positive pressure ventilation, allows for the insertion of a gastric tube to decompress the stomach, and contains an integral bite block; the LMA Fastrach is designed as a conduit for tracheal intubation; and the LMA Flexible, intended for intraoral and nasopharyngeal operations, has a wire-reinforced, flexible shaft that allows it to be easily positioned away from the surgical field.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103864 Version 1.0</div></div></div>"},"103867":{"type":"graphic_picture","displayName":"LMA Proseal","title":"LMA Proseal","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">LMA Proseal</div><div class=\"cntnt\"><img style=\"width:446px; height:610px;\" src=\"images/ANEST/103867_LMA_proseal.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Closeup view of the LMA Proseal, optimized for positive pressure ventilation. The LMA Proseal also contains an integral bite block and a port that allows for insertion of a gastric tube. A helpful illustrative video is also available at <A href=\"http://www.youtube.com/watch?v=-535q8xn-1Y&amp;index=2&amp;list=PL9386F751C3F924B1\" target=_blank>http://www.youtube.com/watch?v=-535q8xn-1Y&amp;index=2&amp;list=PL9386F751C3F924B1</A>.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103867 Version 1.0</div></div></div>"},"103872":{"type":"graphic_picture","displayName":"Flexible LMAs","title":"Flexible LMAs","html":"<div class=\"graphic\"><div style=\"width: 797px\" class=\"figure\"><div class=\"ttl\">Flexible LMAs</div><div class=\"cntnt\"><img style=\"width:777px; height:564px;\" src=\"images/ANEST/103872_Flexible_LMAs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Flexible, reinforced LMAs have wire-reinforced, flexible airway tubes with a smaller diameter than other LMAs. These features allow them to be positioned away from the surgical field, which is particularly useful for otolaryngologic, dental, and other head and neck procedures in which the surgeon and anesthesiologist are sharing the airway or the surgical field. Examples include the LMA flexible (A), the Ambu AuraFlex (B), and the Tru-cuff Ultra Flex EX (C).</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</li>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2015 Ambu A/S. All rights reserved.​</li>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2015 AES, Inc. All rights reserved.</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103872 Version 1.0</div></div></div>"},"103884":{"type":"graphic_diagnosticimage","displayName":"Obstructed infracardiac TAPVC","title":"Obstructed total anomalous pulmonary venous connection","html":"<div class=\"graphic\"><div style=\"width: 632px\" class=\"figure\"><div class=\"ttl\">Obstructed total anomalous pulmonary venous connection</div><div class=\"cntnt\"><img style=\"width:612px; height:589px;\" src=\"images/PEDS/103884_Obstrctd_infracardiac_TAPVC.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Chest radiograph of a newborn infant with obstructed infracardiac total anomalous pulmonary venous connection (TAPVC). The lungs have a ground glass appearance due to pulmonary vascular congestion and diffuse interstitial and alveolar edema.</div><div id=\"graphicVersion\">Graphic 103884 Version 2.0</div></div></div>"},"103886":{"type":"graphic_picture","displayName":"Tru-Cuff laryngeal mask inflation syringe","title":"Tru-Cuff laryngeal mask inflation syringe","html":"<div class=\"graphic\"><div style=\"width: 735px\" class=\"figure\"><div class=\"ttl\">Tru-Cuff laryngeal mask inflation syringe</div><div class=\"cntnt\"><img style=\"width:715px; height:349px;\" src=\"images/ANEST/103886_Tr_Cff_lrng_msk_inflt_syrng.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The Tru-Cuff LM syringe is attached to the LMA, and the cuff is inflated until the black line is in the green zone on the syringe.</div><div class=\"graphic_footnotes\">LM: laryngeal mask; LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 AES, Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103886 Version 1.0</div></div></div>"},"103892":{"type":"graphic_picture","displayName":"Air-Q SP LMA","title":"Air-Q SP LMA","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Air-Q SP LMA</div><div class=\"cntnt\"><img style=\"width:217px; height:632px;\" src=\"images/ANEST/103892_AirQ_SP_LMA.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The air-Q LMA has a self-pressurizing cuff that&nbsp;inflates during positive pressure ventilation and deflates to some extent during exhalation.</div><div class=\"graphic_footnotes\">SP: self-pressurizing; LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Mercury Medical. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103892 Version 1.0</div></div></div>"},"103893":{"type":"graphic_table","displayName":"Weight-based guide to choosing LMA size","title":"Weight-based guide to choosing LMA size","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Weight-based guide to choosing LMA size</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"3\" width=\"33\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Weight, kg</td> <td class=\"subtitle1\">LMA size</td> <td class=\"subtitle1\">Max cuff volume, mL</td> </tr> <tr> <td>&#60;5</td> <td>1</td> <td>4</td> </tr> <tr> <td>5-10</td> <td>1.5</td> <td>7</td> </tr> <tr> <td>10-20</td> <td>2</td> <td>10</td> </tr> <tr> <td>20-30</td> <td>2.5</td> <td>14</td> </tr> <tr> <td>30-50</td> <td>3</td> <td>20</td> </tr> <tr> <td>50-70</td> <td>4</td> <td>30</td> </tr> <tr> <td>70-100</td> <td>5</td> <td>40</td> </tr> <tr> <td>&#62;100</td> <td>6</td> <td>50</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Guide to choosing LMA size. Note that these are guidelines only, and clinical judgment may be needed. In general, the size-4 LMA will be suitable for most adult females, and the size-5 for adult males up to 100 kg. The new size-6 is intended for adult patients over 100 kg. The size-3 LMA is now considered to be a pediatric size. Be careful not to exceed the maximum cuff inflation volume; if more than this volume is necessary to maintain a seal, consider the use of a larger size, as a better seal may be obtained by using a larger size with less air. Using too small a mask and overinflating the cuff may result in a poor fit within the oropharyngeal space and may possibly injure the oropharyngeal mucosa. Many clinicians measure the cuff pressure to ensure that it never exceeds 60 cmH<SUB>2</SUB>O (ie, 41 mmHg).</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway; kg: kilogram; mL: milliliter; cmH<sub>2</sub>O: centimeter of water; mmHg: milliliter of mercury.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103893 Version 2.0</div></div></div>"},"103894":{"type":"graphic_figure","displayName":"Standard LMA insertion method","title":"Standard LMA insertion method","html":"<div class=\"graphic\"><div style=\"width: 584px\" class=\"figure\"><div class=\"ttl\">Standard LMA insertion method</div><div class=\"cntnt\"><img style=\"width:564px; height:722px;\" src=\"images/ANEST/103894_Stndrd_LMA_insrt_mthd.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The \"standard\" LMA insertion method. Hold the LMA with the index finger at the junction of the cuff and the tube (Step 1). With the head first positioned as for normal intubation, keep the neck flexed and head extended by pushing the head from behind with one hand while inserting the LMA into the mouth with the other, initially directing the tip against the hard palate (Step 2). Then, using the index finger, push the LMA backwards and downwards against the palate (Step 3). As the LMA advances into position, maintain pressure against the posterior pharyngeal wall. Advance until resistance is felt. Press down on the LMA tube with the non-dominant hand while the finger is removed (Step 4). Inflate the cuff with air, tape the LMA in place along with a bite block, and connect to breathing circuit (Step 5).</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">Reproduced with permission. Copyright &copy; 2015 Teleflex Incorporated. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103894 Version 1.0</div></div></div>"},"103895":{"type":"graphic_picture","displayName":"Comparison of LMA types","title":"Comparison of LMA types","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Comparison of LMA types</div><div class=\"cntnt\"><img style=\"width:436px; height:709px;\" src=\"images/ANEST/103895_Cmprsn_LMA_typ.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">This graphic shows three of the many types of second-generation supraglottic airways.<br />(A) The air-Q<sup>[1]</sup>.<br />(B) The i-gel<sup>[2]</sup>.<br />(C) The Ambu Aura-i<sup>[3]</sup>.</div><div class=\"graphic_footnotes\">LMA: laryngeal mask airway.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2010 Mercury Medical. All rights reserved.</li>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2016 Intersurgical Incorporated. All rights reserved.​</li>&#xD;&#xA;    <li>Reproduced with permission. Copyright &copy; 2015 Ambu A/S. All rights reserved.​</li>&#xD;&#xA;</ol></div><div id=\"graphicVersion\">Graphic 103895 Version 3.0</div></div></div>"},"103900":{"type":"graphic_figure","displayName":"Changes in annual incidence of Y. enterocolitica 1996-2009","title":"Changes in the annual incidence of Yersinia enterocolitica infections in children <5 years old, by year and race, FoodNet, United States, 1996-2009","html":"<div class=\"graphic\"><div style=\"width: 698px\" class=\"figure\"><div class=\"ttl\">Changes in the annual incidence of Yersinia enterocolitica infections in children &lt;5 years old, by year and race, FoodNet, United States, 1996-2009</div><div class=\"cntnt\"><img style=\"width:678px; height:399px;\" src=\"images/ID/103900_Chng_annl_incdn_Y_entrcltc_96_09.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">Reproduced from: Ong KL, Gould LH, Chen DL, et al. Changing epidemiology of Yersinia enterocolitica infections: markedly decreased rates in young black children, Foodborne Diseases Active Surveillance Network (FoodNet), 1996-2009. Clin Infect Dis 2012; 54 Suppl 5:S385, by permission of Oxford University Press on behalf of the Infectious Diseases Society of America. Copyright © 2012 Oxford University Press.</div><div id=\"graphicVersion\">Graphic 103900 Version 3.0</div></div></div>"},"103903":{"type":"graphic_table","displayName":"Echocardiography criteria","title":"Echocardiography criteria*","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Echocardiography criteria*</div><div class=\"cntnt\"><table cellspacing=\"0\"><tbody> <tr> <td>LVH (LV mass index &#62;110 g/m<sup>2</sup> for women and &#62;130 g/m<sup>2</sup> for men or &#62;47 g/m<sup>2.7</sup> for women and &#62;50 g/m<sup>2.7</sup> for men). Latter measure is LV mass calculated by the area-length method and indexed to height<sup>[1-3]</sup>.</td> </tr> <tr> <td>Increased LV volume index &#62;86 mL/m<sup>2</sup> diastolic or &#62;37 mL/m<sup>2</sup> systolic.</td> </tr> <tr> <td>Left atrial enlargement (left atrial volume index &#8805;34 mL/m<sup>2</sup>).</td> </tr> <tr> <td>Diastolic dysfunction (ASE grade &#8805;2).</td> </tr> <tr> <td>Moderate to severe mitral or aortic valvular disease (stenosis or regurgitation).</td> </tr> <tr> <td>RV systolic dysfunction by accepted criteria (eg, TAPSE &#60;17 mm).</td> </tr> <tr> <td>LV ejection fraction &#8804;45%.</td> </tr> <tr> <td>Regional wall motion abnormality of LV (&#62;10% of the myocardium).</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">LVH: left ventricular hypertrophy; LV: left ventricle; ASE: American Society of Echocardiography; RV: right ventricle; TAPSE: tricuspid annular plane systolic excursion.<br />* At least one (of eight) listed criteria must be abnormal to fulfill the definition of echocardiographic evidence of heart disease.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification: A report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber of Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005; 18:1440.</li>&#xD;&#xA;    <li>de Simone G, Devereux RM, Daniels SR, et al. Effect of growth on variability of left ventricular mass: Assessment of allometric signals in adults and children and their capacity to predict cardiovascular risk. J Am Coll Cardiol 1995; 25:1056.</li>&#xD;&#xA;    <li>Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry: The Framingham Heart Study. JAMA 1991; 266:231.</li>&#xD;&#xA;</ol>&#xD;&#xA;Reproduced from: Chawla LS, Herzog CA, Costanzo MR, et al. Proposal for a functional classification system of heart failure in patients with end-stage renal disease: Proceedings of the Acute Dialysis Quality Intiative (ADQI) XI workgroup. J Am Coll Cardiol 2014; 63:1246. Table used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103903 Version 1.0</div></div></div>"},"103906":{"type":"graphic_picture","displayName":"Location of three bursae in the anterior knee","title":"Location of three bursae in the anterior knee","html":"<div class=\"graphic\"><div style=\"width: 613px\" class=\"figure\"><div class=\"ttl\">Location of three bursae in the anterior knee</div><div class=\"cntnt\"><img style=\"width:593px; height:648px;\" src=\"images/RHEUM/103906_Loc_three_bursae_ant_knee.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Upper marker, prepatellar bursae; middle marker, superficial infrapatellar (pretendinous) bursa; lower marker, deep infrapatellar bursa.</div><div class=\"graphic_reference\">Courtesy of Juan Canoso, MD.</div><div id=\"graphicVersion\">Graphic 103906 Version 1.0</div></div></div>"},"103907":{"type":"graphic_table","displayName":"Bursal fluid findings in subcutaneous bursitis","title":"Bursal fluid findings in subcutaneous bursitis","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Bursal fluid findings in subcutaneous bursitis</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"7\" width=\"14%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">Volume<br /> (mL)</td> <td class=\"subtitle1\">Leukocyte<br /> <span style=\"white-space: nowrap;\">(per mm<sup>3</sup>)</span></td> <td class=\"subtitle1\"><span style=\"white-space: nowrap;\">% PMN</span></td> <td class=\"subtitle1\">Erythrocytes<br /> <span style=\"white-space: nowrap;\">(per mm<sup>3</sup>)</span></td> <td class=\"subtitle1\">Crystals</td> <td class=\"subtitle1\">Culture</td> </tr> <tr> <td style=\"white-space: nowrap;\"><strong>Traumatic (115)</strong>*</td> <td>7</td> <td>350</td> <td>5</td> <td>26,750</td> <td class=\"divider_bottom\" rowspan=\"2\">None</td> <td class=\"divider_bottom\" rowspan=\"2\">All negative</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Median range </li> </ul> </td> <td>0.5 to 35</td> <td>0 to 24,500</td> <td>0 to 98</td> <td>100 to Hct 43%</td> </tr> <tr> <td><strong>Septic (51)</strong></td> <td>3</td> <td>13,500</td> <td>94</td> <td>7900</td> <td class=\"divider_bottom\" rowspan=\"2\">None</td> <td class=\"divider_bottom\" rowspan=\"2\">All positive<sup>&#182;</sup></td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Median range </li> </ul> </td> <td>Trace to 21</td> <td>1000 to 425,000</td> <td>30 to 100</td> <td>150 to Hct 10%</td> </tr> <tr> <td><strong>Gout (25)</strong></td> <td>1</td> <td>2375</td> <td>40</td> <td>10,200</td> <td class=\"divider_bottom\" rowspan=\"2\">All MSU</td> <td class=\"divider_bottom\" rowspan=\"2\">All negative</td> </tr> <tr class=\"divider_bottom\"> <td> <ul class=\"decimal_heading\"> <li>Median range </li> </ul> </td> <td>Trace to 15</td> <td>650 to 12,000</td> <td>2 to 98</td> <td>200 to 104,500</td> </tr> <tr> <td><strong>RA (13)</strong></td> <td>5.5</td> <td>2500</td> <td>30</td> <td>4700</td> <td rowspan=\"2\">Cholesterol in 6</td> <td rowspan=\"2\">All negative</td> </tr> <tr> <td> <ul class=\"decimal_heading\"> <li>Median range </li> </ul> </td> <td>1.5 to 35</td> <td>200 to 25,200</td> <td>2 to 86</td> <td>200 to 888,000</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">PMN: polymorphonuclear leukocytes; Hct: hematocrit; MSU: monosodium urate; RA: rheumatoid arthritis.<br />* Parentheses indicate number of observations.<br />&para; <em>Staphylococcus aureus</em>, 45; <em>Staphylococcus epidermidis</em>, 1; hemolytic streptococci 5 (group A, 3; group B, 1; group G, 1).</div><div class=\"graphic_reference\">Modified from: Canoso JJ. Bursal membrane and bursal fluid. In: Laboratory Diagnostic Procedures in the Rheumatic Diseases, 3rd ed, Cohen AS (Ed), Grune &amp; Stratton, 1985.</div><div id=\"graphicVersion\">Graphic 103907 Version 1.0</div></div></div>"},"103909":{"type":"graphic_figure","displayName":"TandemHeart","title":"TandemHeart","html":"<div class=\"graphic\"><div style=\"width: 726px\" class=\"figure\"><div class=\"ttl\">TandemHeart</div><div class=\"cntnt\"><img style=\"width:706px; height:759px;\" src=\"images/CARD/103909_Tandem_Heart.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">TandemHeart consists of a 21F inflow cannula in the left atrium after femoral venous access and transseptal puncture and a 15 to 17 F arterial cannula in the iliac artery. The externalized centrifugal motor rotates at maximal speed of 7500 rotations per minute, delivering 4 L/min of continuous flow.</div><div class=\"graphic_reference\">From: Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. Circulation 2011; 123:533. DOI: <a href=\"http://circ.ahajournals.org/content/123/5/533.extract\" spellcheck=\"true\" target=\"_blank\">10.1161/CIRCULATIONAHA.110.945055</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2011 American Heart Association. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103909 Version 1.0</div></div></div>"},"103910":{"type":"graphic_figure","displayName":"Impella","title":"Impella","html":"<div class=\"graphic\"><div style=\"width: 572px\" class=\"figure\"><div class=\"ttl\">Impella</div><div class=\"cntnt\"><img style=\"width:552px; height:334px;\" src=\"images/CARD/103910_Impella.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Impella 2.5 circulatory support system components.</div><div class=\"graphic_reference\">Reproduced with permission. All rights reserved. Copyright &copy; 2015 ABIOMED.</div><div id=\"graphicVersion\">Graphic 103910 Version 1.0</div></div></div>"},"103911":{"type":"graphic_diagnosticimage","displayName":"Echo of Ebstein anomaly","title":"Two-dimensional echocardiographic apical four-chamber view showing Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 740px\" class=\"figure\"><div class=\"ttl\">Two-dimensional echocardiographic apical four-chamber view showing Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:720px; height:450px;\" src=\"images/CARD/103911_Echo_ebstn_anmly.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Two-dimensional echocardiographic apical four-chamber view (A) from a patient with Ebstein anomaly shows marked apical displacement of the septal tricuspid leaflet compared&nbsp;with the anterior mitral leaflet (asterisk). Note the large right atrium (RA). There was associated severe tricuspid valve regurgitation (TR) evidenced by color-flow Doppler (B).</div><div class=\"graphic_footnotes\">RV: right ventricle; LV: left ventricle; TR: tricuspid regurgitation.</div><div class=\"graphic_reference\">Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103911 Version 1.0</div></div></div>"},"103912":{"type":"graphic_diagnosticimage","displayName":"Pre- and postop CXR of patient with Ebstein anomaly","title":"Pre- and postoperative chest radiographs of patient with Ebstein anomaly","html":"<div class=\"graphic\"><div style=\"width: 844px\" class=\"figure\"><div class=\"ttl\">Pre- and postoperative chest radiographs of patient with Ebstein anomaly</div><div class=\"cntnt\"><img style=\"width:824px; height:446px;\" src=\"images/CARD/103912_Pre_pstp_CXR_ptnt_ebstn_anm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Pre- and postoperative (A and B, respectively) chest radiograph from a 28-year-old female with Ebstein anomaly. Note marked enlargement of the cardiac silhouette with striking reduction in size six months after tricuspid valve repair.</div><div class=\"graphic_reference\">Courtesy of Heidi Connolly, MD. Used with permission of Mayo Foundation for Medical Education and Research. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103912 Version 4.0</div></div></div>"},"103917":{"type":"graphic_table","displayName":"Interventional techniques","title":"Interventional bronchoscopic techniques for management of central airway obstruction and hemoptysis in patients with lung cancer","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Interventional bronchoscopic techniques for management of central airway obstruction and hemoptysis in patients with lung cancer</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup width=\"25%\"></colgroup><colgroup span=\"5\" width=\"15%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Tumor location:</td> <td class=\"subtitle1\" colspan=\"2\">Endoluminal</td> <td class=\"subtitle1\">Extrinsic</td> <td class=\"subtitle1\" colspan=\"2\">Mixed</td> </tr> <tr> <td class=\"subtitle2\">Clinical problem</td> <td class=\"subtitle2\">Airway obstruction</td> <td class=\"subtitle2\">Hemoptysis</td> <td class=\"subtitle2\">Airway obstruction</td> <td class=\"subtitle2\">Airway obstruction</td> <td class=\"subtitle2\">Hemoptysis</td> </tr> <tr> <td class=\"divider_bottom\" colspan=\"6\">Laser</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nd:YAG</li> </ul> </td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Nd:YAP</li> </ul> </td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>Ho:YAG</li> </ul> </td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr> <td class=\"indent1\"> <ul> <li>KTP</li> </ul> </td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\"> <ul> <li>CO<sub>2</sub></li> </ul> </td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Electrocautery</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Argon plasma coagulation</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Cryotherapy (contact)</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Photodynamic therapy</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Brachytherapy</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> <tr class=\"divider_bottom\"> <td>Mechanical debridement</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Rigid bronchoscopy</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> </tr> <tr class=\"divider_bottom\"> <td>Balloon dilatation</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">&#177;</td> <td class=\"centered\">&ndash;</td> </tr> <tr> <td>Stenting</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> <td class=\"centered\">+</td> <td class=\"centered\">+</td> <td class=\"centered\">&ndash;</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Interventional techniques for management of airway obstruction or hemoptysis in patients with lung cancer. Airway obstruction may manifest as dyspnea, cough, wheeze, atelectasis, or collapse and can be as extreme as respiratory failure. In both airway obstruction and hemoptysis, airway security should be a priority and may require an invasive artificial airway or rigid bronchoscopy. This table reflects only airway obstruction due to malignant causes. Interventional bronchoscopy requires a multidisciplinary team and is based on the availability of the technology and the appropriate experience and skill of the operator. These procedures should only be performed at centers with experience.</div><div class=\"graphic_footnotes\">+: indicated; –: not indicated; Nd:YAG: neodymium-doped yttrium-aluminum-garnet; Nd:YAP: neodymium-doped yttrium-aluminum-perovskite; Ho:YAG: holmium yttrium-aluminum-garnet; KTP: potassium-titanyl-phosphate; ±: equivocal; CO<SUB>2</SUB>: carbon dioxide.</div><div class=\"graphic_reference\">From: Simoff MJ, Lally B, Slade MG, et al. Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2013; 143:e455S. Copyright &copy; 2013. Reproduced with permission from the American College of Chest Physicians.</div><div id=\"graphicVersion\">Graphic 103917 Version 2.0</div></div></div>"},"103923":{"type":"graphic_figure","displayName":"Common mechanisms for PCL injury","title":"Common mechanisms for posterior cruciate ligament (PCL) injury","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Common mechanisms for posterior cruciate ligament (PCL) injury</div><div class=\"cntnt\"><img style=\"width:521px; height:677px;\" src=\"images/SM/103923_Common_mechanisms_for_PCL_injury.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Posterior cruciate ligament (PCL) injuries occur&nbsp;when a posteriorly directed sheer force is applied to a flexed knee. One example is the classic \"dashboard injury\" in which the anterior knee, including the proximal tibia, of the driver or a front seat passenger collides with the car's dashboard (picture A). During sports, PCL injuries occur when an athlete falls onto their flexed knee while the foot is plantar-flexed (picture B),&nbsp;or from a direct blow to the anterior knee (picture C).&nbsp;</div><div id=\"graphicVersion\">Graphic 103923 Version 1.0</div></div></div>"},"103924":{"type":"graphic_figure","displayName":"Quadriceps active test to diagnose PCL tear","title":"Quadriceps active test to diagnose PCL tear","html":"<div class=\"graphic\"><div style=\"width: 558px\" class=\"figure\"><div class=\"ttl\">Quadriceps active test to diagnose PCL tear</div><div class=\"cntnt\"><img style=\"width:538px; height:402px;\" src=\"images/SM/103924_Quadriceps_active_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The quadriceps active test is used to help diagnose a PCL tear. The test is performed with the patient supine and their knee flexed to 90 degrees. While the clinician holds the foot in place against the examination table, the patient is asked to contract their quadriceps muscles. In a patient with an intact PCL, the knee does not move forward noticeably during such a contraction. In a patient with a PCL tear, the tibia shifts anteriorly with the contraction.&nbsp;This is because during contraction the quadriceps pull the patella, patellar tendon, and ultimately the tibial tubercle, returning the tibia back to a reduced position. </div><div class=\"graphic_footnotes\">PCL: posterior cruciate ligament injury.</div><div id=\"graphicVersion\">Graphic 103924 Version 1.0</div></div></div>"},"103926":{"type":"graphic_algorithm","displayName":"Abnormal PT/aPTT algorithm","title":"Algorithm for the evaluation of abnormal coagulation times (PT and/or aPTT)","html":"<div class=\"graphic\"><div style=\"width: 1059px\" class=\"figure\"><div class=\"ttl\">Algorithm for the evaluation of abnormal coagulation times (PT and/or aPTT)</div><div class=\"cntnt\"><img style=\"width:1039px; height:642px;\" src=\"images/HEME/103926_Abnormal_PT_aPTT_algo.gif\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Refer to UpToDate content on the use of coagulation testing for further information.</div><div class=\"graphic_footnotes\">PT: prothrombin time; aPTT: activated partial thromboplastin time; DIC: disseminated intravascular coagulation; TT: thrombin time; RT: reptilase time; FVII:&nbsp;factor VII;&nbsp;VWD: von Willebrand disease.<br />* Additional testing may include the following: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Testing based on inhibitor characteristics: &#xD;&#xA;<UL>&#xD;&#xA;<LI>If delayed appearance of inhibitor (2 hours &gt; 5 minutes), check factor VIII activity level</LI>&#xD;&#xA;<LI>If immediate appearance of inhibitor (2 hours = 5 minutes), check factor VIII, IX, and XI activity</LI>&#xD;&#xA;<LI>If inhibitor corrects with phospholipid addition, additional antiphospholipid antibody testing</LI></UL></LI>&#xD;&#xA;<LI>Testing for intrinsic pathway defects: &#xD;&#xA;<UL>&#xD;&#xA;<LI>VWD testing (refer to UpToDate content on VWD)</LI>&#xD;&#xA;<LI>Factor VIII, IX, and XI testing</LI>&#xD;&#xA;<LI>If these are normal, factor XII testing</LI></UL></LI>&#xD;&#xA;<LI>Testing for fibrinogen disorders: Refer to UpToDate content on fibrinogen disorders</LI>&#xD;&#xA;<LI>Testing for common pathway defects: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Mixing studies with the PT and aPTT</LI>&#xD;&#xA;<LI>Factor X, V, and II (prothrombin) activity testing</LI>&#xD;&#xA;<LI>Trial of vitamin K supplementation</LI></UL></LI></UL></div><div id=\"graphicVersion\">Graphic 103926 Version 4.0</div></div></div>"},"103927":{"type":"graphic_picture","displayName":"X-linked ichthyosis back","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 804px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:784px; height:519px;\" src=\"images/DERM/103927_X_lnkd_ichthys_bck.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild desquamation and erythema on the back in a two-year-old boy with X-linked ichthyosis.</div><div id=\"graphicVersion\">Graphic 103927 Version 1.0</div></div></div>"},"103928":{"type":"graphic_picture","displayName":"X-linked ichthyosis abdomen","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 540px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:520px; height:340px;\" src=\"images/DERM/103928_X_lnk_ichthys_abdmn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Mild scaling over the abdomen in three-year-old boy with X-linked ichthyosis.</div><div class=\"graphic_reference\">Reproduced from: Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103928 Version 1.0</div></div></div>"},"103929":{"type":"graphic_picture","displayName":"X-linked ichthyosis shoulder","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 537px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:517px; height:647px;\" src=\"images/DERM/103929_X_lnk_ichthys_shldr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin scaling on the left shoulder and upper aspect of the back of a one-year-old boy with X-linked ichthyosis.</div><div class=\"graphic_reference\">Reproduced from: Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103929 Version 1.0</div></div></div>"},"103930":{"type":"graphic_picture","displayName":"X-linked ichthyosis leg","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:361px; height:717px;\" src=\"images/DERM/103930_X_lnk_ichthys_leg.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Thin scaling of the front lower aspect of the left leg lacking prominent polygonal or dark-colored scale in an 11-month-old boy with X-linked ichthyosis and concurrent atopic dermatitis.</div><div class=\"graphic_reference\">Reproduced from: Hand JL, Runke CK, Hodge JC. The phenotype spectrum of X-linked ichthyosis identified by chromosomal microarray. J Am Acad Dermatol 2015; 72:617. Illustration used with the permission of Elsevier Inc. All rights reserved.</div><div id=\"graphicVersion\">Graphic 103930 Version 1.0</div></div></div>"},"103931":{"type":"graphic_picture","displayName":"X-linked ichthyosis popliteal sparing","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103931_X_lnk_ichthys_ppltl_spr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical sparing of the popliteal fossae in this boy with X-linked recessive ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103931 Version 1.0</div></div></div>"},"103932":{"type":"graphic_picture","displayName":"X-linked ichthyosis antecubital sparing","title":"X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103932_X_lnk_ichthys_antcbtl_spr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Typical sparing of the antecubital fossae in this boy with X-linked recessive ichthyosis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103932 Version 1.0</div></div></div>"},"103933":{"type":"graphic_algorithm","displayName":"Algorithm for immediate treatment of hypereosinophilia","title":"Algorithm for immediate treatment of hypereosinophilia","html":"<div class=\"graphic\"><div style=\"width: 524px\" class=\"figure\"><div class=\"ttl\">Algorithm for immediate treatment of hypereosinophilia</div><div class=\"cntnt\"><img style=\"width:504px; height:365px;\" src=\"images/ALLRG/103933_Algotxhypereosinophilia.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">HE: hypereosinophilia; AEC: absolute eosinophil count.<br />* Peripheral blood HE is defined AEC &gt;1.5 &times; 10<sup>9</sup>/L or &gt;1500/microL.<br />&para; Tissue HE is defined by:&#xD;&#xA;<ul>&#xD;&#xA;    <li>On bone marrow section, a percentage of eosinophils that exceeds 20% of all nucleated cells, and/or</li>&#xD;&#xA;    <li>Tissue infiltration that is extensive in the opinion of a pathologist and/or</li>&#xD;&#xA;    <li>Marked deposition of eosinophil granule proteins in tissue (in the absence or presence of major tissue infiltration by eosinophils).</li>&#xD;&#xA;</ul>&#xD;&#xA;&Delta; Refer to the UpToDate topic on clinical manifestations, pathophysiology, and diagnosis of hypereosinophilic syndromes.<br /><span class=\"lozenge\">&loz;</span> Potentially life-threatening complications of HE include:&#xD;&#xA;<ul>&#xD;&#xA;    <li>Acute heart failure or evidence of likely developing eosinophil-mediated cardiac damage (based on either clinical findings or elevated troponins when clinical cardiac impairment is not yet clinically evident).</li>&#xD;&#xA;    <li>Thromboemboli, often of cardiac origin, which can present as diffuse watershed central nervous system (CNS) infarctions or focal CNS thromboemboli.</li>&#xD;&#xA;    <li>Pulmonary signs or symptoms, in concert with substantial eosinophil-associated disease on computed tomography (CT) imaging of the chest.</li>&#xD;&#xA;</ul></div><div id=\"graphicVersion\">Graphic 103933 Version 3.0</div></div></div>"},"103934":{"type":"graphic_picture","displayName":"X-linked ichthyosis cornea","title":"Corneal opacities in X-linked recessive ichthyosis","html":"<div class=\"graphic\"><div style=\"width: 745px\" class=\"figure\"><div class=\"ttl\">Corneal opacities in X-linked recessive ichthyosis</div><div class=\"cntnt\"><img style=\"width:725px; height:290px;\" src=\"images/DERM/103934_X_lnk_ichthys_crn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Slit-lamp examination of both eyes reveals a granular posterior stromal haze in the right eye (punctate corneal opacities).</div><div class=\"graphic_reference\">From: Hung C, Ayabe RI, Wang C. Pre-Descemet corneal dystrophy and X-linked ichthyosis associated with deletion of Xp22.31 containing the STS gene. Cornea 2013; 32:1283. DOI: <a href=\"http://journals.lww.com/corneajrnl/pages/articleviewer.aspx?year=2013&amp;issue=09000&amp;article=00020&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/ICO.0b013e318298e176</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2013 The Cornea Society. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103934 Version 1.0</div></div></div>"},"103939":{"type":"graphic_picture","displayName":"Pronation abduction test for tarsometatarsal (Lisfranc) injury","title":"Pronation abduction test for tarsometatarsal (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 470px\" class=\"figure\"><div class=\"ttl\">Pronation abduction test for tarsometatarsal (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:412px; height:527px;\" src=\"images/SM/103939_Prnt_abdut_trsmttrs_lsfrnc_injuy.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Simultaneous pronation and abduction of the forefoot while the hindfoot remains in place typically elicits pain in the patient who has sustained a tarsometatarsal injury.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 103939 Version 1.0</div></div></div>"},"103947":{"type":"graphic_picture","displayName":"Squeeze test for tarsometatarsal (Lisfranc) injury","title":"Squeeze test for tarsometatarsal (Lisfranc) injury","html":"<div class=\"graphic\"><div style=\"width: 729px\" class=\"figure\"><div class=\"ttl\">Squeeze test for tarsometatarsal (Lisfranc) injury</div><div class=\"cntnt\"><img style=\"width:709px; height:470px;\" src=\"images/SM/103947_Sqz_tst_trsmttr_lsfrc_injr.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The squeeze test pictured above compresses the midfoot and generally elicits pain in patients with a tarsometatarsal injury.</div><div class=\"graphic_reference\">Courtesy of Anthony Beutler, MD.</div><div id=\"graphicVersion\">Graphic 103947 Version 1.0</div></div></div>"},"103959":{"type":"graphic_table","displayName":"PK data analgesic medications in normal state and CKD","title":"Pharmacokinetic data on analgesic medications in the normal state and in the context of chronic kidney disease","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Pharmacokinetic data on analgesic medications in the normal state and in the context of chronic kidney disease</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"6\" width=\"10%\"></colgroup><colgroup width=\"40%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Medication</td> <td class=\"subtitle1\">Percent excreted in the urine</td> <td class=\"subtitle1\">T one-half normal (hours)</td> <td class=\"subtitle1\">T one-half Dialysis (ESRD) (hours)</td> <td class=\"subtitle1\">Hemodialysis</td> <td class=\"subtitle1\">Peritoneal dialysis</td> <td class=\"subtitle1\">Comments and recommendations on use in CKD</td> </tr> <tr class=\"divider_bottom\"> <td>Acetaminophen (paracetamol)<sup>[1-4]</sup></td> <td>&#60;5</td> <td>1 to 4</td> <td>Unchanged</td> <td>Dialyzed</td> <td>Not dialyzed</td> <td>Accumulation of inactive metabolites. Analgesic of choice for mild-moderate pain. No dose reduction required.</td> </tr> <tr class=\"divider_bottom\"> <td>Codeine<sup>[5-7]</sup></td> <td>0 to 16</td> <td>2.5 to 4</td> <td>13 to 18.9</td> <td>Not dialyzed</td> <td>Unlikely to be dialyzed</td> <td>Metabolized to morphine derivatives and known to cause profound hypotension and CNS and respiratory depression. Not recommended in CKD.</td> </tr> <tr class=\"divider_bottom\"> <td>Tramadol<sup>[8-10]</sup></td> <td>90 (30% unchanged 60% as metabolites)</td> <td>6</td> <td>11</td> <td>Dialyzed</td> <td>Unknown</td> <td> <p>eGFR 30 to 10 mL/min: 50 to 100 mg twice daily.</p> eGFR &#60;10 mL/min (and on dialysis): 50 mg twice daily. Hemodialysis significantly removes tramadol, so administration is best given after each dialysis.</td> </tr> <tr class=\"divider_bottom\"> <td>Morphine</td> <td>10</td> <td>2 to 3</td> <td>Unchanged</td> <td>Parent and active metabolites dialyzed</td> <td>Not dialyzed</td> <td>Rapid accumulation of active metabolites in CKD resulting in clinically significant opioid toxicity including sedation, confusion, myoclonus, and respiratory depression. Not recommended in CKD.</td> </tr> <tr class=\"divider_bottom\"> <td>Hydromorphone<sup>[11,12]</sup></td> <td>6</td> <td>2 to 5</td> <td>3.2 on dialysis; 5.9 nondialysis days</td> <td>Active metabolite (H3G) dialyzed</td> <td>Unknown</td> <td>Much better tolerated in CKD than morphine with less toxic metabolites. Pharmacodynamic data have shown less neuroexcitation compared with morphine and a greater than 65% reduction in pain over dosing intervals with no clinically significant opioid toxicity when given in low doses and monitored carefully.</td> </tr> <tr class=\"divider_bottom\"> <td>Fentanyl<sup>[13]</sup></td> <td>&#60;7</td> <td>2 to 7</td> <td>Possibly increased</td> <td>Not dialyzed</td> <td>Not dialyzed</td> <td>Inactive metabolites. Most pharmacokinetic studies in CKD use parenteral rather than transdermal fentanyl. Generally considered safe for use in CKD if monitored carefully.</td> </tr> <tr class=\"divider_bottom\"> <td>Alfentanil<sup>[14]</sup></td> <td>0.4</td> <td>1 to 2</td> <td>Unchanged</td> <td>Not dialyzed</td> <td>Not dialyzed</td> <td>Although pharmacokinetics of fentanyl analogs alfentanil and sufentanil do not appear to differ in CKD, there is a single case report of prolonged respiratory depression in a patient with ESRD where there was an elevated plasma concentration of sufentanil.</td> </tr> <tr class=\"divider_bottom\"> <td>Buprenorphine<sup>[15-18]</sup></td> <td>Minimal</td> <td>30</td> <td>Unchanged</td> <td>Dialyzed</td> <td>Dialyzed</td> <td>Buprenorphine may be given in standard doses to patients with CKD. Generally considered safe for use in CKD if monitored carefully.</td> </tr> <tr class=\"divider_bottom\"> <td>Oxycodone<sup>[19-22]</sup></td> <td>&#60;10</td> <td>2 to 4</td> <td>3 to 5</td> <td>Dialyzed</td> <td>Unknown</td> <td>There are case reports of toxicity in association with CKD, yet overall consensus from the literature is that oxycodone is reasonably safe to use in CKD if monitored carefully.</td> </tr> <tr class=\"divider_bottom\"> <td>Methadone<sup>[23,24]</sup></td> <td>15 to 60</td> <td>13 to 47</td> <td>Unknown</td> <td>Not dialyzed</td> <td>Not dialyzed</td> <td>Primarily excreted in the feces. Plasma concentrations are similar in CKD compared with those with normal renal function. Generally considered safe for use in CKD if monitored carefully.</td> </tr> <tr class=\"divider_bottom\"> <td>Gabapentin<sup>[25-27]</sup></td> <td>Approximately 100</td> <td>5 to 7</td> <td>52 to 132</td> <td>Dialyzed</td> <td>Possibly dialyzed</td> <td>Freely crosses the blood-brain barrier. Dose postdialysis. <ul class=\"decimal_heading\"> <li>eGFR 50 to 79 mL/min: 600 mg three times per day </li> <li>eGFR 30 to 49 mL/min: 300 mg three times per day </li> <li>eGFR 15 to 29 mL/min: 300 mg twice per day </li> <li>eGFR &#60;15 mL/min: 300 mg once per day </li> </ul> A more conservative dosing regimen is available in the Lexicomp monograph included within UpToDate.</td> </tr> <tr class=\"divider_bottom\"> <td>Pregabalin<sup>[28,29]</sup></td> <td>92 to 99</td> <td>5 to 6.5</td> <td>Increased</td> <td>Dialyzed (50% dialyzed in four hours)</td> <td>Dialyzed</td> <td> <p>Similar mechanism of action as gabapentin. Can give supplementary dose postdialysis (75 mg).</p> Dose regimen equivalent to approximately 600 mg per day of pregabalin in patient with normal renal function: <ul class=\"decimal_heading\"> <li>eGFR &#62;30 to 60 mL/min: 150 mg twice per day </li> <li>eGFR 15 to 30 mL/min: 150 mg once per day </li> <li>eGFR &#60;15 mL/min: 75 mg once per day </li> </ul> A more conservative dosing regimen is available in the Lexicomp monograph included within UpToDate.</td> </tr> <tr class=\"divider_bottom\"> <td>Duloxetine<sup>[6,30]</sup></td> <td>&#60;1</td> <td>8 to 17</td> <td>Unchanged</td> <td>Not dialyzed</td> <td>Not dialyzed</td> <td>Reduced starting dose in CKD (30 mg) with a maximum dose of 60 mg per day. Some sources recommend avoiding in patients with a CrCl of &#60;30 mL/min. Others suggest starting at a very low dose and increase according to response, with a maximum dose of 30 mg daily.</td> </tr> <tr class=\"divider_bottom\"> <td>Ketamine<sup>[6]</sup></td> <td>2 to 4</td> <td>2 to 4</td> <td>Unchanged</td> <td>Not dialyzed</td> <td>Unlikely to be dialyzed</td> <td>Dose as per normal renal function.</td> </tr> <tr> <td>Amitriptyline<sup>[31,32]</sup></td> <td>&#60;2</td> <td>9 to 25</td> <td>Unchanged</td> <td>Not dialyzed</td> <td>Not dialyzed</td> <td>Although no dose reduction is required, a low starting dose is recommended given likelihood of anticholinergic adverse effects.</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Detailed dosing and dose adjustment recommendations for use in patients with CKD are available in the individual drug monographs (Lexicomp) included within UpToDate.</div><div class=\"graphic_footnotes\">ESRD: end-stage renal disease; CNS: central nervous system; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; H3G: hydromorphone-3-glucuronide.</div><div class=\"graphic_reference\">References:&#xD;&#xA;<ol>&#xD;&#xA;    <li>Barakzoy AS, Moss AH. Efficacy of the World Health Organization analgesic ladder to treat pain in end-stage renal disease. CJASN 2006; 17:3198. </li>&#xD;&#xA;    <li>Prescott LF. Analgesic nephropathy: A reassessment of the role of phenacetin and other analgesics. Drugs 1982; 23:75.</li>&#xD;&#xA;    <li>Davison SN, Chambers EJ, Ferro CJ. Management of pain in renal failure. In: Supportive Care for the Renal Patient. 2nd ed, Chambers EJ, Brown E, Germain M. (Eds), Oxford University Press, New York 2010. p.139.</li>&#xD;&#xA;    <li>Prescott LF, Speirs GC, Critchley JA, et al. Paracetamol disposition and metabolite kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 1989; 36:291.</li>&#xD;&#xA;    <li>Guay DR, Awni WM, Findlay JW, et al. Pharmacokinetics and pharmacodynamics of codeine in end-stage renal disease. Clin Pharmacol Ther 1988; 43:63.</li>&#xD;&#xA;    <li>Ashley C, Currie AE. The Renal Drug Handbook. Radcliffe Publishing, Oxford 2009.</li>&#xD;&#xA;    <li>Way EL, Adler TK. The pharmacologic implications of the fate of morphine and its surrogates. Pharmacol Rev 1960; 12:383.</li>&#xD;&#xA;    <li>Schug SA, Morgan J. Treatment of cancer pain: Special considerations in patients with renal disease. Am J Cancer 2004; 3:247.</li>&#xD;&#xA;    <li>Izzedine H, Launay-Vacher V, Abbara C, et al. Pharmacokinetics of tramadol in a hemodialysis patient. Nephron 202; 92:755.</li>&#xD;&#xA;    <li>Gibson TP. Pharmacokinetics, efficacy, and safety of analgesia with a focus on tramadol HCl. Am J Med 1996; 101:47S.</li>&#xD;&#xA;    <li>Paramanandam G, Prommer E, Schwenke DC. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone. J Palliat Med 2011; 14:1029.</li>&#xD;&#xA;    <li>Davison SN, Mayo PR. Pain management in chronic kidney disease: The pharmacokinetics and pharmacodynamics of hydromorphone and hydromorphone-3-glucuronide in hemodialysis patients. J Opioid Manag 2008; 4:335.</li>&#xD;&#xA;    <li>Davies G, Kingswood C, Street M. Pharmacokinetics of opioids in renal dysfunction. Clinical Pharmacokinet 1996; 31:410.</li>&#xD;&#xA;    <li>Chauvin M, Lebrault C, Levron JC, Duvaldestin P. Pharmacokinetics of alfentanil in chronic renal failure. Anesth Analg 1987; 66:53.</li>&#xD;&#xA;    <li>Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5:197.</li>&#xD;&#xA;    <li>Filitz J, Griessinger N, Sittl R, et al. Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine. Eur J Pain 2006; 10:743.</li>&#xD;&#xA;    <li>Mordarski S. Efficacy and safety of buprenorphine in patients receiving haemodialysis. J App Ther Res 2009; 7:46.</li>&#xD;&#xA;    <li>Berg KJ, Talseth T. Acute renal effects of sulindac and indomethacin in chronic renal failure. Clin Pharmacol Ther 1985; 37:447.</li>&#xD;&#xA;    <li>Kirvela M, Lindgren L, Seppala T, Olkkola KT. The pharmacokinetics of oxycodone in uremic patients undergoing renal transplantation. J Clin Anaesth 1996; 8:13.</li>&#xD;&#xA;    <li>Fitzgerald J. Narcotic analgesics in renal failure. Connecticut Medicine 1991; 55:701.</li>&#xD;&#xA;    <li>Foral PA, Ineck JR, Nystrom KK. Oxycodone accumulation in a hemodialysis patient. South Med J 2007; 100:212.</li>&#xD;&#xA;    <li>Kaiko R, Benziger D, Cheng C, et al. Clinical pharmacokinetics of controlled-release oxycodone in renal impairment. Clin Pharmacol Ther 1996; 59:130.</li>&#xD;&#xA;    <li>Inturrisi CE, Verebely K. Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 1972; 13:923.</li>&#xD;&#xA;    <li>Kreek MJ, Schecter AJ, Gutjahr CL, Hecht M. Methadone use in patients with chronic renal disease. Drug Alcohol Depend 1980; 5:197.</li>&#xD;&#xA;    <li>Naylor HK, Raymond CB. Treatment of neuropathic pain in patients with chronic kidney disease. CANNT J 2011; 21:34.</li>&#xD;&#xA;    <li>Wong MO, Eldon MA, Keane WF, et al. Disposition of gabapentin in anuric subjects on hemodialysis. J Clin Pharmacol 1995; 35:622.</li>&#xD;&#xA;    <li>Blum RA, Comstock TJ, Sica DA, et al. Pharmacokinetics of gabapentin in subjects with various degrees of renal function. Clini Pharmacol Ther 1994; 56:154.</li>&#xD;&#xA;    <li>MIMS Annual. St. Leonards, NSW, UBM Medica Australia, 2010.</li>&#xD;&#xA;    <li>Randinitis EJ, Posvar EL, Alvey CW, et al. Pharmacokinetics of pregabalin in subjects with various degrees of renal function. J Clin Pharmacol 2003; 43:277.</li>&#xD;&#xA;    <li>Pop-Busui R, Roberts L, Pennathur S, et al. The management of diabetic neuropathy in CKD. Am J Kidney Dis 2010; 55:365.</li>&#xD;&#xA;    <li>Lieberman JA, Cooper TB, Suckow RF, et al. Tricyclic antidepressant and metabolite levels in chronic renal failure. Clin Pharmacol Ther 1985; 37:301.</li>&#xD;&#xA;    <li>Sandoz M, Vandel S, Vandel B, et al. Metabolism of amitriptyline in patients with chronic renal failure. Eur J Clin Pharmacol 1984; 26:227.</li>&#xD;&#xA;</ol>&#xD;&#xA;From: Davison SN, Koncicki H, Brennan F. Pain in chronic kidney disease: A scoping review. Semin Dial 2014; 27:188. <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/sdi.12196/abstract\" target=\"_blank\">http://onlinelibrary.wiley.com/doi/10.1111/sdi.12196/abstract</a>. Copyright &copy; 2014 Wiley Periodicals, Inc. Modified and reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103959 Version 1.0</div></div></div>"},"103960":{"type":"graphic_figure","displayName":"\"Pusher\" techniques for reduction of posterior elbow dislocation","title":"\"Pusher\" techniques for reduction of posterior elbow dislocation","html":"<div class=\"graphic\"><div style=\"width: 634px\" class=\"figure\"><div class=\"ttl\">\"Pusher\" techniques for reduction of posterior elbow dislocation</div><div class=\"cntnt\"><img style=\"width:614px; height:402px;\" src=\"images/SM/103960_Pusher_redct_post_elbw_dslc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction by \"pusher\" techniques.<br />(A) Lavine's method. The child is held by the parent while the elbow is draped over the edge of the chair. The olecranon is pushed distally past the humerus by the thumb of the physician while the other arm pulls distally along the axis of the forearm.<br />(B) Meyn's technique with patient lying prone on the table.</div><div class=\"graphic_reference\">Reproduced with permission from: Stans AA, Lawrence JTR. Dislocations of the elbows, medial epicondylar humerus fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103960 Version 1.0</div></div></div>"},"103961":{"type":"graphic_figure","displayName":"\"Puller\" technique for reduction of a posterior elbow dislocatio","title":"\"Puller\" technique for reduction of posterior elbow dislocation","html":"<div class=\"graphic\"><div style=\"width: 815px\" class=\"figure\"><div class=\"ttl\">\"Puller\" technique for reduction of posterior elbow dislocation</div><div class=\"cntnt\"><img style=\"width:795px; height:323px;\" src=\"images/EM/103961_Puller_rdct_post_elbw_dislc.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Reduction by \"puller\" techniques in a supine position.<br />(A) With the elbow flexed to almost 90 degrees, a force is applied to the anterior portion of the forearm with one hand while the other hand pulls distally along the forearm. A counterforce is applied to offset the manipulating forces by direct stabilization of the patient by a second medical person.<br />(B) The counterforce is applied with a sheet around the chest in the ipsilateral axilla.</div><div class=\"graphic_reference\">Reproduced with permission from: Stans AA, Lawrence JTR. Dislocations of the elbows, medial epicondylar humerus fractures. In: Rockwood and Wilkins' Fractures in Children, 8th ed, Flynn JM, Skaggs DL, Waters PM (Eds), Wolters Kluwer, Philadelphia 2015. Copyright &copy; 2015 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103961 Version 1.0</div></div></div>"},"103962":{"type":"graphic_figure","displayName":"Risk calculator of de novo stress incontinence","title":"Risk calculator of de novo stress incontinence after prolapse surgery","html":"<div class=\"graphic\"><div style=\"width: 618px\" class=\"figure\"><div class=\"ttl\">Risk calculator of de novo stress incontinence after prolapse surgery</div><div class=\"cntnt\"><img style=\"width:598px; height:586px;\" src=\"images/OBGYN/103962_Rsk_clcl_de_nv_strss_incntn.gif\" alt=\"Image\"/></div><div class=\"graphic_reference\">From: Jelovsek&nbsp;JE, Chagin K, Brubaker L,&nbsp;et al. A model for predicting the risk of de novo stress urinary incontinence in women undergoing pelvic organ prolapse surgery. Obstet Gynecol 2014; 123:279. DOI: <a href=\"http://journals.lww.com/greenjournal/pages/articleviewer.aspx?year=2014&amp;issue=02000&amp;article=00009&amp;type=abstract\" spellcheck=\"true\" target=\"_blank\">10.1097/AOG.0000000000000094</a>. Reproduced with permission from Lippincott Williams &amp; Wilkins. Copyright &copy; 2014 American College of Obstetricians and Gynecologists. Unauthorized reproduction of this material is prohibited.</div><div id=\"graphicVersion\">Graphic 103962 Version 1.0</div></div></div>"},"103964":{"type":"graphic_picture","displayName":"Axillary block ultrasound probe placement","title":"Axillary block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Axillary block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:655px; height:559px;\" src=\"images/ANEST/103964_Axllry_blck_ultrsnd_prb_plcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound guided axillary block, the transducer is placed high in the axilla in a transverse orientation. For further details, refer to the UpToDate topic on upper extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 103964 Version 1.0</div></div></div>"},"103965":{"type":"graphic_picture","displayName":"Infraclavicular block ultrasound probe placement","title":"Infraclavicular block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 595px\" class=\"figure\"><div class=\"ttl\">Infraclavicular block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:575px; height:537px;\" src=\"images/ANEST/103965_Infrclvclr_blck_ultrsnd_prb_plcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided infraclavicular block, the transducer is positioned in the parasagittal plane below the clavicle, just medial to the coracoid process. For further details, refer to the UpToDate topic on upper extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 103965 Version 1.0</div></div></div>"},"103967":{"type":"graphic_diagnosticimage","displayName":"Infraclavicular brachial plexus block ultrasound","title":"Infraclavicular brachial plexus block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 602px\" class=\"figure\"><div class=\"ttl\">Infraclavicular brachial plexus block ultrasound</div><div class=\"cntnt\"><img style=\"width:582px; height:756px;\" src=\"images/ANEST/103967_Infraclavicular_brchl_plxs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided infraclavicular block, the axillary artery and the cords of the brachial plexus are identified. The needle tip is placed adjacent to the axillary artery in the cranio-posterior quadrant for injection of local anesthetic. The needle trajectory is shown by the arrow. For further details, refer to UpToDate content on upper extremity nerve blocks.</div><div id=\"graphicVersion\">Graphic 103967 Version 1.0</div></div></div>"},"103968":{"type":"graphic_picture","displayName":"Interscalene block ultrasound probe placement","title":"Interscalene block ultrasound probe placement","html":"<div class=\"graphic\"><div style=\"width: 730px\" class=\"figure\"><div class=\"ttl\">Interscalene block ultrasound probe placement</div><div class=\"cntnt\"><img style=\"width:710px; height:538px;\" src=\"images/ANEST/103968_Intescln_blck_ultrsnd_prb_plcm.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">For ultrasound-guided interscalene block, the transducer is placed in a transverse position on the neck just above the clavicle. For further details, refer to the UpToDate topic on upper extremity nerve block techniques.</div><div id=\"graphicVersion\">Graphic 103968 Version 1.0</div></div></div>"},"103969":{"type":"graphic_diagnosticimage","displayName":"Interscalene brachial plexus block ultrasound","title":"Interscalene brachial plexus block ultrasound","html":"<div class=\"graphic\"><div style=\"width: 776px\" class=\"figure\"><div class=\"ttl\">Interscalene brachial plexus block ultrasound</div><div class=\"cntnt\"><img style=\"width:756px; height:276px;\" src=\"images/ANEST/103969_Interscalene_brachial_plexs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The dashed arrow shows the needle trajectory using an&nbsp;in-plane approach, while the solid arrow shows the needle trajectory using an out-of-plane approach, for ultrasound-guided interscalene block. For further details, refer to UpToDate content on interscalene brachial plexus block.</div><div class=\"graphic_footnotes\">m.: muscle.</div><div id=\"graphicVersion\">Graphic 103969 Version 1.0</div></div></div>"},"103976":{"type":"graphic_table","displayName":"The COLDS score","title":"The COLDS score","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">The COLDS score</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">&nbsp;</td> <td class=\"subtitle1\">1</td> <td class=\"subtitle1\">2</td> <td class=\"subtitle1\">5</td> </tr> <tr> <td><strong>C:</strong> Current signs/symptoms</td> <td>None</td> <td>Mild</td> <td>Moderate/severe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">Examples: Parent confirms URI and/or congestion, rhinorrhea, sore throat, sneezing, low fever, or dry cough</td> <td class=\"indent1\">Examples: Purulence, wet cough, abnormal lung sounds, lethargy, \"toxic\" appearance, or high fever</td> </tr> <tr class=\"divider_bottom\"> <td><strong>O: </strong>Onset</td> <td>&#62;4 weeks ago</td> <td>&nbsp;2-4 weeks ago</td> <td>&nbsp;&#60;2 weeks ago</td> </tr> <tr> <td><strong>L:</strong> Lung disease</td> <td>None</td> <td>Mild</td> <td>Moderate/severe</td> </tr> <tr class=\"divider_bottom\"> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">Examples: Hx of RSV, mild intermittent asthma, CLD if &#62;1 year old, loud snoring, or passive smoker</td> <td class=\"indent1\">Examples: Moderate persistent asthma, infant with CLD, OSA, or pulmonary HTN</td> </tr> <tr class=\"divider_bottom\"> <td><strong>D:</strong> Airway device planned</td> <td>None or facemask</td> <td>Laryngeal mask airway or supraglottic airway</td> <td>Tracheal tube</td> </tr> <tr> <td><strong>S: </strong>Airway surgery planned</td> <td>Other (including ear tubes)</td> <td>Minor airway</td> <td>Major airway</td> </tr> <tr> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">&nbsp;</td> <td class=\"indent1\">Examples: T/A, NLD probe, flexible bronchoscopy, and dental extractions</td> <td class=\"indent1\">Examples: Cleft palate, rigid bronchoscopy, and maxillofacial</td> </tr> </tbody></table></div><div class=\"graphic_lgnd\">Each category (column 1) is assigned 1, 2, or 5 points (columns 2-4), to obtain a total score ranging from 5 to 25. Examples are illustrative and not intended to be all-inclusive.</div><div class=\"graphic_footnotes\">URI: upper respiratory tract infection; Hx: history; RSV: respiratory syncytial virus; CLD: chronic lung disease; OSA: obstructive sleep apnea; T/A: tonsillectomy and/or adenoidectomy; NLD: nasolacrimal duct.</div><div class=\"graphic_reference\">From: Lee BJ, August DA. COLDS: A heuristic preanesthetic risk score for children with upper respiratory tract infection. Paediatr Anaesth 2014; 24:349. DOI: <a href=\"http://onlinelibrary.wiley.com/doi/10.1111/pan.12337/abstract\" spellcheck=\"true\" target=\"_blank\">10.1111/pan.12337</a>. Copyright &copy; 2014. Reproduced with permission of John Wiley &amp; Sons Inc. This image has been provided by or is owned by Wiley. Further permission is needed before it can be downloaded to PowerPoint, printed, shared or emailed. Please contact Wiley's permissions department either via email: <a href=\"mailto:permissions@wiley.com\" spellcheck=\"true\" target=\"_blank\">permissions@wiley.com</a> or use the RightsLink service by clicking on the 'Request Permission' link accompanying this article on Wiley Online Library (<a href=\"http://onlinelibrary.wiley.com/\" spellcheck=\"true\" target=\"_blank\">http://onlinelibrary.wiley.com</a>).</div><div id=\"graphicVersion\">Graphic 103976 Version 1.0</div></div></div>"},"103978":{"type":"graphic_picture","displayName":"Ulcerative tinea pedis with erosions","title":"Ulcerative tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ulcerative tinea pedis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103978_Ulcrtv_tn_pds_ersn.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Extensive erosions in a patient with tinea pedis.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103978 Version 1.0</div></div></div>"},"103979":{"type":"graphic_picture","displayName":"Ulcerative tinea pedis","title":"Ulcerative tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Ulcerative tinea pedis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103979_Ulcrtv_tinea_pds.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erosions and ulceration on the distal plantar foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103979 Version 1.0</div></div></div>"},"103981":{"type":"graphic_picture","displayName":"Hyperkeratotic (moccasin-type) tinea pedis","title":"Hyperkeratotic (moccasin-type) tinea pedis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Hyperkeratotic (moccasin-type) tinea pedis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103981_Hprkrttc_mccsn_tn_pds_2.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Diffuse scale on the plantar surface and side of the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103981 Version 1.0</div></div></div>"},"103982":{"type":"graphic_figure","displayName":"Pronator compression test","title":"Pronator compression test","html":"<div class=\"graphic\"><div style=\"width: 541px\" class=\"figure\"><div class=\"ttl\">Pronator compression test</div><div class=\"cntnt\"><img style=\"width:521px; height:405px;\" src=\"images/SM/103982_Pronator_compression_test.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The pronator compression test is performed by having the examiner place pressure with the thumb over the pronator teres muscles in both forearms&nbsp;as shown for a full 30 seconds or less if symptoms are elicited. A positive test consists of the occurrence of paresthesias in the distributions of the median nerve (thumb, pointer, middle, and half of the ring fingers) on the affected side with no symptoms in the uninvolved arm. </div><div id=\"graphicVersion\">Graphic 103982 Version 2.0</div></div></div>"},"103983":{"type":"graphic_picture","displayName":"Dyshidrotic eczema on foot","title":"Dyshidrotic eczema","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Dyshidrotic eczema</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103983_Dyshdrtc_eczema_foot.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Multiple small vesicles and postinflammatory hyperpigmentation on the foot.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103983 Version 1.0</div></div></div>"},"103984":{"type":"graphic_picture","displayName":"Tinea corporis plaques","title":"Tinea corporis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Tinea corporis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103984_Tinea_crprs_plaq.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Annular, scaly plaques.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103984 Version 1.0</div></div></div>"},"103985":{"type":"graphic_picture","displayName":"Inverse psoriasis extensive","title":"Inverse psoriasis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Inverse psoriasis</div><div class=\"cntnt\"><img style=\"width:700px; height:525px;\" src=\"images/DERM/103985_Inverse_psrss_extnsv.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Shiny, erythematous plaques within skin folds.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103985 Version 2.0</div></div></div>"},"103986":{"type":"graphic_picture","displayName":"Seborrheic dermatitis in inguinal crease","title":"Seborrheic dermatitis","html":"<div class=\"graphic\"><div style=\"width: 720px\" class=\"figure\"><div class=\"ttl\">Seborrheic dermatitis</div><div class=\"cntnt\"><img style=\"width:700px; height:526px;\" src=\"images/DERM/103986_Sbrrhc_drmtts_ingnl_crs.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">Erythematous patch in the inguinal crease.</div><div class=\"graphic_reference\">Reproduced with permission from: <a href=\"http://www.visualdx.com/\" spellcheck=\"true\" target=\"_blank\">www.visualdx.com</a>. Copyright Logical Images, Inc.</div><div id=\"graphicVersion\">Graphic 103986 Version 1.0</div></div></div>"},"103987":{"type":"graphic_table","displayName":"Differentiating nocturnal frontal epilepsy and parasomnias","title":"Clinical features that may help differentiate nocturnal frontal epilepsy and parasomnias","html":"<div class=\"graphic\"><div class=\"figure\"><div class=\"ttl\">Clinical features that may help differentiate nocturnal frontal epilepsy and parasomnias</div><div class=\"cntnt\"><table cellspacing=\"0\"><colgroup span=\"4\" width=\"25%\"></colgroup> <tbody> <tr> <td class=\"subtitle1\">Feature</td> <td class=\"subtitle1\">Nocturnal frontal seizures</td> <td class=\"subtitle1\">NREM disorders of arousal</td> <td class=\"subtitle1\">REM sleep behavior disorder</td> </tr> <tr> <td>Age of onset</td> <td>Variable, typically first or second decade of life</td> <td>Usually first decade of life</td> <td>50 years and older</td> </tr> <tr> <td>Sleep stage of origin</td> <td>N1 or N2, sleep-wake transitions</td> <td>N3</td> <td>REM</td> </tr> <tr> <td>Timing of episodes</td> <td>Anytime</td> <td>First third of sleep period</td> <td>Last third of sleep period</td> </tr> <tr> <td>Duration of episodes</td> <td>5 to 60 seconds</td> <td>2 to 30 minutes</td> <td>Seconds to 2 minutes</td> </tr> <tr> <td>Frequency of episodes</td> <td>Nightly clusters</td> <td>Sporadic, rare clusters</td> <td>Sporadic, rare clusters</td> </tr> <tr> <td>Onset and offset</td> <td>Sudden</td> <td>Gradual</td> <td>Sudden</td> </tr> <tr> <td>Semiology of episodes</td> <td>Highly stereotyped, hypermotor, asymmetric tonic/dystonic</td> <td>Not stereotyped, variable complexity</td> <td>Not highly stereotyped, vocalizations with dream recall, self-protective behaviors</td> </tr> <tr> <td>Level of consciousness during episodes</td> <td>Usually preserved</td> <td>Variable</td> <td>Poorly responsive</td> </tr> <tr> <td>Post-event confusion</td> <td>Typically absent</td> <td>Present</td> <td>Absent</td> </tr> <tr> <td>Risk of injury</td> <td>Low</td> <td>High</td> <td>Moderate</td> </tr> <tr> <td>Polysomnography with EEG findings</td> <td>Surface epileptiform activity detected in &#60;50%</td> <td>Slow wave sleep arousals, rhythmic delta pattern</td> <td>REM sleep without atonia</td> </tr> </tbody></table></div><div class=\"graphic_footnotes\">REM: rapid eye movement; NREM: non-REM; EEG: electroencephalography.</div><div id=\"graphicVersion\">Graphic 103987 Version 1.0</div></div></div>"},"103988":{"type":"graphic_diagnosticimage","displayName":"Lateral radiograph of knee with PCL injury","title":"Lateral radiograph of knee with posterior cruciate ligament (PCL) injury","html":"<div class=\"graphic\"><div style=\"width: 626px\" class=\"figure\"><div class=\"ttl\">Lateral radiograph of knee with posterior cruciate ligament (PCL) injury</div><div class=\"cntnt\"><img style=\"width:606px; height:352px;\" src=\"images/SM/103988_Lat_rdgrph_knee_PCL_injry.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">The image on the left&nbsp;(A) is a lateral radiograph of an uninjured knee. A line drawn along the anterior border of the tibial shaft intersects with the medial femoral condyle, demonstrating the absence of any posterior displacement. The image on the right&nbsp;(B) is a lateral radiograph of a patient with a posterior cruciate ligament (PCL)&nbsp;tear and demonstrates posterior displacement of the tibia. Note the disparity indicated by the arrow between the posterior line drawn along the tibial shaft and the anterior line drawn along the anterior aspect of the medial femoral condyle.</div><div class=\"graphic_reference\">Courtesy of James MacDonald, MD and Richard Rodenberg, MD.</div><div id=\"graphicVersion\">Graphic 103988 Version 2.0</div></div></div>"},"103995":{"type":"graphic_figure","displayName":"Actigram in irregular sleep-wake rhythm disorder","title":"Actigram from a patient with irregular sleep-wake rhythm disorder","html":"<div class=\"graphic\"><div style=\"width: 675px\" class=\"figure\"><div class=\"ttl\">Actigram from a patient with&nbsp;irregular sleep-wake rhythm disorder</div><div class=\"cntnt\"><img style=\"width:655px; height:966px;\" src=\"images/SLEEP/103995_Actigraph_patient_dementia.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">(A) 72-hour actigram&nbsp;in a patient with dementia showing a relatively well perceived sleep-wake pattern. Although sleep is fragmented, there are distinct day-night differences.<br />(B) 72-hour actigram&nbsp;in another&nbsp;patient with dementia showing severe sleep fragmentation, consistent with irregular sleep-wake rhythm disorder. There are no long intervals of consolidated sleep or consolidated wake.<br />Note that these are double plots, so that the data from midnight-to-midnight at the end of day one are repeated at the beginning of day two, etc. The activity data have been scored for wake (thin line under the activity data) or sleep (thick line under the activity data).</div><div class=\"graphic_reference\">Reproduced with permission from: Ancoli-Israel S, Jones DW, Hanger MA, et al. Sleep in the nursing home. In: Sleep and Respiration in Aging Adults, Kuna ST, Suratt PM, Remmers JE (Eds), Elsevier, New York 1991. p.77. Copyright &copy; 1991 Samuel T. Kuna, MD.</div><div id=\"graphicVersion\">Graphic 103995 Version 2.0</div></div></div>"},"103996":{"type":"graphic_algorithm","displayName":"Outpatient treatment of ABRS in children","title":"Suggested approach to empiric antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in children*","html":"<div class=\"graphic\"><div style=\"width: 848px\" class=\"figure\"><div class=\"ttl\">Suggested approach to empiric antimicrobial therapy for outpatient treatment of uncomplicated acute bacterial rhinosinusitis (ABRS) in children*</div><div class=\"cntnt\"><img style=\"width:828px; height:822px;\" src=\"images/PEDS/103996_Outpatient_tx_ABRS_children.gif\" alt=\"Image\"/></div><div class=\"graphic_footnotes\">IM: intramuscularly.<br />* Inpatient therapy is indicated for patients who have toxic-appearance (eg, lethargy, poor perfusion, cardiorespiratory compromise) and complications or suspected complications. If a pathogen is identified, antimicrobial therapy should be adjusted according to susceptibilities.<br />¶ Complications of ABRS include: preseptal and orbital cellulitis; subperiosteal abscess (orbital or frontal [Pott puffy tumor]); epidural, subdural, or brain abscess; septic cavernous sinus thrombosis, and meningitis. Complicated sinusitis should be suspected in children with: &#xD;&#xA;<UL>&#xD;&#xA;<LI>The combination of periorbital/orbital swelling with persistent headache and vomiting</LI>&#xD;&#xA;<LI>Vomiting and headache that requires hospital admission, particularly in older children</LI>&#xD;&#xA;<LI>Vomiting that persists for more than 24 hours</LI>&#xD;&#xA;<LI>Altered level of consciousness</LI>&#xD;&#xA;<LI>Focal neurologic deficits</LI>&#xD;&#xA;<LI>Signs of meningeal irritation (eg, stiff neck)</LI></UL>Δ Refer to UpToDate topic on treatment of acute bacterial rhinosinusitis in children for details.<br /><FONT class=lozenge>◊</FONT> Refer to UpToDate topics on penicillin allergy and cephalosporin allergy for details.<br />§ Risk factors for antimicrobial resistance: &#xD;&#xA;<UL>&#xD;&#xA;<LI>Living in an area with high endemic rates (ie, ≥10 percent) of invasive penicillin nonsusceptible <EM>Streptococcus pneumoniae</EM></LI>&#xD;&#xA;<LI>Age &lt;2 years</LI>&#xD;&#xA;<LI>Daycare attendance</LI>&#xD;&#xA;<LI>Antibiotic therapy within the past month</LI>&#xD;&#xA;<LI>Hospitalization within the past five days</LI>&#xD;&#xA;<LI>Unimmunized or underimmunized with pneumococcal conjugate vaccine</LI></UL>¥ If vomiting precludes administration of oral antibiotics, can administer ceftriaxone 50 mg/kg IM for one dose (maximum dose 1 g), followed by amoxicillin-clavulanate, cefpodoxime, or cefdinir 24 hours later.<br />‡ If vomiting precludes administration of oral antibiotics, admit patient for parenteral therapy until vomiting resolves.</div><div id=\"graphicVersion\">Graphic 103996 Version 2.0</div></div></div>"},"103997":{"type":"graphic_picture","displayName":"Single-leg Romanian deadlift exercise","title":"Single-leg Romanian deadlift (RDL) exercise","html":"<div class=\"graphic\"><div style=\"width: 759px\" class=\"figure\"><div class=\"ttl\">Single-leg Romanian deadlift (RDL) exercise</div><div class=\"cntnt\"><img style=\"width:739px; height:330px;\" src=\"images/SM/103997_Single_leg_RDL_exercise.jpg\" alt=\"Image\"/></div><div class=\"graphic_lgnd\">A deadlift performed with the knee only slightly bent throughout the exercise movement&nbsp;(so-called straight leg) is commonly referred to as a Romanian&nbsp;Deadlift, or&nbsp;RDL. The RDL places relatively greater stress on the hamstring muscles. The photographs above show this&nbsp;exercise being performed on a single leg with weight carried in the contralateral hand.</div><div class=\"graphic_reference\">Reproduced with permission from: Chandler TJ, Brown LE. Biomechanics of human movement. In: Conditioning for Strength and Human Performance, 2nd ed, Lippincott Williams &amp; Wilkins, Philadelphia 2013. Copyright &copy; 2013 Lippincott Williams &amp; Wilkins. <a href=\"http://www.lww.com/\" target=\"_blank\">www.lww.com</a>.</div><div id=\"graphicVersion\">Graphic 103997 Version 1.0</div></div></div>"}};